{"b67376db380379b48690b43ab52ae56c4ec3cfc3": [["INTRODUCTIONWith the advent of high-throughput technologies genomic science has experienced great leaps, rapidly expanding its domain beyond the characterization of short genomic reads in the early days of sequencing to the possibility of obtaining personalized genomes, once considered the holy grail of genomic methodology and technology development.", [["short genomic reads", "PROBLEM", 165, 184], ["great", "OBSERVATION_MODIFIER", 92, 97], ["leaps", "OBSERVATION_MODIFIER", 98, 103]]], ["The value of personalized genomic analysis, and evaluation of variant associations to disease, is becoming more apparent, even spurring directly to consumer implementations.", [["personalized genomic analysis", "TEST", 13, 42], ["evaluation", "TEST", 48, 58], ["disease", "PROBLEM", 86, 93], ["spurring", "OBSERVATION", 127, 135]]], ["Further developments in the last few years now lead to a more ambitious goal: the longitudinal monitoring of multiple omics components in individuals and the characterization of the molecular changes associated with disease onset in individuals, at an unprecedented level.", [["the longitudinal monitoring", "TEST", 78, 105], ["the characterization", "TEST", 154, 174], ["the molecular changes", "PROBLEM", 178, 199], ["disease onset in individuals", "PROBLEM", 216, 244]]], ["In this review we describe technological and methodological developments in personal genomics, and the new promise of multiple omics profiling, including transcriptomes, proteomes, metabolomes, autoantibodyomes and so forth, (sample omics analysis workflows shown in Figures 1-4) .", [["multiple omics profiling", "PROBLEM", 118, 142], ["sample omics analysis workflows", "TEST", 226, 257], ["Figures", "TEST", 267, 274]]], ["We then discuss a framework on how such data may be integrated with a view towards the application of a personalized precise and preventive medicine, and describe an implementation of this approach.", [["this approach", "TREATMENT", 184, 197]]], ["The technological developments and methodology allow for inroads into the future of quantitative personal medicine, which we can now plan carefully by taking into account not only the scientific developments that need to be implemented, but also the social implications coupled to ethical and legal considerations.GENOMIC SEQUENCINGIn 2001 the completion of the Human Genome Project (HGP) was announced effectively with the publication of the first complete human genome sequence.", [["Human", "ORGANISM", 362, 367], ["human", "ORGANISM", 458, 463], ["human genome sequence", "DNA", 458, 479], ["Human", "SPECIES", 362, 367], ["human", "SPECIES", 458, 463], ["human", "SPECIES", 458, 463], ["quantitative personal medicine", "TREATMENT", 84, 114]]], ["The HGP came at a hefty $2.7 billion cost using the best technology of the time, making it seemingly prohibitive to expect personal genome sequences to be achieved shortly thereafter.", [["personal genome sequences", "DNA", 123, 148]]], ["Yet the immense technological advancement, spurred by motivation by the National Institute of Health (NIH) and the National Human Genome Research Institute (NHGRI) to bring down genomic costs, led to an unprecedented growth in technology and methodology, enabling the drop in sequencing costs (http://www. genome.gov/sequencingcosts) to continue at a rate beyond the most optimistic projections of 2001 ( < $4000 currently).", [["Human", "SPECIES", 124, 129]]], ["While initially the human genome was a combination of multiple individual genomic data [1] [2] [3] , the developments by 2008 had allowed the determination of genomic individual makeup [4] [5] [6] [7] .", [["human", "ORGANISM", 20, 25], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 185, 200], ["human genome", "DNA", 20, 32], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["multiple individual genomic data", "PROBLEM", 54, 86]]], ["These developments encouraged efforts to characterize disease on a genomic level, towards the application of an all-encompassing genomic medicine, at the molecular level.", [["disease on a genomic level", "PROBLEM", 54, 80], ["an all-encompassing genomic medicine", "TREATMENT", 109, 145]]], ["The initial goals were the characterization of populations for large studies, now shifting to the individual.Multiple technologies development/dropping costsThe HGP relied on technology using Sanger-based capillary sequencing [1] with an estimated production of 115k base pairs per day (kbp/day) [9] .", [["capillary", "ANATOMY", 205, 214], ["capillary", "TISSUE", 205, 214], ["HGP", "PROTEIN", 161, 164], ["large studies", "TEST", 63, 76], ["dropping costs", "PROBLEM", 143, 157], ["Sanger-based capillary sequencing", "TREATMENT", 192, 225], ["dropping costs", "OBSERVATION", 143, 157]]], ["The NHGRI spurred progress by encouragement through the $1000 genome program (http://www.genome.gov/11008124-al-4), leading to the industry development of multiple massively parallel [10] sequencing platforms (e.g., Roche/454, based on pyrosequencing [11] [12] [13] ; Life Technologies SOLiD [14] [15] [16] ; Illumina [5, 6] ; Complete Genomics based on DNA nanoball sequencing [17] ; Helicos Biosciences [18] ; and recently single molecule real-time technology [19, 20] by Pacific Biosciences).", [["DNA", "CELLULAR_COMPONENT", 354, 357], ["NHGRI", "DNA", 4, 9], ["sequencing platforms", "TEST", 188, 208], ["pyrosequencing", "TEST", 236, 250], ["Life Technologies SOLiD", "TEST", 268, 291], ["Illumina", "TEST", 309, 317], ["Complete Genomics", "TEST", 327, 344], ["DNA nanoball sequencing", "TEST", 354, 377], ["Helicos Biosciences", "TEST", 385, 404]]], ["The technological developments and competition resulted in a drastic and continuing drop in sequencing cost, processing times and exponential increases in number of reads produced.Multiple technologies development/dropping costsAn alternative to sequencing the whole genome has been whole exome sequencing (WES) [23] .", [["a drastic and continuing drop in sequencing cost", "PROBLEM", 59, 107], ["dropping costs", "PROBLEM", 214, 228], ["drastic", "OBSERVATION_MODIFIER", 61, 68], ["exponential", "OBSERVATION_MODIFIER", 130, 141], ["increases", "OBSERVATION_MODIFIER", 142, 151], ["dropping costs", "OBSERVATION", 214, 228]]], ["This technology aims to study the exonic regions of the genome (~2%-3%), which are associated to several Mendelian disorders.", [["Mendelian disorders", "DISEASE", 105, 124], ["genome", "CELLULAR_COMPONENT", 56, 62], ["exonic regions", "DNA", 34, 48], ["several Mendelian disorders", "PROBLEM", 97, 124], ["genome", "ANATOMY", 56, 62], ["several", "OBSERVATION_MODIFIER", 97, 104], ["Mendelian disorders", "OBSERVATION", 105, 124]]], ["It offers a lower cost option (e.g., Illumina, Agilent, and Niblegen platforms, see Clark et al. for a comparison of the latter two [24] ) and has received immense attention, including the Exome Sequencing Project (ESP) (see the Exome Variant Server at http://evs. gs.washington.edu/EVS/), supported by the National Heart, Lung and Blood Institute (NHLBI).Quantitating genomic variationConcurrently with the technological developments, our understanding of the human genome has grown immensely since the publication of the reference genome in 2003.", [["Heart", "ANATOMY", 316, 321], ["Lung", "ANATOMY", 323, 327], ["Blood", "ANATOMY", 332, 337], ["Heart, Lung and Blood Institute", "DISEASE", 316, 347], ["Lung", "ORGAN", 323, 327], ["Blood", "ORGANISM_SUBSTANCE", 332, 337], ["human", "ORGANISM", 461, 466], ["human genome", "DNA", 461, 473], ["reference genome", "DNA", 523, 539], ["human", "SPECIES", 461, 466], ["human", "SPECIES", 461, 466], ["a lower cost option", "TREATMENT", 10, 29], ["Quantitating genomic variation", "PROBLEM", 356, 386], ["Heart", "ANATOMY", 316, 321], ["Lung", "ANATOMY", 323, 327], ["genomic variation", "OBSERVATION", 369, 386]]], ["The aim was to determine the precise role of each base in the genome and identify genomic variants ( Figure 1 ).", [["genomic variants", "OBSERVATION", 82, 98]]], ["Several collaborative large-scale efforts pursued such investigations.", [["such investigations", "TEST", 50, 69], ["collaborative", "OBSERVATION_MODIFIER", 8, 21], ["large", "OBSERVATION_MODIFIER", 22, 27], ["-scale", "OBSERVATION_MODIFIER", 27, 33]]], ["The International HapMap Consortium [25, 26] tried to identify common population variants and led to the development of public databases, such as dbSNP [27] (http://www.ncbi.nlm.nih.gov/SNP/), which catalogues Single Nucleotide Polymorphisms (SNPs) (defined as occurring in >1% of the population to differentiate from Single Nucleotide Variants (SNVs)).", [["dbSNP", "TEST", 146, 151], ["Single Nucleotide Polymorphisms (SNPs)", "TREATMENT", 210, 248], ["Single Nucleotide Variants (SNVs)", "TREATMENT", 318, 351]]], ["This has revealed great genomic variation both in global populations [28, 29] and populations of admixed ancestry [30] [31] [32] [33] .Quantitating genomic variationTypically the technologies involve the assignment of reads to the reference genome to determine the structure of the underlying sequence, including variation ( Figure 1 ).", [["reference genome", "DNA", 231, 247], ["great genomic variation", "PROBLEM", 18, 41], ["Quantitating genomic variation", "PROBLEM", 135, 165], ["great", "OBSERVATION_MODIFIER", 18, 23], ["genomic", "OBSERVATION_MODIFIER", 24, 31], ["variation", "OBSERVATION_MODIFIER", 32, 41], ["both", "OBSERVATION_MODIFIER", 42, 46], ["global", "OBSERVATION_MODIFIER", 50, 56], ["populations", "OBSERVATION_MODIFIER", 57, 68], ["genomic variation", "OBSERVATION", 148, 165]]], ["Beyond nucleotide variation, other genomic differences have been investigated, including small insertions and deletions (indels), copy number variations (CNVs) indicating varying numbers of segments and longer chromosomal segments that contribute to Structural Variation (SVs) -SVs are defined for segments of chromosomes larger than 1000 bp ( Figure 1A ).", [["chromosomal", "ANATOMY", 210, 221], ["chromosomes", "ANATOMY", 310, 321], ["nucleotide", "CHEMICAL", 7, 17], ["nucleotide", "CHEMICAL", 7, 17], ["chromosomes", "CELLULAR_COMPONENT", 310, 321], ["SVs", "DNA", 278, 281], ["chromosomes", "DNA", 310, 321], ["nucleotide variation", "PROBLEM", 7, 27], ["other genomic differences", "PROBLEM", 29, 54], ["small insertions and deletions (indels)", "PROBLEM", 89, 128], ["varying numbers of segments and longer chromosomal segments", "PROBLEM", 171, 230], ["Structural Variation (SVs)", "PROBLEM", 250, 276], ["SVs", "PROBLEM", 278, 281], ["segments of chromosomes", "PROBLEM", 298, 321], ["bp", "TEST", 339, 341], ["nucleotide variation", "OBSERVATION", 7, 27], ["small", "OBSERVATION_MODIFIER", 89, 94], ["insertions", "OBSERVATION_MODIFIER", 95, 105], ["varying", "OBSERVATION_MODIFIER", 171, 178], ["numbers", "OBSERVATION_MODIFIER", 179, 186], ["segments", "ANATOMY_MODIFIER", 190, 198], ["Structural Variation", "OBSERVATION", 250, 270]]], ["Such efforts have been based on microarray methodology [34] [35] [36] [37] and even higher-resolution in structural variants may be achieved with other methods [38] [39] [40] [41] .", [["[38] [39] [40] [41]", "SIMPLE_CHEMICAL", 160, 179], ["microarray methodology", "TEST", 32, 54]]], ["Structural variants have been publically made available in the database of Genomic Structural Variation (dbVAR; http:// www.ncbi.nlm.nih.gov/dbvar/).", [["Structural Variation", "OBSERVATION", 83, 103]]], ["Furthermore, functional elements have been extensively catalogued by the Encyclopedia of DNA Elements consortium (ENCODE; http://genome.gov/encode~10 production projects), with funding from the NHGRI.", [["DNA", "CELLULAR_COMPONENT", 89, 92], ["functional elements", "DNA", 13, 32], ["NHGRI", "DNA", 194, 199]]], ["ENCODE data, including regulatory elements and RNA and protein level elements, have now been released and the project has received widespread attention [42] [43] [44] [45] .", [["[42] [43] [44] [45]", "SIMPLE_CHEMICAL", 152, 171], ["regulatory elements", "DNA", 23, 42], ["RNA and protein level elements", "DNA", 47, 77], ["ENCODE data", "TEST", 0, 11], ["RNA and protein level elements", "TEST", 47, 77]]], ["The ENCODE project aims at a biochemical genomic characterization, with a thorough mapping of transcribed regions, transcription factor binding sites, open chromatin signatures, chromatin modification and DNA methylation.", [["chromatin", "ANATOMY", 156, 165], ["chromatin", "ANATOMY", 178, 187], ["chromatin", "CELLULAR_COMPONENT", 156, 165], ["chromatin", "CELLULAR_COMPONENT", 178, 187], ["DNA", "CELLULAR_COMPONENT", 205, 208], ["transcribed regions", "DNA", 94, 113], ["transcription factor binding sites", "DNA", 115, 149], ["open chromatin signatures", "DNA", 151, 176], ["chromatin", "DNA", 178, 187], ["a biochemical genomic characterization", "TEST", 27, 65], ["transcription factor binding sites", "PROBLEM", 115, 149], ["open chromatin signatures", "PROBLEM", 151, 176], ["chromatin modification", "TREATMENT", 178, 200], ["DNA methylation", "TREATMENT", 205, 220], ["chromatin signatures", "OBSERVATION", 156, 176], ["chromatin modification", "OBSERVATION", 178, 200]]], ["Such extensive data still needs to be annotated [46] interpreted in terms of biological significance, mechanisms and connections to phenotype and will likely prove invaluable in our interpretation of personalized genomic differences.Quantitating genomic variationThough initially limited by the number of complete genomic sequences, such data are now continuously updated and expanded by information from other projects such as the 1000 Genomes Project [47] as discussed QB Figure 1 .", [["genomic sequences", "DNA", 314, 331], ["Quantitating genomic variation", "PROBLEM", 233, 263], ["genomic variation", "OBSERVATION", 246, 263]]], ["Genomic variants.", [["Genomic variants", "PROBLEM", 0, 16]]], ["(A) Variation in the human genome.", [["human", "ORGANISM", 21, 26], ["human genome", "DNA", 21, 33], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["human genome", "OBSERVATION", 21, 33]]], ["The personal genomic code can differ from the published reference genome.", [["reference genome", "DNA", 56, 72]]], ["Basic examples of variation are shown on a single or few base variants (e.g., point mutations, insertions and deletions), or a larger scale for structural variants (>1000 bp, e.g., large insertions, deletions, inversions, tandem repeats, translocations).", [["a single or few base variants", "PROBLEM", 41, 70], ["point mutations, insertions and deletions)", "PROBLEM", 78, 120], ["structural variants", "PROBLEM", 144, 163], ["bp", "TEST", 171, 173], ["large insertions, deletions", "PROBLEM", 181, 208], ["inversions", "PROBLEM", 210, 220], ["variation", "OBSERVATION_MODIFIER", 18, 27], ["large", "OBSERVATION_MODIFIER", 181, 186]]], ["(B) Sample variant analysis workflow.", [["Sample variant analysis workflow", "TEST", 4, 36]]], ["In a genomic variant analysis, for example, after sample preparation and sequencing the raw files can be passed through quality control (e.g., using FastQC (http://www.bioinformatics.bbsrc.ac.uk/projects/ fastqc/) and removing PCR artifacts using tools as Picard (http://picard.sourceforge.net)).", [["sample", "ANATOMY", 50, 56], ["sample preparation", "TEST", 50, 68], ["sequencing the raw files", "TEST", 73, 97], ["FastQC (http://www.bioinformatics.bbsrc.ac.uk/projects/ fastqc/", "TREATMENT", 149, 212], ["PCR artifacts", "PROBLEM", 227, 240]]], ["Reads are mapped to the genome and variants are assessed, e.g., mapping with several algorithms, including ELAND II (Illumina), SOAP [221] , MAQ and Burrows-Wheeler Aligner (BWA) [222] and Novoalign by \u00a9 Novocraft Technologies (http://www.novocraft.com).", [["genome", "CELLULAR_COMPONENT", 24, 30], ["ELAND II", "DNA", 107, 115], ["several algorithms", "TEST", 77, 95], ["SOAP", "TEST", 128, 132], ["MAQ", "TEST", 141, 144], ["Novoalign", "TREATMENT", 189, 198]]], ["Read re-alignment can be performed, e.g., using Genome Analysis Toolkit (GATK) [223] , or HugeSeq [211] , to call variants, including implementations with Sequence Alignment Map format Tools (SAMtools) [224] , annotation using Annovar [225] , SIFT [226] and Polyphen [227] for determining variant effects on proteomic translation [228] .", [["Polyphen", "TREATMENT", 258, 266]]], ["For example the paired-end mapping method considers how paired-end reads mapped to the reference to assign deletions and insertions, from reads whose mapped span is longer or shorter than the average span; inversions, from position and relative orientations of the ends of reads [39, 40] .", [["paired-end reads", "DNA", 56, 72], ["inversions", "PROBLEM", 206, 216]]], ["In the approach of Abyzov et al. [229] the read depth considered as an image is analyzed using image processing techniques, viz. mean-shift-theory [230] .", [["an image", "TEST", 68, 76], ["image processing techniques", "TEST", 95, 122], ["mean", "TEST", 129, 133]]], ["Programs such as Pindel [231] and BreakSeq [232] consider split-read analysis to determine breakpoints of insertions and deletions.", [["split-read analysis", "TEST", 58, 77], ["breakpoints of insertions and deletions", "PROBLEM", 91, 130]]], ["DELLY [233] by Rausch et al. takes into account paired-end and split-read methods for determining structural variants.", [["paired-end", "DNA", 48, 58]]], ["Many packages for analysis are available through the Bioconductor [234] project as implemented in the freely available R statistical analysis platform (http://www.R-project.org).Quantitating genomic variationbelow, which has allowed us to have a better view of the great variability in each individual genome (~3-4\u00c210 6 SNPs, > 200000 SVs of varying sizes,~1500 SVs> 2 kbp), with much of the variation considered rare (1%-5%).", [["analysis", "TEST", 18, 26], ["SNPs", "TEST", 320, 324], ["SVs", "TEST", 362, 365], ["genomic variationbelow", "OBSERVATION", 191, 213], ["great variability", "OBSERVATION", 265, 282]]], ["Genome-Wide Association Studies (GWAS) try to associate the common variants to disease, by combining the now readily available extensive variant information and allelic variability, with linkage disequilibrium (a description of the correlation patterns between proximal variants).", [["disease", "PROBLEM", 79, 86], ["allelic variability", "PROBLEM", 161, 180], ["linkage disequilibrium", "PROBLEM", 187, 209], ["disease", "OBSERVATION", 79, 86], ["allelic variability", "OBSERVATION", 161, 180]]], ["The NHGRI provides a publically available catalogue of published GWAS (http://www.genome.gov/ gwastudies) [48] .", [["NHGRI", "DNA", 4, 9]]], ["The early expectations of finding common traits and genomic features unique to diseases have proven more complicated, as the genomic variability turns out to be higher than expected and additionally the genetic variants need further validation.Quantitating genomic variationUse of WGS and WES has been successful in the identification of somatic mutations.", [["WGS", "DNA", 281, 284], ["WES", "DNA", 289, 292], ["diseases", "PROBLEM", 79, 87], ["further validation", "TEST", 225, 243], ["Quantitating genomic variationUse of WGS", "PROBLEM", 244, 284], ["somatic mutations", "PROBLEM", 338, 355], ["higher", "OBSERVATION_MODIFIER", 161, 167]]], ["Mendelian disorders including neurological disorders, and cancer have been characterized using WES [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] , including some recent single-cell studies [59, 60] .", [["neurological", "ANATOMY", 30, 42], ["cancer", "ANATOMY", 58, 64], ["Mendelian disorders", "DISEASE", 0, 19], ["neurological disorders", "DISEASE", 30, 52], ["cancer", "DISEASE", 58, 64], ["WES [49] [50] [51] [52] [53] [54] [55] [56] [57] [58]", "CHEMICAL", 95, 148], ["cancer", "CANCER", 58, 64], ["50] [51] [52] [53] [54] [55] [56] [57] [58]", "SIMPLE_CHEMICAL", 105, 148], ["Mendelian disorders", "PROBLEM", 0, 19], ["neurological disorders", "PROBLEM", 30, 52], ["cancer", "PROBLEM", 58, 64]]], ["Genomics may help classifying cancer subtypes, and possible treatment, and such research is at the center of WGS, with projects such as the Cancer Genome Atlas [61] (http://cancer-genome.nih. gov/), and the International Cancer Genome Consortium (http://www.icgc.org).", [["cancer", "ANATOMY", 30, 36], ["cancer", "DISEASE", 30, 36], ["Cancer", "DISEASE", 140, 146], ["Cancer", "DISEASE", 221, 227], ["cancer", "CANCER", 30, 36], ["cancer subtypes", "PROBLEM", 30, 45], ["treatment", "TREATMENT", 60, 69], ["Cancer", "OBSERVATION", 221, 227]]], ["Additionally, cancer specific public databases already are available [62] , including a cancer cell line encyclopedia [63] , and genome characterization has been carried out, for example in ovarian cancer [61] , melanoma [64] , lymphocytic leukemia [65] , breast cancer [66] [67] [68] [69] and acute myeloid leukemia (AML) [70, 71] .Personalized risk evaluationOne of the goals of personalized genome interpretation is the evaluation of disease risk factors based on an individual's variant and allelic distribution composition.", [["cancer", "ANATOMY", 14, 20], ["cancer cell line", "ANATOMY", 88, 104], ["ovarian cancer", "ANATOMY", 190, 204], ["melanoma", "ANATOMY", 212, 220], ["lymphocytic leukemia", "ANATOMY", 228, 248], ["breast cancer", "ANATOMY", 256, 269], ["acute myeloid leukemia", "ANATOMY", 294, 316], ["AML", "ANATOMY", 318, 321], ["cancer", "DISEASE", 14, 20], ["cancer", "DISEASE", 88, 94], ["ovarian cancer", "DISEASE", 190, 204], ["melanoma", "DISEASE", 212, 220], ["lymphocytic leukemia", "DISEASE", 228, 248], ["breast cancer", "DISEASE", 256, 269], ["acute myeloid leukemia", "DISEASE", 294, 316], ["AML", "DISEASE", 318, 321], ["cancer", "CANCER", 14, 20], ["cancer cell line", "CELL", 88, 104], ["ovarian cancer", "CANCER", 190, 204], ["melanoma [64] ,", "CANCER", 212, 227], ["lymphocytic leukemia", "CANCER", 228, 248], ["breast cancer", "CANCER", 256, 269], ["[66] [67", "CANCER", 270, 278], ["acute myeloid leukemia", "CANCER", 294, 316], ["AML", "CANCER", 318, 321], ["cancer", "PROBLEM", 14, 20], ["a cancer cell line encyclopedia", "PROBLEM", 86, 117], ["genome characterization", "TEST", 129, 152], ["ovarian cancer", "PROBLEM", 190, 204], ["melanoma", "PROBLEM", 212, 220], ["lymphocytic leukemia", "PROBLEM", 228, 248], ["breast cancer", "PROBLEM", 256, 269], ["acute myeloid leukemia", "PROBLEM", 294, 316], ["AML", "TEST", 318, 321], ["the evaluation", "TEST", 419, 433], ["disease risk factors", "PROBLEM", 437, 457], ["allelic distribution composition", "PROBLEM", 495, 527], ["cancer", "OBSERVATION", 14, 20], ["cancer cell line", "OBSERVATION", 88, 104], ["ovarian", "ANATOMY", 190, 197], ["cancer", "OBSERVATION", 198, 204], ["melanoma", "OBSERVATION", 212, 220], ["lymphocytic leukemia", "OBSERVATION", 228, 248], ["breast", "ANATOMY", 256, 262], ["cancer", "OBSERVATION", 263, 269], ["acute myeloid leukemia", "OBSERVATION", 294, 316], ["allelic distribution", "OBSERVATION", 495, 515]]], ["Such information may be compared to similar individuals with known disease associations to assess whether an individual shows increased or decreased risk compared to the control group.", [["known disease associations", "PROBLEM", 61, 87], ["decreased risk", "PROBLEM", 139, 153], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["decreased", "OBSERVATION_MODIFIER", 139, 148]]], ["A combination of know SNPs and personalized variants has been found to be effective [72] [73] [74] [75] and has been used in clinical studies; more recently, a seminal study by Ashley et al. [76] evaluated disease risk for a patient with family history of vascular disease.Personalized risk evaluationPersonalized evaluation of potential drug responses can be based on the effects of variants [77, 78] , including drug selection, sensitivity and dosage estimation, e.g., cardiovascular drugs [79] , schizophrenia related medications [80] .", [["vascular", "ANATOMY", 256, 264], ["cardiovascular", "ANATOMY", 471, 485], ["vascular disease", "DISEASE", 256, 272], ["schizophrenia", "DISEASE", 499, 512], ["patient", "ORGANISM", 225, 232], ["vascular", "MULTI-TISSUE_STRUCTURE", 256, 264], ["patient", "SPECIES", 225, 232], ["know SNPs", "TREATMENT", 17, 26], ["personalized variants", "PROBLEM", 31, 52], ["clinical studies", "TEST", 125, 141], ["a seminal study", "TEST", 158, 173], ["vascular disease", "PROBLEM", 256, 272], ["Personalized risk evaluation", "TEST", 273, 301], ["Personalized evaluation", "TEST", 301, 324], ["drug selection", "TREATMENT", 414, 428], ["dosage estimation", "TEST", 446, 463], ["cardiovascular drugs", "TREATMENT", 471, 491], ["schizophrenia related medications", "TREATMENT", 499, 532], ["vascular", "ANATOMY", 256, 264], ["disease", "OBSERVATION", 265, 272]]], ["For example, PharmGKB (http://www.pharmgkb. org) provides a curated database of possible genomics information [81, 82] , exploring the impact of genomic variation on drug responses as these relate to expressed genes and associated pathways and disorders.", [["PharmGKB", "PROTEIN", 13, 21], ["disorders", "PROBLEM", 244, 253]]], ["The future applications are to include a precise drug dosage for an individual, avoiding trial and error methods and providing more effective treatment.Personalized risk evaluationThe evaluation of personalized risk based on genomes is now appearing in direct-to-consumer services.", [["a precise drug dosage", "TREATMENT", 39, 60], ["error methods", "TREATMENT", 99, 112], ["more effective treatment", "TREATMENT", 127, 151], ["Personalized risk evaluation", "TEST", 152, 180], ["The evaluation", "TEST", 180, 194]]], ["Companies like 23andMe, deCODEme, (and previously Navigenics), offer to assess individual genotypes and offer disease based interpretation services based on Mendelian disorder evaluation and including pharmacogenomics responses.", [["Mendelian disorder", "DISEASE", 157, 175], ["Mendelian disorder evaluation", "TEST", 157, 186]]], ["These are mostly based on SNPs evaluation and the tests though limited in scope do offer interpretation attractive to multiple consumers.Personal Genomes ProjectPresently thousands of genomes have been completely sequenced.", [["SNPs evaluation", "TEST", 26, 41], ["the tests", "TEST", 46, 55]]], ["One of the first large scale projects has been the 1000 Genomes Project [47] , that has made its data publically available, and has encouraged the development of streamlined bioinformatics tools to analyze the variation in the individual genomes ( Figure 1 ).", [["large", "OBSERVATION_MODIFIER", 17, 22]]], ["This project aims to combine data from 2500 individuals from multiple populations, at a 4\u00c2 coverage.Personal Genomes ProjectAnother grand scale effort driven by George Church's group at Harvard University is the Personal Genome Project (PGP) [83] [84] [85] .", [["a 4\u00c2 coverage", "TREATMENT", 86, 99]]], ["The volunteers share full DNA sequences, RNA and protein profile information in addition to extensive phenotype information including medical records and environmental considerations, with all the data made publically available, and plans to expand to 100000 individuals [86] .", [["volunteers", "ORGANISM", 4, 14], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["DNA sequences", "DNA", 26, 39], ["full DNA sequences", "TEST", 21, 39], ["protein profile", "TEST", 49, 64]]], ["One of the rather unique features of the PGP project is that it differs in consent of participants as compared to traditional studies.", [["PGP", "GENE_OR_GENE_PRODUCT", 41, 44], ["participants", "SPECIES", 86, 98], ["traditional studies", "TEST", 114, 133]]], ["The ownership of the data is to be open and publically available without restrictions, not only for the initial perspective of the study, but open to follow-up or additional investigations.", [["the study", "TEST", 127, 136], ["additional investigations", "TEST", 163, 188]]], ["The scope is participatory, with the volunteers for the project interacting directly with the researchers.", [["volunteers", "ORGANISM", 37, 47]]], ["To address informed consent, participants pass a basic genetic literacy exam and must understand the project's scope.", [["participants", "SPECIES", 29, 41], ["a basic genetic literacy exam", "TEST", 47, 76]]], ["Additionally, they provide complete medical history, immunization and medications history, which becomes part of the publically available subject information.", [["immunization", "TREATMENT", 53, 65], ["medications", "TREATMENT", 70, 81]]], ["The availability of extensive patient and omic information will be invaluable to researchers in developing robust analysis models for characterizing genomes and disease and the PGP project, and its publically open structure model, will be at the forefront of such efforts.BEYOND THE GENOME: OTHER OMICS TranscriptomicsThough the genetic code in DNA is the almost identical (besides cellular variation), different cells have different gene expressions, corresponding to the kind of cell, developmental stage and physiological state.", [["cellular", "ANATOMY", 382, 390], ["cells", "ANATOMY", 413, 418], ["cell", "ANATOMY", 481, 485], ["patient", "ORGANISM", 30, 37], ["PGP", "GENE_OR_GENE_PRODUCT", 177, 180], ["DNA", "CELLULAR_COMPONENT", 345, 348], ["cellular", "CELL", 382, 390], ["cells", "CELL", 413, 418], ["cell", "CELL", 481, 485], ["patient", "SPECIES", 30, 37], ["disease", "PROBLEM", 161, 168], ["the PGP", "TEST", 173, 180], ["different cells", "PROBLEM", 403, 418], ["different gene expressions", "PROBLEM", 424, 450], ["developmental stage and physiological state", "PROBLEM", 487, 530], ["cellular variation", "OBSERVATION", 382, 400], ["different", "OBSERVATION_MODIFIER", 424, 433], ["gene expressions", "OBSERVATION", 434, 450]]], ["The collection of the transcripts in a cell (e.g., mRNA, non-coding RNA and small RNAs), the transcriptome, is essential in our understanding of cell function, and response to disease.", [["cell", "ANATOMY", 39, 43], ["cell", "ANATOMY", 145, 149], ["cell", "CELL", 39, 43], ["cell", "CELL", 145, 149], ["mRNA", "RNA", 51, 55], ["non-coding RNA", "RNA", 57, 71], ["small RNAs", "RNA", 76, 86], ["a cell (e.g., mRNA, non-coding RNA and small RNAs", "PROBLEM", 37, 86], ["disease", "PROBLEM", 176, 183], ["collection", "OBSERVATION_MODIFIER", 4, 14], ["small RNAs", "OBSERVATION_MODIFIER", 76, 86], ["cell function", "OBSERVATION", 145, 158]]], ["Considerations must include start and end sites of genes, and coding, alternative splicing and post-transcriptional modifications.BEYOND THE GENOME: OTHER OMICS TranscriptomicsInitially inroads were made using high-density oligo microarrays, and in-house custom made microarrays [87] , with high-density arrays having resolutions up to 100 bp [88] [89] [90] [91] .", [["start and end sites", "DNA", 28, 47], ["end sites of genes", "PROBLEM", 38, 56], ["alternative splicing", "TREATMENT", 70, 90], ["post-transcriptional modifications", "TREATMENT", 95, 129], ["high-density oligo microarrays", "TREATMENT", 210, 240], ["microarrays", "TEST", 267, 278], ["bp", "TEST", 340, 342], ["post-transcriptional modifications", "OBSERVATION", 95, 129]]], ["While relatively inexpensive, these methods suffered from relying on prior knowledge of the genome, and faced technical issues such as background and saturation effects [92] .", [["faced technical issues", "PROBLEM", 104, 126]]], ["Hybridization interactions between probe sets in short oligo microarrays lead to spurious correlations [92, 93] .BEYOND THE GENOME: OTHER OMICS TranscriptomicsThe development of RNA sequencing (RNA-Seq) brought higher coverage, better precision and quantitation, and higher resolution and sensitivity, bringing RNA-Seq technology and transcriptomics on par with genomic sequencing [94] [95] [96] [97] [98] .", [["Hybridization interactions between probe sets in short oligo microarrays", "PROBLEM", 0, 72], ["spurious correlations", "TEST", 81, 102], ["RNA sequencing", "TEST", 178, 192], ["RNA", "TEST", 194, 197], ["quantitation", "TEST", 249, 261], ["sensitivity", "TEST", 289, 300], ["RNA", "TEST", 311, 314], ["genomic sequencing", "TEST", 362, 380], ["RNA sequencing", "OBSERVATION", 178, 192]]], ["RNA-Seq considers reads that correspond to millions of transcriptomic fragments that are mapped to the reference genome, to provide information on transcripts that may not be in the existing genomic annotation, allowing the search for novel transcripts, and even identification of SNPs and other variants, while showing remarkable reproducibility ( Figure 2 ).", [["transcriptomic fragments", "DNA", 55, 79], ["reference genome", "DNA", 103, 119], ["SNPs", "DNA", 281, 285], ["RNA", "TEST", 0, 3], ["transcriptomic fragments", "PROBLEM", 55, 79], ["SNPs and other variants", "PROBLEM", 281, 304], ["millions", "OBSERVATION_MODIFIER", 43, 51], ["transcriptomic fragments", "OBSERVATION", 55, 79]]], ["Transcriptome profiling has included looking at cancers [99] [100] [101] , including breast cancer [102] , gastrointestinal tumors [103] and prostate cancer [104] .Mass spectrometry, proteomics and metabolomicsGene expression was expected to correlate with protein levels in a cell and it was thought that methods such as RNA-Seq would be enough to ascertain the proteomic expression corresponding to gene expression.", [["cancers", "ANATOMY", 48, 55], ["breast cancer", "ANATOMY", 85, 98], ["gastrointestinal tumors", "ANATOMY", 107, 130], ["prostate cancer", "ANATOMY", 141, 156], ["cell", "ANATOMY", 277, 281], ["cancers", "DISEASE", 48, 55], ["breast cancer", "DISEASE", 85, 98], ["gastrointestinal tumors", "DISEASE", 107, 130], ["prostate cancer", "DISEASE", 141, 156], ["cancers", "CANCER", 48, 55], ["breast cancer", "CANCER", 85, 98], ["gastrointestinal tumors", "CANCER", 107, 130], ["prostate cancer", "CANCER", 141, 156], ["cell", "CELL", 277, 281], ["looking at cancers", "PROBLEM", 37, 55], ["breast cancer", "PROBLEM", 85, 98], ["gastrointestinal tumors", "PROBLEM", 107, 130], ["prostate cancer", "PROBLEM", 141, 156], ["Mass spectrometry", "PROBLEM", 164, 181], ["proteomics", "TEST", 183, 193], ["metabolomics", "TEST", 198, 210], ["protein levels", "TEST", 257, 271], ["breast", "ANATOMY", 85, 91], ["cancer", "OBSERVATION", 92, 98], ["gastrointestinal", "ANATOMY", 107, 123], ["tumors", "OBSERVATION", 124, 130], ["prostate", "ANATOMY", 141, 149], ["cancer", "OBSERVATION", 150, 156]]], ["Proteins are expected to be closer to phenotype, as they participate in every aspect of cellular biology, but their expression levels are difficult to quantitate, partly because of translational control in cells, possible degradation and sampling issues [105] [106] [107] .", [["cellular", "ANATOMY", 88, 96], ["cells", "ANATOMY", 206, 211], ["cellular", "CELL", 88, 96], ["cells", "CELL", 206, 211], ["translational control in cells", "PROBLEM", 181, 211], ["possible", "UNCERTAINTY", 213, 221]]], ["The development of electrospray ionization brought mass spectrometry (MS) to the field of proteomics and the possible identification of thousands of molecules based on mass [108] [109] [110] [111] [112] .", [["electrospray ionization", "TREATMENT", 19, 42], ["mass spectrometry", "PROBLEM", 51, 68], ["thousands of molecules", "PROBLEM", 136, 158], ["mass", "TEST", 168, 172]]], ["As the techniques matured, liquid chromatography tandem mass spectrometry (LC-MS/MS) has become standard, and novel instruments (e.g., Velos family [115] by Thermo Scientific; quadrupole time-of-flight mass spectrometers (QTOFs) by Agilent) allow unprecedented precision to enable the development of methods to QB Figure 2 .", [["the techniques", "TREATMENT", 3, 17], ["liquid chromatography tandem mass spectrometry", "TEST", 27, 73], ["LC", "TEST", 75, 77], ["MS", "PROBLEM", 81, 83]]], ["RNA-Seq analysis.", [["RNA", "TEST", 0, 3], ["Seq analysis", "TEST", 4, 16]]], ["In RNA-Seq analysis, short reads can be assembled and then mapped to the reference genome (with tools such as Illumina's ELAND, MAQ and BWA [222] , Bowtie [235] [236] [237] , SOAP [221] , and others).", [["reference genome", "DNA", 73, 89], ["Seq analysis", "TEST", 7, 19], ["Illumina's ELAND", "TEST", 110, 126], ["MAQ", "TEST", 128, 131], ["BWA", "TEST", 136, 139], ["Bowtie", "TEST", 148, 154], ["SOAP", "TEST", 175, 179]]], ["A recent protocol by Trapnell et al. [238] describes in detail the use of dedicated RNA-Seq programs from the Tuxedo suite, such as TopHat [239] , Cufflinks [240, 241] and an R implementation called CummeRBund as a Bioconductor package (an alternative is to run these directly or using GenePattern [242, 243] , which also includes possible reconstruction by Scripture [244] ).", [["A recent protocol", "TEST", 0, 17], ["a Bioconductor package", "TREATMENT", 213, 235]]], ["Other programs such as DESeq, another package in Bioconductor, can also help test for differential expression [245] .", [["DESeq", "DNA", 23, 28]]], ["The numerous analyses availabilities are now publically discussed online, in a forum (http://SEQanswers.com/) that discusses many other examples and all aspects of the mapping process [246] .Mass spectrometry, proteomics and metabolomicsidentify thousands of proteins (~4000-6000 over 2 days), and quantitate protein levels [73, 116] (Figure 3 ).", [["Mass spectrometry", "TEST", 191, 208], ["proteomics", "TEST", 210, 220], ["proteins", "TEST", 259, 267], ["protein levels", "TEST", 309, 323]]], ["One set of methods uses stable isotopic labeling by amino acids in cell culture (SILAC) to label cell in light and heavy isotopes of amino acids providing double spectral peaks in MS for identification and quantitation [117] [118] [119] [120] this method is now supplemented by 'spike-in'/'super' SILAC which has been used to measure biopsy tumor proteomes [121] .", [["cell", "ANATOMY", 67, 71], ["cell", "ANATOMY", 97, 101], ["biopsy tumor", "ANATOMY", 334, 346], ["amino acids", "CHEMICAL", 52, 63], ["amino acids", "CHEMICAL", 133, 144], ["tumor", "DISEASE", 341, 346], ["amino acids", "CHEMICAL", 52, 63], ["amino acids", "CHEMICAL", 133, 144], ["amino acids", "AMINO_ACID", 52, 63], ["cell", "CELL", 67, 71], ["cell", "CELL", 97, 101], ["amino acids", "AMINO_ACID", 133, 144], ["biopsy tumor", "CANCER", 334, 346], ["amino acids", "TEST", 52, 63], ["cell culture", "TEST", 67, 79], ["amino acids", "TEST", 133, 144], ["double spectral peaks", "PROBLEM", 155, 176], ["quantitation", "TEST", 206, 218], ["'/'super' SILAC", "TREATMENT", 287, 302], ["biopsy tumor proteomes", "TEST", 334, 356]]], ["Another possibility is to use isobaric tags for relative and absolute quantitation (iTRAQ) [122, 123] or tandem mass tag (TMT) labeling [73, 124, 125] , and other methods, including spiking in peptides for absolute quantitation.", [["isobaric tags", "TEST", 30, 43], ["absolute quantitation", "TEST", 61, 82], ["tandem mass tag", "TEST", 105, 120], ["other methods", "TEST", 157, 170], ["absolute quantitation", "TEST", 206, 227]]], ["Finally, it is possible to employ label-free methods for quantitation, which do not rely on tags, including integrating signal methods and MS spectral counting [126] [127] [128] [129] [130] [131] .Mass spectrometry, proteomics and metabolomicsIn comparison to whole transcriptome profiling, the numbers of proteins identified in proteome profiling tend to be less in comparison, particularly since low peptide levels cannot be amplified (cf. polymerase chain reaction methods for sequencing methods).", [["integrating signal methods", "TEST", 108, 134], ["MS spectral counting", "TEST", 139, 159], ["Mass spectrometry", "PROBLEM", 197, 214], ["proteomics", "TEST", 216, 226], ["metabolomics", "TEST", 231, 243], ["whole transcriptome profiling", "TEST", 260, 289], ["proteome profiling", "TEST", 329, 347], ["low peptide levels", "PROBLEM", 398, 416], ["polymerase chain reaction", "PROBLEM", 442, 467], ["sequencing methods", "TEST", 480, 498]]], ["Additionally, the current bottom-up (shotgun) proteomics methodology uses digestion with endopeptidases such as trypsin to obtain peptides of small enough mass to be identified by MS/MS, resulting in many fragments that cannot be identified in MS, which may possibly be alleviated by top down approaches that do not employ a digestion step [132] [133] [134] [135] [136] .", [["trypsin", "GENE_OR_GENE_PRODUCT", 112, 119], ["endopeptidases", "PROTEIN", 89, 103], ["trypsin", "PROTEIN", 112, 119], ["endopeptidases", "TREATMENT", 89, 103], ["trypsin", "TREATMENT", 112, 119], ["small enough mass", "PROBLEM", 142, 159], ["MS/MS", "PROBLEM", 180, 185], ["many fragments", "PROBLEM", 200, 214], ["small", "OBSERVATION_MODIFIER", 142, 147], ["mass", "OBSERVATION", 155, 159], ["many", "OBSERVATION_MODIFIER", 200, 204], ["fragments", "OBSERVATION", 205, 214], ["cannot be", "UNCERTAINTY", 220, 229], ["may possibly be", "UNCERTAINTY", 254, 269]]], ["However, proteomics provides insights that are missing from transcriptomic analysis, especially given the low correlations between protein and transcriptome differential gene expressions [73, [137] [138] [139] [140] [141] [142] .Mass spectrometry, proteomics and metabolomicsMultiple proteomes have been quantitatively profiled, including characterization of ovarian cancer [143] , an integrated approach that combines transcriptome and proteome information in a human cancer cell line by Nagaraj et al. [144] , integrative gastric cancer characterization and effects of post-translational modifications [145] , and looking for biomarkers in other cancers [146, 147] .Mass spectrometry, proteomics and metabolomicsIn addition to developments in proteomics, MS has encouraged the study of small molecules.", [["ovarian cancer", "ANATOMY", 359, 373], ["cancer cell line", "ANATOMY", 469, 485], ["gastric cancer", "ANATOMY", 524, 538], ["cancers", "ANATOMY", 648, 655], ["ovarian cancer", "DISEASE", 359, 373], ["cancer", "DISEASE", 469, 475], ["gastric cancer", "DISEASE", 524, 538], ["cancers", "DISEASE", 648, 655], ["ovarian cancer", "CANCER", 359, 373], ["human", "ORGANISM", 463, 468], ["cancer cell line", "CELL", 469, 485], ["gastric cancer", "CANCER", 524, 538], ["cancers", "CANCER", 648, 655], ["human cancer cell line", "CELL_LINE", 463, 485], ["human", "SPECIES", 463, 468], ["human", "SPECIES", 463, 468], ["transcriptomic analysis", "TEST", 60, 83], ["the low correlations between protein and transcriptome differential gene expressions", "PROBLEM", 102, 186], ["Mass spectrometry", "TEST", 229, 246], ["proteomics", "TEST", 248, 258], ["ovarian cancer", "PROBLEM", 359, 373], ["a human cancer cell line", "TREATMENT", 461, 485], ["integrative gastric cancer characterization", "TREATMENT", 512, 555], ["post-translational modifications", "TREATMENT", 571, 603], ["other cancers", "PROBLEM", 642, 655], ["Mass spectrometry", "PROBLEM", 668, 685], ["proteomics", "TEST", 687, 697], ["metabolomics", "TEST", 702, 714], ["the study", "TEST", 775, 784], ["small molecules", "PROBLEM", 788, 803], ["ovarian", "ANATOMY", 359, 366], ["cancer", "OBSERVATION", 367, 373], ["cancer cell line", "OBSERVATION", 469, 485], ["gastric", "ANATOMY", 524, 531], ["cancer", "OBSERVATION", 532, 538], ["cancers", "OBSERVATION", 648, 655]]], ["The behavior of small molecules in cells though difficult to track provides insight into many common disorders.", [["cells", "ANATOMY", 35, 40], ["cells", "CELL", 35, 40], ["small molecules in cells", "PROBLEM", 16, 40], ["many common disorders", "PROBLEM", 89, 110], ["small", "OBSERVATION_MODIFIER", 16, 21], ["molecules", "OBSERVATION", 22, 31]]], ["The set of all cellular small molecules is collectively called the metabolome.", [["cellular", "ANATOMY", 15, 23], ["cellular", "CELL", 15, 23], ["cellular small molecules", "PROTEIN", 15, 39], ["all", "OBSERVATION_MODIFIER", 11, 14], ["cellular", "OBSERVATION_MODIFIER", 15, 23], ["small molecules", "OBSERVATION", 24, 39]]], ["Metabolic processes are vital in biological pathways and a systems analysis of molecular cell complexity might lead to biomarker discovery, and possibly disease risk assessment, diagnosis and treatment [148] .", [["cell", "ANATOMY", 89, 93], ["cell", "CELL", 89, 93], ["Metabolic processes", "PROBLEM", 0, 19], ["a systems analysis", "TEST", 57, 75], ["molecular cell complexity", "PROBLEM", 79, 104], ["disease risk assessment", "TEST", 153, 176], ["treatment", "TREATMENT", 192, 201], ["molecular cell", "OBSERVATION", 79, 93], ["possibly", "UNCERTAINTY", 144, 152]]], ["Similar to proteomics, metabolomics can employ mass spectrometry to identify compounds [149] In quantitative proteomics using mass spectrometry typical approaches employ trypsin digestion coupled with tagging methodsnon label-free methods include use of isotopic labeling (SILAC) or isobaric tagging (iTRAQ, TMT).", [["trypsin", "GENE_OR_GENE_PRODUCT", 170, 177], ["trypsin", "PROTEIN", 170, 177], ["mass spectrometry", "TEST", 47, 64], ["mass spectrometry", "PROBLEM", 126, 143], ["trypsin digestion", "PROBLEM", 170, 187], ["isotopic labeling (SILAC)", "TREATMENT", 254, 279], ["isobaric tagging", "TREATMENT", 283, 299]]], ["One typical bottom-up-approach setup uses a combination of high affinity liquid chromatography coupled with two rounds of mass spectrometry (LC-MS/MS) to fractionate peptides for identification and obtain their mass spectra.", [["approach setup", "TREATMENT", 22, 36], ["high affinity liquid chromatography", "TREATMENT", 59, 94], ["mass spectrometry", "TEST", 122, 139], ["MS", "PROBLEM", 147, 149], ["fractionate peptides", "TREATMENT", 154, 174], ["identification", "TEST", 179, 193], ["their mass spectra", "PROBLEM", 205, 223], ["bottom", "OBSERVATION_MODIFIER", 12, 18], ["mass", "OBSERVATION", 211, 215]]], ["The mass spectra can be mapped to known protein using a protein library, or less frequently de novo assembled, using an array of programs (e.g., X!Tandem [251] , SEQUEST [252] , Mascot [253] , Open Mass Spectrometry Search Algorithm (OMSSA) [254] , Proteome Discoverer by Thermo Scientific, or MassHunter Workstation by Agilent).", [["The mass spectra", "PROBLEM", 0, 16], ["a protein library", "TEST", 54, 71], ["Open Mass Spectrometry", "TEST", 193, 215], ["mass", "OBSERVATION", 4, 8]]], ["Quantitation can be carried out to estimate relative levels of proteins in different samples (employing standardization and normalization of average sample ratios to a unit mean).", [["samples", "ANATOMY", 85, 92], ["Quantitation", "TEST", 0, 12], ["proteins in different samples", "PROBLEM", 63, 92]]], ["Some of the analysis can be performed using suites and programs, such as PEAKS [257] , the Trans-Proteomic Pipeline (TPP) [258] [259] [260] [261] , multiple tools from ProteoWizard [250] , OpenMS [262] [263] [264] or vendor complete solutions Proteome Discoverer and MassHunter Workstation mentioned above.", [["the analysis", "TEST", 8, 20], ["ProteoWizard", "TEST", 168, 180]]], ["Multiple other programs for mass spectrometry are available (e.g., see http://www.msutils.org).", [["mass spectrometry", "PROBLEM", 28, 45]]], ["4) and cataloguing is under way, with thousands of metabolites identified by structure, mass and occasionally associated biological processes [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] .", [["[152] [153] [154] [155] [156] [157] [158] [159] [160] [161]", "SIMPLE_CHEMICAL", 154, 213], ["mass", "PROBLEM", 88, 92], ["occasionally associated biological processes", "PROBLEM", 97, 141], ["mass", "OBSERVATION", 88, 92]]], ["The identification of compounds can be based on MS/MS application and use of known compound spectra, or via use of standards against which mass spectra are compared.", [["MS/MS application", "TREATMENT", 48, 65], ["mass spectra", "PROBLEM", 139, 151], ["mass", "OBSERVATION", 139, 143]]], ["The profiling of metabolic components on an individualized basis can provide insights into pharmacogenomics and personalized medications, in addition to potential biomarkers, for example cholesterol levels and coronary artery [162, 163] .", [["coronary artery", "ANATOMY", 210, 225], ["cholesterol", "CHEMICAL", 187, 198], ["cholesterol", "CHEMICAL", 187, 198], ["cholesterol", "SIMPLE_CHEMICAL", 187, 198], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 210, 225], ["personalized medications", "TREATMENT", 112, 136], ["potential biomarkers", "TEST", 153, 173], ["example cholesterol levels", "TEST", 179, 205], ["metabolic components", "OBSERVATION", 17, 37], ["coronary artery", "ANATOMY", 210, 225]]], ["The metabolomics of cancer has been extensively studied [164] [165] [166] and Type 2 Diabetes has been investigated [167] , and in vivo interactions with proteins are being evaluated [168] .Other omicsGenomes, transcriptomes and metabolomes have received widespread attention and currently offer the most quantitative data, provided by robust and comprehensive omics technologies, both in terms of experimental, as well as computational methodology.", [["cancer", "ANATOMY", 20, 26], ["cancer", "DISEASE", 20, 26], ["Diabetes", "DISEASE", 85, 93], ["cancer", "CANCER", 20, 26], ["cancer", "PROBLEM", 20, 26], ["Type 2 Diabetes", "PROBLEM", 78, 93], ["cancer", "OBSERVATION", 20, 26]]], ["However multiple other omics are available, and these numbers are increasing, with a few notable technologies mentioned below:Other omicsAutoantibodyomes: In addition to profiling of proteins directly, the reactivity of proteins to autoantibodies may be profiled on a large scale.", [["autoantibodies", "PROTEIN", 232, 246], ["profiling of proteins", "PROBLEM", 170, 191], ["autoantibodies", "PROBLEM", 232, 246], ["a large scale", "TREATMENT", 266, 279], ["increasing", "OBSERVATION_MODIFIER", 66, 76]]], ["Spotted protein arrays [169] [170] [171] [172] [173] have been implemented to study for example effects in cancer [174] , immune response [175] and recently diabetes [176] .", [["cancer", "ANATOMY", 107, 113], ["cancer", "DISEASE", 107, 113], ["diabetes", "DISEASE", 157, 165], ["cancer", "CANCER", 107, 113], ["Spotted protein arrays", "TEST", 0, 22], ["example effects in cancer", "PROBLEM", 88, 113], ["immune response", "PROBLEM", 122, 137], ["recently diabetes", "PROBLEM", 148, 165]]], ["Another approach is the Nucleic Acid Programmable Protein Array (NAPPA) constructed by spotting plasmid DNA to effectively express and code the proteins on the array and used for immunoprofiling [177, 178] .", [["plasmid", "ANATOMY", 96, 103], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["NAPPA", "PROTEIN", 65, 70], ["spotting plasmid DNA", "DNA", 87, 107], ["the Nucleic Acid Programmable Protein Array (NAPPA)", "TREATMENT", 20, 71], ["spotting plasmid DNA", "TREATMENT", 87, 107]]], ["Furthermore functional peptide arrays have also been constructed [179, 180] .", [["functional peptide arrays", "TEST", 12, 37]]], ["Complementary technologies such as bead-based immunoassays are also being actively developed, such as the Luminex xMAP assay [181] .Other omicsMicrobiomes: Omics profiling could also include mapping of the personal microbiome, the complete set of microbes in an individual (e.g., found mainly on the skin or in the gut, conjunctiva, saliva and mucosa) using possibly a combined omics approach to look at genetic makeup and metabolic components [182] [183] [184] [185] [186] [187] .", [["skin", "ANATOMY", 300, 304], ["gut", "ANATOMY", 315, 318], ["conjunctiva", "ANATOMY", 320, 331], ["saliva", "ANATOMY", 333, 339], ["mucosa", "ANATOMY", 344, 350], ["skin", "ORGAN", 300, 304], ["gut", "ORGANISM_SUBDIVISION", 315, 318], ["conjunctiva", "MULTI-TISSUE_STRUCTURE", 320, 331], ["saliva", "ORGANISM_SUBSTANCE", 333, 339], ["mucosa", "MULTI-TISSUE_STRUCTURE", 344, 350], ["Complementary technologies", "TREATMENT", 0, 26], ["bead-based immunoassays", "TEST", 35, 58], ["the Luminex xMAP assay", "TEST", 102, 124], ["Omics profiling", "TEST", 156, 171], ["a combined omics approach", "TREATMENT", 367, 392], ["metabolic components", "TEST", 423, 443], ["microbes", "OBSERVATION", 247, 255], ["skin", "ANATOMY", 300, 304], ["gut", "ANATOMY", 315, 318], ["conjunctiva", "ANATOMY", 320, 331], ["mucosa", "ANATOMY", 344, 350]]], ["The human microbiota (http://www.human-microbiome.org) have been associated to obesity [188] and diabetes [189, 190] and have also been suspected to play an active role in the development of immunity [191] .", [["obesity", "DISEASE", 79, 86], ["diabetes", "DISEASE", 97, 105], ["human", "ORGANISM", 4, 9], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["obesity", "PROBLEM", 79, 86], ["diabetes", "PROBLEM", 97, 105], ["obesity", "OBSERVATION", 79, 86], ["active", "OBSERVATION_MODIFIER", 157, 163]]], ["The dynamic monitoring of microbiome-related changes can help identify the specific microbiota involved in disease responses, elucidate microbiome-host interactions and how the individual variability in components impacts developmental and metabolic processes.Other omicsMethylomes: In addition to genomics, epigenomic information, such probing the methylome, i.e., identifying all genomic sites of cytosine methylation [192, 193] , might provide information about differentiation and regulation of gene expression.", [["cytosine", "CHEMICAL", 399, 407], ["cytosine", "CHEMICAL", 399, 407], ["cytosine", "SIMPLE_CHEMICAL", 399, 407], ["genomic sites", "DNA", 382, 395], ["disease responses", "PROBLEM", 107, 124], ["cytosine methylation", "TREATMENT", 399, 419], ["metabolic processes", "OBSERVATION", 240, 259]]], ["Methylation analysis and data interpretation can be challenging [194, 195] but methods are improving as more data becomes available.", [["Methylation analysis", "TEST", 0, 20], ["data interpretation", "TEST", 25, 44]]], ["Methylome analysis has now been carried out in blood components [196] , stem cells [197] and ovarian cancer [61] , and it might prove invaluable in assessing epigenomic effects on individual development and In metabolomics analysis chromatography columns are used for purification and preparation of samples coupled to mass spectrometry (gas chromatography (GC) or liquid chromatography (LC)-MS); standards for specific compounds may also be used in parallel for positive identification.", [["blood", "ANATOMY", 47, 52], ["stem cells", "ANATOMY", 72, 82], ["ovarian cancer", "ANATOMY", 93, 107], ["ovarian cancer", "DISEASE", 93, 107], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["stem cells", "CELL", 72, 82], ["ovarian cancer", "CANCER", 93, 107], ["stem cells", "CELL_TYPE", 72, 82], ["Methylome analysis", "TEST", 0, 18], ["blood components", "TEST", 47, 63], ["stem cells", "TEST", 72, 82], ["ovarian cancer", "PROBLEM", 93, 107], ["metabolomics analysis chromatography columns", "TEST", 210, 254], ["purification", "TREATMENT", 268, 280], ["samples", "TEST", 300, 307], ["mass spectrometry", "TEST", 319, 336], ["gas chromatography", "TEST", 338, 356], ["liquid chromatography", "TEST", 365, 386], ["specific compounds", "TREATMENT", 411, 429], ["ovarian", "ANATOMY", 93, 100], ["cancer", "OBSERVATION", 101, 107]]], ["The spectral data may be aligned for retention time and mass intensity calibration, e.g., using XCMS [265] [266] [267] , SIEVE by Thermo Scientific, Matlab toolboxes by MathWorks, MassHunterProfiler by Agilent, MzMine [268, 269] .", [["The spectral data", "TEST", 0, 17], ["mass intensity calibration", "TEST", 56, 82]]], ["After quality control and statistical analysis, masses of interest can be annotated using databases, e.g., Metlin [155, 156] , KEGG [151] , MetaCyc [153, 270, 271] , Reactome [157] [158] [159] [160] [161] .Other omicshealth.PERSONALIZED MEDICINEThe developments of the many different omics technologies outlined above have given us tremendous insight into the human genome and associations to diseases, especially with the rise of the personal genome.", [["human", "ORGANISM", 360, 365], ["human genome", "DNA", 360, 372], ["personal genome", "DNA", 435, 450], ["human", "SPECIES", 360, 365], ["human", "SPECIES", 360, 365], ["statistical analysis", "TEST", 26, 46], ["masses", "PROBLEM", 48, 54], ["KEGG", "TEST", 127, 131], ["MetaCyc", "TEST", 140, 147], ["Reactome", "TEST", 166, 174], ["diseases", "PROBLEM", 393, 401], ["diseases", "OBSERVATION", 393, 401]]], ["The NHGRI recognizing the importance of these developments and the directions necessary to enhance health care, outlined in 2011 a vision for the future of personalized medicine [198] encompassing five domains of development that included understanding the structure of genomes, their biology, improving our understanding of the biology of disease, advancing medicine and improving the effectiveness of healthcare.", [["personalized medicine", "TREATMENT", 156, 177], ["disease", "PROBLEM", 340, 347], ["advancing medicine", "TREATMENT", 349, 367]]], ["The aims had been set to a shift towards personalized medicine within two decades, but the availability of the technology and constant decreasing costs have made pilot investigations of personalized medicine a current possibility [73] .", [["pilot investigations", "TEST", 162, 182], ["personalized medicine", "TREATMENT", 186, 207]]], ["Genetic variation has proven adequate for understanding group differences in disorders, but a truly personalized implementation needs to consider an individual.", [["Genetic variation", "PROBLEM", 0, 17], ["understanding group differences in disorders", "PROBLEM", 42, 86]]], ["Clinicians are already considering molecular markers in their evaluation of patients, and particularly cancer [199] [200] [201] [202] [203] .", [["cancer", "ANATOMY", 103, 109], ["cancer", "DISEASE", 103, 109], ["patients", "ORGANISM", 76, 84], ["cancer", "CANCER", 103, 109], ["patients", "SPECIES", 76, 84], ["their evaluation", "TEST", 56, 72]]], ["The typical clinical diagnosis involves the observation of symptoms traditionally confirmed utilizing a small set of molecular markers.", [["molecular markers", "PROTEIN", 117, 134], ["symptoms", "PROBLEM", 59, 67]]], ["In diseases that share a common set of symptoms, some rare, such diagnosis is often complicated and prolonged, especially for heterogeneous disorders that need additional information to enable classification and subsequent specific treatments.", [["symptoms", "PROBLEM", 39, 47], ["heterogeneous disorders", "PROBLEM", 126, 149], ["subsequent specific treatments", "TREATMENT", 212, 242], ["diseases", "OBSERVATION", 3, 11]]], ["Genetic and environmental factors create additional variability in disease severity, progression and treatment responses.", [["Genetic and environmental factors", "PROBLEM", 0, 33], ["disease severity", "PROBLEM", 67, 83]]], ["Thus, traditional assays together with the aforementioned current omics technologies, that allow monitoring of thousands of molecular components, will facilitate and accelerate differential diagnostics and sub-classification through utilizing a more complete set of disease markers.", [["disease markers", "PROTEIN", 266, 281], ["traditional assays", "TEST", 6, 24], ["differential diagnostics", "TEST", 177, 201], ["disease markers", "TEST", 266, 281]]], ["A personalized approach will result in better targeting of diseases, introduce higher precision through measurement of larger sets of molecular components and ideally implemented at an early age to assess disease risk and have a preventative rather than retrospective treatment focus.PERSONALIZED MEDICINEA personal approach is by its nature an n = 1 study, which helps eliminate variation between individuals that are treated as a group, but still requires some verification and establishment of a baseline for comparison.", [["A personalized approach", "TREATMENT", 0, 23], ["diseases", "PROBLEM", 59, 67], ["disease risk", "PROBLEM", 205, 217], ["retrospective treatment focus", "TREATMENT", 254, 283], ["an n = 1 study", "TEST", 342, 356], ["diseases", "OBSERVATION", 59, 67], ["larger", "OBSERVATION_MODIFIER", 119, 125]]], ["As such, the profiling of healthy physiological states in a longitudinal approach may provide such a basis, if multiple time points with similar physiological state makeup are sampled.", [["a longitudinal approach", "TREATMENT", 58, 81]]], ["Multiple omics can supply multiple supporting datasets at each time point, with each complementary technology providing additional supporting information for a baseline establishment.", [["multiple", "OBSERVATION_MODIFIER", 26, 34]]], ["This introduces the concept of complete omics monitoring of individuals over time, making personalized medicine a more dynamic proposition.", [["personalized medicine", "TREATMENT", 90, 111]]], ["The dynamic changes of molecular components may be associated to the individual's changing physiological states, and mapped onto pathways to identify the onset and progression of disease, including possible preventive measures.", [["disease", "PROBLEM", 179, 186], ["preventive measures", "TREATMENT", 207, 226], ["dynamic", "OBSERVATION_MODIFIER", 4, 11], ["molecular components", "OBSERVATION", 23, 43], ["may be associated to", "UNCERTAINTY", 44, 64], ["progression", "OBSERVATION_MODIFIER", 164, 175], ["disease", "OBSERVATION", 179, 186]]], ["In our suggested implementation, termed integrative Personal Omics Profiling (iPOP) which we followed in the study discussed below [73] we integrate the omics components discussed above in a longitudinal approach with three essential steps ( Figure 5 ): I) Risk estimation: As discussed above the personal and common genomic variants determined in an individual genome can be associated to disease [76] , with pharmacogenomic evaluation to determine possible drug response.", [["the study", "TEST", 105, 114], ["the personal and common genomic variants", "PROBLEM", 293, 333], ["pharmacogenomic evaluation", "TEST", 410, 436], ["drug response", "PROBLEM", 459, 472]]], ["An early age whole genome sequencing, possibly at birth, can provide a list of possible increased risk disorders and lead to taking preventive measures.", [["increased risk disorders", "PROBLEM", 88, 112], ["preventive measures", "TREATMENT", 132, 151]]], ["This may be done in combination with a complete medical and family history, as for example implemented in the PGP project, and in conjunction with classical clinical risk factor profiling.PERSONALIZED MEDICINEII) Dynamic profiling of multiple omics: Starting with a healthy or 'steady state' baseline, by monitoring changes in the molecular components over multiple time points, drastic or gradual changes in physiological states might be assessed and the dynamic onset of disease profiled, and possibly prevented.", [["drastic or gradual changes in physiological states", "PROBLEM", 379, 429], ["disease", "PROBLEM", 473, 480], ["drastic", "OBSERVATION_MODIFIER", 379, 386], ["gradual", "OBSERVATION_MODIFIER", 390, 397], ["disease", "OBSERVATION", 473, 480], ["possibly prevented", "UNCERTAINTY", 495, 513]]], ["Such profiling may be done on blood components, which are easily obtainable currently in the clinic.", [["blood", "ANATOMY", 30, 35], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["blood components", "TEST", 30, 46], ["may be", "UNCERTAINTY", 15, 21]]], ["The individual blood components are excellent reflectors of generalized physiological state of an individual, as the blood circulates and receives inputs from multiple tissues throughout the body.", [["blood", "ANATOMY", 15, 20], ["blood", "ANATOMY", 117, 122], ["tissues", "ANATOMY", 168, 175], ["body", "ANATOMY", 191, 195], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["tissues", "TISSUE", 168, 175], ["body", "ORGANISM_SUBDIVISION", 191, 195], ["generalized physiological state", "PROBLEM", 60, 91], ["the blood circulates", "TEST", 113, 133], ["excellent", "OBSERVATION_MODIFIER", 36, 45], ["reflectors", "OBSERVATION_MODIFIER", 46, 56], ["generalized", "OBSERVATION_MODIFIER", 60, 71], ["physiological state", "OBSERVATION", 72, 91], ["multiple tissues", "OBSERVATION", 159, 175], ["body", "ANATOMY", 191, 195]]], ["The components may be processed to track multiple omics, such as transcriptome, proteome, metabolome and autoantibodyome, etc., which as mentioned offer complementary information, especially given the modest correlation observed between transcriptomic and proteomic components [137] [138] [139] [140] [141] [142] .", [["may be", "UNCERTAINTY", 15, 21]]], ["A recent study of profiles of tumors changing over time also employed an integrative approach on genomic and transcriptomic components [204] .", [["tumors", "ANATOMY", 30, 36], ["tumors", "DISEASE", 30, 36], ["tumors", "CANCER", 30, 36], ["A recent study", "TEST", 0, 14], ["tumors", "PROBLEM", 30, 36], ["genomic and transcriptomic components", "TREATMENT", 97, 134], ["tumors", "OBSERVATION", 30, 36]]], ["Implementing this monitoring on healthy individuals will allow the monitoring of disease onset and physiological changes from various healthy, disease and recovery states, and following thousands of molecular component levels and responses at corresponding physiological states.PERSONALIZED MEDICINEIII) Data integration and biological impact assessment: The multiple omics data can be analyzed individually to characterize their temporal response profile.", [["this monitoring", "TEST", 13, 28], ["disease onset", "PROBLEM", 81, 94], ["physiological changes", "PROBLEM", 99, 120], ["disease", "PROBLEM", 143, 150], ["The multiple omics data", "TEST", 355, 378]]], ["This may be done using standard statistical time-series analysis, extensively used in all quantitative disciplines, such as physics, economics and finance, as discussed by Bar-Joseph et al. [205] .", [["series analysis", "TEST", 49, 64]]], ["The dynamic signature of the signals for each molecular component can be studied for autocorrelation, periodicity or spikey behavior, corre-QB Figure 5 . iPOP for personalized medicine.", [["iPOP", "CHEMICAL", 154, 158], ["iPOP", "SIMPLE_CHEMICAL", 154, 158], ["personalized medicine", "TREATMENT", 163, 184]]], ["The framework described in the text employs multi-omics analyses (see above and Figures 1-4) that may be implemented for individuals.", [["multi-omics analyses", "TEST", 44, 64]]], ["In step I) Risk estimation for disease is carried out using a whole genome sequencing to perform variant analysis coupled to medical history, environmental considerations and pharmacogenomics evaluations.", [["disease", "PROBLEM", 31, 38], ["a whole genome sequencing", "TREATMENT", 60, 85], ["variant analysis", "TEST", 97, 113], ["pharmacogenomics evaluations", "TEST", 175, 203]]], ["Thus thousands of molecular components are collected over time for III) Data integration and biological impact assessment, using temporal patterns to obtain matched omics information, correlate and classify responses, compare against pathway databases and visualize components, e.g., current pathway tools include DAVID [206, 272] , KEGG [151] , Reactome [157] [158] [159] [160] [161] , Ingenuity Pathway Analysis (IPA); networks can be visualized using Cytoscape [207] , various R packages through Bioconductor [234] , Matlab by MathWorks and several others.", [["molecular components", "PROBLEM", 18, 38], ["biological impact assessment", "TEST", 93, 121], ["KEGG", "TEST", 333, 337], ["Reactome", "TEST", 346, 354], ["Ingenuity Pathway Analysis", "TEST", 387, 413], ["Cytoscape", "TEST", 454, 463]]], ["The future iPOP implementations may be gathered into a curated database of iPOP-disease associations that may help in categorizing an omics dynamic response to a catalogued physiological state and disease onset, with potential diagnostic capabilities. sponding to causal changes or abnormal physiological state conditions resulting from the onset of disease, infections, or environmental effects.", [["infections", "DISEASE", 359, 369], ["iPOP", "GENE_OR_GENE_PRODUCT", 75, 79], ["disease associations", "PROBLEM", 80, 100], ["causal changes", "PROBLEM", 264, 278], ["abnormal physiological state conditions", "PROBLEM", 282, 321], ["disease", "PROBLEM", 350, 357], ["infections", "PROBLEM", 359, 369], ["environmental effects", "PROBLEM", 374, 395], ["disease", "OBSERVATION", 350, 357], ["infections", "OBSERVATION", 359, 369]]], ["The different classes of temporal response can be checked for biological pathway and gene ontology enrichment [151, [157] [158] [159] [160] [161] [206] [207] [208] [209] [210] , and corresponding disease associations in comparison to a database of other longitudinal profiles (coupled to complete electronic records of omic and medical histories).", [["gene ontology enrichment", "TEST", 85, 109], ["corresponding disease associations", "PROBLEM", 182, 216], ["disease", "OBSERVATION", 196, 203]]], ["Such a database is a necessary and powerful resource towards the realization of personalized medicine based on omics data profiling.Example implementation of personalized medicine: iPOPTo show the feasibility and practical applicability of iPOP we profiled a healthy individual, 54, over a period of initially 14 (now 33) months [73] .", [["iPOPTo", "SIMPLE_CHEMICAL", 181, 187], ["iPOP", "SIMPLE_CHEMICAL", 240, 244], ["personalized medicine", "TREATMENT", 80, 101], ["omics data profiling", "TEST", 111, 131]]], ["This initial time series covered healthy states, and two viral states, including a human rhinovirus (HRV) infection at the initiation of the study and a respiratory syncytial virus (RSV) infection 289 days later.", [["human rhinovirus (HRV) infection", "DISEASE", 83, 115], ["respiratory syncytial virus (RSV) infection", "DISEASE", 153, 196], ["human", "ORGANISM", 83, 88], ["rhinovirus", "ORGANISM", 89, 99], ["respiratory syncytial virus", "ORGANISM", 153, 180], ["RSV", "ORGANISM", 182, 185], ["human", "SPECIES", 83, 88], ["rhinovirus", "SPECIES", 89, 99], ["respiratory syncytial virus", "SPECIES", 153, 180], ["human rhinovirus", "SPECIES", 83, 99], ["HRV", "SPECIES", 101, 104], ["respiratory syncytial virus", "SPECIES", 153, 180], ["RSV", "SPECIES", 182, 185], ["two viral states", "PROBLEM", 53, 69], ["a human rhinovirus (HRV) infection", "PROBLEM", 81, 115], ["the study", "TEST", 137, 146], ["a respiratory syncytial virus (RSV) infection", "PROBLEM", 151, 196], ["infection", "OBSERVATION", 106, 115], ["respiratory", "ANATOMY", 153, 164], ["syncytial virus", "OBSERVATION", 165, 180]]], ["The iPOP used blood samples to extract omic components from peripheral blood mononuclear cells (PBMCs) and serum, which were analyzed to obtain a complete DNA, RNA, protein, metabolite and autoantibody profile.", [["blood samples", "ANATOMY", 14, 27], ["peripheral blood mononuclear cells", "ANATOMY", 60, 94], ["PBMCs", "ANATOMY", 96, 101], ["serum", "ANATOMY", 107, 112], ["iPOP", "SIMPLE_CHEMICAL", 4, 8], ["blood samples", "ORGANISM_SUBSTANCE", 14, 27], ["peripheral blood mononuclear cells", "CELL", 60, 94], ["PBMCs", "CELL", 96, 101], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["DNA", "CELLULAR_COMPONENT", 155, 158], ["iPOP", "PROTEIN", 4, 8], ["peripheral blood mononuclear cells", "CELL_TYPE", 60, 94], ["PBMCs", "CELL_TYPE", 96, 101], ["blood samples", "TEST", 14, 27], ["peripheral blood mononuclear cells", "TEST", 60, 94], ["PBMCs", "TEST", 96, 101], ["serum", "TEST", 107, 112], ["a complete DNA", "TEST", 144, 158], ["RNA", "TEST", 160, 163], ["protein", "TEST", 165, 172], ["autoantibody profile", "TEST", 189, 209], ["peripheral", "ANATOMY_MODIFIER", 60, 70], ["blood", "ANATOMY", 71, 76], ["mononuclear cells", "OBSERVATION", 77, 94]]], ["Initially a complete medical exam was performed with standard clinical tests before time-point profiling began.", [["a complete medical exam", "TEST", 10, 33], ["standard clinical tests", "TEST", 53, 76]]], ["In a first step, WGS with two platforms was carried out (Complete Genomics and Illumina, at 150-and 120-fold coverage respectively) and WES with three platforms (Nimblegen, Illumina and Agilent) and helped identify a large number of variants (> 3\u00c210 6 SNPs; > 2\u00c210 5 indels; > 2000 SVs).", [["WGS", "TEST", 17, 20], ["two platforms", "TEST", 26, 39], ["Illumina", "TEST", 79, 87], ["Illumina and Agilent)", "TREATMENT", 173, 194], ["SNPs", "TEST", 252, 256], ["large", "OBSERVATION_MODIFIER", 217, 222]]], ["Evaluation of genetic disease risks based on variants was carried out, both by looking for known disease associations using dbSNP and the Online Mendelian Inheritance in Man (OMIM, http://omim.org/) database and using the RiskO-Gram algorithm [76] which integrates information from multiple alleles to assess risk against a similarly matched data cohort.", [["Evaluation", "TEST", 0, 10], ["genetic disease risks", "PROBLEM", 14, 35], ["variants", "PROBLEM", 45, 53], ["known disease associations", "PROBLEM", 91, 117]]], ["This revealed significantly increased risk for various disorders, including open angle glaucoma, dyslipidemia, coronary artery disease, basal cell carcinoma, type 2 diabetes (T2D), age related macular degeneration and psoriasis.", [["coronary artery", "ANATOMY", 111, 126], ["basal cell carcinoma", "ANATOMY", 136, 156], ["macular", "ANATOMY", 193, 200], ["open angle glaucoma", "DISEASE", 76, 95], ["dyslipidemia", "DISEASE", 97, 109], ["coronary artery disease", "DISEASE", 111, 134], ["basal cell carcinoma", "DISEASE", 136, 156], ["type 2 diabetes", "DISEASE", 158, 173], ["T2D", "DISEASE", 175, 178], ["macular degeneration", "DISEASE", 193, 213], ["psoriasis", "DISEASE", 218, 227], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 111, 126], ["basal cell carcinoma", "CANCER", 136, 156], ["macular", "TISSUE", 193, 200], ["various disorders", "PROBLEM", 47, 64], ["open angle glaucoma", "PROBLEM", 76, 95], ["dyslipidemia", "PROBLEM", 97, 109], ["coronary artery disease", "PROBLEM", 111, 134], ["basal cell carcinoma", "PROBLEM", 136, 156], ["type 2 diabetes (T2D)", "PROBLEM", 158, 179], ["macular degeneration", "PROBLEM", 193, 213], ["psoriasis", "PROBLEM", 218, 227], ["significantly", "OBSERVATION_MODIFIER", 14, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["various disorders", "OBSERVATION", 47, 64], ["angle glaucoma", "OBSERVATION", 81, 95], ["dyslipidemia", "OBSERVATION", 97, 109], ["coronary artery", "ANATOMY", 111, 126], ["basal cell carcinoma", "OBSERVATION", 136, 156], ["diabetes", "OBSERVATION", 165, 173], ["macular degeneration", "OBSERVATION", 193, 213], ["psoriasis", "OBSERVATION", 218, 227]]], ["This encouraged the subject to follow up on these disorders, and also start monitoring glucose and glycated hemoglobin (HbA1c) levels, which surprisingly increased beyond normal levels following the RSV infection, and the subject was diagnosed by his physician for T2D 369 days into the study.", [["glucose", "CHEMICAL", 87, 94], ["RSV infection", "DISEASE", 199, 212], ["T2D", "DISEASE", 265, 268], ["glucose", "CHEMICAL", 87, 94], ["glucose", "SIMPLE_CHEMICAL", 87, 94], ["glycated hemoglobin", "GENE_OR_GENE_PRODUCT", 99, 118], ["HbA1c", "GENE_OR_GENE_PRODUCT", 120, 125], ["RSV", "ORGANISM", 199, 202], ["glycated hemoglobin", "PROTEIN", 99, 118], ["HbA1c", "PROTEIN", 120, 125], ["RSV", "SPECIES", 199, 202], ["these disorders", "PROBLEM", 44, 59], ["monitoring glucose", "TEST", 76, 94], ["glycated hemoglobin", "TEST", 99, 118], ["HbA1c) levels", "TEST", 120, 133], ["the RSV infection", "PROBLEM", 195, 212], ["the study", "TEST", 283, 292], ["increased", "OBSERVATION_MODIFIER", 154, 163], ["RSV", "ANATOMY", 199, 202], ["infection", "OBSERVATION", 203, 212]]], ["Related to T2D, pharmacogenomic considerations revealed a possibly favorable (glucose lowering) response to diabetic drugs rosiglitazone and metformin, should treatment become necessary.", [["T2D", "DISEASE", 11, 14], ["glucose", "CHEMICAL", 78, 85], ["diabetic", "DISEASE", 108, 116], ["rosiglitazone", "CHEMICAL", 123, 136], ["metformin", "CHEMICAL", 141, 150], ["glucose", "CHEMICAL", 78, 85], ["rosiglitazone", "CHEMICAL", 123, 136], ["metformin", "CHEMICAL", 141, 150], ["glucose", "SIMPLE_CHEMICAL", 78, 85], ["rosiglitazone", "SIMPLE_CHEMICAL", 123, 136], ["metformin", "SIMPLE_CHEMICAL", 141, 150], ["T2D", "PROBLEM", 11, 14], ["favorable (glucose lowering)", "PROBLEM", 67, 95], ["diabetic drugs rosiglitazone", "TREATMENT", 108, 136], ["metformin", "TREATMENT", 141, 150], ["treatment", "TREATMENT", 159, 168], ["T2D", "OBSERVATION", 11, 14], ["possibly", "UNCERTAINTY", 58, 66], ["favorable", "OBSERVATION_MODIFIER", 67, 76]]], ["Furthermore, the autoantibodyome profiling of the subject (Invitrogen ProtoArrays profiling of 9483 protein reactivities to Immunoglobulin G (IgG)) revealed increased reactivity in multiple proteins, including DOK6 (related to insulin receptors), and GOSR1, BTK and ASPA, previously reported to show high reactivity by Winer et al. in insulin resistant patients [176] .", [["Immunoglobulin G", "GENE_OR_GENE_PRODUCT", 124, 140], ["IgG", "GENE_OR_GENE_PRODUCT", 142, 145], ["DOK6", "GENE_OR_GENE_PRODUCT", 210, 214], ["insulin", "GENE_OR_GENE_PRODUCT", 227, 234], ["GOSR1", "GENE_OR_GENE_PRODUCT", 251, 256], ["BTK", "GENE_OR_GENE_PRODUCT", 258, 261], ["ASPA", "GENE_OR_GENE_PRODUCT", 266, 270], ["insulin", "GENE_OR_GENE_PRODUCT", 335, 342], ["patients", "ORGANISM", 353, 361], ["Immunoglobulin G", "PROTEIN", 124, 140], ["IgG", "PROTEIN", 142, 145], ["multiple proteins", "PROTEIN", 181, 198], ["DOK6", "PROTEIN", 210, 214], ["insulin receptors", "PROTEIN", 227, 244], ["GOSR1", "PROTEIN", 251, 256], ["BTK", "PROTEIN", 258, 261], ["ASPA", "PROTEIN", 266, 270], ["patients", "SPECIES", 353, 361], ["the autoantibodyome profiling", "TEST", 13, 42], ["Invitrogen ProtoArrays profiling", "TEST", 59, 91], ["protein reactivities", "TEST", 100, 120], ["Immunoglobulin G (IgG)", "TEST", 124, 146], ["increased reactivity in multiple proteins", "PROBLEM", 157, 198], ["DOK6", "PROBLEM", 210, 214], ["insulin receptors", "TEST", 227, 244], ["GOSR1", "TEST", 251, 256], ["ASPA", "TEST", 266, 270], ["high reactivity", "PROBLEM", 300, 315], ["increased", "OBSERVATION_MODIFIER", 157, 166], ["reactivity", "OBSERVATION", 167, 177], ["multiple proteins", "OBSERVATION", 181, 198], ["high reactivity", "OBSERVATION", 300, 315]]], ["The subject initiated and still maintains a strict dietary and exercise regiment supplemented with low doses of acetylsalicylic acid, which helped him control his glucose and HbA1c levels, which after a considerable time period (~months) have now returned to normal levels.Example implementation of personalized medicine: iPOPIn addition a range of omics were profiled over time for up to 20 different timepoints over the span of the study including high coverage transcriptome (RNA-Seq of PBMCs, 2.67 billion reads mapped to 19714 isoforms corresponding to 12659 genes), proteome (MS of PBMCs, identifying a total of 6280 proteins; 3731 consistently across most timepoints), metabolome (MS of serum, profiling 6862 and 4228 metabolites during periods of HRV and RSV infections respectively, with 20% identified based on mass and retention times alone).", [["PBMCs", "ANATOMY", 490, 495], ["PBMCs", "ANATOMY", 588, 593], ["serum", "ANATOMY", 694, 699], ["acetylsalicylic acid", "CHEMICAL", 112, 132], ["glucose", "CHEMICAL", 163, 170], ["RSV infections", "DISEASE", 763, 777], ["acetylsalicylic acid", "CHEMICAL", 112, 132], ["glucose", "CHEMICAL", 163, 170], ["acetylsalicylic acid", "SIMPLE_CHEMICAL", 112, 132], ["glucose", "SIMPLE_CHEMICAL", 163, 170], ["HbA1c", "SIMPLE_CHEMICAL", 175, 180], ["PBMCs", "CELL", 490, 495], ["PBMCs", "CELL", 588, 593], ["serum", "ORGANISM_SUBSTANCE", 694, 699], ["RSV", "ORGANISM", 763, 766], ["PBMCs", "CELL_TYPE", 490, 495], ["12659 genes", "DNA", 558, 569], ["PBMCs", "CELL_TYPE", 588, 593], ["6280 proteins", "PROTEIN", 618, 631], ["RSV", "SPECIES", 763, 766], ["exercise regiment", "TREATMENT", 63, 80], ["acetylsalicylic acid", "TREATMENT", 112, 132], ["his glucose", "TEST", 159, 170], ["HbA1c levels", "TEST", 175, 187], ["the study", "TEST", 430, 439], ["high coverage transcriptome", "TREATMENT", 450, 477], ["PBMCs", "TEST", 490, 495], ["PBMCs", "TEST", 588, 593], ["metabolome (MS of serum", "TEST", 676, 699], ["HRV", "PROBLEM", 755, 758], ["RSV infections", "PROBLEM", 763, 777], ["mass", "PROBLEM", 821, 825], ["mass", "OBSERVATION", 821, 825]]], ["The dynamic transcriptome, proteome and metabolome profiles were analyzed in a novel integrated framework based on spectral analysis of the time series.", [["metabolome profiles", "TEST", 40, 59], ["spectral analysis", "TEST", 115, 132]]], ["This allowed the identification of temporal patterns in the combined data, corresponding to biological processes that varied with physiological state changes, including the onset of T2D seen in multiple omics components, and common signatures of HRV and RSV infections.", [["T2D", "DISEASE", 182, 185], ["RSV infections", "DISEASE", 254, 268], ["RSV", "ORGANISM", 254, 257], ["RSV", "SPECIES", 254, 257], ["physiological state changes", "PROBLEM", 130, 157], ["T2D", "PROBLEM", 182, 185], ["HRV", "PROBLEM", 246, 249], ["RSV infections", "PROBLEM", 254, 268], ["temporal", "OBSERVATION_MODIFIER", 35, 43], ["RSV infections", "OBSERVATION", 254, 268]]], ["While several gene associations to pathways were known, multiple genes showed similar patterns that had not been reported before and merit further investigation.OTHER CONSIDERATIONS AND FUTURE DIRECTIONSThe iPOP study discussed above revealed the complexities and characteristics of personal genomes, transcriptomes, proteomes and metabolomes and showed the feasibility of personalized longitudinal profiling that can provide actionable health information.", [["multiple genes", "DNA", 56, 70], ["merit further investigation", "TEST", 133, 160], ["FUTURE DIRECTIONSThe iPOP study", "TEST", 186, 217]]], ["Multiple omics data integration still presents a formidable challenge and merits further development.", [["Multiple omics data integration", "PROBLEM", 0, 31], ["a formidable challenge", "TREATMENT", 47, 69]]], ["Additionally, each omics set requires its own quality control analysis, further confounded by different error and noise levels associated to the different technologies.", [["different error and noise levels", "PROBLEM", 94, 126]]], ["As each of the data sets also presents different signal and noise distributions, this makes uniform normalization approaches across omics challenging, especially if considering multimodal dynamic data.OTHER CONSIDERATIONS AND FUTURE DIRECTIONSFurthermore, the amounts of information per omics set can vary, e.g.,~5000 proteins,~20000 transcript isoforms,~6000-10000 metabolites,~9000 autoantibodyprotein reactivities and so forth.", [["different signal and noise distributions", "PROBLEM", 39, 79], ["multimodal dynamic data", "TEST", 177, 200], ["noise distributions", "OBSERVATION", 60, 79]]], ["The integration of information per component is made more difficult with multiple existing gene and protein annotations, often resulting in a many-to-many map in the geneprotein integration, and correspondingly lacking metabolite-protein/gene annotations and associations.", [["geneprotein", "GENE_OR_GENE_PRODUCT", 166, 177], ["protein annotations", "TEST", 100, 119]]], ["Finally, if considering dynamic datasets, this also results in multiple instances where time points might be missing data for some of the molecular components (especially evident in mass spectrometry and shotgun proteomics, where proteins are identified through different peptides).", [["missing data", "PROBLEM", 109, 121], ["the molecular components", "PROBLEM", 134, 158], ["mass spectrometry", "PROBLEM", 182, 199], ["shotgun proteomics", "TEST", 204, 222]]], ["These complications of omics data integration necessitate that each individual omics data set is analyzed independently up to normalization, and then integrated with the other information.", [["omics data integration", "TREATMENT", 23, 45]]], ["New integrative methodology has to account for such different normalizations, missing data, and also integration that is not gene-based, but rather incorporates time-series analyses, as for example was carried out in the iPOP study [73] .", [["such different normalizations", "PROBLEM", 47, 76], ["series analyses", "TEST", 166, 181], ["the iPOP study", "TEST", 217, 231]]], ["Classification of changes by temporal response, and possibly interaction data leads to an interpretation of components based on shared similar dynamics and avoids some of the issues of insufficient annotations and missing information.", [["temporal response", "OBSERVATION", 29, 46]]], ["Such an interpretation lends itself to a clinical setting where dynamic changes are associated to varying personalized physiological states, and may be adopted by the medical community.OTHER CONSIDERATIONS AND FUTURE DIRECTIONSTo facilitate the wide adoption of the methods into personalized medicine, the integrated data analysis will require optimization of current computational tools to rapidly and efficiently handle as well as visualize the multiple omics data.", [["dynamic changes", "PROBLEM", 64, 79], ["personalized medicine", "TREATMENT", 279, 300], ["the integrated data analysis", "TEST", 302, 330]]], ["As a first step, the amount of computation time for different analyses must be reduced from days (in the case of mapping sequence data and quantitative proteomics in current omics analyses presented above) to hours or less to have immediate relevance to active medical examinations.", [["different analyses", "TEST", 52, 70], ["mapping sequence data", "TEST", 113, 134], ["quantitative proteomics", "TEST", 139, 162], ["active medical examinations", "TEST", 254, 281]]], ["Secondly, better visualizations of omics data, though difficult, are also necessary, as multidimensional information is difficult to collate, present, and interpret (many efforts are addressing this, e.g., Circos plots that allow multiple sequence information to be displayed together are now widely adopted [212] ).", [["omics data", "TEST", 35, 45]]], ["Incorporating such information with clinical data and phenotypes presents a new challenge, requiring browsers that combine temporal information with multi-dimensional omics sets.", [["clinical data", "TEST", 36, 49]]], ["We believe network analysis [213] [214] [215] [216] [217] presents an excellent visualization and integration possibility, allowing the combinations of multiple levels of networks, dynamically changing, that will include cellular information, component and corresponding disease temporal progressions, as well as medical assay data in a modularized approach.", [["cellular", "ANATOMY", 221, 229], ["cellular", "CELL", 221, 229], ["network analysis", "TEST", 11, 27], ["corresponding disease temporal progressions", "PROBLEM", 257, 300], ["medical assay data", "TEST", 313, 331], ["a modularized approach", "TREATMENT", 335, 357]]], ["The computational analyses and visualization of omics data integration also reveal the known need to manage large amounts of data [218, 219] , both in terms of processing power, as well as storage capacity and maintaining easy accessibility, especially for the practicing clinicianwith the recent advent of cloud computing providing one possible solution.", [["The computational analyses", "TEST", 0, 26], ["omics data integration", "TEST", 48, 70]]], ["Finally, the combination of omics data with medical records presents another challenge, with privacy and ethical issues that must be considered.", [["ethical issues", "TREATMENT", 105, 119]]], ["Such improvements and standardization of approaches will help make the analysis available in a clinical setting and an increasingly larger set of patients, while encouraging the early adaptation of the integrated approaches by the scientific community towards personalized medicine applications.OTHER CONSIDERATIONS AND FUTURE DIRECTIONSAs technology improves we expect to see advancements in each omics implementation discussed above.", [["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["the analysis", "TEST", 67, 79], ["personalized medicine applications", "TREATMENT", 260, 294]]], ["In terms of sequencing, continual improvements in depth and read length will allow unambiguous precise sequence mapping and additionally the querying of lower gene expression, coupled to higher accuracy in variant calling.", [["unambiguous precise sequence mapping", "TEST", 83, 119], ["lower gene expression", "PROBLEM", 153, 174]]], ["With sequencing times becoming faster (e.g., whole genome sequencing in~5-30 hours depending on platform at deep,~100\u00c2 coverage), and hardware more compact, eventually such technology will be available in the clinic, enabling the incorporation of all genomic, transcriptomic, microbiomic and autoantibodyomic profiling as parts of regular medical examinations.", [["whole genome sequencing", "TEST", 45, 68], ["hardware", "TREATMENT", 134, 142], ["microbiomic and autoantibodyomic profiling", "TREATMENT", 276, 318], ["regular medical examinations", "TEST", 331, 359]]], ["Correspondingly, mass spectrometry improvements (including table-top hardware now available) will improve mass accuracy, and higher sensitivity, allowing increases in the number of proteins identified and better quantitation, which can already be implemented in a clinical setting.", [["mass spectrometry improvements", "PROBLEM", 17, 47], ["table-top hardware", "TREATMENT", 59, 77], ["mass accuracy", "TEST", 106, 119], ["higher sensitivity", "PROBLEM", 125, 143], ["mass", "OBSERVATION", 17, 21], ["mass", "OBSERVATION", 106, 110], ["increases", "OBSERVATION_MODIFIER", 154, 163]]], ["The MS improvements in combination with better metabolite cataloguing will also improve the identification of small molecules.", [["The MS improvements", "PROBLEM", 0, 19], ["better metabolite cataloguing", "PROBLEM", 40, 69], ["small molecules", "PROBLEM", 110, 125], ["small molecules", "OBSERVATION", 110, 125]]], ["The protocol and methodology advancements will allow using a smaller volume of patient sample needed for iPOP (decreasing from~80 mL to drops of blood) making it feasible to probe the omics on more regular basis for each patient, even providing home kits to send in self-collected samples (akin to what is already implemented to some degree by companies, e.g., 23andMe, that collect saliva samples for phenotyping).OTHER CONSIDERATIONS AND FUTURE DIRECTIONSThe technological and methodological advancements will allow for effective iPOP implementations with multiple patients, but it will still take some time to evaluate what constitutes actionable information and which components will be most informative.", [["blood", "ANATOMY", 145, 150], ["samples", "ANATOMY", 390, 397], ["patient", "ORGANISM", 79, 86], ["iPOP", "SIMPLE_CHEMICAL", 105, 109], ["blood", "ORGANISM_SUBSTANCE", 145, 150], ["patient", "ORGANISM", 221, 228], ["patients", "ORGANISM", 567, 575], ["patient", "SPECIES", 79, 86], ["patient", "SPECIES", 221, 228], ["patients", "SPECIES", 567, 575], ["The protocol", "TREATMENT", 0, 12], ["methodology advancements", "TREATMENT", 17, 41], ["a smaller volume of patient sample", "TREATMENT", 59, 93], ["iPOP", "TREATMENT", 105, 109], ["home kits", "TREATMENT", 245, 254], ["saliva samples", "TEST", 383, 397], ["methodological advancements", "TREATMENT", 479, 506], ["effective iPOP implementations", "TREATMENT", 522, 552]]], ["This will certainly be alleviated by multiple iPOP studies providing the necessary aggregated information.", [["multiple iPOP studies", "TEST", 37, 58]]], ["However, clinical and psychological concerns need to be addressed and the possible impact to patient health being of paramount importance, in a medical process in which the patient is actively participating [220] .", [["patient", "ORGANISM", 93, 100], ["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 93, 100], ["patient", "SPECIES", 173, 180], ["clinical and psychological concerns", "PROBLEM", 9, 44]]], ["Such active participation requires the training of the public and health professionals to an understanding of genomic information, and how this omics knowledge impacts their health, and their families.", [["active", "OBSERVATION_MODIFIER", 5, 11]]], ["Informed consent will be necessary, but this requires an understanding of basic genomic terms that are not apparent to non-experts.", [["not apparent", "UNCERTAINTY", 103, 115]]], ["Such research is at the forefront of medical science, and may help the characterization of disorders and the implementation of precise personal medicine aimed towards prevention rather than treatment.", [["disorders", "PROBLEM", 91, 100], ["precise personal medicine", "TREATMENT", 127, 152], ["treatment", "TREATMENT", 190, 199]]]], "d20a14d4abe09b3f84c63efc2578ff3599f71ef3": [["BackgroundAt the start of April 2020, the human health and disruptive effects of the COVID-19 pandemic were being felt globally.", [["human", "ORGANISM", 42, 47], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["the COVID", "TREATMENT", 81, 90]]], ["For example, numerous modelling studies have been produced that illustrate the anticipated impacts of various interventions (e.g. social distancing) on the epidemic curve of COVID-19 [1, 2] .", [["numerous modelling studies", "TEST", 13, 39], ["various interventions", "TREATMENT", 102, 123], ["COVID", "TEST", 174, 179]]], ["While these models show epidemic curves that stretch into the fall and into 2021, there are sufficient uncertainties (e.g. how long will immunity last?) and complex dynamics (e.g. how will citizens react as social distancing measures remain in place?), meaning such results should not be used as the sole basis for planning for the future.BackgroundIn 2009, the Public Health Agency of Canada (PHAC) produced a planning document, to help prepare for Canada's anticipated fall wave of pandemic H1N1 influenza [3] .", [["influenza", "DISEASE", 498, 507], ["pandemic H1N1 influenza", "SPECIES", 484, 507], ["epidemic curves", "PROBLEM", 24, 39], ["social distancing measures", "TREATMENT", 207, 233], ["pandemic H1N1 influenza", "PROBLEM", 484, 507]]], ["This document contained: (a) descriptions of plausible future scenarios for how Canada might experience the 2009 pandemic; and (b) planning considerations for PHAC including factors that could impact human and financial resources.", [["human", "ORGANISM", 200, 205], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 200, 205]]], ["The PHAC report was underpinned by two planning methodologies: scenario planning [4] , which aims to describe the range of plausible futures so that decisions and plans can be robust in the face of uncertainty; and a modified Political, Economic, Social, Technological (PEST) analysis [5] , a framework for identifying macro-level factors in the wider environment that can impact organisations' abilities to function.", [["macro-level factors", "PROTEIN", 319, 338]]], ["Its purpose was to prepare PHAC staff to think about the different ways the future could unfold, and to think about the different factors that could impact the way they did business, so that planning and decisions could be more robust and less likely to be thwarted by surprise.BackgroundThis paper applies a similar approach, in order to: (a) outline some current uncertainties related to COVID-19, and what they might mean for plausible futures for which we should prepare; and (b) list factors that we as individual faculty members and university institutions should be considering now, when planning for the future under COVID-19.", [["COVID", "TEST", 390, 395]]], ["Although the contextual focus of this paper is Canada, the content is likely applicable to other places where the COVID-19 epidemic curve is in its initial rising stage, and where universities are predominantly publicly funded institutions.", [["the COVID", "TEST", 110, 119], ["predominantly", "OBSERVATION_MODIFIER", 197, 210]]], ["Given that the pandemic is rapidly evolving, the applicability of this work to various contexts is also expected to change over time.COVID-19: what might the future bring?There are several key 'axes of uncertainty' about how the pandemic will unfold in Canada, that we should consider when planning for the future, for time horizons of the Fall 2020 term (September to December 2020), the 2020/2021 academic year (September 2020 to August 2021) and beyond.", [["rapidly", "OBSERVATION_MODIFIER", 27, 34]]], ["These uncertainties mean that we could find ourselves in situations like 'things are similar to what they are now', or 'things are more restrictive, and we need to deliver upcoming terms even more remotely' or 'things are back to normal, but with uncertainties and the need to change quickly if the virus throws us a curveball or three'.", [["the virus", "PROBLEM", 295, 304]]], ["Impact on our people: from 'on our radar but rare', to 'big losses, heavy impacts'COVID-19: what might the future bring?At the time of writing, most individuals within the university community (and Ontario and Canada as a whole) are mainly impacted by COVID-19 via the social distancing measures currently in place, but it is reasonable to expect that the direct health impacts of the virus will become more widely felt.", [["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20], ["COVID", "TEST", 252, 257], ["the social distancing measures", "TREATMENT", 265, 295], ["the virus", "PROBLEM", 381, 390]]], ["Will we lose substantial workforce capacity (e.g. capacity for individual research projects, for university-wide operations, or to cover for absent instructors and administrators)?", [["university-wide operations", "TREATMENT", 97, 123]]], ["Will we face widespread grief, burnout and mental health impacts related to illness, intensive care, intubation, death or isolation?", [["grief", "DISEASE", 24, 29], ["burnout", "DISEASE", 31, 38], ["illness", "DISEASE", 76, 83], ["death", "DISEASE", 113, 118], ["burnout and mental health impacts", "PROBLEM", 31, 64], ["illness", "PROBLEM", 76, 83], ["intensive care", "TREATMENT", 85, 99], ["intubation", "TREATMENT", 101, 111], ["death", "PROBLEM", 113, 118], ["isolation", "TREATMENT", 122, 131]]], ["How will these impacts intersect with our cultures and customs?", [["our cultures", "TEST", 38, 50]]], ["These uncertainties mean that we could find ourselves in situations like 'most people are not feeling substantial personal impacts', as we are now, to 'many people are substantially impacted' (e.g. they are sick or dealing with death and grief of family, friends and colleagues, there are deaths among the University community, there is a noticeable loss of workforce).COVID-19: what might the future bring?Universities as part of society: from 'doing what we usually do', to 'widespread mobilisation'COVID-19: what might the future bring?At the time of writing, most of the university community (i.e. staff, faculty and students) are in the same roles and with essentially the same responsibilities as they were pre-pandemic.", [["death", "DISEASE", 228, 233], ["grief", "DISEASE", 238, 243], ["deaths", "DISEASE", 289, 295], ["people", "ORGANISM", 79, 85], ["people", "ORGANISM", 157, 163], ["people", "SPECIES", 79, 85], ["people", "SPECIES", 157, 163]]], ["And although we are seeing academia voluntarily donating goods (e.g. personal protective equipment, reagents, swabs) and services S. E. Majowicz (e.g. medical students conducting contact tracing) [6, 7] , the vast majority of university physical and human resources are still being used for the same purposes as they were pre-pandemic.", [["human", "ORGANISM", 250, 255], ["human", "SPECIES", 250, 255], ["S. E. Majowicz", "SPECIES", 130, 144], ["human", "SPECIES", 250, 255]]], ["A widespread and often subconscious assumption people seem to be making is that our roles and responsibilities as individual faculty or as universities, for example, are guaranteed to continue to be 'business as usual, albeit maybe remotely'.", [["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["widespread", "OBSERVATION_MODIFIER", 2, 12]]], ["Will university resources be called upon in new ways to help the pandemic response, for example using laboratory or dormitory space for testing and community care? [8] Will we 'lose' faculty, staff or students to front-line institutions so they can help aide response efforts, and if yes for how long?", [["testing", "TEST", 136, 143]]], ["Will immune individuals be mobilised (e.g. to fulfill essential public/ in-person functions, to donate plasma)?", [["plasma", "ANATOMY", 103, 109], ["plasma", "ORGANISM_SUBSTANCE", 103, 109]]], ["These uncertainties mean that we could find ourselves in situations like 'we are doing the same business we've always been doing', to 'ad hoc or individual volunteering of physical and/or human resources to support pandemic responses', to 'universities are obligated to repurpose resources to aide in the pandemic response', or perhapsin the most extremeeven to 'universities see their public funding diverted to pandemic response'.COVID-19 planning considerations for faculty and universitiesThere are many dynamic factors influencing the pandemic and how it will unfold.", [["pandemic", "DISEASE", 215, 223], ["human", "ORGANISM", 188, 193], ["human", "SPECIES", 188, 193], ["human", "SPECIES", 188, 193], ["many dynamic factors", "PROBLEM", 503, 523], ["many", "OBSERVATION_MODIFIER", 503, 507], ["dynamic factors", "OBSERVATION", 508, 523]]], ["Considering and organising these factors by Characteristics that predispose people to severe outcomes Assess which segments of the university community are particularly vulnerable to severe outcomes, and create policies or accommodations to ensure adequate protection.ImmunityBecause the duration of immunity is unclear, prepare for a possible future where a proportion of the University community is susceptible (and perhaps in isolation) at any given time.ImmunityDistribution of cases/death (e.g. by age, sex, risk factors)ImmunityAssess which segments of the university community are particularly vulnerable to illness/death; beyond policies/accommodations to protect them, create contingency plans to function in their absence (e.g. the older cohort of faculty and staff).Population VulnerabilitiesSocial, economic factors Create flexible options (e.g. for remote classes) that function in the face of changing socio-economic disadvantage (e.g. ability to afford internet connections) and broader social forces (e.g. caregiving responsibilities).Population VulnerabilitiesGroups that society/academia marginalises, or excludes from power, privilegePopulation VulnerabilitiesCreate equitable institutional policies that adequately support groups that are typically marginalised or excluded.Social, Technological, Economic, Environmental, Political, Legal/Regulatory, Ethical FactorsCompliance Consider situations where staff, faculty and students may not, or cannot, comply with public health directives or organisational policies, and create incentives for compliance (e.g. adjusting performance assessments so those whose research suffers when on-campus activities are suspended are not disproportionately disadvantaged).Social, Technological, Economic, Environmental, Political, Legal/Regulatory, Ethical FactorsWorkforce availability Consider how a proportion of the population ill or unable to work may drive the availability of external or temporary workers (e.g. sessional lecturers paid per course, casual staff), by reducing broader workforce availability while also increasing the demand for highly qualified individuals.Social, Technological, Economic, Environmental, Political, Legal/Regulatory, Ethical FactorsPolitical decisions Make contingency plans in case political decisions (e.g. restrictions on supplies, protectionist policies) impact activities (e.g. ability to share data, research resources).Social, Technological, Economic, Environmental, Political, Legal/Regulatory, Ethical FactorsSocial, political appetite for new ways of working Consider how successfully conducting university activities under pandemic conditions (e.g. delivering remote classes) may lead to post-pandemic views on how universities can/should function (e.g. push for cost-saving, multi-institution online courses).Social, Technological, Economic, Environmental, Political, Legal/Regulatory, Ethical FactorsEquitable access to technology Identify how issues like cost, geographic availability and connectivity to different technologies can (dis)advantage different groups (e.g. rural students with intermittent internet may attend fewer video classes).Organisational capacity to respondWorkforce capacity Make contingency plans for classes, research projects and administrative tasks that account for some % of the workforce missing, some % at less than full capacity (overall, and at different times), and absent expertise, experience, authority and skills (e.g. identify instructors to cover different courses in the event of sudden illness/absenteeism).Organisational capacity to respondTrust and reputation Identify core business functions that rely on reputation and trust (e.g. universities' abilities to recruit students; researchers' abilities to build and sustain partnerships), and ensure all actions do not erode said trust/reputation (e.g. ways that students are treated during the pandemic will demonstrate how the institution values students).Organisational capacity to respondFaculty expertise Identify ways to reconsider workload, so faculty experts critical to the pandemic response (e.g. mathematical modelling, epidemiology), and key to the organisation's own planning (e.g. scenario planning, digital pedagogy, crisis communication, ethics) can devote adequate time to new activities.Organisational capacity to respondbroad categories can challenge us to think broadly and plan for influences from 'unexpected' domains.", [["death", "DISEASE", 488, 493], ["illness", "DISEASE", 615, 622], ["death", "DISEASE", 623, 628], ["sudden illness", "DISEASE", 3529, 3543], ["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["death", "PROBLEM", 488, 493], ["death", "PROBLEM", 623, 628], ["changing socio-economic disadvantage", "PROBLEM", 907, 943], ["organisational policies", "TREATMENT", 1511, 1534], ["performance assessments", "TEST", 1589, 1612], ["post-pandemic views", "TEST", 2694, 2713], ["cost-saving", "TREATMENT", 2769, 2780], ["multi-institution online courses", "TREATMENT", 2782, 2814], ["Organisational capacity", "PROBLEM", 3153, 3176], ["sudden illness", "PROBLEM", 3529, 3543], ["absenteeism", "PROBLEM", 3544, 3555], ["Organisational capacity", "PROBLEM", 3557, 3580], ["Organisational capacity", "PROBLEM", 3958, 3981], ["Organisational capacity", "PROBLEM", 4305, 4328]]], ["The PEST framework [5] uses political, economic, social and technological categories, which the PHAC H1N1 planning document [3] expanded to also include: the disease; population vulnerabilities; regulatory factors and the capacity to respond.", [["regulatory factors", "PROTEIN", 195, 213], ["the disease", "PROBLEM", 154, 165], ["population vulnerabilities", "PROBLEM", 167, 193], ["regulatory factors", "PROBLEM", 195, 213], ["the capacity", "PROBLEM", 218, 230], ["disease", "OBSERVATION", 158, 165]]], ["A diagram showing the types of factors within these categories is given in Figure 1 , and Table 1 presents a selection of these factors, together with practical ways that faculty and universities might consider them in their planning.", [["A diagram", "TEST", 0, 9]]], ["Such planning can draw on existing contingency planning literature, including in the areas of outbreaks, disaster and emergency response and business operations, e.g. [11] [12] [13] .", [["business operations", "TREATMENT", 141, 160]]], ["Departments and Institutions can, for example, create contingency plans for teaching commitments and administrative functions by identifying back-ups, or determining which can be temporarily suspended.", [["teaching commitments", "TREATMENT", 76, 96]]], ["Additionally, Departments and Institutions can take a unit-or organisation-wide approach to allocating or redistributing common resources (e.g. online teaching supports) to best serve the needs of the whole.Organisational capacity to respondIt is important to note that the factors and examples provided here do not form a complete list, and that different individuals, departments and institutions will have specific or unique issues with which they will have to deal (e.g. disruption of in-person data collection such as visit schedules for clinical trials).", [["online teaching supports", "TREATMENT", 144, 168], ["Organisational capacity", "PROBLEM", 207, 230]]], ["Thus, comprehensive planning should include a full assessment of possible issues specific to each individual, department or institution, and should not be limited to the factors and examples presented here.Next stepsGiven the range of uncertainties we currently face with COVID-19, and the numerous broader forces that will influence how the pandemic will unfold, what concrete actions can we take?Next stepsFirst, we can use the possible future situations to 'test' how well the decisions and plans we are currently making could hold up, under a range of different futures.", [["a full assessment", "TEST", 44, 61], ["COVID", "TEST", 272, 277]]], ["For example, in preparing courses for fall offerings, we might choose to build in flexibility to allow pivoting between in person and remote delivery quickly, should the pandemic shift.", [["person", "SPECIES", 123, 129], ["fall", "PROBLEM", 38, 42]]], ["For example, research project supervisors can consider what alternate training to give graduate students and technical staff now, so they can cover for each other in case of illness and absence.Next stepsThird, we can use the broad list of factors to 'test' whether decisions and plans being made now might need to change if these factors change.", [["illness", "DISEASE", 174, 181], ["illness", "PROBLEM", 174, 181], ["these factors change", "PROBLEM", 325, 345]]], ["Or, as another example, staying abreast of information about predisposing factors (e.g. comorbidities) and immunity will allow institutions to remain flexible so our most vulnerable can continue to self-isolate at home even if social distancing measures lift.Next stepsFourth, we can apply an equity lens throughout our planning and decision-making, to ensure thatat a bare minimumwe do not perpetuate or amplify existing barriers or disadvantages because of our individual and organisational decisions.", [["flexible", "TREATMENT", 150, 158]]], ["Specifically, we can work towards equitable policies, plans and decisions by taking three actions, by 'valuing all individuals and populations equally, recognising and rectifying historical injustices and providing resources according to need' [18] .Next stepsFinally, the axes of uncertainty and macro-environment factors given here can be expanded, both as the pandemic unfolds and new knowledge is generated, and by integrating perspectives from a wide range of backgrounds (e.g. economics, ethics, history, sociology, geography, planning) to identify additional key uncertainties about the future and key planning considerations.", [["macro-environment factors", "PROTEIN", 297, 322], ["macro-environment factors", "PROBLEM", 297, 322]]], ["Additionally, individuals and institutions in locations that are further along in the pandemic (e.g. Asia) can delineate additional uncertainties and macro-environmental factors, for example those related to lifting social distancing measures, planning for subsequent potential waves, rebuilding resources or dealing with longer-term health and other impacts of both COVID-19 and our responses to it.", [["macro-environmental factors", "PROBLEM", 150, 177], ["both COVID", "TREATMENT", 362, 372]]], ["It will also be critical to hear how faculty and universities decide to deal with these issues, including in real time and via post-pandemic assessments (such as those aimed at improving pandemic plans).", [["post-pandemic assessments", "TEST", 127, 152]]]], "9f28ffc6d0ffd16df162075e55d9a76e09226957": [["IntroductionOn 24 th March 2020 the UK introduced a range of 'lockdown' restrictions intended to slow the progression of the COVID19 outbreak.", [["a range of 'lockdown' restrictions", "TREATMENT", 50, 84]]], ["Emerging evidence indicates that the COVID19 outbreak is associated with adverse mental health and wellbeing outcomes for healthcare workers in China 1 and the general public in Italy 2 .", [["COVID19", "GENE_OR_GENE_PRODUCT", 37, 44]]], ["The current study investigated whether mental health and wellbeing outcomes in UK adults are associated with: 1) Experiencing symptoms of COVID19; 2) Being in a group vulnerable to COVID19; 3) Being categorised as an 'essential worker'; 4) Experiencing COVID19-related isolation; 5) Local community interactions.", [["COVID19", "CHEMICAL", 253, 260], ["The current study", "TEST", 0, 17], ["symptoms of COVID19", "PROBLEM", 126, 145], ["COVID19-related isolation", "TREATMENT", 253, 278]]], ["Furthermore, the current study explored if level of social support was associated with mental health and wellbeing outcomes.MethodsA cross-sectional design was used.", [["the current study", "TEST", 13, 30], ["MethodsA cross-sectional design", "TREATMENT", 124, 155]]], ["To be eligible, people had to be adults (+18 years), speak English, and be living in the UK at the time of the COVID19 outbreak.", [["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22]]], ["The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.", [["human", "ORGANISM", 156, 161], ["human", "SPECIES", 156, 161], ["human", "SPECIES", 156, 161], ["all procedures", "TREATMENT", 24, 38]]], ["All procedures involving human participants were approved by the Central University Research Ethics Committees, University of Liverpool (ref:7633).", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["participants", "SPECIES", 31, 43], ["human", "SPECIES", 25, 30]]], ["Written informed consent was obtained from all participants.MethodsThe survey included: (i) demographic questions, (ii) COVID19-related questions, (iii) Hospital Anxiety and Depression Scale (HADS 3 ), (iv) WHO-5 measure of well-being 4 , (v) Oxford CAPabilities questionnaire-Mental Health (OXCAP-MH 5 ) measure of quality of life (QoL), (vi) Multidimensional Scale of Perceived Social Support 6 .MethodsSix-hundred participants (74% female, mean age = 36.75 years, SD = 13.44, range = 18-76 years) completed at a minimum the demographic and COVID19-related questions.", [["Anxiety and Depression", "DISEASE", 162, 184], ["participants", "ORGANISM", 417, 429], ["participants", "SPECIES", 47, 59], ["participants", "SPECIES", 417, 429], ["Anxiety", "PROBLEM", 162, 169], ["Depression Scale (HADS", "TREATMENT", 174, 196], ["Mental Health (OXCAP-MH", "TREATMENT", 277, 300]]], ["Participants were mainly White (93.6%) and employed (65%).", [["Participants", "SPECIES", 0, 12]]], ["Around a quarter of participants (26.3%) self-reported currently receiving treatment for mental disorders -including mood disorders (18%) and neurotic, stress-related and somatoform disorders (14.3%).", [["mood disorders", "DISEASE", 117, 131], ["neurotic", "DISEASE", 142, 150], ["somatoform disorders", "DISEASE", 171, 191], ["participants", "ORGANISM", 20, 32], ["participants", "SPECIES", 20, 32], ["treatment", "TREATMENT", 75, 84], ["mental disorders", "PROBLEM", 89, 105], ["mood disorders", "PROBLEM", 117, 131], ["neurotic", "PROBLEM", 142, 150], ["somatoform disorders", "PROBLEM", 171, 191]]], ["No participants had been diagnosed with COVID19.ResultsThe mean scores on HADS Anxiety subscale (M=10.23, SD=4.98) and HADS Depression subscale (M=7.57, SD = 4.39) exceeded the \"normal\" range (i.e. scores of 0-7).", [["Depression", "DISEASE", 124, 134], ["participants", "SPECIES", 3, 15], ["COVID19", "TREATMENT", 40, 47], ["The mean scores", "TEST", 55, 70], ["HADS", "TEST", 74, 78], ["Anxiety subscale", "TEST", 79, 95], ["M", "TEST", 97, 98], ["SD", "TEST", 106, 108], ["HADS Depression subscale", "PROBLEM", 119, 143], ["SD", "TEST", 153, 155]]], ["The mean scores on WHO-5 and OXCAP-MH were 10.43 (SD = 5.40) and 69.45 (SD = 11.91) respectively.Results(Insert Table 1 )ResultsBeing in a vulnerable group (12.5%) or experiencing symptoms of COVID19 (11.7%), was not associated with significant differences in mental health and wellbeing outcomes.", [["COVID19", "DISEASE", 192, 199], ["The mean scores", "TEST", 0, 15], ["WHO", "TEST", 19, 22], ["OXCAP", "TEST", 29, 34], ["SD", "TEST", 50, 52], ["SD", "TEST", 72, 74], ["symptoms", "PROBLEM", 180, 188], ["COVID19", "TEST", 192, 199], ["significant differences in mental health and wellbeing outcomes", "PROBLEM", 233, 296], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["not associated with", "UNCERTAINTY", 213, 232]]], ["Participants who self-isolated prior to lockdown due to symptoms of COVID19 (11.8%), relative to those who did not, had higher levels of anxiety (t (584) = 2.77, p = 0.006) and depression (t (550) = 2.83, p = 0.005) and lower levels of wellbeing (t (534) = -2.29, p = 0.022) and QoL (t (466) = -3.56, p < 0.001).", [["anxiety", "DISEASE", 137, 144], ["depression", "DISEASE", 177, 187], ["Participants", "SPECIES", 0, 12], ["lockdown", "TREATMENT", 40, 48], ["symptoms", "PROBLEM", 56, 64], ["COVID19", "TEST", 68, 75], ["anxiety", "PROBLEM", 137, 144], ["depression", "PROBLEM", 177, 187], ["p", "TEST", 264, 265], ["QoL", "TEST", 279, 282]]], ["Participants who felt more isolated than usual during lockdown (69%) had higher levels of anxiety (t (513)=-5.95, p < 0.001) and depression (t (250.86) = -7.77, p < 0.001), and lower levels of wellbeing (t (191.84) = 6.18, p < 0.001) and QoL (t (441) = 4.16, p < 0.001).ResultsParticipants who were essential workers (32%) had significantly lower depression (t (400.76) = -2.18, p = 0.030).", [["anxiety", "DISEASE", 90, 97], ["depression", "DISEASE", 129, 139], ["depression", "DISEASE", 347, 357], ["Participants", "SPECIES", 0, 12], ["anxiety", "PROBLEM", 90, 97], ["depression", "PROBLEM", 129, 139], ["QoL", "TEST", 238, 241], ["significantly lower depression", "PROBLEM", 327, 357]]], ["Participants who agreed that the COVID19 outbreak was threatening their livelihood (46.0%) had higher depression (t (544) = -2.55, p = 0.011) and lower QoL (t (461) = 2.73, p = 0.007).ResultsParticipants who agreed that since the COVID19 outbreak people's kindness towards others in their local area had increased (68.8%) had lower depression (t (551) = 2.25, p = 0.025), higher QoL (t (467) = -4.56, p < 0.001) and higher wellbeing (t (535)= -2.85, p = 0.005).", [["depression", "DISEASE", 102, 112], ["depression", "DISEASE", 332, 342], ["people", "ORGANISM", 247, 253], ["Participants", "SPECIES", 0, 12], ["people", "SPECIES", 247, 253], ["higher depression", "PROBLEM", 95, 112], ["lower depression", "PROBLEM", 326, 342], ["increased", "OBSERVATION_MODIFIER", 304, 313]]], ["Similarly, participants who agreed that since the COVID19 outbreak felt more connected to the members of their local community (40.0%) had lower depression (t (552)= 2.11, p = 0.035), and higher QoL (t (467) = -3.87, p < 0.001) and higher wellbeing (t (536)= -2.83, p = 0.005).ResultsThe level of perceived social support had significant negative correlations with depression (r = -0.33, p < 0.001) and anxiety (r = -0.17, p < 0.001), and significant positive correlations with QoL (r = 0.52, p < 0.001) and wellbeing (r = 0.29, p < 0.001).DiscussionThis study sought to investigate the mental health and wellbeing impact of the COVID19 outbreak on a convenience sample of UK adults.", [["depression", "DISEASE", 145, 155], ["depression", "DISEASE", 365, 375], ["anxiety", "DISEASE", 403, 410], ["participants", "SPECIES", 11, 23], ["lower depression", "PROBLEM", 139, 155], ["depression", "PROBLEM", 365, 375], ["anxiety", "PROBLEM", 403, 410], ["QoL", "TEST", 478, 481], ["p", "TEST", 493, 494], ["wellbeing", "TEST", 508, 517], ["This study", "TEST", 550, 560]]], ["The anxiety and depression scores for the sample were markedly higher than normative data derived for the UK adult population's levels of anxiety (females = 6.78, SD = 4.23; males = 5.51, SD = 4.04) and depression (females = 4.12, SD = 3.78; males = 3.83, SD = 3.74) 7 .DiscussionHigher depression scores were associated with participants having to self-isolate prior to lockdown due to symptoms of COVID19, feeling more isolated than usual during lockdown, or agreeing that the COVID19 was threatening their livelihood.", [["anxiety", "DISEASE", 4, 11], ["depression", "DISEASE", 16, 26], ["anxiety", "DISEASE", 138, 145], ["depression", "DISEASE", 203, 213], ["depression", "DISEASE", 287, 297], ["participants", "SPECIES", 326, 338], ["The anxiety", "PROBLEM", 0, 11], ["depression scores", "PROBLEM", 16, 33], ["the sample", "TEST", 38, 48], ["anxiety", "PROBLEM", 138, 145], ["SD", "TEST", 163, 165], ["males", "TEST", 174, 179], ["SD", "TEST", 188, 190], ["depression", "PROBLEM", 203, 213], ["SD", "TEST", 231, 233], ["DiscussionHigher depression scores", "PROBLEM", 270, 304], ["symptoms", "PROBLEM", 387, 395], ["COVID19", "PROBLEM", 399, 406]]], ["On the other hand, agreeing that people's kindness towards others had increased, agreeing that he/she felt more connected to people in the local community, or working in an essential job was associated with significantly lower depression scores.", [["depression", "DISEASE", 227, 237], ["people", "ORGANISM", 33, 39], ["people", "ORGANISM", 125, 131], ["people", "SPECIES", 33, 39], ["people", "SPECIES", 125, 131], ["significantly lower depression scores", "PROBLEM", 207, 244]]], ["Notably, the mean depression score for the essential workers (M=7.01, SD = 4.04) remained at the upper limit of the normal range.", [["depression", "DISEASE", 18, 28], ["the mean depression score", "PROBLEM", 9, 34], ["SD", "TEST", 70, 72], ["upper limit", "OBSERVATION_MODIFIER", 97, 108], ["normal range", "OBSERVATION", 116, 128]]], ["These findings are open to interpretation, but it may be that the importance of their work, and/or public acknowledgment of their efforts buffer against higher levels of depression.DiscussionThe significant findings relating to isolation (self-isolating prior to lockdown or feeling more isolated during lockdown) and levels of perceived social support, highlight the importance of exploring innovative ways to maintain connection and social support during periods of lockdown and beyond.DiscussionComparatively high levels of both wellbeing and QoL were associated with participants agreeing that: levels of kindness in the local area had increased, and they felt more connected to others in the local community during the COVID19.", [["depression", "DISEASE", 170, 180], ["COVID19", "DNA", 724, 731], ["participants", "SPECIES", 571, 583], ["depression", "PROBLEM", 170, 180], ["isolation", "TREATMENT", 228, 237], ["perceived social support", "TREATMENT", 328, 352], ["social support", "TREATMENT", 435, 449], ["kindness", "PROBLEM", 609, 617], ["the COVID19", "TREATMENT", 720, 731], ["increased", "OBSERVATION_MODIFIER", 640, 649]]], ["QoL, but not wellbeing, was comparatively lower in participants who indicated that their livelihood was threatened by COVID19.", [["COVID19", "GENE_OR_GENE_PRODUCT", 118, 125], ["COVID19", "PROTEIN", 118, 125], ["participants", "SPECIES", 51, 63]]], ["We believe that the Capability Approach (Nussbaum 2011), which focuses specifically on the extent to which people have the freedom to engage in valued forms of being and doing (assessed by the OXCAP-MH), provides an important framework for understanding the impact of COVID19 and associated lockdown.DiscussionThere were a number of important limitations associated with the current study.", [["people", "ORGANISM", 107, 113], ["COVID19", "GENE_OR_GENE_PRODUCT", 268, 275], ["COVID19", "PROTEIN", 268, 275], ["people", "SPECIES", 107, 113], ["COVID19", "TREATMENT", 268, 275], ["the current study", "TEST", 371, 388]]], ["The convenience sample relied on people who access online social media forums.", [["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39]]], ["The cross-sectional nature of the analyses limits the conclusions that can be drawn.", [["the analyses", "TEST", 30, 42]]], ["This study is part of a longer programme of research aimed at tracking the impact of the COVID19 outbreak and associated government restrictions on mental health and wellbeing.DiscussionThe study highlights that whereas personal experience of COVID19 symptoms and being part of a group vulnerable to the effects of COVID19 were not associated with poorer mental health and wellbeing, factors associated with isolation and COVID19-related livelihood concerns were.", [["COVID19", "GENE_OR_GENE_PRODUCT", 243, 250], ["COVID19", "GENE_OR_GENE_PRODUCT", 315, 322], ["This study", "TEST", 0, 10], ["the COVID19 outbreak", "PROBLEM", 85, 105], ["The study", "TEST", 186, 195], ["COVID19 symptoms", "PROBLEM", 243, 259], ["COVID19", "TREATMENT", 315, 322], ["isolation", "TREATMENT", 408, 417], ["COVID19", "TREATMENT", 422, 429]]], ["On the other hand, perceiving increased kindness and connectedness in local areas was associated with better mental health and wellbeing outcomes.", [["perceiving increased kindness", "PROBLEM", 19, 48], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["kindness", "OBSERVATION", 40, 48]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.24.20078550 doi: medRxiv preprint Author contribution: Ross G. White formulated the research questions, designed the study, conducted the study, analysed the data and wrote the article.(which was not certified by peer review)Carine van der Boor formulated the research questions, designed the study, conducted the study, analysed the data and wrote the article.(which was not certified by peer review).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["the study", "TEST", 423, 432], ["the study", "TEST", 444, 453], ["the study", "TEST", 599, 608], ["the study", "TEST", 620, 629], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.24.20078550 doi: medRxiv preprintDeclaration of Interest: None.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.24.20078550 doi: medRxiv preprint Funding Statement: This research received no specific grant from any funding agency, commercial or not-for-profit sectors.(which was not certified by peer review).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "4739a4a950905418cb9770696727b29d2a3deb4d": [["IntroductionCoronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, Hubei Province, China, in December 2019 [1] .", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["acute respiratory syndrome coronavirus", "DISEASE", 56, 94], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 49, 96], ["SARS-CoV-2", "ORGANISM", 98, 108], ["severe acute respiratory syndrome coronavirus", "SPECIES", 49, 94], ["SARS-CoV-2", "SPECIES", 98, 108], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 49, 94], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["respiratory syndrome", "OBSERVATION", 62, 82]]], ["In the following weeks, infections spread rapidly across China and other countries [2] .", [["infections", "DISEASE", 24, 34], ["infections", "PROBLEM", 24, 34], ["infections", "OBSERVATION", 24, 34]]], ["Published studies showed that COVID-19 had the feature of strong human-tohuman transmission [2, 3] .", [["COVID-19", "CHEMICAL", 30, 38], ["human", "ORGANISM", 65, 70], ["COVID-19", "DNA", 30, 38], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["Published studies", "TEST", 0, 17], ["COVID", "TEST", 30, 35]]], ["The Chinese government implemented strict quarantine measures to contain the spread of the disease with obvious effects.", [["strict quarantine measures", "TREATMENT", 35, 61], ["the disease", "PROBLEM", 87, 98], ["disease", "OBSERVATION", 91, 98]]], ["However, COVID-19 rapidly spread worldwide.", [["COVID-19", "CHEMICAL", 9, 17], ["COVID", "TEST", 9, 14]]], ["On March 27, 2020, the WHO reported more than half a million confirmed cases of COVID-19 and more than 20,000 deaths [4] .IntroductionTo control the spread of the disease, early identification of COVID-19 infection and immediate isolation of patients are essential.", [["COVID", "DISEASE", 80, 85], ["deaths", "DISEASE", 110, 116], ["infection", "DISEASE", 205, 214], ["COVID-19", "ORGANISM", 196, 204], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["COVID-19", "SPECIES", 196, 204], ["COVID", "TEST", 80, 85], ["Introduction", "TREATMENT", 122, 134], ["the disease", "PROBLEM", 159, 170], ["COVID-19 infection", "PROBLEM", 196, 214], ["disease", "OBSERVATION", 163, 170], ["infection", "OBSERVATION", 205, 214]]], ["Real-time reverse transcription polymerase chain reaction (RT-PCR) was the reference standard for a definite diagnosis of COVID-19 infection according to the guideline of the Diagnosis and Treatment of Pneumonia Caused by COVID-19 (Trial Version 3) published by the National Health Commission of the People's Republic of China (NHCPRC) [5] , which is the key indicator for hospitalization.", [["infection", "DISEASE", 131, 140], ["Pneumonia", "DISEASE", 202, 211], ["COVID-19", "CELL", 122, 130], ["COVID-19", "SPECIES", 122, 130], ["RT-PCR", "TEST", 59, 65], ["COVID-19 infection", "PROBLEM", 122, 140], ["Pneumonia", "PROBLEM", 202, 211], ["COVID", "TEST", 222, 227], ["infection", "OBSERVATION", 131, 140], ["Pneumonia", "OBSERVATION", 202, 211]]], ["However, the low sensitivity of RT-PCR (71%) [6] and lack of RT-PCR assays in the early stage of the outbreak limited the prompt diagnosis of infected patients, which means that many COVID-19 patients were not detected and timely isolated.", [["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 192, 200], ["RT-PCR", "TEST", 32, 38], ["RT-PCR assays", "TEST", 61, 74], ["low", "OBSERVATION_MODIFIER", 13, 16], ["infected", "OBSERVATION", 142, 150]]], ["These patients were bound to become infection sources and infect a large population due to the highly contagious nature of the virus.", [["infection", "DISEASE", 36, 45], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["infection sources", "PROBLEM", 36, 53], ["a large population", "PROBLEM", 65, 83], ["the virus", "PROBLEM", 123, 132], ["infection", "OBSERVATION", 36, 45], ["large", "OBSERVATION_MODIFIER", 67, 72], ["virus", "OBSERVATION", 127, 132]]], ["The reasons for the low efficiency of viral nucleic acid detection included (1) immature development of nucleic acid detection technology, (2) variations in the detection rates from different manufacturers, (3) low patient viral loads, and (4) improper clinical sampling [6] .IntroductionChest computed tomography (CT) is a non-invasive diagnostic imaging tool for pneumonia that is relatively easy to perform and provides rapid diagnoses.", [["nucleic acid", "CHEMICAL", 44, 56], ["nucleic acid", "CHEMICAL", 104, 116], ["pneumonia", "DISEASE", 365, 374], ["patient", "ORGANISM", 215, 222], ["patient", "SPECIES", 215, 222], ["viral nucleic acid detection", "TEST", 38, 66], ["nucleic acid detection technology", "PROBLEM", 104, 137], ["the detection rates", "TEST", 157, 176], ["low patient viral loads", "PROBLEM", 211, 234], ["IntroductionChest computed tomography (CT)", "TEST", 276, 318], ["a non-invasive diagnostic imaging tool", "TEST", 322, 360], ["pneumonia", "PROBLEM", 365, 374], ["viral loads", "OBSERVATION", 223, 234], ["Chest", "ANATOMY", 288, 293], ["pneumonia", "OBSERVATION", 365, 374]]], ["The sensitivity of chest CT in the detection of COVID-19 pneumonia was 98% [6] .", [["chest", "ANATOMY", 19, 24], ["COVID", "DISEASE", 48, 53], ["pneumonia", "DISEASE", 57, 66], ["chest", "ORGAN", 19, 24], ["chest CT", "TEST", 19, 27], ["COVID", "TEST", 48, 53], ["pneumonia", "PROBLEM", 57, 66], ["chest", "ANATOMY", 19, 24], ["pneumonia", "OBSERVATION", 57, 66]]], ["Studies have reported the imaging features, including GGO (ground glass opacity), patchy consolidation, and crazy paving signs [7] [8] [9] .", [["GGO", "DISEASE", 54, 57], ["the imaging features", "TEST", 22, 42], ["GGO (ground glass opacity", "PROBLEM", 54, 79], ["patchy consolidation", "PROBLEM", 82, 102], ["crazy paving signs", "TEST", 108, 126], ["ground glass opacity", "OBSERVATION", 59, 79], ["patchy", "OBSERVATION_MODIFIER", 82, 88], ["consolidation", "OBSERVATION", 89, 102], ["crazy", "OBSERVATION_MODIFIER", 108, 113]]], ["However, few studies reported the time differences in RT-PCR results and CT abnormalities [6, 10] , or focused on the dynamic CT changes in COVID-19 pneumonia [11] .", [["pneumonia", "DISEASE", 149, 158], ["few studies", "TEST", 9, 20], ["RT-PCR", "TEST", 54, 60], ["CT abnormalities", "TEST", 73, 89], ["the dynamic CT changes", "TEST", 114, 136], ["COVID", "TEST", 140, 145], ["pneumonia", "PROBLEM", 149, 158], ["pneumonia", "OBSERVATION", 149, 158]]], ["To better understand the early diagnostic value of chest CT and the disease course, we investigated the temporal relationship between serial RT-PCR results and serial CT imaging, and serial CT changes in patients with COVID-19 pneumonia.Patient population and clinical arrangementThe institutional review board of our hospital approved this retrospective study (FK20202815), and informed consent was waived.", [["chest", "ANATOMY", 51, 56], ["pneumonia", "DISEASE", 227, 236], ["chest", "ORGANISM_SUBDIVISION", 51, 56], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["Patient", "SPECIES", 237, 244], ["chest CT", "TEST", 51, 59], ["serial RT-PCR", "TEST", 134, 147], ["serial CT imaging", "TEST", 160, 177], ["serial CT changes", "TEST", 183, 200], ["COVID", "TEST", 218, 223], ["pneumonia", "PROBLEM", 227, 236], ["this retrospective study", "TEST", 336, 360], ["chest", "ANATOMY", 51, 56], ["pneumonia", "OBSERVATION", 227, 236]]], ["From January 21 to February 18, 2020, patients who were suspected of having novel coronavirus infection and confirmed were retrospectively enrolled in our study.", [["coronavirus infection", "DISEASE", 82, 103], ["patients", "ORGANISM", 38, 46], ["coronavirus", "ORGANISM", 82, 93], ["patients", "SPECIES", 38, 46], ["novel coronavirus infection", "PROBLEM", 76, 103], ["our study", "TEST", 151, 160], ["coronavirus infection", "OBSERVATION", 82, 103]]], ["All patients were confirmed by laboratory virus nucleic acid test (real-time fluorescence polymerase chain reaction revealed positive detection of COVID-19, RT-PCR assays using throat swab samples) according to the guideline of the Diagnosis and Treatment of Pneumonia Caused by COVID-19 (Trial Version 3) published by the Chinese government [5] .", [["throat swab samples", "ANATOMY", 177, 196], ["nucleic acid", "CHEMICAL", 48, 60], ["Pneumonia", "DISEASE", 259, 268], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["laboratory virus nucleic acid test", "TEST", 31, 65], ["fluorescence polymerase chain reaction", "TEST", 77, 115], ["COVID", "TEST", 147, 152], ["RT", "TEST", 157, 159], ["PCR assays", "TEST", 160, 170], ["throat swab samples", "TEST", 177, 196], ["Pneumonia", "PROBLEM", 259, 268], ["COVID", "TEST", 279, 284], ["Pneumonia", "OBSERVATION", 259, 268]]], ["COVID-19 infection was diagnosed as soon as any one of the nucleic acid test results was positive.", [["infection", "DISEASE", 9, 18], ["nucleic acid", "CHEMICAL", 59, 71], ["COVID-19", "SPECIES", 0, 8], ["COVID", "TEST", 0, 5], ["infection", "PROBLEM", 9, 18], ["the nucleic acid test", "TEST", 55, 76], ["infection", "OBSERVATION", 9, 18]]], ["Chest CT imaging was also conducted to determine whether pneumonia was present.", [["pneumonia", "DISEASE", 57, 66], ["Chest CT imaging", "TEST", 0, 16], ["pneumonia", "PROBLEM", 57, 66], ["pneumonia", "OBSERVATION", 57, 66]]], ["All confirmed patients underwent serial RT-PCR assays and serial chest CT imaging to provide evidence to treat the disease.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["serial RT-PCR assays", "TEST", 33, 53], ["serial chest CT imaging", "TEST", 58, 81], ["the disease", "PROBLEM", 111, 122], ["chest", "ANATOMY", 65, 70], ["disease", "OBSERVATION", 115, 122]]], ["The RT-PCR test was repeated every 3 to 5 days to monitor the dynamic conversion of the RT-PCR results (negative to positive, positive to negative).", [["The RT-PCR test", "TEST", 0, 15], ["the RT-PCR", "TEST", 84, 94]]], ["The RT-PCR results were reviewed in our hospital information system (HIS).", [["The RT-PCR", "TEST", 0, 10]]], ["We compared the differences in the time points of both methods suggesting the diagnosis of COVID-19 infection.Patient population and clinical arrangementThe RT-PCR assays were conducted with TaqMan One-Step RT-PCR kits obtained from Huirui Biotechnology Co., Ltd., which were approved by the China Food and Drug Administration (CFDA).The chest CT protocolChest CTs were conducted every 2 to 7 days to confirm the presence of pneumonia and monitor the changes in lung appearance according to the guideline of the Diagnosis and Treatment of Pneumonia Caused by COVID-19 (Trial Version 3) published by the Chinese government [5] .", [["chest", "ANATOMY", 338, 343], ["lung", "ANATOMY", 462, 466], ["COVID-19", "CHEMICAL", 91, 99], ["infection", "DISEASE", 100, 109], ["pneumonia", "DISEASE", 425, 434], ["Pneumonia", "DISEASE", 539, 548], ["lung", "ORGAN", 462, 466], ["Patient", "SPECIES", 110, 117], ["COVID-19", "SPECIES", 91, 99], ["COVID-19 infection", "PROBLEM", 91, 109], ["The RT-PCR assays", "TEST", 153, 170], ["PCR kits", "TEST", 210, 218], ["The chest CT protocolChest CTs", "TEST", 334, 364], ["pneumonia", "PROBLEM", 425, 434], ["the changes in lung appearance", "PROBLEM", 447, 477], ["Pneumonia", "PROBLEM", 539, 548], ["COVID", "TEST", 559, 564], ["infection", "OBSERVATION", 100, 109], ["chest", "ANATOMY", 338, 343], ["pneumonia", "OBSERVATION", 425, 434], ["lung", "ANATOMY", 462, 466], ["Pneumonia", "OBSERVATION", 539, 548]]], ["All images were acquired on 2 CT scanners (Brilliance iCT, Philips Healthcare, and Aqulion 64, Toshiba) using the following parameters: tube voltage, 120 kVp; automatic tube current modulation; pitch, 0.76-1.22; matrix = 512 \u00d7 512; field of volume = 400 \u00d7 400 mm; and slice thickness, 5.0 mm.", [["slice", "ANATOMY", 268, 273], ["tube", "TISSUE", 136, 140], ["slice", "TISSUE", 268, 273], ["All images", "TEST", 0, 10], ["tube voltage", "TEST", 136, 148], ["kVp", "TEST", 154, 157], ["automatic tube current modulation", "TREATMENT", 159, 192], ["pitch", "TEST", 194, 199], ["matrix", "TEST", 212, 218], ["field of volume", "TEST", 232, 247], ["slice thickness", "TEST", 268, 283], ["5.0 mm", "OBSERVATION_MODIFIER", 285, 291]]], ["All images were reconstructed with slice thickness of 1.0 mm at the same increment.", [["All images", "TEST", 0, 10], ["slice thickness", "TEST", 35, 50]]], ["Lung and mediastinum windows were simultaneously reconstructed.Image interpretation and analysisChest imaging was analyzed by two radiologists, blinded to RT-PCR results.", [["Lung", "ANATOMY", 0, 4], ["mediastinum", "ANATOMY", 9, 20], ["Lung", "ORGAN", 0, 4], ["mediastinum", "ORGAN", 9, 20], ["Lung and mediastinum windows", "TEST", 0, 28], ["Image interpretation", "TEST", 63, 83], ["analysis", "TEST", 88, 96], ["Chest imaging", "TEST", 96, 109], ["RT-PCR", "TEST", 155, 161], ["mediastinum", "ANATOMY", 9, 20], ["Chest", "ANATOMY", 96, 101]]], ["The epidemiological history and clinical symptoms were obtained when they reviewed the images.", [["clinical symptoms", "PROBLEM", 32, 49], ["the images", "TEST", 83, 93]]], ["The time point of the first positive lung CT (after the onset of the initial symptoms) and serial CT features and changes were subsequently recorded.Image interpretation and analysisThe CT features of new coronavirus-infected pneumonitis included GGO, consolidation, crazy paving patterns (inter-or intra-lobular septal thickening superimposed on GGO), fibrotic lesions, air bronchogram signs, small-vessel thickening, and pleural effusion according to expert recommendations from the Chinese Society of Radiology [12] .", [["lung", "ANATOMY", 37, 41], ["septal", "ANATOMY", 313, 319], ["fibrotic lesions", "ANATOMY", 353, 369], ["air bronchogram", "ANATOMY", 371, 386], ["vessel", "ANATOMY", 400, 406], ["pleural", "ANATOMY", 423, 430], ["coronavirus-infected pneumonitis", "DISEASE", 205, 237], ["GGO", "DISEASE", 247, 250], ["pleural effusion", "DISEASE", 423, 439], ["lung", "ORGAN", 37, 41], ["coronavirus", "ORGANISM", 205, 216], ["septal", "MULTI-TISSUE_STRUCTURE", 313, 319], ["lesions", "PATHOLOGICAL_FORMATION", 362, 369], ["vessel", "MULTI-TISSUE_STRUCTURE", 400, 406], ["the first positive lung CT", "TEST", 18, 44], ["the initial symptoms", "PROBLEM", 65, 85], ["serial CT features", "TEST", 91, 109], ["Image interpretation", "TEST", 149, 169], ["analysis", "TEST", 174, 182], ["The CT", "TEST", 182, 188], ["new coronavirus", "PROBLEM", 201, 216], ["infected pneumonitis", "PROBLEM", 217, 237], ["GGO", "PROBLEM", 247, 250], ["consolidation", "PROBLEM", 252, 265], ["crazy paving patterns", "PROBLEM", 267, 288], ["inter-or intra-lobular septal thickening", "PROBLEM", 290, 330], ["GGO)", "PROBLEM", 347, 351], ["fibrotic lesions", "PROBLEM", 353, 369], ["air bronchogram signs", "PROBLEM", 371, 392], ["small-vessel thickening", "PROBLEM", 394, 417], ["pleural effusion", "PROBLEM", 423, 439], ["lung", "ANATOMY", 37, 41], ["new", "OBSERVATION_MODIFIER", 201, 204], ["coronavirus", "OBSERVATION", 205, 216], ["infected", "OBSERVATION_MODIFIER", 217, 225], ["pneumonitis", "OBSERVATION", 226, 237], ["GGO", "OBSERVATION", 247, 250], ["consolidation", "OBSERVATION", 252, 265], ["crazy", "OBSERVATION_MODIFIER", 267, 272], ["inter", "OBSERVATION_MODIFIER", 290, 295], ["septal", "ANATOMY_MODIFIER", 313, 319], ["thickening", "OBSERVATION", 320, 330], ["GGO", "OBSERVATION", 347, 350], ["fibrotic", "OBSERVATION_MODIFIER", 353, 361], ["lesions", "OBSERVATION", 362, 369], ["air bronchogram", "OBSERVATION", 371, 386], ["small", "OBSERVATION_MODIFIER", 394, 399], ["vessel", "ANATOMY", 400, 406], ["thickening", "OBSERVATION", 407, 417], ["pleural", "ANATOMY", 423, 430], ["effusion", "OBSERVATION", 431, 439]]], ["We divided CT findings into main features (GGO, consolidation, crazy paving patterns, and fibrotic lesions) and secondary features (air bronchogram signs, small-vessel thickening, and pleural effusion).", [["fibrotic lesions", "ANATOMY", 90, 106], ["small-vessel", "ANATOMY", 155, 167], ["pleural effusion", "ANATOMY", 184, 200], ["GGO", "DISEASE", 43, 46], ["pleural effusion", "DISEASE", 184, 200], ["fibrotic lesions", "CANCER", 90, 106], ["vessel", "MULTI-TISSUE_STRUCTURE", 161, 167], ["CT findings", "TEST", 11, 22], ["GGO", "PROBLEM", 43, 46], ["consolidation", "PROBLEM", 48, 61], ["crazy paving patterns", "PROBLEM", 63, 84], ["fibrotic lesions", "PROBLEM", 90, 106], ["secondary features (air bronchogram signs", "PROBLEM", 112, 153], ["small-vessel thickening", "PROBLEM", 155, 178], ["pleural effusion", "PROBLEM", 184, 200], ["main", "OBSERVATION_MODIFIER", 28, 32], ["GGO", "OBSERVATION", 43, 46], ["consolidation", "OBSERVATION", 48, 61], ["crazy", "OBSERVATION_MODIFIER", 63, 68], ["fibrotic", "OBSERVATION_MODIFIER", 90, 98], ["lesions", "OBSERVATION", 99, 106], ["air bronchogram", "OBSERVATION", 132, 147], ["small", "OBSERVATION_MODIFIER", 155, 160], ["vessel", "ANATOMY", 161, 167], ["thickening", "OBSERVATION", 168, 178], ["pleural", "ANATOMY", 184, 191], ["effusion", "OBSERVATION", 192, 200]]], ["The number of lung lobes involved and distribution of lung abnormalities were also evaluated.", [["lung lobes", "ANATOMY", 14, 24], ["lung", "ANATOMY", 54, 58], ["lung abnormalities", "DISEASE", 54, 72], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 14, 24], ["lung", "ORGAN", 54, 58], ["lung abnormalities", "PROBLEM", 54, 72], ["number", "OBSERVATION_MODIFIER", 4, 10], ["lung", "ANATOMY", 14, 18], ["lobes", "ANATOMY_MODIFIER", 19, 24], ["distribution", "OBSERVATION_MODIFIER", 38, 50], ["lung", "ANATOMY", 54, 58], ["abnormalities", "OBSERVATION", 59, 72]]], ["The lesion distribution was classified into sub-pleural areas (predominantly the peripheral one third of the lung involved), central areas, and sub-pleural plus central areas.Image interpretation and analysisCT imaging progression presented as increasing number, size, extent and density of GGO, consolidation and crazy paving patterns, or GGO evolving to consolidation and crazy paving patterns [7, 11, 13] .", [["lesion", "ANATOMY", 4, 10], ["sub-pleural areas", "ANATOMY", 44, 61], ["lung", "ANATOMY", 109, 113], ["central areas", "ANATOMY", 125, 138], ["pleural", "ANATOMY", 148, 155], ["GGO", "DISEASE", 291, 294], ["lesion", "CANCER", 4, 10], ["pleural", "PATHOLOGICAL_FORMATION", 48, 55], ["lung", "ORGAN", 109, 113], ["pleural", "MULTI-TISSUE_STRUCTURE", 148, 155], ["The lesion distribution", "PROBLEM", 0, 23], ["sub-pleural plus central areas", "PROBLEM", 144, 174], ["Image interpretation", "TEST", 175, 195], ["analysisCT imaging progression", "TEST", 200, 230], ["GGO", "PROBLEM", 291, 294], ["consolidation", "PROBLEM", 296, 309], ["crazy paving patterns", "PROBLEM", 314, 335], ["GGO", "PROBLEM", 340, 343], ["consolidation", "PROBLEM", 356, 369], ["crazy paving patterns", "PROBLEM", 374, 395], ["lesion", "OBSERVATION", 4, 10], ["sub", "OBSERVATION_MODIFIER", 44, 47], ["pleural", "ANATOMY", 48, 55], ["areas", "ANATOMY_MODIFIER", 56, 61], ["predominantly", "OBSERVATION_MODIFIER", 63, 76], ["peripheral", "ANATOMY_MODIFIER", 81, 91], ["one third", "ANATOMY_MODIFIER", 92, 101], ["lung", "ANATOMY", 109, 113], ["central", "OBSERVATION_MODIFIER", 125, 132], ["areas", "OBSERVATION_MODIFIER", 133, 138], ["sub-", "OBSERVATION_MODIFIER", 144, 148], ["pleural", "ANATOMY", 148, 155], ["plus", "ANATOMY_MODIFIER", 156, 160], ["central", "ANATOMY_MODIFIER", 161, 168], ["increasing", "OBSERVATION_MODIFIER", 244, 254], ["number", "OBSERVATION_MODIFIER", 255, 261], ["size", "OBSERVATION_MODIFIER", 263, 267], ["extent", "OBSERVATION_MODIFIER", 269, 275], ["density", "OBSERVATION_MODIFIER", 280, 287], ["GGO", "OBSERVATION", 291, 294], ["consolidation", "OBSERVATION", 296, 309], ["crazy", "OBSERVATION_MODIFIER", 314, 319], ["GGO", "OBSERVATION_MODIFIER", 340, 343], ["consolidation", "OBSERVATION", 356, 369], ["crazy", "OBSERVATION_MODIFIER", 374, 379]]], ["The smaller size, number, extent, and density of these signs predicted COVID-19 pneumonia improvement [13] [14] [15] [16] .", [["pneumonia", "DISEASE", 80, 89], ["these signs", "TEST", 49, 60], ["COVID", "TEST", 71, 76], ["pneumonia improvement", "PROBLEM", 80, 101], ["smaller", "OBSERVATION_MODIFIER", 4, 11], ["size", "OBSERVATION_MODIFIER", 12, 16], ["number", "OBSERVATION_MODIFIER", 18, 24], ["extent", "OBSERVATION_MODIFIER", 26, 32], ["density", "OBSERVATION_MODIFIER", 38, 45], ["pneumonia", "OBSERVATION", 80, 89]]], ["The relationship between the RT-PCR results with chest imaging changes was analyzed.Therapeutic approachesGeneral treatment included supportive care, monitoring routine blood, urinalysis, biochemistry, coagulation function, chest CT, oxygen therapy, and antiviral therapy.", [["chest", "ANATOMY", 49, 54], ["blood", "ANATOMY", 169, 174], ["chest", "ANATOMY", 224, 229], ["oxygen", "CHEMICAL", 234, 240], ["oxygen", "CHEMICAL", 234, 240], ["chest", "ORGANISM_SUBDIVISION", 49, 54], ["blood", "ORGANISM_SUBSTANCE", 169, 174], ["oxygen", "SIMPLE_CHEMICAL", 234, 240], ["the RT-PCR", "TEST", 25, 35], ["chest imaging changes", "TEST", 49, 70], ["Therapeutic approaches", "TREATMENT", 84, 106], ["General treatment", "TREATMENT", 106, 123], ["supportive care", "TREATMENT", 133, 148], ["monitoring routine blood", "TEST", 150, 174], ["urinalysis", "TEST", 176, 186], ["biochemistry", "TEST", 188, 200], ["coagulation function", "TEST", 202, 222], ["chest CT", "TEST", 224, 232], ["oxygen therapy", "TREATMENT", 234, 248], ["antiviral therapy", "TREATMENT", 254, 271], ["chest", "ANATOMY", 49, 54], ["chest", "ANATOMY", 224, 229]]], ["Respiratory and circulation support were used for severe patients.Discharge criteriaThe nucleic acid test and CT imaging were following up to the time of discharge.", [["nucleic acid", "CHEMICAL", 88, 100], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["Respiratory and circulation support", "TREATMENT", 0, 35], ["The nucleic acid test", "TEST", 84, 105], ["CT imaging", "TEST", 110, 120], ["circulation support", "OBSERVATION", 16, 35]]], ["According to the guideline of the Diagnosis and Treatment of Pneumonia Caused by COVID-19 (Trial Version 3) published by the Chinese government [5] , the criteria of hospital discharge met all of the following conditions: (1) body temperature returned to normal for at least 3 days; (2) respiratory symptoms markedly improved; (3) chest imaging distinctly improved; and (4) continuous RT-PCR assays with sputum samples or nasopharyngeal or throat swab samples converted to negative at 2 time intervals of at least 24 h.Statistical analysisContinuous variables were presented as mean \u00b1 standard deviation, and categorical variables were expressed as frequencies and percentages.", [["body", "ANATOMY", 226, 230], ["respiratory", "ANATOMY", 287, 298], ["chest", "ANATOMY", 331, 336], ["sputum samples", "ANATOMY", 404, 418], ["nasopharyngeal", "ANATOMY", 422, 436], ["throat swab samples", "ANATOMY", 440, 459], ["Pneumonia", "DISEASE", 61, 70], ["body", "ORGANISM_SUBDIVISION", 226, 230], ["chest", "ORGAN", 331, 336], ["nasopharyngeal", "CANCER", 422, 436], ["Pneumonia", "PROBLEM", 61, 70], ["COVID", "TEST", 81, 86], ["body temperature", "TEST", 226, 242], ["respiratory symptoms", "PROBLEM", 287, 307], ["chest imaging", "TEST", 331, 344], ["continuous RT-PCR assays", "TEST", 374, 398], ["sputum samples", "TEST", 404, 418], ["nasopharyngeal or throat swab samples", "TEST", 422, 459], ["mean \u00b1 standard deviation, and categorical variables", "PROBLEM", 578, 630], ["Pneumonia", "OBSERVATION", 61, 70], ["normal", "OBSERVATION", 255, 261], ["chest", "ANATOMY", 331, 336], ["nasopharyngeal", "ANATOMY", 422, 436], ["throat", "ANATOMY", 440, 446]]], ["The t test was used to determine the differences in the time of RT-PCR first positive results and chest CT first positive findings (after the onset of the initial symptoms), the time of RT-PCR conversion to negative and CT finding improvements (after the onset of the initial symptoms).", [["The t test", "TEST", 0, 10], ["RT-PCR", "TEST", 64, 70], ["chest CT", "TEST", 98, 106], ["the initial symptoms", "PROBLEM", 151, 171], ["RT-PCR conversion", "TREATMENT", 186, 203], ["CT", "TEST", 220, 222], ["the initial symptoms", "PROBLEM", 264, 284], ["chest", "ANATOMY", 98, 103]]], ["The chi-squared test and Fisher's exact test were performed to compare the changes in CT features, number of lung lobes involved, and lesion distribution on serial CT images.", [["lung lobes", "ANATOMY", 109, 119], ["lesion", "ANATOMY", 134, 140], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 109, 119], ["The chi-squared test", "TEST", 0, 20], ["Fisher's exact test", "TEST", 25, 44], ["CT features", "TEST", 86, 97], ["serial CT images", "TEST", 157, 173], ["lung", "ANATOMY", 109, 113], ["lobes", "ANATOMY_MODIFIER", 114, 119], ["lesion", "OBSERVATION", 134, 140]]], ["A two-tailed p value < 0.05 was considered statistically significant.", [["A two-tailed p value", "TEST", 0, 20], ["significant", "OBSERVATION_MODIFIER", 57, 68]]], ["All statistical analyses were conducted using SPSS version 21.0 (SPSS Inc).Study populationFrom January 21 to February 18, 2020, 155 consecutive patients confirmed with COVID-19 pneumonia (87 males and 68 females aged from 9 months to 82 years, mean age 42.97 \u00b1 14.85 years, including 4 pediatric patients aged 9 months, 6 years, 6.5 years, and 8 years respectively) were included in this study.", [["pneumonia", "DISEASE", 178, 187], ["patients", "ORGANISM", 145, 153], ["patients", "ORGANISM", 297, 305], ["patients", "SPECIES", 145, 153], ["patients", "SPECIES", 297, 305], ["All statistical analyses", "TEST", 0, 24], ["SPSS version", "TEST", 46, 58], ["pneumonia", "PROBLEM", 178, 187], ["this study", "TEST", 384, 394], ["pneumonia", "OBSERVATION", 178, 187]]], ["All patients had history of Wuhan exposure or close contact with the patients confirmed or highly suspected of COVID-19 infection within 2 weeks before the onset of illness.", [["infection", "DISEASE", 120, 129], ["illness", "DISEASE", 165, 172], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 69, 77], ["COVID-19 infection", "PROBLEM", 111, 129], ["illness", "PROBLEM", 165, 172], ["infection", "OBSERVATION", 120, 129]]], ["The initial symptoms included fever, cough, chest distress, shortness of breath, fatigue, and diarrhea.", [["chest", "ANATOMY", 44, 49], ["fever", "DISEASE", 30, 35], ["cough", "DISEASE", 37, 42], ["chest distress", "DISEASE", 44, 58], ["shortness of breath", "DISEASE", 60, 79], ["fatigue", "DISEASE", 81, 88], ["diarrhea", "DISEASE", 94, 102], ["chest", "ORGANISM_SUBDIVISION", 44, 49], ["The initial symptoms", "PROBLEM", 0, 20], ["fever", "PROBLEM", 30, 35], ["cough", "PROBLEM", 37, 42], ["chest distress", "PROBLEM", 44, 58], ["shortness of breath", "PROBLEM", 60, 79], ["fatigue", "PROBLEM", 81, 88], ["diarrhea", "PROBLEM", 94, 102], ["chest", "ANATOMY", 44, 49], ["fatigue", "OBSERVATION", 81, 88], ["diarrhea", "OBSERVATION", 94, 102]]], ["The initial laboratory examinations showed decreased lymphocyte percentages and increased C-reactive protein and erythrocyte sedimentation rates.", [["lymphocyte", "ANATOMY", 53, 63], ["erythrocyte", "ANATOMY", 113, 124], ["lymphocyte", "CELL", 53, 63], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 90, 108], ["erythrocyte", "CELL", 113, 124], ["C-reactive protein", "PROTEIN", 90, 108], ["The initial laboratory examinations", "TEST", 0, 35], ["decreased lymphocyte percentages", "PROBLEM", 43, 75], ["increased C-reactive protein", "PROBLEM", 80, 108], ["erythrocyte sedimentation rates", "TEST", 113, 144], ["decreased lymphocyte percentages", "OBSERVATION", 43, 75], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["-reactive protein", "OBSERVATION", 91, 108], ["erythrocyte sedimentation", "OBSERVATION", 113, 138]]], ["All patients were discharged upon meeting the discharge criteria and continuously quarantined at home after an average hospitalization period of 17.27 \u00b1 5.68 days (range, 10-30 days).The time comparison between serial RT-PCR results and chest CT findingsAll patients underwent RT-PCR assays 3 to 7 times with time intervals of 3 to 5 days (average 4.5 days), and chest CT scans 4 to 6 times (4 times for every pediatric patient) with time intervals of 2 to 7 days (average 4.7 days).", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 258, 266], ["patient", "ORGANISM", 420, 427], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 258, 266], ["patient", "SPECIES", 420, 427], ["serial RT-PCR", "TEST", 211, 224], ["chest CT findings", "TEST", 237, 254], ["RT-PCR assays", "TEST", 277, 290], ["chest CT scans", "TEST", 363, 377], ["chest", "ANATOMY", 237, 242], ["chest", "ANATOMY", 363, 368]]], ["Numbers of patients with CT abnormality and who were RT-PCR positive at each day are listed in Table 2 .The time comparison between serial RT-PCR results and chest CT findingsThe initial RT-PCR positive results and lung CT abnormality time, RT-PCR conversion to negative time, and CT finding improvement time (after the onset of initial symptoms) are summarized in Table 3Serial chest CT image evaluationBased on the degree of lung involvement and CT findings, three stages were identified from the onset of initial symptoms: stage 1 (0-3 days), stage 2 (4-7 days), and stage 3 (8-14 days and later).Serial chest CT image evaluationThe typical course of COVID-19 pneumonia is demonstrated by serial chest CT images (Figs.", [["lung", "ANATOMY", 215, 219], ["lung", "ANATOMY", 427, 431], ["pneumonia", "DISEASE", 663, 672], ["patients", "ORGANISM", 11, 19], ["lung", "ORGAN", 215, 219], ["lung", "ORGAN", 427, 431], ["patients", "SPECIES", 11, 19], ["CT abnormality", "TEST", 25, 39], ["RT-PCR", "TEST", 53, 59], ["serial RT-PCR", "TEST", 132, 145], ["chest CT findings", "TEST", 158, 175], ["The initial RT-PCR", "TEST", 175, 193], ["lung CT abnormality", "TEST", 215, 234], ["CT", "TEST", 281, 283], ["initial symptoms", "PROBLEM", 329, 345], ["3Serial chest CT image", "TEST", 371, 393], ["lung involvement", "PROBLEM", 427, 443], ["CT findings", "TEST", 448, 459], ["initial symptoms", "PROBLEM", 508, 524], ["stage 2", "PROBLEM", 546, 553], ["Serial chest CT image evaluation", "TEST", 600, 632], ["COVID-19 pneumonia", "PROBLEM", 654, 672], ["serial chest CT images", "TEST", 692, 714], ["chest", "ANATOMY", 158, 163], ["lung", "ANATOMY", 215, 219], ["chest", "ANATOMY", 379, 384], ["lung", "ANATOMY", 427, 431], ["involvement", "OBSERVATION", 432, 443], ["chest", "ANATOMY", 607, 612], ["typical", "OBSERVATION_MODIFIER", 636, 643], ["course", "OBSERVATION_MODIFIER", 644, 650], ["pneumonia", "OBSERVATION", 663, 672], ["chest", "ANATOMY", 699, 704]]], ["The CT characteristics are summarized in Table 4 .", [["The CT characteristics", "TEST", 0, 22]]], ["In the main CT features, GGO was predominant in stage 1, then consolidation and crazy paving signs dramatically increased in stage 2.", [["GGO", "DISEASE", 25, 28], ["GGO", "PROBLEM", 25, 28], ["stage 1", "PROBLEM", 48, 55], ["consolidation", "PROBLEM", 62, 75], ["crazy paving signs", "PROBLEM", 80, 98], ["GGO", "OBSERVATION", 25, 28], ["predominant", "OBSERVATION_MODIFIER", 33, 44], ["stage 1", "OBSERVATION_MODIFIER", 48, 55], ["consolidation", "OBSERVATION", 62, 75], ["crazy", "OBSERVATION_MODIFIER", 80, 85], ["paving", "OBSERVATION_MODIFIER", 86, 92], ["signs", "OBSERVATION_MODIFIER", 93, 98], ["dramatically", "OBSERVATION_MODIFIER", 99, 111], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["stage 2", "OBSERVATION_MODIFIER", 125, 132]]], ["In stage 3, fibrotic lesion growth markedly increased, accompanied by consolidation and crazy paving signs (Fig. 4 ).", [["fibrotic lesion", "ANATOMY", 12, 27], ["fibrotic lesion", "PATHOLOGICAL_FORMATION", 12, 27], ["fibrotic lesion growth", "PROBLEM", 12, 34], ["consolidation", "PROBLEM", 70, 83], ["crazy paving signs", "PROBLEM", 88, 106], ["stage 3", "OBSERVATION_MODIFIER", 3, 10], ["fibrotic", "OBSERVATION_MODIFIER", 12, 20], ["lesion", "OBSERVATION", 21, 27], ["growth", "OBSERVATION_MODIFIER", 28, 34], ["markedly", "OBSERVATION_MODIFIER", 35, 43], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["consolidation", "OBSERVATION", 70, 83], ["crazy", "OBSERVATION_MODIFIER", 88, 93]]], ["There were significant differences in the main CT features among the different stages (\u03c7 2 = 219.00, p = 0.000).", [["significant", "OBSERVATION_MODIFIER", 11, 22], ["differences", "OBSERVATION_MODIFIER", 23, 34], ["main", "OBSERVATION_MODIFIER", 42, 46]]], ["The comparison among groups also demonstrated significant differences between stages 1 and 2 (\u03c7 2 = 155.98, p = 0.000), stages 1 and 3 (\u03c7 2 = 186.45, p = 0.000), and stages 2 and 3 (\u03c7 2 = 16.99, p = 0.001).Serial chest CT image evaluationAmong the secondary CT features, small-vessel thickening dominated stage 1.", [["small-vessel", "ANATOMY", 271, 283], ["vessel", "MULTI-TISSUE_STRUCTURE", 277, 283], ["p", "TEST", 108, 109], ["stages", "TEST", 120, 126], ["p", "TEST", 150, 151], ["stages", "TEST", 166, 172], ["p", "TEST", 195, 196], ["Serial chest CT image evaluation", "TEST", 206, 238], ["the secondary CT features", "TEST", 244, 269], ["small-vessel thickening", "PROBLEM", 271, 294], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["chest", "ANATOMY", 213, 218], ["small", "OBSERVATION_MODIFIER", 271, 276], ["vessel", "ANATOMY", 277, 283], ["thickening", "OBSERVATION", 284, 294]]], ["Air bronchogram signs gradually increased in stages 2 and 3.", [["Air bronchogram signs", "TEST", 0, 21], ["bronchogram", "OBSERVATION", 4, 15], ["gradually", "OBSERVATION_MODIFIER", 22, 31], ["increased", "OBSERVATION_MODIFIER", 32, 41]]], ["Pleural effusion was rare throughout the disease course (Fig. 5 ).", [["Pleural effusion", "ANATOMY", 0, 16], ["Pleural effusion", "DISEASE", 0, 16], ["Pleural", "PATHOLOGICAL_FORMATION", 0, 7], ["Pleural effusion", "PROBLEM", 0, 16], ["effusion", "OBSERVATION", 8, 16]]], ["There were significant differences in the secondary CT features among the different stages (\u03c7 2 = 48.58, p = 0.000).", [["the secondary CT features", "TEST", 38, 63], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["differences", "OBSERVATION_MODIFIER", 23, 34]]], ["The comparison among groups also demonstrated significant differences between stages 1 and 2 (\u03c7 2 = 23.87, p = 0.000) and stages 1 and 3 (\u03c7 2 = 48.10, p = 0.000), but no differences between stages 2 and 3 (\u03c7 2 = 3.70, p = 0.157).Serial chest CT image evaluationThe changes in the number of lung lobes involved on serial CT scans are demonstrated in Fig. 6 .", [["lung lobes", "ANATOMY", 290, 300], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 290, 300], ["significant differences between stages", "PROBLEM", 46, 84], ["p", "TEST", 107, 108], ["stages", "TEST", 122, 128], ["p", "TEST", 151, 152], ["p", "TEST", 218, 219], ["Serial chest CT image evaluation", "TEST", 229, 261], ["serial CT scans", "TEST", 313, 328], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["no", "UNCERTAINTY", 167, 169], ["chest", "ANATOMY", 236, 241], ["number", "OBSERVATION_MODIFIER", 280, 286], ["lung", "ANATOMY", 290, 294], ["lobes", "ANATOMY_MODIFIER", 295, 300]]], ["For the number of lung lobes involved, there were statistically significant differences among the different stages (\u03c7 2 = 29.30, p = 0.001).", [["lung lobes", "ANATOMY", 18, 28], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 18, 28], ["lung", "ANATOMY", 18, 22], ["lobes", "ANATOMY_MODIFIER", 23, 28], ["statistically", "OBSERVATION_MODIFIER", 50, 63], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["differences", "OBSERVATION_MODIFIER", 76, 87]]], ["The comparison among groups demonstrated statistically significant differences between stages 1 and 3 (\u03c7 2 = 25.55, p = 0.000), but no differences between stages 1 and 2 (\u03c7 2 = 9.29, p = 0.098) and stages 2 and 3 (\u03c7 2 = 8.55, p = 0.129).Serial chest CT image evaluationThere were statistically significant differences in lesion distribution among the different stages (\u03c7 2 = 50.99, p = 0.000).", [["lesion", "ANATOMY", 321, 327], ["lesion", "CANCER", 321, 327], ["p", "TEST", 183, 184], ["stages", "TEST", 198, 204], ["p", "TEST", 226, 227], ["Serial chest CT image evaluation", "TEST", 237, 269], ["statistically significant differences in lesion distribution", "PROBLEM", 280, 340], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["no", "UNCERTAINTY", 132, 134], ["chest", "ANATOMY", 244, 249], ["statistically", "OBSERVATION_MODIFIER", 280, 293], ["significant", "OBSERVATION_MODIFIER", 294, 305], ["differences", "OBSERVATION_MODIFIER", 306, 317], ["lesion", "OBSERVATION", 321, 327], ["different", "OBSERVATION_MODIFIER", 351, 360], ["stages", "OBSERVATION_MODIFIER", 361, 367]]], ["The comparison among groups demonstrated significant differences between stages 1 and 2 (p = 0.000) and stages 1 and 3 (p = 0.000), but no differences between stages 2 and 3 (\u03c7 2 = 0.841, p = 0.359).DiscussionIn this study, we evaluated the temporal relationship between the appearance and resolution of CT findings and the RT-PCR evidence of COVID-19 virus presence and investigated lung imaging changes in COVID-19 pneumonia over time.", [["lung", "ANATOMY", 384, 388], ["pneumonia", "DISEASE", 417, 426], ["COVID-19 virus", "ORGANISM", 343, 357], ["lung", "ORGAN", 384, 388], ["COVID-19 virus", "SPECIES", 343, 357], ["COVID-19", "SPECIES", 408, 416], ["p", "TEST", 188, 189], ["this study", "TEST", 212, 222], ["CT findings", "TEST", 304, 315], ["the RT-PCR", "TEST", 320, 330], ["COVID-19 virus presence", "PROBLEM", 343, 366], ["lung imaging", "TEST", 384, 396], ["COVID", "TEST", 408, 413], ["pneumonia", "PROBLEM", 417, 426], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["no", "UNCERTAINTY", 136, 138], ["lung", "ANATOMY", 384, 388], ["pneumonia", "OBSERVATION", 417, 426]]], ["This study's major findings were twofold: first, the initial chest CT abnormality time was significantly shorter than the initial RT-PCR positive results, and the lung CT improvement time was shorter than the RT-PCR conversion to negative; second, chest CT is a reliable, non-invasive, rapid tool to monitor the occurrence, deterioration, and improvements in COVID-19 pneumonia.", [["chest", "ANATOMY", 61, 66], ["lung", "ANATOMY", 163, 167], ["pneumonia", "DISEASE", 368, 377], ["chest", "ORGAN", 61, 66], ["lung", "ORGAN", 163, 167], ["This study", "TEST", 0, 10], ["the initial chest CT abnormality", "TEST", 49, 81], ["the lung CT", "TEST", 159, 170], ["the RT", "TEST", 205, 211], ["PCR conversion", "TEST", 212, 226], ["chest CT", "TEST", 248, 256], ["deterioration", "PROBLEM", 324, 337], ["COVID", "TEST", 359, 364], ["pneumonia", "PROBLEM", 368, 377], ["chest", "ANATOMY", 61, 66], ["lung", "ANATOMY", 163, 167], ["chest", "ANATOMY", 248, 253], ["pneumonia", "OBSERVATION", 368, 377]]], ["The confirmation of COVID-19 infection depended on viral nucleic acid test using RT-PCR assays, which determined whether patients should be hospitalized or quarantine at home.", [["infection", "DISEASE", 29, 38], ["nucleic acid", "CHEMICAL", 57, 69], ["COVID-19", "ORGANISM", 20, 28], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["COVID-19", "SPECIES", 20, 28], ["The confirmation", "TEST", 0, 16], ["COVID", "TEST", 20, 25], ["19 infection", "PROBLEM", 26, 38], ["viral nucleic acid test", "TEST", 51, 74], ["RT-PCR assays", "TEST", 81, 94], ["infection", "OBSERVATION", 29, 38]]], ["But the RT-PCR test had distinct limitations due to its low sensitivity, insufficient stability, and relatively long processing time to obtain results.", [["the RT-PCR test", "TEST", 4, 19], ["its low sensitivity", "PROBLEM", 52, 71], ["stability", "OBSERVATION_MODIFIER", 86, 95]]], ["Some studies reported that the positive rate of RT-PCR assays for throat swab samples was 30-60% [17, 18] .", [["throat swab samples", "ANATOMY", 66, 85], ["throat swab samples", "CANCER", 66, 85], ["Some studies", "TEST", 0, 12], ["RT", "TEST", 48, 50], ["PCR assays", "TEST", 51, 61], ["throat swab samples", "TEST", 66, 85]]], ["Many factors can affect the RT-PCR results, including sampling operations, specimen sources (upper or lower respiratory tract), sampling timing, and the detection kit's performance [18] .", [["specimen", "ANATOMY", 75, 83], ["lower respiratory tract", "ANATOMY", 102, 125], ["upper", "ORGANISM_SUBDIVISION", 93, 98], ["lower", "ORGANISM_SUBDIVISION", 102, 107], ["respiratory tract", "ORGANISM_SUBDIVISION", 108, 125], ["the RT-PCR", "TEST", 24, 34], ["sampling operations", "TREATMENT", 54, 73], ["specimen sources (upper or lower respiratory tract", "PROBLEM", 75, 125], ["sampling timing", "TEST", 128, 143], ["the detection kit's performance", "TEST", 149, 180], ["upper", "ANATOMY_MODIFIER", 93, 98], ["lower", "ANATOMY_MODIFIER", 102, 107], ["respiratory tract", "ANATOMY", 108, 125]]], ["A recent study showed that the salivary viral load was highest during the first week after symptom onset [19] , which could account for the rapid spread of this pandemic at the early stage.", [["salivary", "ANATOMY", 31, 39], ["salivary", "ORGAN", 31, 39], ["A recent study", "TEST", 0, 14], ["the salivary viral load", "PROBLEM", 27, 50], ["symptom onset", "PROBLEM", 91, 104], ["the rapid spread", "PROBLEM", 136, 152], ["this pandemic", "PROBLEM", 156, 169], ["could account for", "UNCERTAINTY", 118, 135], ["rapid", "OBSERVATION_MODIFIER", 140, 145], ["spread", "OBSERVATION_MODIFIER", 146, 152]]], ["Patients without timely isolation and therapy due to initial negative RT-PCR results definitely cause COVID-19 to spread.DiscussionChest CT is a non-invasive, rapid, convenient imaging diagnostic tool and can detect mild lung abnormalities at the early stage of COVID-19 pneumonia.", [["lung", "ANATOMY", 221, 225], ["lung abnormalities", "DISEASE", 221, 239], ["pneumonia", "DISEASE", 271, 280], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 221, 225], ["Patients", "SPECIES", 0, 8], ["timely isolation", "TREATMENT", 17, 33], ["therapy", "TREATMENT", 38, 45], ["PCR", "TEST", 73, 76], ["COVID", "TEST", 102, 107], ["DiscussionChest CT", "TEST", 121, 139], ["convenient imaging diagnostic tool", "TEST", 166, 200], ["mild lung abnormalities", "PROBLEM", 216, 239], ["COVID", "TEST", 262, 267], ["pneumonia", "PROBLEM", 271, 280], ["mild", "OBSERVATION_MODIFIER", 216, 220], ["lung", "ANATOMY", 221, 225], ["abnormalities", "OBSERVATION", 226, 239], ["early stage", "OBSERVATION_MODIFIER", 247, 258], ["pneumonia", "OBSERVATION", 271, 280]]], ["Our study showed that the initial chest CT abnormality time (3.23 \u00b1 3.04 days) was significantly shorter than that of the initial RT-PCR positive results (5.84 \u00b1 3.23 days).", [["chest", "ANATOMY", 34, 39], ["chest", "ORGAN", 34, 39], ["Our study", "TEST", 0, 9], ["the initial chest CT abnormality", "TEST", 22, 54], ["chest", "ANATOMY", 34, 39]]], ["Our study was in agreement with previous research [6] that revealed that 29% (15/51) of patients had negative RT-PCR and positive CT results at initial presentation and 2% (1/51) demonstrated the opposite [6] .", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["Our study", "TEST", 0, 9]]], ["Therefore, CT plays a vital role in the early detection of COVID-19 pneumonia, especially for patients with initial negative RT-PCR results.", [["pneumonia", "DISEASE", 68, 77], ["patients", "ORGANISM", 94, 102], ["CT", "PROTEIN", 11, 13], ["patients", "SPECIES", 94, 102], ["COVID-19", "SPECIES", 59, 67], ["CT", "TEST", 11, 13], ["COVID", "TEST", 59, 64], ["pneumonia", "PROBLEM", 68, 77], ["pneumonia", "OBSERVATION", 68, 77]]], ["However, the specificity of CT for diagnosing COVID-19 pneumonia varies.", [["pneumonia", "DISEASE", 55, 64], ["CT", "TEST", 28, 30], ["diagnosing", "TEST", 35, 45], ["COVID", "TEST", 46, 51], ["pneumonia varies", "PROBLEM", 55, 71], ["pneumonia", "OBSERVATION", 55, 64]]], ["Tao et al [17] reported that the sensitivity and specificity of chest CT for indicating COVID-19 infection was 97% and 25%, respectively.", [["chest", "ANATOMY", 64, 69], ["infection", "DISEASE", 97, 106], ["chest", "ORGAN", 64, 69], ["COVID-19", "SPECIES", 88, 96], ["the sensitivity", "TEST", 29, 44], ["chest CT", "TEST", 64, 72], ["COVID", "TEST", 88, 93], ["infection", "PROBLEM", 97, 106], ["chest", "ANATOMY", 64, 69]]], ["Bai et al reported that seven radiologists demonstrated sensitivities of 80%, 67%, 97%, 93%, 83%, 73%, and 70% and specificities of 100%, 93%, 7%, 100%, 93%, 93%, and 100% [20] .", [["sensitivities", "TEST", 56, 69], ["specificities", "TEST", 115, 128]]], ["Although the RT-PCR test is the gold standard for the diagnosis of COVID-19 infection, chest CT examination is essential for the early identification of potential patients and Fig. 1 A 42 -year-old female patient presented with fever for 2 days. a The baseline CT scan (2 days after initial symptom, stage 1) obtained 2 days before the first positive RT-PCR test showed discrete GGO and consolidation in her bilateral lower lobes. b The follow-up CT 2 days later (day 4, stage 2) showed enlarged patchy consolidation in her bilateral lower lobes, accompanied by air bronchogram signs.", [["chest", "ANATOMY", 87, 92], ["lower lobes", "ANATOMY", 418, 429], ["lower lobes", "ANATOMY", 534, 545], ["infection", "DISEASE", 76, 85], ["fever", "DISEASE", 228, 233], ["COVID-19", "CELL", 67, 75], ["chest", "ORGAN", 87, 92], ["patients", "ORGANISM", 163, 171], ["female", "ORGANISM", 198, 204], ["patient", "ORGANISM", 205, 212], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 418, 429], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 534, 545], ["patients", "SPECIES", 163, 171], ["patient", "SPECIES", 205, 212], ["COVID-19", "SPECIES", 67, 75], ["the RT-PCR test", "TEST", 9, 24], ["COVID-19 infection", "PROBLEM", 67, 85], ["chest CT examination", "TEST", 87, 107], ["fever", "PROBLEM", 228, 233], ["The baseline CT scan", "TEST", 248, 268], ["initial symptom", "PROBLEM", 283, 298], ["PCR test", "TEST", 354, 362], ["discrete GGO", "PROBLEM", 370, 382], ["consolidation in her bilateral lower lobes", "PROBLEM", 387, 429], ["The follow-up CT", "TEST", 433, 449], ["enlarged patchy consolidation in her bilateral lower lobes", "PROBLEM", 487, 545], ["air bronchogram signs", "PROBLEM", 562, 583], ["infection", "OBSERVATION", 76, 85], ["chest", "ANATOMY", 87, 92], ["fever", "OBSERVATION", 228, 233], ["discrete", "OBSERVATION_MODIFIER", 370, 378], ["GGO", "OBSERVATION", 379, 382], ["consolidation", "OBSERVATION", 387, 400], ["bilateral", "ANATOMY_MODIFIER", 408, 417], ["lower lobes", "ANATOMY", 418, 429], ["enlarged", "OBSERVATION_MODIFIER", 487, 495], ["patchy", "OBSERVATION_MODIFIER", 496, 502], ["consolidation", "OBSERVATION", 503, 516], ["bilateral", "ANATOMY_MODIFIER", 524, 533], ["lower lobes", "ANATOMY", 534, 545], ["air bronchogram", "OBSERVATION", 562, 577]]], ["New GGO was detected in the right middle lobe and left lingual segment. c The follow-up CT 5 days later (day 9, stage 3) obtained 2 days before RT-PCR converting to negative showed that the size of consolidation decreased. d Another 3 days later (day 12, stage 3), CT scan demonstrated that the lesions were further reduced in size and fibrotic lesions were predominant helps to determine treatment strategies.", [["right middle lobe", "ANATOMY", 28, 45], ["left lingual segment", "ANATOMY", 50, 70], ["lesions", "ANATOMY", 295, 302], ["fibrotic lesions", "ANATOMY", 336, 352], ["GGO", "CANCER", 4, 7], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 34, 45], ["lingual segment", "MULTI-TISSUE_STRUCTURE", 55, 70], ["c", "GENE_OR_GENE_PRODUCT", 72, 73], ["lesions", "PATHOLOGICAL_FORMATION", 295, 302], ["fibrotic lesions", "CANCER", 336, 352], ["New GGO", "PROBLEM", 0, 7], ["The follow-up CT", "TEST", 74, 90], ["RT-PCR", "TEST", 144, 150], ["consolidation", "PROBLEM", 198, 211], ["CT scan", "TEST", 265, 272], ["the lesions", "PROBLEM", 291, 302], ["fibrotic lesions", "PROBLEM", 336, 352], ["treatment strategies", "TREATMENT", 389, 409], ["GGO", "OBSERVATION", 4, 7], ["right middle lobe", "ANATOMY", 28, 45], ["left", "ANATOMY_MODIFIER", 50, 54], ["lingual", "ANATOMY_MODIFIER", 55, 62], ["segment", "ANATOMY_MODIFIER", 63, 70], ["size", "OBSERVATION_MODIFIER", 190, 194], ["consolidation", "OBSERVATION", 198, 211], ["decreased", "OBSERVATION_MODIFIER", 212, 221], ["lesions", "OBSERVATION", 295, 302], ["reduced", "OBSERVATION_MODIFIER", 316, 323], ["size", "OBSERVATION_MODIFIER", 327, 331], ["fibrotic", "OBSERVATION_MODIFIER", 336, 344], ["lesions", "OBSERVATION", 345, 352]]], ["COVID-19 infection was upgraded from epidemic to pandemic by the World Health Organization (WHO) on March 11, 2020 [21] .", [["COVID-19", "CHEMICAL", 0, 8], ["infection", "DISEASE", 9, 18], ["COVID-19", "SPECIES", 0, 8], ["COVID", "TEST", 0, 5], ["infection", "PROBLEM", 9, 18], ["infection", "OBSERVATION", 9, 18]]], ["Thus, chest CT will certainly play a crucial role in the early detection of the disease to contain the pandemic's spread.DiscussionOur study also found that the lung CT improvement time (11.58 \u00b1 4.59 days) was significantly shorter than that of RT-PCR conversion to negative (14.38 \u00b1 5.78 days).", [["chest", "ANATOMY", 6, 11], ["lung", "ANATOMY", 161, 165], ["lung", "ORGAN", 161, 165], ["chest CT", "TEST", 6, 14], ["the disease", "PROBLEM", 76, 87], ["the pandemic's spread", "PROBLEM", 99, 120], ["DiscussionOur study", "TEST", 121, 140], ["the lung CT", "TEST", 157, 168], ["RT", "TEST", 245, 247], ["PCR conversion", "TEST", 248, 262], ["chest", "ANATOMY", 6, 11], ["disease", "OBSERVATION", 80, 87], ["pandemic", "OBSERVATION_MODIFIER", 103, 111], ["lung", "ANATOMY", 161, 165]]], ["This indicates that CT is very useful for monitoring the course of COVID-19 pneumonia to direct clinicians to adjust the therapeutic strategy.DiscussionIn our study, dynamic serial chest CT examination (4-6 times) with a relatively large patient population provided reliable data to observe the disease course.", [["chest", "ANATOMY", 181, 186], ["pneumonia", "DISEASE", 76, 85], ["patient", "ORGANISM", 238, 245], ["patient", "SPECIES", 238, 245], ["COVID-19", "SPECIES", 67, 75], ["CT", "TEST", 20, 22], ["COVID", "TEST", 67, 72], ["pneumonia", "PROBLEM", 76, 85], ["the therapeutic strategy", "TREATMENT", 117, 141], ["our study", "TEST", 155, 164], ["dynamic serial chest CT examination", "TEST", 166, 201], ["a relatively large patient population", "PROBLEM", 219, 256], ["the disease course", "PROBLEM", 291, 309], ["pneumonia", "OBSERVATION", 76, 85], ["chest", "ANATOMY", 181, 186], ["large", "OBSERVATION_MODIFIER", 232, 237]]], ["We divided the disease into 3 stages according to the time since the onset of the initial symptoms.", [["the disease", "PROBLEM", 11, 22], ["the initial symptoms", "PROBLEM", 78, 98], ["disease", "OBSERVATION", 15, 22]]], ["At the early stage, the CT features of COVID-19 are predominantly GGO and small-vessel thickening.", [["small-vessel", "ANATOMY", 74, 86], ["GGO", "DISEASE", 66, 69], ["vessel", "MULTI-TISSUE_STRUCTURE", 80, 86], ["the CT features", "TEST", 20, 35], ["COVID", "TEST", 39, 44], ["predominantly GGO", "PROBLEM", 52, 69], ["small-vessel thickening", "PROBLEM", 74, 97], ["predominantly", "OBSERVATION_MODIFIER", 52, 65], ["GGO", "OBSERVATION", 66, 69], ["small", "OBSERVATION_MODIFIER", 74, 79], ["vessel", "ANATOMY", 80, 86], ["thickening", "OBSERVATION", 87, 97]]], ["GGO is the main CT feature, and small-vessel thickening is the secondary feature.", [["small-vessel", "ANATOMY", 32, 44], ["GGO", "DISEASE", 0, 3], ["vessel", "MULTI-TISSUE_STRUCTURE", 38, 44], ["GGO", "PROBLEM", 0, 3], ["small-vessel thickening", "PROBLEM", 32, 55], ["main", "OBSERVATION_MODIFIER", 11, 15], ["small", "OBSERVATION_MODIFIER", 32, 37], ["vessel", "ANATOMY", 38, 44], ["thickening", "OBSERVATION", 45, 55], ["secondary", "OBSERVATION_MODIFIER", 63, 72]]], ["As the disease progresses, GGO evolves to consolidation.", [["GGO", "DISEASE", 27, 30], ["GGO", "PROBLEM", 27, 30], ["consolidation", "PROBLEM", 42, 55], ["disease", "OBSERVATION", 7, 14], ["GGO", "OBSERVATION", 27, 30], ["consolidation", "OBSERVATION", 42, 55]]], ["Crazy paving signs are also markedly enhanced as the disease progresses.", [["signs", "OBSERVATION", 13, 18], ["markedly", "OBSERVATION_MODIFIER", 28, 36], ["enhanced", "OBSERVATION_MODIFIER", 37, 45], ["disease", "OBSERVATION", 53, 60]]], ["At stage 2, air bronchogram signs are also dramatically increased as secondary signs of consolidation.", [["air bronchogram signs", "PROBLEM", 12, 33], ["consolidation", "PROBLEM", 88, 101], ["air bronchogram", "OBSERVATION", 12, 27], ["dramatically", "OBSERVATION_MODIFIER", 43, 55], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["consolidation", "OBSERVATION", 88, 101]]], ["Small-vessel thickening is still abundant as the secondary sign of GGO and consolidation.", [["vessel", "ANATOMY", 6, 12], ["GGO", "DISEASE", 67, 70], ["vessel", "MULTI-TISSUE_STRUCTURE", 6, 12], ["Small-vessel thickening", "PROBLEM", 0, 23], ["GGO", "PROBLEM", 67, 70], ["consolidation", "PROBLEM", 75, 88], ["-", "OBSERVATION_MODIFIER", 5, 6], ["vessel", "ANATOMY", 6, 12], ["thickening", "OBSERVATION", 13, 23], ["GGO", "OBSERVATION", 67, 70], ["consolidation", "OBSERVATION", 75, 88]]], ["We also noticed that fibrotic lesions were gradually added, which represents the reparative process.", [["fibrotic lesions", "ANATOMY", 21, 37], ["fibrotic lesions", "CANCER", 21, 37], ["fibrotic lesions", "PROBLEM", 21, 37], ["the reparative process", "PROBLEM", 77, 99], ["fibrotic", "OBSERVATION_MODIFIER", 21, 29], ["lesions", "OBSERVATION", 30, 37], ["reparative process", "OBSERVATION", 81, 99]]], ["At stage 3, fibrotic lesions significantly increased, accompanied by more consolidation, GGO, and crazy paving signs.", [["fibrotic lesions", "ANATOMY", 12, 28], ["GGO", "DISEASE", 89, 92], ["fibrotic lesions", "PATHOLOGICAL_FORMATION", 12, 28], ["fibrotic lesions", "PROBLEM", 12, 28], ["consolidation", "PROBLEM", 74, 87], ["GGO", "PROBLEM", 89, 92], ["crazy paving signs", "PROBLEM", 98, 116], ["fibrotic", "OBSERVATION_MODIFIER", 12, 20], ["lesions", "OBSERVATION", 21, 28], ["significantly", "OBSERVATION_MODIFIER", 29, 42], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["more", "OBSERVATION_MODIFIER", 69, 73], ["consolidation", "OBSERVATION", 74, 87], ["GGO", "OBSERVATION", 89, 92], ["crazy", "OBSERVATION_MODIFIER", 98, 103]]], ["This indicates the reparative and progressive process of COVID-19 pneumonia simultaneously, and various CT features coexist at stage 3.", [["pneumonia", "DISEASE", 66, 75], ["COVID", "TEST", 57, 62], ["pneumonia", "PROBLEM", 66, 75], ["various CT features", "TEST", 96, 115], ["reparative", "OBSERVATION_MODIFIER", 19, 29], ["progressive", "OBSERVATION_MODIFIER", 34, 45], ["pneumonia", "OBSERVATION", 66, 75]]], ["Our study demonstrated that the lung improvement time was 11.58 \u00b1 4.59 days.", [["lung", "ANATOMY", 32, 36], ["lung", "ORGAN", 32, 36], ["Our study", "TEST", 0, 9], ["lung", "ANATOMY", 32, 36], ["improvement", "OBSERVATION_MODIFIER", 37, 48]]], ["The CT feature changes during follow-up in our study were in agreement with other reports [22, 23] .", [["The CT", "TEST", 0, 6], ["our study", "TEST", 43, 52]]], ["The recently published proposed COVID-RADS and common lexicon would improve the communication of imaging findings and facilitate the diagnosis and management of COVID-19 patients [23] .DiscussionThe lung CT appearance may be consistent with the pathology.", [["lung", "ANATOMY", 199, 203], ["COVID", "DISEASE", 161, 166], ["patients", "ORGANISM", 170, 178], ["lung", "ORGAN", 199, 203], ["patients", "SPECIES", 170, 178], ["COVID-RADS", "TREATMENT", 32, 42], ["common lexicon", "PROBLEM", 47, 61], ["imaging findings", "TEST", 97, 113], ["COVID", "TEST", 161, 166], ["The lung CT", "TEST", 195, 206], ["the pathology", "PROBLEM", 241, 254], ["lung", "ANATOMY", 199, 203], ["may be consistent with", "UNCERTAINTY", 218, 240], ["pathology", "OBSERVATION", 245, 254]]], ["The autopsy and histological examination of COVID-19 pneumonia showed bilateral diffuse alveolar damage with proteinaceous exudate, cellular fibromyxoid exudate, pulmonary edema, reactive hyperplasia of pneumocytes, desquamation of pneumocytes, hyaline membrane formation, fibroblastic plugs in airspaces, and interstitial mononuclear inflammatory infiltration [24, 25] , which may be in accordance with the Fig. 3 A 26-year-old female patient presented with fever for 1 day. a The baseline CT scan (day 1, stage 1) obtained 3 days before the first positive RT-PCR test showed discrete GGO in her bilateral lower lobes. b The follow-up CT 2 days later (day 3, stage 1) showed that the size of GGO was markedly enlarged in the left lower lobe, accompanied by smallvessel thickening. c The follow-up CT obtained 3 days later (day 6, stage 2) showed that the lesions had progressed to consolidation in the left lower lobes and new GGO was identified in the right lower lobe.", [["alveolar", "ANATOMY", 88, 96], ["exudate", "ANATOMY", 123, 130], ["cellular fibromyxoid exudate", "ANATOMY", 132, 160], ["pulmonary", "ANATOMY", 162, 171], ["pneumocytes", "ANATOMY", 203, 214], ["pneumocytes", "ANATOMY", 232, 243], ["hyaline membrane", "ANATOMY", 245, 261], ["fibroblastic plugs", "ANATOMY", 273, 291], ["airspaces", "ANATOMY", 295, 304], ["interstitial mononuclear", "ANATOMY", 310, 334], ["lower lobes", "ANATOMY", 607, 618], ["left lower lobe", "ANATOMY", 726, 741], ["smallvessel", "ANATOMY", 758, 769], ["lesions", "ANATOMY", 856, 863], ["left lower lobes", "ANATOMY", 903, 919], ["GGO", "ANATOMY", 928, 931], ["right lower lobe", "ANATOMY", 954, 970], ["pneumonia", "DISEASE", 53, 62], ["alveolar damage", "DISEASE", 88, 103], ["pulmonary edema", "DISEASE", 162, 177], ["fever", "DISEASE", 459, 464], ["GGO", "DISEASE", 693, 696], ["GGO", "DISEASE", 928, 931], ["alveolar", "TISSUE", 88, 96], ["exudate", "ORGANISM_SUBSTANCE", 123, 130], ["cellular", "CELL", 132, 140], ["fibromyxoid exudate", "TISSUE", 141, 160], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 162, 177], ["pneumocytes", "CELL", 203, 214], ["pneumocytes", "CELL", 232, 243], ["hyaline membrane", "CELLULAR_COMPONENT", 245, 261], ["fibroblastic plugs", "TISSUE", 273, 291], ["airspaces", "MULTI-TISSUE_STRUCTURE", 295, 304], ["interstitial mononuclear", "CELL", 310, 334], ["female", "ORGANISM", 429, 435], ["patient", "ORGANISM", 436, 443], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 607, 618], ["GGO", "CANCER", 693, 696], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 731, 741], ["c", "GENE_OR_GENE_PRODUCT", 782, 783], ["lesions", "PATHOLOGICAL_FORMATION", 856, 863], ["lower lobes", "ORGAN", 908, 919], ["GGO", "CANCER", 928, 931], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 960, 970], ["patient", "SPECIES", 436, 443], ["The autopsy", "TEST", 0, 11], ["histological examination", "TEST", 16, 40], ["COVID", "TEST", 44, 49], ["pneumonia", "PROBLEM", 53, 62], ["bilateral diffuse alveolar damage", "PROBLEM", 70, 103], ["proteinaceous exudate", "PROBLEM", 109, 130], ["cellular fibromyxoid exudate", "PROBLEM", 132, 160], ["pulmonary edema", "PROBLEM", 162, 177], ["reactive hyperplasia of pneumocytes", "PROBLEM", 179, 214], ["desquamation of pneumocytes", "PROBLEM", 216, 243], ["hyaline membrane formation", "PROBLEM", 245, 271], ["fibroblastic plugs in airspaces", "PROBLEM", 273, 304], ["interstitial mononuclear inflammatory infiltration", "PROBLEM", 310, 360], ["fever", "PROBLEM", 459, 464], ["The baseline CT scan", "TEST", 478, 498], ["the first positive RT-PCR test", "TEST", 539, 569], ["discrete GGO in her bilateral lower lobes", "PROBLEM", 577, 618], ["The follow-up CT", "TEST", 622, 638], ["GGO", "PROBLEM", 693, 696], ["markedly enlarged in the left lower lobe", "PROBLEM", 701, 741], ["smallvessel thickening", "PROBLEM", 758, 780], ["The follow-up CT", "TEST", 784, 800], ["the lesions", "PROBLEM", 852, 863], ["consolidation in the left lower lobes", "PROBLEM", 882, 919], ["new GGO", "PROBLEM", 924, 931], ["bilateral", "ANATOMY_MODIFIER", 70, 79], ["diffuse", "OBSERVATION_MODIFIER", 80, 87], ["alveolar damage", "OBSERVATION", 88, 103], ["proteinaceous", "OBSERVATION_MODIFIER", 109, 122], ["exudate", "OBSERVATION", 123, 130], ["cellular", "OBSERVATION_MODIFIER", 132, 140], ["fibromyxoid exudate", "OBSERVATION", 141, 160], ["pulmonary", "ANATOMY", 162, 171], ["edema", "OBSERVATION", 172, 177], ["reactive", "OBSERVATION_MODIFIER", 179, 187], ["hyperplasia", "OBSERVATION", 188, 199], ["pneumocytes", "OBSERVATION", 203, 214], ["desquamation", "OBSERVATION_MODIFIER", 216, 228], ["pneumocytes", "OBSERVATION", 232, 243], ["hyaline membrane formation", "OBSERVATION", 245, 271], ["fibroblastic plugs", "OBSERVATION", 273, 291], ["airspaces", "ANATOMY_MODIFIER", 295, 304], ["interstitial", "ANATOMY_MODIFIER", 310, 322], ["mononuclear", "OBSERVATION_MODIFIER", 323, 334], ["inflammatory", "OBSERVATION_MODIFIER", 335, 347], ["may be", "UNCERTAINTY", 378, 384], ["fever", "OBSERVATION", 459, 464], ["discrete", "OBSERVATION_MODIFIER", 577, 585], ["GGO", "OBSERVATION", 586, 589], ["bilateral", "ANATOMY_MODIFIER", 597, 606], ["lower lobes", "ANATOMY", 607, 618], ["size", "OBSERVATION_MODIFIER", 685, 689], ["GGO", "OBSERVATION", 693, 696], ["markedly", "OBSERVATION_MODIFIER", 701, 709], ["enlarged", "OBSERVATION", 710, 718], ["left lower lobe", "ANATOMY", 726, 741], ["smallvessel", "OBSERVATION_MODIFIER", 758, 769], ["thickening", "OBSERVATION", 770, 780], ["lesions", "OBSERVATION", 856, 863], ["consolidation", "OBSERVATION", 882, 895], ["left lower lobes", "ANATOMY", 903, 919], ["new", "OBSERVATION_MODIFIER", 924, 927], ["GGO", "OBSERVATION", 928, 931], ["right lower lobe", "ANATOMY", 954, 970]]], ["Crazy paving signs were detected in the left lower lobe. d Another 3 days later (day 9, stage 3), a CT scan showed lesion progression in the right lower lobe, accompanied by crazy paving signs. e The follow-up CT scan 3 days later (day 12, stage 3), 3 days before RT-PCR converting to negative, showed that the size of the lesions decreased, fibrotic lesions were predominant in the right lower lobe, and crazy paving signs dominated the left lower lesion. f Another 3 days later (day 15, stage 3), a CT scan demonstrated that the lesions were further improved and fibrotic lesions left [25] .", [["left lower lobe", "ANATOMY", 40, 55], ["lesion", "ANATOMY", 115, 121], ["right lower lobe", "ANATOMY", 141, 157], ["lesions", "ANATOMY", 323, 330], ["fibrotic lesions", "ANATOMY", 342, 358], ["right lower lobe", "ANATOMY", 383, 399], ["left lower lesion", "ANATOMY", 438, 455], ["lesions", "ANATOMY", 531, 538], ["fibrotic lesions", "ANATOMY", 565, 581], ["lesion progression in the right lower lobe", "DISEASE", 115, 157], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 45, 55], ["lower lobe", "ORGANISM_SUBDIVISION", 147, 157], ["lesions", "PATHOLOGICAL_FORMATION", 323, 330], ["fibrotic lesions", "CANCER", 342, 358], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 389, 399], ["lower lesion", "PATHOLOGICAL_FORMATION", 443, 455], ["lesions", "PATHOLOGICAL_FORMATION", 531, 538], ["fibrotic lesions", "CANCER", 565, 581], ["a CT scan", "TEST", 98, 107], ["lesion progression in the right lower lobe", "PROBLEM", 115, 157], ["crazy paving signs", "PROBLEM", 174, 192], ["The follow-up CT scan", "TEST", 196, 217], ["RT-PCR", "TEST", 264, 270], ["the lesions", "PROBLEM", 319, 330], ["fibrotic lesions", "PROBLEM", 342, 358], ["crazy paving signs", "PROBLEM", 405, 423], ["the left lower lesion", "PROBLEM", 434, 455], ["a CT scan", "TEST", 499, 508], ["the lesions", "PROBLEM", 527, 538], ["fibrotic lesions", "PROBLEM", 565, 581], ["left lower lobe", "ANATOMY", 40, 55], ["lesion", "OBSERVATION", 115, 121], ["progression", "OBSERVATION_MODIFIER", 122, 133], ["right lower lobe", "ANATOMY", 141, 157], ["crazy", "OBSERVATION_MODIFIER", 174, 179], ["size", "OBSERVATION_MODIFIER", 311, 315], ["lesions", "OBSERVATION", 323, 330], ["decreased", "OBSERVATION_MODIFIER", 331, 340], ["fibrotic", "OBSERVATION_MODIFIER", 342, 350], ["lesions", "OBSERVATION", 351, 358], ["predominant", "OBSERVATION_MODIFIER", 364, 375], ["right lower lobe", "ANATOMY", 383, 399], ["crazy", "OBSERVATION_MODIFIER", 405, 410], ["left", "ANATOMY_MODIFIER", 438, 442], ["lower", "ANATOMY_MODIFIER", 443, 448], ["lesion", "OBSERVATION", 449, 455], ["lesions", "OBSERVATION", 531, 538], ["improved", "OBSERVATION_MODIFIER", 552, 560], ["fibrotic", "OBSERVATION_MODIFIER", 565, 573], ["lesions", "OBSERVATION", 574, 581], ["left", "ANATOMY_MODIFIER", 582, 586]]], ["Notably, when the patients met the discharge criteria, there was still patchy consolidation left in the lung.", [["lung", "ANATOMY", 104, 108], ["patients", "ORGANISM", 18, 26], ["lung", "ORGAN", 104, 108], ["patients", "SPECIES", 18, 26], ["still patchy consolidation left in the lung", "PROBLEM", 65, 108], ["patchy", "OBSERVATION_MODIFIER", 71, 77], ["consolidation", "OBSERVATION", 78, 91], ["left", "ANATOMY_MODIFIER", 92, 96], ["lung", "ANATOMY", 104, 108]]], ["This suggests that patients should quarantine at home for an additional period (2 weeks in China) after hospital discharge.DiscussionOur study also showed that typical COVID-19 pneumonia started as unilateral or bilateral sub-pleural GGO, then evolved to consolidation involving the sub-pleural and central areas.", [["sub-pleural GGO", "ANATOMY", 222, 237], ["pleural", "ANATOMY", 287, 294], ["pneumonia", "DISEASE", 177, 186], ["patients", "ORGANISM", 19, 27], ["sub-pleural GGO", "CANCER", 222, 237], ["pleural", "MULTI-TISSUE_STRUCTURE", 287, 294], ["patients", "SPECIES", 19, 27], ["DiscussionOur study", "TEST", 123, 142], ["typical COVID", "TEST", 160, 173], ["pneumonia", "PROBLEM", 177, 186], ["unilateral", "PROBLEM", 198, 208], ["bilateral sub-pleural GGO", "PROBLEM", 212, 237], ["consolidation", "PROBLEM", 255, 268], ["pneumonia", "OBSERVATION", 177, 186], ["unilateral", "OBSERVATION_MODIFIER", 198, 208], ["bilateral", "ANATOMY_MODIFIER", 212, 221], ["sub", "OBSERVATION_MODIFIER", 222, 225], ["pleural", "ANATOMY", 226, 233], ["GGO", "OBSERVATION", 234, 237], ["consolidation", "OBSERVATION", 255, 268], ["sub", "OBSERVATION_MODIFIER", 283, 286], ["pleural", "ANATOMY", 287, 294], ["central", "ANATOMY_MODIFIER", 299, 306], ["areas", "ANATOMY_MODIFIER", 307, 312]]], ["We also found that 12.9% of patients demonstrated normal chest CT images at the early stage.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["normal chest CT images", "TEST", 50, 72], ["chest", "ANATOMY", 57, 62]]], ["Then the number of lung lobes involved increased at stage 2.", [["lung lobes", "ANATOMY", 19, 29], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 19, 29], ["lung", "ANATOMY", 19, 23], ["lobes", "ANATOMY_MODIFIER", 24, 29], ["increased", "OBSERVATION_MODIFIER", 39, 48]]], ["However, the number of lung lobes involved remained high at stage 3 and demonstrated no significant differences compared to stage 2.", [["lung lobes", "ANATOMY", 23, 33], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 23, 33], ["significant differences", "PROBLEM", 88, 111], ["lung", "ANATOMY", 23, 27], ["lobes", "ANATOMY_MODIFIER", 28, 33], ["high", "OBSERVATION_MODIFIER", 52, 56], ["no", "UNCERTAINTY", 85, 87], ["significant", "OBSERVATION_MODIFIER", 88, 99], ["differences", "OBSERVATION_MODIFIER", 100, 111]]], ["Residual GGO, scattered consolidation, and sub-pleural parenchymal bands persisted at stage 3.", [["pleural parenchymal", "ANATOMY", 47, 66], ["GGO", "DISEASE", 9, 12], ["pleural parenchymal", "PATHOLOGICAL_FORMATION", 47, 66], ["Residual GGO", "PROBLEM", 0, 12], ["scattered consolidation", "PROBLEM", 14, 37], ["sub-pleural parenchymal bands", "PROBLEM", 43, 72], ["GGO", "OBSERVATION", 9, 12], ["scattered", "OBSERVATION_MODIFIER", 14, 23], ["consolidation", "OBSERVATION", 24, 37], ["sub-", "OBSERVATION_MODIFIER", 43, 47], ["pleural", "ANATOMY", 47, 54], ["parenchymal", "ANATOMY_MODIFIER", 55, 66], ["bands", "OBSERVATION", 67, 72], ["stage 3", "OBSERVATION_MODIFIER", 86, 93]]], ["Thus, patients still need to be followed up after hospital discharge.DiscussionThis study had limitations that merit mention.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["This study", "TEST", 79, 89]]], ["First, this is a short-term retrospective study, and long-term radiological follow-up is needed to monitor the pulmonary outcome due to the novel coronavirus infection.", [["pulmonary", "ANATOMY", 111, 120], ["coronavirus infection", "DISEASE", 146, 167], ["pulmonary", "ORGAN", 111, 120], ["coronavirus", "ORGANISM", 146, 157], ["a short-term retrospective study", "TEST", 15, 47], ["the pulmonary outcome", "PROBLEM", 107, 128], ["the novel coronavirus infection", "PROBLEM", 136, 167], ["pulmonary", "ANATOMY", 111, 120], ["coronavirus", "OBSERVATION_MODIFIER", 146, 157], ["infection", "OBSERVATION", 158, 167]]], ["Second, this study lacked severe COVID-19 pneumonia patients (including respiratory failure requiring mechanical ventilation, shock, multiple organ failure necessitating ICU care) [5] , so the changes in these patients' CT findings need to be investigated in future research.", [["respiratory", "ANATOMY", 72, 83], ["organ", "ANATOMY", 142, 147], ["pneumonia", "DISEASE", 42, 51], ["respiratory failure", "DISEASE", 72, 91], ["shock", "DISEASE", 126, 131], ["organ failure", "DISEASE", 142, 155], ["patients", "ORGANISM", 52, 60], ["organ", "ORGAN", 142, 147], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 210, 218], ["this study", "TEST", 8, 18], ["severe COVID", "PROBLEM", 26, 38], ["pneumonia", "PROBLEM", 42, 51], ["respiratory failure", "PROBLEM", 72, 91], ["mechanical ventilation", "TREATMENT", 102, 124], ["shock", "PROBLEM", 126, 131], ["multiple organ failure", "PROBLEM", 133, 155], ["ICU care", "TREATMENT", 170, 178], ["CT findings", "TEST", 220, 231], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["pneumonia", "OBSERVATION", 42, 51], ["respiratory failure", "OBSERVATION", 72, 91], ["mechanical ventilation", "OBSERVATION", 102, 124], ["organ", "ANATOMY", 142, 147], ["failure", "OBSERVATION", 148, 155]]], ["Third, the CT scans' radiation doses were not evaluated, but it is more important to detect infected patients, understand the disease course, manage patients, and contain the pandemic.DiscussionIn conclusion, chest CT plays a vital role in the early detection of COVID-19 pneumonia, monitoring lesion progression, and improving treatment strategies.", [["chest", "ANATOMY", 209, 214], ["lesion", "ANATOMY", 294, 300], ["pneumonia", "DISEASE", 272, 281], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 149, 157], ["chest", "ORGAN", 209, 214], ["lesion", "CANCER", 294, 300], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 149, 157], ["COVID-19", "SPECIES", 263, 271], ["the CT scans' radiation doses", "TEST", 7, 36], ["the pandemic", "PROBLEM", 171, 183], ["chest CT", "TEST", 209, 217], ["COVID", "TEST", 263, 268], ["pneumonia", "PROBLEM", 272, 281], ["monitoring lesion progression", "PROBLEM", 283, 312], ["improving treatment strategies", "TREATMENT", 318, 348], ["chest", "ANATOMY", 209, 214], ["pneumonia", "OBSERVATION", 272, 281]]], ["Our results indicated that CT showed lung abnormalities earlier than the time of initial positive nucleic acid tests with RT-PCR for the detection of COVID-19 infection, and demonstrated lung improvements earlier than the RT-PCR conversion to negative time.", [["lung", "ANATOMY", 37, 41], ["lung", "ANATOMY", 187, 191], ["lung abnormalities", "DISEASE", 37, 55], ["nucleic acid", "CHEMICAL", 98, 110], ["infection", "DISEASE", 159, 168], ["lung", "ORGAN", 37, 41], ["lung", "ORGAN", 187, 191], ["COVID-19", "SPECIES", 150, 158], ["CT", "TEST", 27, 29], ["lung abnormalities", "PROBLEM", 37, 55], ["initial positive nucleic acid tests", "PROBLEM", 81, 116], ["RT-PCR", "TEST", 122, 128], ["the detection", "TEST", 133, 146], ["COVID-19 infection", "PROBLEM", 150, 168], ["lung improvements", "PROBLEM", 187, 204], ["the RT", "TEST", 218, 224], ["lung", "ANATOMY", 37, 41], ["abnormalities", "OBSERVATION", 42, 55], ["infection", "OBSERVATION", 159, 168], ["lung", "ANATOMY", 187, 191], ["improvements", "OBSERVATION", 192, 204]]], ["Chest CT should be considered as a useful tool to perform in the early stage of suspected COVID-19 infection, especially during the pandemic.DiscussionFunding The authors state that this work has not received any funding.Compliance with ethical standardsGuarantor The scientific guarantor of this publication is Tao Li.Conflict of interestThe authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.Eur RadiolStatistics and biometry No complex statistical methods were necessary for this paper.Eur RadiolInformed consent Written informed consent was waived by the Institutional Review Board.Eur RadiolEthical approval Institutional Review Board approval was obtained.Methodology\u2022 retrospective \u2022 observational \u2022 multicenter study", [["infection", "DISEASE", 99, 108], ["COVID-19", "SPECIES", 90, 98], ["Chest CT", "TEST", 0, 8], ["suspected COVID-19 infection", "PROBLEM", 80, 108], ["ethical standards", "TREATMENT", 237, 254], ["complex statistical methods", "PROBLEM", 530, 557], ["multicenter study", "TEST", 806, 823], ["infection", "OBSERVATION", 99, 108], ["complex", "OBSERVATION_MODIFIER", 530, 537], ["statistical", "OBSERVATION", 538, 549]]]], "PMC4269077": [["IntroductionSince 2007 an increase in newborn calves with the bleeding syndrome Bovine Neonatal Pancytopenia (BNP) was observed all over Europe [1-3].", [["bleeding", "DISEASE", 62, 70], ["Neonatal Pancytopenia", "DISEASE", 87, 108], ["calves", "ORGANISM", 46, 52], ["Bovine", "ORGANISM", 80, 86], ["calves", "SPECIES", 46, 52], ["Bovine", "SPECIES", 80, 86], ["newborn calves", "TREATMENT", 38, 52], ["the bleeding syndrome", "PROBLEM", 58, 79], ["Bovine Neonatal Pancytopenia", "PROBLEM", 80, 108], ["BNP", "TEST", 110, 113], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["Pancytopenia", "OBSERVATION", 96, 108]]], ["Epidemiological studies showed a strong association between the occurrence of BNP in calves and vaccination of their dams with the PregSure\u00a9 BVD vaccine (Pfizer Animal Health) [2].", [["PregSure\u00a9", "CHEMICAL", 131, 140], ["BNP", "GENE_OR_GENE_PRODUCT", 78, 81], ["calves", "ORGANISM", 85, 91], ["dams", "ORGANISM", 117, 121], ["calves", "SPECIES", 85, 91], ["BVD", "SPECIES", 141, 144], ["Epidemiological studies", "TEST", 0, 23], ["BNP in calves", "PROBLEM", 78, 91], ["the PregSure\u00a9 BVD vaccine", "TREATMENT", 127, 152], ["strong", "OBSERVATION_MODIFIER", 33, 39], ["BNP", "OBSERVATION", 78, 81]]], ["Symptoms of BNP are severe internal and external bleeding, first seen around 10\u201320 days of age.", [["internal and external bleeding", "DISEASE", 27, 57], ["BNP", "GENE_OR_GENE_PRODUCT", 12, 15], ["Symptoms of BNP", "PROBLEM", 0, 15], ["severe internal and external bleeding", "PROBLEM", 20, 57], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["internal", "OBSERVATION_MODIFIER", 27, 35], ["external", "OBSERVATION_MODIFIER", 40, 48], ["bleeding", "OBSERVATION", 49, 57]]], ["Hematological signs are severe leukopenia and thrombocytopenia.", [["leukopenia", "DISEASE", 31, 41], ["thrombocytopenia", "DISEASE", 46, 62], ["Hematological signs", "TEST", 0, 19], ["severe leukopenia", "PROBLEM", 24, 41], ["thrombocytopenia", "PROBLEM", 46, 62], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["leukopenia", "OBSERVATION", 31, 41], ["thrombocytopenia", "OBSERVATION", 46, 62]]], ["In addition, trilineage hypoplasia of the bone marrow can be observed upon post-mortem examination [3-5].IntroductionColostrum of dams that had previously given birth to a calf which developed BNP contained alloantibodies recognizing bovine leukocytes [6-9].", [["bone marrow", "ANATOMY", 42, 53], ["leukocytes", "ANATOMY", 241, 251], ["hypoplasia", "DISEASE", 24, 34], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 42, 53], ["dams", "ORGANISM", 130, 134], ["calf", "ORGANISM", 172, 176], ["BNP", "GENE_OR_GENE_PRODUCT", 193, 196], ["bovine", "ORGANISM", 234, 240], ["leukocytes", "CELL", 241, 251], ["BNP", "PROTEIN", 193, 196], ["alloantibodies", "PROTEIN", 207, 221], ["bovine leukocytes", "CELL_TYPE", 234, 251], ["calf", "SPECIES", 172, 176], ["bovine", "SPECIES", 234, 240], ["bovine", "SPECIES", 234, 240], ["trilineage hypoplasia of the bone marrow", "PROBLEM", 13, 53], ["post-mortem examination", "TEST", 75, 98], ["BNP", "TEST", 193, 196], ["alloantibodies", "PROBLEM", 207, 221], ["bovine leukocytes", "TEST", 234, 251], ["trilineage", "OBSERVATION_MODIFIER", 13, 23], ["hypoplasia", "OBSERVATION", 24, 34], ["bone", "ANATOMY", 42, 46], ["marrow", "OBSERVATION", 47, 53], ["calf", "ANATOMY", 172, 176], ["bovine leukocytes", "OBSERVATION", 234, 251]]], ["Feeding this colostrum to healthy neonatal calves induced the symptoms of BNP [4,8,10].", [["colostrum", "ANATOMY", 13, 22], ["colostrum", "ORGANISM", 13, 22], ["calves", "ORGANISM", 43, 49], ["BNP", "GENE_OR_GENE_PRODUCT", 74, 77], ["calves", "SPECIES", 43, 49], ["the symptoms", "PROBLEM", 58, 70], ["BNP", "TEST", 74, 77]]], ["Proteins from the bovine kidney cell line MDBK [11], used to grow the BVD type 1 virus present in PregSure\u00a9 BVD, are the likely source of alloantigens that induce alloantibody production in vaccinated dams.", [["kidney cell line MDBK", "ANATOMY", 25, 46], ["bovine", "ORGANISM", 18, 24], ["kidney cell line MDBK", "CELL", 25, 46], ["BVD type 1 virus", "ORGANISM", 70, 86], ["PregSure\u00a9 BVD", "ORGANISM", 98, 111], ["dams", "ORGANISM", 201, 205], ["bovine kidney cell line", "CELL_LINE", 18, 41], ["alloantigens", "PROTEIN", 138, 150], ["bovine", "SPECIES", 18, 24], ["BVD type 1 virus", "SPECIES", 70, 86], ["BVD", "SPECIES", 108, 111], ["Proteins", "TEST", 0, 8], ["the bovine kidney cell line", "TREATMENT", 14, 41], ["MDBK", "TEST", 42, 46], ["the BVD type 1 virus", "PROBLEM", 66, 86], ["PregSure\u00a9 BVD", "PROBLEM", 98, 111], ["alloantigens", "PROBLEM", 138, 150], ["alloantibody production", "PROBLEM", 163, 186], ["kidney", "ANATOMY", 25, 31], ["cell line", "OBSERVATION", 32, 41], ["MDBK", "OBSERVATION_MODIFIER", 42, 46], ["BVD", "OBSERVATION", 108, 111]]], ["The alloantibodies bind MDBK cells and it was shown that an important target of these antibodies were MHC class I proteins [7,9,12].", [["MDBK cells", "ANATOMY", 24, 34], ["MDBK cells", "CELL", 24, 34], ["MHC class I", "GENE_OR_GENE_PRODUCT", 102, 113], ["alloantibodies", "PROTEIN", 4, 18], ["MDBK cells", "CELL_LINE", 24, 34], ["antibodies", "PROTEIN", 86, 96], ["MHC class I proteins", "PROTEIN", 102, 122], ["The alloantibodies bind MDBK cells", "PROBLEM", 0, 34], ["these antibodies", "TEST", 80, 96], ["MDBK cells", "OBSERVATION", 24, 34]]], ["Moreover, MDBK derived MHC class I proteins were detected in the PregSure\u00a9 BVD vaccine [9,12] and immunization of calves with PregSure\u00a9 BVD induced alloantibodies recognizing MDBK cells [7,13].IntroductionSince the incidence of BNP calves born to PregSure\u00a9 BVD vaccinated dams was estimated to be lower than 0.3% [7,9,13], it was hypothesized that factors other than vaccination per s\u00e9 play a role in the etiology of BNP.", [["MDBK", "ANATOMY", 10, 14], ["MDBK cells", "ANATOMY", 175, 185], ["PregSure", "CHEMICAL", 126, 134], ["MDBK", "CELL", 10, 14], ["MHC class I", "GENE_OR_GENE_PRODUCT", 23, 34], ["PregSure\u00a9 BVD", "ORGANISM", 65, 78], ["calves", "ORGANISM", 114, 120], ["BVD", "ORGANISM", 136, 139], ["MDBK cells", "CELL", 175, 185], ["BNP", "ORGANISM", 228, 231], ["calves", "ORGANISM_SUBDIVISION", 232, 238], ["PregSure\u00a9 BVD", "ORGANISM", 247, 260], ["dams", "ORGANISM", 272, 276], ["BNP", "GENE_OR_GENE_PRODUCT", 417, 420], ["MHC class I proteins", "PROTEIN", 23, 43], ["MDBK cells", "CELL_LINE", 175, 185], ["BNP", "PROTEIN", 417, 420], ["calves", "SPECIES", 114, 120], ["calves", "SPECIES", 232, 238], ["MDBK", "SPECIES", 10, 14], ["BVD", "SPECIES", 75, 78], ["calves", "SPECIES", 114, 120], ["BVD", "SPECIES", 136, 139], ["BVD", "SPECIES", 257, 260], ["the PregSure\u00a9 BVD vaccine", "TREATMENT", 61, 86], ["immunization of calves", "TREATMENT", 98, 120], ["PregSure", "TREATMENT", 126, 134], ["BVD induced alloantibodies recognizing MDBK cells", "PROBLEM", 136, 185], ["BNP calves", "TREATMENT", 228, 238], ["BVD vaccinated dams", "TREATMENT", 257, 276], ["vaccination", "TREATMENT", 367, 378], ["BNP", "PROBLEM", 417, 420], ["MDBK cells", "OBSERVATION", 175, 185]]], ["The prevailing hypothesis is that the pathogenesis of BNP resembles a histocompatibility (mis)match between dam and calf and is based on immunization of the dam with MDBK derived MHC class I [9,12].", [["MDBK", "ANATOMY", 166, 170], ["BNP", "GENE_OR_GENE_PRODUCT", 54, 57], ["calf", "ORGANISM_SUBDIVISION", 116, 120], ["BNP", "PROTEIN", 54, 57], ["MHC class I", "PROTEIN", 179, 190], ["calf", "SPECIES", 116, 120], ["MDBK", "SPECIES", 166, 170], ["the pathogenesis of BNP", "PROBLEM", 34, 57], ["immunization", "TREATMENT", 137, 149], ["calf", "ANATOMY", 116, 120]]], ["First, in the dam MDBK cell derived proteins, present in the Pregsure\u00a9 BVD vaccine, are presented in the context of MHC class II.", [["MDBK cell", "ANATOMY", 18, 27], ["MDBK cell", "CELL", 18, 27], ["Pregsure\u00a9 BVD", "ORGANISM", 61, 74], ["MHC class II", "GENE_OR_GENE_PRODUCT", 116, 128], ["dam MDBK cell", "CELL_LINE", 14, 27], ["MHC class II", "PROTEIN", 116, 128], ["MDBK", "SPECIES", 18, 22], ["BVD", "SPECIES", 71, 74], ["the Pregsure\u00a9 BVD vaccine", "TREATMENT", 57, 82]]], ["The resulting T cell help to B cells recognizing allogeneic differences between MDBK cells and the dam will result in the generation of alloantibodies which are also present in the colostrum.", [["T cell", "ANATOMY", 14, 20], ["B cells", "ANATOMY", 29, 36], ["MDBK cells", "ANATOMY", 80, 90], ["colostrum", "ANATOMY", 181, 190], ["T cell", "CELL", 14, 20], ["B cells", "CELL", 29, 36], ["MDBK cells", "CELL", 80, 90], ["colostrum", "ORGANISM", 181, 190], ["B cells", "CELL_TYPE", 29, 36], ["MDBK cells", "CELL_LINE", 80, 90], ["alloantibodies", "PROTEIN", 136, 150], ["allogeneic differences between MDBK cells", "PROBLEM", 49, 90], ["alloantibodies", "PROBLEM", 136, 150], ["MDBK cells", "OBSERVATION", 80, 90], ["alloantibodies", "OBSERVATION", 136, 150]]], ["Due to tolerance to self-antigens, dams do not exhibit adverse effects after vaccination, i.e. the vaccine induced alloantibodies do not recognize alloantigens expressed in the dam.", [["dams", "ORGANISM", 35, 39], ["alloantigens", "GENE_OR_GENE_PRODUCT", 147, 159], ["alloantibodies", "PROTEIN", 115, 129], ["alloantigens", "PROTEIN", 147, 159], ["adverse effects", "PROBLEM", 55, 70], ["vaccination", "TREATMENT", 77, 88], ["the vaccine", "TREATMENT", 95, 106], ["alloantibodies", "PROBLEM", 115, 129]]], ["The maternal alloantibodies transferred to the calf via the colostrum will recognize alloantigens in case of a partial alloantigen match between MDBK cells and the calf.", [["colostrum", "ANATOMY", 60, 69], ["MDBK cells", "ANATOMY", 145, 155], ["calf", "ANATOMY", 164, 168], ["calf", "ORGANISM", 47, 51], ["colostrum", "ORGANISM", 60, 69], ["MDBK cells", "CELL", 145, 155], ["calf", "ORGANISM_SUBDIVISION", 164, 168], ["alloantigens", "PROTEIN", 85, 97], ["alloantigen", "PROTEIN", 119, 130], ["MDBK cells", "CELL_LINE", 145, 155], ["calf", "SPECIES", 47, 51], ["calf", "SPECIES", 164, 168], ["The maternal alloantibodies", "TREATMENT", 0, 27], ["a partial alloantigen match between MDBK cells", "TREATMENT", 109, 155], ["alloantibodies", "OBSERVATION", 13, 27], ["calf", "ANATOMY", 47, 51], ["colostrum", "ANATOMY", 60, 69], ["MDBK cells", "OBSERVATION", 145, 155], ["calf", "ANATOMY", 164, 168]]], ["We hypothesized that the rare occurrence of BNP after Pregsure\u00a9 BVD vaccination may depend both on the capability of the dam\u2019s immune system to present the MDBK alloantigens via MHC class II, as well as the degree of alloantigen (mis)match between the dam and the MDBK cell line (and the calf and the MDBK cell line, respectively) and the ensuing immune response of the dam.", [["MDBK", "ANATOMY", 156, 160], ["MDBK cell line", "ANATOMY", 264, 278], ["calf", "ANATOMY", 288, 292], ["MDBK cell line", "ANATOMY", 301, 315], ["BNP", "GENE_OR_GENE_PRODUCT", 44, 47], ["Pregsure\u00a9 BVD", "ORGANISM", 54, 67], ["MDBK alloantigens", "CELL", 156, 173], ["MHC class II", "GENE_OR_GENE_PRODUCT", 178, 190], ["alloantigen", "GENE_OR_GENE_PRODUCT", 217, 228], ["MDBK cell line", "CELL", 264, 278], ["calf", "ORGANISM", 288, 292], ["MDBK cell line", "CELL", 301, 315], ["MDBK alloantigens", "PROTEIN", 156, 173], ["MHC class II", "PROTEIN", 178, 190], ["alloantigen", "PROTEIN", 217, 228], ["MDBK cell line", "CELL_LINE", 264, 278], ["MDBK cell line", "CELL_LINE", 301, 315], ["calf", "SPECIES", 288, 292], ["BVD", "SPECIES", 64, 67], ["MDBK", "SPECIES", 156, 160], ["BNP", "PROBLEM", 44, 47], ["Pregsure\u00a9 BVD vaccination", "TREATMENT", 54, 79], ["alloantigen (mis", "TREATMENT", 217, 233], ["the MDBK cell line", "TREATMENT", 260, 278], ["the MDBK cell line", "TREATMENT", 297, 315], ["MDBK cell line", "OBSERVATION", 264, 278], ["calf", "ANATOMY", 288, 292], ["MDBK cell line", "OBSERVATION", 301, 315]]], ["Since alloantigens (including MHC I and MHC class I associated B2M) and MHC class II are genetically determined and therefore heritable, we studied whether differences in these genes between dams and/or calves may explain why BNP only occurs in part of the calves born to PregSure\u00a9 BVD vaccinated dams.", [["PregSure\u00a9", "CHEMICAL", 272, 281], ["alloantigens", "GENE_OR_GENE_PRODUCT", 6, 18], ["MHC I", "GENE_OR_GENE_PRODUCT", 30, 35], ["MHC class I", "GENE_OR_GENE_PRODUCT", 40, 51], ["B2M", "GENE_OR_GENE_PRODUCT", 63, 66], ["MHC class II", "GENE_OR_GENE_PRODUCT", 72, 84], ["dams", "ORGANISM", 191, 195], ["calves", "ORGANISM", 203, 209], ["BNP", "GENE_OR_GENE_PRODUCT", 226, 229], ["calves", "ORGANISM", 257, 263], ["PregSure\u00a9 BVD", "ORGANISM", 272, 285], ["alloantigens", "PROTEIN", 6, 18], ["MHC I", "PROTEIN", 30, 35], ["MHC class I", "PROTEIN", 40, 51], ["B2M", "PROTEIN", 63, 66], ["MHC class II", "PROTEIN", 72, 84], ["BNP", "PROTEIN", 226, 229], ["calves", "SPECIES", 203, 209], ["calves", "SPECIES", 257, 263], ["BVD", "SPECIES", 282, 285], ["BNP", "TEST", 226, 229], ["calves", "ANATOMY", 203, 209]]], ["First we studied the heritability of the development of BNP in the calf as a potential dam or calf trait.", [["calf", "ANATOMY", 67, 71], ["BNP", "GENE_OR_GENE_PRODUCT", 56, 59], ["calf", "ORGANISM_SUBDIVISION", 67, 71], ["calf", "ORGANISM_SUBDIVISION", 94, 98], ["BNP", "PROTEIN", 56, 59], ["calf", "SPECIES", 67, 71], ["calf", "SPECIES", 94, 98], ["BNP in the calf", "PROBLEM", 56, 71], ["calf trait", "PROBLEM", 94, 104], ["BNP", "OBSERVATION", 56, 59], ["calf", "ANATOMY", 67, 71], ["calf", "ANATOMY", 94, 98]]], ["Next, to elucidate if these genes genes play a role in the development of BNP we sequenced and compared the MHC and B2M candidate genes and characterized BNP associated alloantibodies.Heritability study ::: Materials and methodsThe data used for the heritability study were a subset of data from a large multi country epidemiological study on BNP [2] and concerned Dutch farms that participated in this study.", [["BNP", "GENE_OR_GENE_PRODUCT", 74, 77], ["B2M", "GENE_OR_GENE_PRODUCT", 116, 119], ["BNP", "GENE_OR_GENE_PRODUCT", 154, 157], ["genes genes", "DNA", 28, 39], ["BNP", "PROTEIN", 74, 77], ["MHC and B2M candidate genes", "DNA", 108, 135], ["BNP", "PROTEIN", 154, 157], ["alloantibodies", "PROTEIN", 169, 183], ["BNP", "TEST", 74, 77], ["the MHC", "TEST", 104, 111], ["BNP associated alloantibodies", "PROBLEM", 154, 183], ["Heritability study", "TEST", 184, 202], ["the heritability study", "TEST", 246, 268], ["BNP", "TEST", 343, 346], ["this study", "TEST", 398, 408], ["alloantibodies", "OBSERVATION", 169, 183]]], ["Data on herd matched BNP and non-BNP calves were collected by on farm questionnaires.", [["BNP", "GENE_OR_GENE_PRODUCT", 21, 24], ["calves", "ORGANISM", 37, 43], ["calves", "SPECIES", 37, 43], ["BNP", "TEST", 21, 24]]], ["We looked at the heritability of the development of BNP within the calf as a trait of Pregsure\u00a9 BVD vaccinated dams as well as of calves born to these dams.", [["calf", "ANATOMY", 67, 71], ["BNP", "GENE_OR_GENE_PRODUCT", 52, 55], ["calf", "ORGANISM_SUBDIVISION", 67, 71], ["BVD", "ORGANISM", 96, 99], ["dams", "ORGANISM", 111, 115], ["calves", "ORGANISM", 130, 136], ["dams", "ORGANISM", 151, 155], ["BNP", "PROTEIN", 52, 55], ["calf", "SPECIES", 67, 71], ["calves", "SPECIES", 130, 136], ["BVD", "SPECIES", 96, 99], ["BNP within the calf", "PROBLEM", 52, 71], ["Pregsure\u00a9 BVD vaccinated dams", "TREATMENT", 86, 115], ["BNP", "OBSERVATION", 52, 55], ["calf", "ANATOMY", 67, 71]]], ["The definitions for BNP and non-BNP calves used, were according to Jones et al. [2].", [["BNP", "GENE_OR_GENE_PRODUCT", 20, 23], ["calves", "ORGANISM", 36, 42], ["BNP", "PROTEIN", 20, 23], ["calves", "SPECIES", 36, 42], ["BNP", "TEST", 20, 23], ["non-BNP calves", "TREATMENT", 28, 42]]], ["A BNP calf was defined as a calf that showed one or more BNP clinical signs on or before 28 days of age; bone marrow depletion as assessed by histopathology and/or thrombocytopenia (<150 \u00d7 109/litre) and leucopenia (<5 \u00d7 109/litre).", [["bone marrow", "ANATOMY", 105, 116], ["thrombocytopenia", "DISEASE", 164, 180], ["leucopenia", "DISEASE", 204, 214], ["BNP", "GENE_OR_GENE_PRODUCT", 2, 5], ["calf", "ORGANISM_SUBSTANCE", 6, 10], ["calf", "ORGANISM_SUBDIVISION", 28, 32], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 105, 116], ["calf", "SPECIES", 6, 10], ["calf", "SPECIES", 28, 32], ["A BNP calf", "TEST", 0, 10], ["more BNP clinical signs", "PROBLEM", 52, 75], ["bone marrow depletion", "PROBLEM", 105, 126], ["thrombocytopenia", "PROBLEM", 164, 180], ["leucopenia", "PROBLEM", 204, 214], ["calf", "ANATOMY", 6, 10], ["calf", "ANATOMY", 28, 32], ["bone", "ANATOMY", 105, 109], ["marrow depletion", "OBSERVATION", 110, 126], ["thrombocytopenia", "OBSERVATION", 164, 180]]], ["A non-BNP calf was defined as a calf on the same farm as a case, aged 10\u201328 days at the time of case reporting, no clinical signs of BNP up to 28 days of age, and normal blood parameters (thrombocytes \u2265 300 \u00d7 109/litre, leucocytes \u2265 5 \u00d7 109/litre).", [["non-BNP calf", "ANATOMY", 2, 14], ["blood", "ANATOMY", 170, 175], ["thrombocytes", "ANATOMY", 188, 200], ["leucocytes", "ANATOMY", 220, 230], ["calf", "ORGANISM", 10, 14], ["calf", "ORGANISM_SUBDIVISION", 32, 36], ["BNP", "GENE_OR_GENE_PRODUCT", 133, 136], ["blood", "ORGANISM_SUBSTANCE", 170, 175], ["thrombocytes", "CELL", 188, 200], ["leucocytes", "CELL", 220, 230], ["thrombocytes", "CELL_TYPE", 188, 200], ["leucocytes", "CELL_TYPE", 220, 230], ["calf", "SPECIES", 10, 14], ["calf", "SPECIES", 32, 36], ["A non-BNP calf", "PROBLEM", 0, 14], ["BNP", "TEST", 133, 136], ["thrombocytes", "TEST", 188, 200], ["leucocytes", "TEST", 220, 230], ["calf", "ANATOMY", 10, 14], ["calf", "ANATOMY", 32, 36]]], ["To ensure that the correct phenotype, BNP or non-BNP, was assigned to the dam, only calves that were fed colostrum from their own dam were included.", [["colostrum", "ANATOMY", 105, 114], ["BNP", "GENE_OR_GENE_PRODUCT", 38, 41], ["calves", "ORGANISM", 84, 90], ["colostrum", "ORGANISM_SUBSTANCE", 105, 114], ["BNP", "PROTEIN", 38, 41], ["calves", "SPECIES", 84, 90], ["BNP", "TEST", 38, 41]]], ["Furthermore, dam-calf combinations without pedigree information were excluded.", [["calf", "SPECIES", 17, 21]]], ["Pedigrees of calves and dams were provided by the Dutch Cattle Improvement Organization (CRV, Arnhem, the Netherlands).", [["calves", "ORGANISM", 13, 19], ["dams", "ORGANISM", 24, 28], ["calves", "SPECIES", 13, 19], ["calves", "ANATOMY", 13, 19]]], ["The pedigree of dam-calf combinations meeting the inclusion criteria were traced back up to 21 generations and the final pedigree included 12 586 records.", [["calf", "ORGANISM", 20, 24], ["calf", "SPECIES", 20, 24], ["dam-calf combinations", "TREATMENT", 16, 37], ["calf", "ANATOMY", 20, 24]]], ["The first generation of the pedigree was a 100% complete for calves and 95% complete for dams.", [["calves", "ORGANISM", 61, 67], ["calves", "SPECIES", 61, 67]]], ["The data were analyzed using the software package ASReml [14], a statistical package that fits generalized linear mixed models using Residual Maximum Likelihood.", [["a statistical package", "TREATMENT", 63, 84], ["Maximum Likelihood", "OBSERVATION", 142, 160]]], ["The heritability of the development of BNP within the calf as a dam and calf trait was estimated from the dam and sire variance components of a sire-dam model.", [["calf", "ANATOMY", 54, 58], ["BNP", "GENE_OR_GENE_PRODUCT", 39, 42], ["calf", "ORGANISM_SUBDIVISION", 54, 58], ["calf", "ORGANISM_SUBDIVISION", 72, 76], ["BNP", "PROTEIN", 39, 42], ["calf", "SPECIES", 54, 58], ["calf", "SPECIES", 72, 76], ["BNP", "TEST", 39, 42], ["a dam and calf trait", "PROBLEM", 62, 82], ["a sire-dam model", "TREATMENT", 142, 158], ["BNP", "OBSERVATION", 39, 42], ["calf", "ANATOMY", 54, 58], ["calf", "ANATOMY", 72, 76]]], ["Only alloantigens inherited from the sire can be recognized by maternal alloantibodies and therefore the heritability of the development of BNP as a calf trait was estimated by calculating BNP as a sire trait.", [["alloantigens", "GENE_OR_GENE_PRODUCT", 5, 17], ["BNP", "GENE_OR_GENE_PRODUCT", 140, 143], ["calf", "ORGANISM_SUBDIVISION", 149, 153], ["BNP", "GENE_OR_GENE_PRODUCT", 189, 192], ["alloantigens", "PROTEIN", 5, 17], ["BNP", "PROTEIN", 140, 143], ["BNP", "PROTEIN", 189, 192], ["calf", "SPECIES", 149, 153], ["maternal alloantibodies", "PROBLEM", 63, 86], ["BNP", "TEST", 140, 143], ["a calf trait", "PROBLEM", 147, 159], ["calculating BNP", "PROBLEM", 177, 192], ["a sire trait", "PROBLEM", 196, 208], ["alloantibodies", "OBSERVATION", 72, 86], ["calf", "ANATOMY", 149, 153]]], ["Variables included in the data set were:Vaccination history of the dam (Yes or No) with other BVD vaccines, Blue Tongue Virus, Rota/Corona virus, Infectious Bovine Rhinotracheitis virus or other.The number of Pregsure\u00a9 BVD vaccinations (1, 2, 3, \u2265 4).Time since the last Pregsure\u00a9 BVD vaccination of the dam (divided in classes of three months).Lactation number of the dam (1, 2, 3, 4, \u2265 5).Heritability study ::: Materials and methodsBNP was fitted as a binomial variable using the logistic link function to relate binomial outcome of BNP to the linear predictor used for the generalized linear mixed model.", [["Infectious Bovine Rhinotracheitis virus", "DISEASE", 146, 185], ["BVD", "ORGANISM", 94, 97], ["Blue Tongue Virus", "ORGANISM", 108, 125], ["Rota/Corona virus", "ORGANISM", 127, 144], ["Bovine Rhinotracheitis virus", "ORGANISM", 157, 185], ["BNP", "GENE_OR_GENE_PRODUCT", 536, 539], ["BNP", "PROTEIN", 536, 539], ["Bovine Rhinotracheitis virus", "SPECIES", 157, 185], ["BVD", "SPECIES", 94, 97], ["Blue Tongue Virus, Rota/Corona virus", "SPECIES", 108, 144], ["Bovine Rhinotracheitis virus", "SPECIES", 157, 185], ["BVD", "SPECIES", 281, 284], ["other BVD vaccines", "TREATMENT", 88, 106], ["Blue Tongue Virus", "PROBLEM", 108, 125], ["Rota/Corona virus", "PROBLEM", 127, 144], ["Infectious Bovine Rhinotracheitis virus", "PROBLEM", 146, 185], ["Pregsure\u00a9 BVD vaccinations", "TREATMENT", 209, 235], ["the last Pregsure\u00a9 BVD vaccination", "TREATMENT", 262, 296], ["Heritability study", "TEST", 391, 409], ["methodsBNP", "TREATMENT", 428, 438], ["BNP", "TEST", 536, 539], ["the generalized linear mixed model", "PROBLEM", 573, 607], ["Tongue", "ANATOMY", 113, 119], ["Corona virus", "ANATOMY", 132, 144], ["generalized", "OBSERVATION_MODIFIER", 577, 588], ["linear", "OBSERVATION_MODIFIER", 589, 595], ["mixed model", "OBSERVATION", 596, 607]]]], "PMC5517379": [["INTRODUCTIONMycoplasma pneumoniae is a major cause of respiratory infection in school-age children and adolescents.", [["respiratory", "ANATOMY", 54, 65], ["respiratory infection", "DISEASE", 54, 75], ["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98], ["adolescents", "SPECIES", 103, 114], ["INTRODUCTIONMycoplasma pneumoniae", "SPECIES", 0, 33], ["INTRODUCTIONMycoplasma pneumoniae", "PROBLEM", 0, 33], ["respiratory infection", "PROBLEM", 54, 75], ["pneumoniae", "OBSERVATION", 23, 33], ["respiratory", "ANATOMY", 54, 65], ["infection", "OBSERVATION", 66, 75]]], ["Extrapulmonary manifestations of M. pneumoniae infection are known to affect dermatologic, cardiovascular, neurologic, hematologic and hepatobiliary systems in children, which are usually known to occur as complications after pneumonia [1].", [["cardiovascular", "ANATOMY", 91, 105], ["neurologic", "ANATOMY", 107, 117], ["hematologic", "ANATOMY", 119, 130], ["hepatobiliary", "ANATOMY", 135, 148], ["M. pneumoniae infection", "DISEASE", 33, 56], ["dermatologic, cardiovascular, neurologic, hematologic and hepatobiliary systems", "DISEASE", 77, 156], ["pneumonia", "DISEASE", 226, 235], ["M. pneumoniae", "ORGANISM", 33, 46], ["cardiovascular", "ANATOMICAL_SYSTEM", 91, 105], ["hepatobiliary", "ORGAN", 135, 148], ["children", "ORGANISM", 160, 168], ["M. pneumoniae", "SPECIES", 33, 46], ["children", "SPECIES", 160, 168], ["M. pneumoniae", "SPECIES", 33, 46], ["Extrapulmonary manifestations", "PROBLEM", 0, 29], ["M. pneumoniae infection", "PROBLEM", 33, 56], ["pneumonia", "PROBLEM", 226, 235], ["pneumoniae", "OBSERVATION_MODIFIER", 36, 46], ["infection", "OBSERVATION", 47, 56], ["hepatobiliary", "ANATOMY", 135, 148], ["pneumonia", "OBSERVATION", 226, 235]]], ["However, acute cholestatic hepatitis without pulmonary involvement in children with M. pneumonia infection has rarely been reported [23].", [["pulmonary", "ANATOMY", 45, 54], ["cholestatic hepatitis", "DISEASE", 15, 36], ["M. pneumonia infection", "DISEASE", 84, 106], ["pulmonary", "ORGAN", 45, 54], ["children", "ORGANISM", 70, 78], ["M. pneumonia", "ORGANISM", 84, 96], ["children", "SPECIES", 70, 78], ["M. pneumonia", "SPECIES", 84, 96], ["acute cholestatic hepatitis", "PROBLEM", 9, 36], ["pulmonary involvement", "PROBLEM", 45, 66], ["M. pneumonia infection", "PROBLEM", 84, 106], ["acute", "OBSERVATION_MODIFIER", 9, 14], ["cholestatic", "OBSERVATION_MODIFIER", 15, 26], ["hepatitis", "OBSERVATION", 27, 36], ["without", "UNCERTAINTY", 37, 44], ["pulmonary", "ANATOMY", 45, 54], ["involvement", "OBSERVATION", 55, 66], ["pneumonia", "OBSERVATION", 87, 96]]], ["We report a rare case of a child with M. pneumonia infection presenting with acute cholestatic hepatitis and other extrapulmonary manifestations in the absence of pneumonia.CASE REPORTA 9-year-old boy was admitted to our hospital due to fever and abdominal pain, which had developed 4 days before.", [["extrapulmonary", "ANATOMY", 115, 129], ["abdominal", "ANATOMY", 247, 256], ["M. pneumonia infection", "DISEASE", 38, 60], ["acute cholestatic hepatitis", "DISEASE", 77, 104], ["pneumonia", "DISEASE", 163, 172], ["fever", "DISEASE", 237, 242], ["abdominal pain", "DISEASE", 247, 261], ["child", "ORGANISM", 27, 32], ["boy", "ORGANISM", 197, 200], ["abdominal", "ORGANISM_SUBDIVISION", 247, 256], ["M. pneumonia", "SPECIES", 38, 50], ["boy", "SPECIES", 197, 200], ["M. pneumonia", "SPECIES", 38, 50], ["M. pneumonia infection", "PROBLEM", 38, 60], ["acute cholestatic hepatitis", "PROBLEM", 77, 104], ["other extrapulmonary manifestations", "PROBLEM", 109, 144], ["pneumonia", "PROBLEM", 163, 172], ["fever", "PROBLEM", 237, 242], ["abdominal pain", "PROBLEM", 247, 261], ["pneumonia", "OBSERVATION", 41, 50], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["cholestatic", "OBSERVATION_MODIFIER", 83, 94], ["hepatitis", "OBSERVATION", 95, 104], ["extrapulmonary", "ANATOMY", 115, 129], ["pneumonia", "OBSERVATION", 163, 172], ["fever", "OBSERVATION", 237, 242], ["abdominal", "ANATOMY", 247, 256], ["pain", "OBSERVATION", 257, 261]]], ["Ten days prior to admission, the patient had developed mild cough and body temperature elevation up to 37.6\u2103, which improved within 2 days without treatment.", [["body", "ANATOMY", 70, 74], ["cough", "DISEASE", 60, 65], ["patient", "ORGANISM", 33, 40], ["body", "ORGANISM_SUBDIVISION", 70, 74], ["patient", "SPECIES", 33, 40], ["mild cough", "PROBLEM", 55, 65], ["body temperature elevation", "PROBLEM", 70, 96], ["treatment", "TREATMENT", 147, 156], ["mild", "OBSERVATION_MODIFIER", 55, 59], ["cough", "OBSERVATION", 60, 65]]], ["However, he newly developed fever and right upper quadrant pain 4 days later.", [["right upper quadrant", "ANATOMY", 38, 58], ["fever", "DISEASE", 28, 33], ["right upper quadrant pain", "DISEASE", 38, 63], ["upper quadrant", "ORGANISM_SUBDIVISION", 44, 58], ["fever", "PROBLEM", 28, 33], ["right upper quadrant pain", "PROBLEM", 38, 63], ["fever", "OBSERVATION", 28, 33], ["right", "ANATOMY_MODIFIER", 38, 43], ["upper", "ANATOMY_MODIFIER", 44, 49], ["quadrant", "ANATOMY", 50, 58], ["pain", "OBSERVATION", 59, 63]]], ["Symptoms aggravated and the patient visited our hospital.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["Symptoms", "PROBLEM", 0, 8]]], ["Past medical history of the patient and family were both unremarkable.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["unremarkable", "OBSERVATION", 57, 69]]], ["Vaccination had been performed as scheduled.", [["Vaccination", "TREATMENT", 0, 11]]], ["No recent history of travel or trauma was reported.CASE REPORTOn admission, he was fully conscious and oriented.", [["trauma", "DISEASE", 31, 37], ["trauma", "PROBLEM", 31, 37]]], ["Vital signs showed a blood pressure of 88/51 mmHg, heart rate of 97 beats/min, respiratory rate of 27 breaths/min, and body temperature of 38.7\u2103.", [["blood", "ANATOMY", 21, 26], ["heart", "ANATOMY", 51, 56], ["respiratory", "ANATOMY", 79, 90], ["body", "ANATOMY", 119, 123], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["heart", "ORGAN", 51, 56], ["body", "ORGANISM_SUBDIVISION", 119, 123], ["Vital signs", "TEST", 0, 11], ["a blood pressure", "TEST", 19, 35], ["heart rate", "TEST", 51, 61], ["respiratory rate", "TEST", 79, 95], ["body temperature", "TEST", 119, 135]]], ["His heart beat was regular without murmurs, and breath sounds were clear on both lung fields.", [["heart", "ANATOMY", 4, 9], ["lung", "ANATOMY", 81, 85], ["heart", "ORGAN", 4, 9], ["lung", "ORGAN", 81, 85], ["His heart beat", "TEST", 0, 14], ["murmurs", "PROBLEM", 35, 42], ["breath sounds", "TEST", 48, 61], ["heart", "ANATOMY", 4, 9], ["without", "UNCERTAINTY", 27, 34], ["murmurs", "OBSERVATION", 35, 42], ["clear", "OBSERVATION", 67, 72], ["both", "ANATOMY_MODIFIER", 76, 80], ["lung", "ANATOMY", 81, 85], ["fields", "ANATOMY_MODIFIER", 86, 92]]], ["His abdomen was soft and flat with normoactive bowel sounds.", [["abdomen", "ANATOMY", 4, 11], ["soft", "ANATOMY", 16, 20], ["bowel", "ANATOMY", 47, 52], ["abdomen", "ORGAN", 4, 11], ["bowel", "ORGAN", 47, 52], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 16, 20], ["flat", "OBSERVATION", 25, 29], ["normoactive", "OBSERVATION", 35, 46], ["bowel", "ANATOMY", 47, 52], ["sounds", "OBSERVATION", 53, 59]]], ["However, there was tenderness in the right upper quadrant region and hepatomegaly of 3 fingerbreadths and splenomegaly of 1 fingerbreadth were palpated below the costal margins.", [["right upper quadrant region", "ANATOMY", 37, 64], ["costal margins", "ANATOMY", 162, 176], ["tenderness", "DISEASE", 19, 29], ["hepatomegaly", "DISEASE", 69, 81], ["fingerbreadths", "DISEASE", 87, 101], ["splenomegaly", "DISEASE", 106, 118], ["costal margins", "MULTI-TISSUE_STRUCTURE", 162, 176], ["tenderness in the right upper quadrant region", "PROBLEM", 19, 64], ["hepatomegaly of 3 fingerbreadths", "PROBLEM", 69, 101], ["splenomegaly of 1 fingerbreadth", "PROBLEM", 106, 137], ["tenderness", "OBSERVATION", 19, 29], ["right", "ANATOMY_MODIFIER", 37, 42], ["upper", "ANATOMY_MODIFIER", 43, 48], ["quadrant", "ANATOMY", 49, 57], ["region", "ANATOMY_MODIFIER", 58, 64], ["hepatomegaly", "OBSERVATION", 69, 81], ["3 fingerbreadths", "OBSERVATION_MODIFIER", 85, 101], ["splenomegaly", "OBSERVATION", 106, 118], ["costal", "ANATOMY", 162, 168], ["margins", "ANATOMY_MODIFIER", 169, 176]]], ["Erythematous maculopapular skin rashes without pruritis were observed on both lower extremities.", [["skin", "ANATOMY", 27, 31], ["lower extremities", "ANATOMY", 78, 95], ["skin rashes", "DISEASE", 27, 38], ["pruritis", "DISEASE", 47, 55], ["skin", "ORGAN", 27, 31], ["lower extremities", "ORGANISM_SUBDIVISION", 78, 95], ["Erythematous maculopapular skin rashes", "PROBLEM", 0, 38], ["pruritis", "PROBLEM", 47, 55], ["maculopapular", "OBSERVATION_MODIFIER", 13, 26], ["skin", "ANATOMY", 27, 31], ["rashes", "OBSERVATION", 32, 38], ["without", "UNCERTAINTY", 39, 46], ["pruritis", "OBSERVATION", 47, 55], ["both", "ANATOMY_MODIFIER", 73, 77], ["lower extremities", "ANATOMY", 78, 95]]], ["Neurologic examination was normal.CASE REPORTInitial laboratory exams showed a hemoglobin of 13.1 g/dL, hematocrit 37.0%, white blood cell (WBC) count of 6,310/mm3 with 72% neutrophils, 11% lymphocytes, 2% monocytes, and platelet count of 89,000/mm3.", [["white blood cell", "ANATOMY", 122, 138], ["WBC", "ANATOMY", 140, 143], ["neutrophils", "ANATOMY", 173, 184], ["lymphocytes", "ANATOMY", 190, 201], ["monocytes", "ANATOMY", 206, 215], ["platelet", "ANATOMY", 221, 229], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 79, 89], ["white blood cell", "CELL", 122, 138], ["WBC", "CELL", 140, 143], ["neutrophils", "CELL", 173, 184], ["lymphocytes", "CELL", 190, 201], ["monocytes", "CELL", 206, 215], ["platelet", "CELL", 221, 229], ["hemoglobin", "PROTEIN", 79, 89], ["neutrophils", "CELL_TYPE", 173, 184], ["lymphocytes", "CELL_TYPE", 190, 201], ["monocytes", "CELL_TYPE", 206, 215], ["Neurologic examination", "TEST", 0, 22], ["a hemoglobin", "TEST", 77, 89], ["dL", "TEST", 100, 102], ["hematocrit", "TEST", 104, 114], ["white blood cell", "TEST", 122, 138], ["WBC", "TEST", 140, 143], ["count", "TEST", 145, 150], ["neutrophils", "TEST", 173, 184], ["lymphocytes", "TEST", 190, 201], ["monocytes", "TEST", 206, 215], ["platelet count", "TEST", 221, 235], ["normal", "OBSERVATION", 27, 33], ["platelet count", "OBSERVATION_MODIFIER", 221, 235]]], ["Chemistry exams revealed an elevated C-reactive protein (CRP) level of 2.21 mg/dL (normal range, 0-0.3 mg/dL), aspartate aminotransferase (AST) of 2,689 IU/L (normal range, 0-40 IU/L), alanine aminotransferase (ALT) of 1,079 IU/L (normal range, 0-40 IU/L), total serum bilirubin of 1.6 mg/dL (normal range, 0-1.5 mg/dL), direct serum bilirubin of 1.4 mg/dL (normal range, 0-0.5 mg/dL), gamma-glutamyl transpeptidase of 69 IU/L (normal range, 11-49 mg/dL), serum creatinine kinase (CK) of 4,314 IU/dL (normal range, 24-204 IU/dL), and lactate dehydrogenase (LD) of 9,959 IU/L (normal range, 240-480 IU/L).", [["serum", "ANATOMY", 263, 268], ["serum", "ANATOMY", 328, 333], ["serum", "ANATOMY", 456, 461], ["aspartate", "CHEMICAL", 111, 120], ["alanine", "CHEMICAL", 185, 192], ["bilirubin", "CHEMICAL", 269, 278], ["bilirubin", "CHEMICAL", 334, 343], ["creatinine", "CHEMICAL", 462, 472], ["lactate", "CHEMICAL", 534, 541], ["aspartate", "CHEMICAL", 111, 120], ["alanine", "CHEMICAL", 185, 192], ["bilirubin", "CHEMICAL", 269, 278], ["bilirubin", "CHEMICAL", 334, 343], ["glutamyl", "CHEMICAL", 392, 400], ["creatinine", "CHEMICAL", 462, 472], ["lactate", "CHEMICAL", 534, 541], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 37, 55], ["CRP", "GENE_OR_GENE_PRODUCT", 57, 60], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 111, 137], ["AST", "SIMPLE_CHEMICAL", 139, 142], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 185, 209], ["ALT", "SIMPLE_CHEMICAL", 211, 214], ["serum", "ORGANISM_SUBSTANCE", 263, 268], ["bilirubin", "SIMPLE_CHEMICAL", 269, 278], ["serum", "ORGANISM_SUBSTANCE", 328, 333], ["bilirubin", "SIMPLE_CHEMICAL", 334, 343], ["gamma-glutamyl transpeptidase", "GENE_OR_GENE_PRODUCT", 386, 415], ["serum", "ORGANISM_SUBSTANCE", 456, 461], ["creatinine kinase", "GENE_OR_GENE_PRODUCT", 462, 479], ["CK", "GENE_OR_GENE_PRODUCT", 481, 483], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 534, 555], ["C-reactive protein", "PROTEIN", 37, 55], ["CRP", "PROTEIN", 57, 60], ["aspartate aminotransferase", "PROTEIN", 111, 137], ["AST", "PROTEIN", 139, 142], ["alanine aminotransferase", "PROTEIN", 185, 209], ["ALT", "PROTEIN", 211, 214], ["gamma-glutamyl transpeptidase", "PROTEIN", 386, 415], ["serum creatinine kinase", "PROTEIN", 456, 479], ["CK", "PROTEIN", 481, 483], ["lactate dehydrogenase", "PROTEIN", 534, 555], ["Chemistry exams", "TEST", 0, 15], ["an elevated C-reactive protein", "PROBLEM", 25, 55], ["CRP", "TEST", 57, 60], ["level", "TEST", 62, 67], ["aspartate aminotransferase", "TEST", 111, 137], ["AST", "TEST", 139, 142], ["IU", "TEST", 153, 155], ["alanine aminotransferase", "TEST", 185, 209], ["ALT", "TEST", 211, 214], ["IU", "TEST", 225, 227], ["total serum bilirubin", "TEST", 257, 278], ["direct serum bilirubin", "TEST", 321, 343], ["gamma", "TEST", 386, 391], ["glutamyl transpeptidase", "TEST", 392, 415], ["serum creatinine kinase", "TEST", 456, 479], ["CK", "TEST", 481, 483], ["dL", "TEST", 497, 499], ["lactate dehydrogenase", "TEST", 534, 555], ["elevated", "OBSERVATION", 28, 36]]], ["Total serum protein and albumin was decreased to 5.5 g/dL (normal range, 6.0-8.2 g/dL) and 3.3 g/dL (normal range, 3.5-5.2 g/dL), respectively.", [["serum", "ANATOMY", 6, 11], ["serum", "ORGANISM_SUBSTANCE", 6, 11], ["albumin", "GENE_OR_GENE_PRODUCT", 24, 31], ["serum protein", "PROTEIN", 6, 19], ["Total serum protein", "TEST", 0, 19], ["albumin", "TEST", 24, 31]]], ["Peripheral blood cell morphology revealed left-shifted maturation of granulocytes and moderate thrombocytopenia, while hemolysis was not observed.", [["Peripheral blood cell", "ANATOMY", 0, 21], ["granulocytes", "ANATOMY", 69, 81], ["thrombocytopenia", "DISEASE", 95, 111], ["hemolysis", "DISEASE", 119, 128], ["Peripheral blood cell", "CELL", 0, 21], ["granulocytes", "CELL", 69, 81], ["granulocytes", "CELL_TYPE", 69, 81], ["Peripheral blood cell morphology", "TEST", 0, 32], ["left-shifted maturation of granulocytes", "PROBLEM", 42, 81], ["moderate thrombocytopenia", "PROBLEM", 86, 111], ["hemolysis", "PROBLEM", 119, 128], ["blood", "ANATOMY", 11, 16], ["cell morphology", "OBSERVATION", 17, 32], ["left", "ANATOMY_MODIFIER", 42, 46], ["shifted maturation", "OBSERVATION", 47, 65], ["granulocytes", "OBSERVATION", 69, 81], ["moderate", "OBSERVATION_MODIFIER", 86, 94], ["thrombocytopenia", "OBSERVATION", 95, 111], ["hemolysis", "OBSERVATION", 119, 128]]], ["Coagulation studies revealed a prothrombin time (PT) of 18.5 seconds (normal range, 12.6-14.9 seconds), and 1.57 international normalized ratio (INR; normal range, 0.90-1.10 INR), activated partial thromboplastin time (aPTT) of 95.5 seconds (normal range, 29.1-41.9 seconds), fibrinogen of 99 mg/dL (normal range, 182-380 mg/dL), antithrombin III activity of 75% (normal range, 83-123%).", [["prothrombin", "GENE_OR_GENE_PRODUCT", 31, 42], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 198, 212], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 276, 286], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 330, 346], ["fibrinogen", "PROTEIN", 276, 286], ["antithrombin III", "PROTEIN", 330, 346], ["Coagulation studies", "TEST", 0, 19], ["a prothrombin time", "TEST", 29, 47], ["PT", "TEST", 49, 51], ["INR", "TEST", 145, 148], ["INR", "TEST", 174, 177], ["activated partial thromboplastin time", "TEST", 180, 217], ["aPTT", "TEST", 219, 223], ["fibrinogen", "TEST", 276, 286], ["antithrombin III activity", "TEST", 330, 355]]], ["Other laboratory exams including blood urea nitrogen, creatinine, electrolytes, ammonia, lactic acid, amylase, and lipase were in normal range.CASE REPORTChest radiography conducted on admission was normal without any lesions in the lung (Fig. 1).", [["blood", "ANATOMY", 33, 38], ["lesions", "ANATOMY", 218, 225], ["lung", "ANATOMY", 233, 237], ["blood urea nitrogen", "CHEMICAL", 33, 52], ["creatinine", "CHEMICAL", 54, 64], ["ammonia", "CHEMICAL", 80, 87], ["lactic acid", "CHEMICAL", 89, 100], ["urea", "CHEMICAL", 39, 43], ["nitrogen", "CHEMICAL", 44, 52], ["creatinine", "CHEMICAL", 54, 64], ["ammonia", "CHEMICAL", 80, 87], ["lactic acid", "CHEMICAL", 89, 100], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["urea", "SIMPLE_CHEMICAL", 39, 43], ["creatinine", "SIMPLE_CHEMICAL", 54, 64], ["electrolytes", "SIMPLE_CHEMICAL", 66, 78], ["ammonia", "SIMPLE_CHEMICAL", 80, 87], ["lactic acid", "SIMPLE_CHEMICAL", 89, 100], ["amylase", "GENE_OR_GENE_PRODUCT", 102, 109], ["lipase", "GENE_OR_GENE_PRODUCT", 115, 121], ["lesions", "PATHOLOGICAL_FORMATION", 218, 225], ["lung", "ORGAN", 233, 237], ["amylase", "PROTEIN", 102, 109], ["lipase", "PROTEIN", 115, 121], ["Other laboratory exams", "TEST", 0, 22], ["blood urea nitrogen", "TEST", 33, 52], ["creatinine", "TEST", 54, 64], ["electrolytes", "TEST", 66, 78], ["ammonia", "TEST", 80, 87], ["lactic acid", "TEST", 89, 100], ["amylase", "TEST", 102, 109], ["lipase", "TEST", 115, 121], ["CASE REPORTChest radiography", "TEST", 143, 171], ["any lesions in the lung", "PROBLEM", 214, 237], ["lipase", "ANATOMY", 115, 121], ["normal range", "OBSERVATION", 130, 142], ["normal", "OBSERVATION", 199, 205], ["without", "UNCERTAINTY", 206, 213], ["lesions", "OBSERVATION", 218, 225], ["lung", "ANATOMY", 233, 237]]], ["Computed tomography (CT) scans of the abdominal revealed mild hepatomegaly with periportal edema (Fig. 2A).", [["abdominal", "ANATOMY", 38, 47], ["periportal edema", "ANATOMY", 80, 96], ["hepatomegaly", "DISEASE", 62, 74], ["periportal edema", "DISEASE", 80, 96], ["abdominal", "ORGANISM_SUBDIVISION", 38, 47], ["periportal edema", "PATHOLOGICAL_FORMATION", 80, 96], ["Computed tomography (CT) scans of the abdominal", "TEST", 0, 47], ["mild hepatomegaly", "PROBLEM", 57, 74], ["periportal edema", "PROBLEM", 80, 96], ["abdominal", "ANATOMY", 38, 47], ["mild", "OBSERVATION_MODIFIER", 57, 61], ["hepatomegaly", "OBSERVATION", 62, 74], ["periportal", "ANATOMY", 80, 90], ["edema", "OBSERVATION", 91, 96]]], ["Diffuse edematous change of the gallbladder and small amount of ascites was also found on CT images (Fig. 2B).CASE REPORTSerum antibody and polymerase chain reaction(PCR) tests to rule out other infections, including hepatitis A, hepatitis B, hepatitis C, cytomegalovirus, Epstein-Barr virus, herpes simplex virus, human herpes virus 6, varicella zoster virus, parvorvirus B19, toxoplasmosis and were all negative.", [["Diffuse edematous", "ANATOMY", 0, 17], ["gallbladder", "ANATOMY", 32, 43], ["ascites", "ANATOMY", 64, 71], ["ascites", "DISEASE", 64, 71], ["infections", "DISEASE", 195, 205], ["hepatitis A", "DISEASE", 217, 228], ["hepatitis B", "DISEASE", 230, 241], ["hepatitis C", "DISEASE", 243, 254], ["Epstein-Barr virus", "DISEASE", 273, 291], ["herpes simplex virus", "DISEASE", 293, 313], ["human herpes virus", "DISEASE", 315, 333], ["varicella zoster", "DISEASE", 337, 353], ["parvorvirus B19", "DISEASE", 361, 376], ["toxoplasmosis", "DISEASE", 378, 391], ["gallbladder", "ORGAN", 32, 43], ["hepatitis A", "ORGANISM", 217, 228], ["hepatitis B", "ORGANISM", 230, 241], ["hepatitis C", "ORGANISM", 243, 254], ["cytomegalovirus", "ORGANISM", 256, 271], ["Epstein-Barr virus", "ORGANISM", 273, 291], ["herpes simplex virus", "ORGANISM", 293, 313], ["human herpes virus 6", "ORGANISM", 315, 335], ["varicella zoster virus", "ORGANISM", 337, 359], ["parvorvirus B19", "ORGANISM", 361, 376], ["herpes simplex virus", "SPECIES", 293, 313], ["human", "SPECIES", 315, 320], ["herpes virus 6", "SPECIES", 321, 335], ["varicella zoster virus", "SPECIES", 337, 359], ["parvorvirus B19", "SPECIES", 361, 376], ["hepatitis A", "SPECIES", 217, 228], ["hepatitis B", "SPECIES", 230, 241], ["hepatitis C", "SPECIES", 243, 254], ["Epstein-Barr virus", "SPECIES", 273, 291], ["herpes simplex virus", "SPECIES", 293, 313], ["human herpes virus 6", "SPECIES", 315, 335], ["varicella zoster virus", "SPECIES", 337, 359], ["parvorvirus B19", "SPECIES", 361, 376], ["Diffuse edematous change of the gallbladder", "PROBLEM", 0, 43], ["small amount of ascites", "PROBLEM", 48, 71], ["CT images", "TEST", 90, 99], ["CASE REPORTSerum antibody", "TEST", 110, 135], ["polymerase chain reaction", "TEST", 140, 165], ["PCR) tests", "TEST", 166, 176], ["other infections", "PROBLEM", 189, 205], ["hepatitis A", "PROBLEM", 217, 228], ["hepatitis B", "PROBLEM", 230, 241], ["hepatitis C", "PROBLEM", 243, 254], ["cytomegalovirus", "PROBLEM", 256, 271], ["Epstein", "TEST", 273, 280], ["Barr virus", "PROBLEM", 281, 291], ["herpes simplex virus", "PROBLEM", 293, 313], ["human herpes virus", "PROBLEM", 315, 333], ["varicella zoster virus", "PROBLEM", 337, 359], ["parvorvirus B19", "PROBLEM", 361, 376], ["toxoplasmosis", "PROBLEM", 378, 391], ["edematous", "OBSERVATION", 8, 17], ["gallbladder", "ANATOMY", 32, 43], ["small", "OBSERVATION_MODIFIER", 48, 53], ["amount", "OBSERVATION_MODIFIER", 54, 60], ["ascites", "OBSERVATION", 64, 71], ["infections", "OBSERVATION", 195, 205], ["hepatitis", "OBSERVATION", 217, 226], ["hepatitis", "ANATOMY", 243, 252], ["cytomegalovirus", "OBSERVATION", 256, 271], ["Barr virus", "OBSERVATION", 281, 291]]], ["Respiratory PCR tests of respiratory viruses including adenovirus, influenza, parainfluenza, respiratory syncytial virus, metapneumovirus, rhinovirus, coronavirus were also all negative.", [["respiratory viruses", "DISEASE", 25, 44], ["influenza", "DISEASE", 67, 76], ["parainfluenza", "DISEASE", 78, 91], ["respiratory syncytial virus, metapneumovirus, rhinovirus, coronavirus", "DISEASE", 93, 162], ["adenovirus", "ORGANISM", 55, 65], ["parainfluenza", "ORGANISM", 78, 91], ["respiratory syncytial virus", "ORGANISM", 93, 120], ["metapneumovirus", "ORGANISM", 122, 137], ["rhinovirus", "ORGANISM", 139, 149], ["coronavirus", "ORGANISM", 151, 162], ["parainfluenza", "SPECIES", 78, 91], ["respiratory syncytial virus", "SPECIES", 93, 120], [", metapneumovirus", "SPECIES", 120, 137], ["respiratory syncytial virus", "SPECIES", 93, 120], ["Respiratory PCR tests", "TEST", 0, 21], ["respiratory viruses", "PROBLEM", 25, 44], ["adenovirus", "PROBLEM", 55, 65], ["influenza", "PROBLEM", 67, 76], ["parainfluenza", "PROBLEM", 78, 91], ["respiratory syncytial virus", "PROBLEM", 93, 120], ["metapneumovirus", "PROBLEM", 122, 137], ["rhinovirus", "PROBLEM", 139, 149], ["coronavirus", "PROBLEM", 151, 162], ["respiratory", "ANATOMY", 25, 36], ["respiratory syncytial", "ANATOMY", 93, 114]]], ["Ceruloplasmin level was 33.8 mg/dL (normal range, 20-60 mg/dL), and autoantibodies including anti-nuclear antibody, anti-smooth muscle antibody, and anti-mitochondrial antibody were all negative.", [["Ceruloplasmin", "CHEMICAL", 0, 13], ["Ceruloplasmin", "CHEMICAL", 0, 13], ["Ceruloplasmin", "GENE_OR_GENE_PRODUCT", 0, 13], ["anti-nuclear antibody", "GENE_OR_GENE_PRODUCT", 93, 114], ["anti-smooth muscle antibody", "GENE_OR_GENE_PRODUCT", 116, 143], ["anti-mitochondrial antibody", "GENE_OR_GENE_PRODUCT", 149, 176], ["autoantibodies", "PROTEIN", 68, 82], ["anti-nuclear antibody", "PROTEIN", 93, 114], ["anti-smooth muscle antibody", "PROTEIN", 116, 143], ["anti-mitochondrial antibody", "PROTEIN", 149, 176], ["Ceruloplasmin level", "TEST", 0, 19], ["autoantibodies", "TEST", 68, 82], ["anti-nuclear antibody", "TEST", 93, 114], ["anti-smooth muscle antibody", "TEST", 116, 143], ["anti-mitochondrial antibody", "TEST", 149, 176], ["anti-nuclear antibody", "OBSERVATION", 93, 114], ["anti-smooth muscle", "ANATOMY", 116, 134]]], ["Thyroid function tests were also normal.", [["Thyroid", "ANATOMY", 0, 7], ["Thyroid", "ORGAN", 0, 7], ["Thyroid function tests", "TEST", 0, 22], ["normal", "OBSERVATION", 33, 39]]], ["Serum antibodies to M. pneumoniae detected by enzyme-linked immunosorbent assay (ELISA) were 16.1 AU/mL for immunoglobulin (Ig) G, and 1.3 index value (ratio between the absorbance value of the test sample and that of the cut-off) for IgM.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["M. pneumoniae", "ORGANISM", 20, 33], ["immunoglobulin (Ig) G", "GENE_OR_GENE_PRODUCT", 108, 129], ["Serum antibodies", "PROTEIN", 0, 16], ["immunoglobulin", "PROTEIN", 108, 122], ["Ig", "PROTEIN", 124, 126], ["M. pneumoniae", "SPECIES", 20, 33], ["M. pneumoniae", "SPECIES", 20, 33], ["Serum antibodies", "TEST", 0, 16], ["M. pneumoniae", "TEST", 20, 33], ["enzyme", "TEST", 46, 52], ["immunosorbent assay", "TEST", 60, 79], ["ELISA", "TEST", 81, 86], ["immunoglobulin", "TEST", 108, 122], ["G", "TEST", 128, 129], ["index value", "TEST", 139, 150], ["ratio", "TEST", 152, 157], ["the absorbance value", "TEST", 166, 186], ["the test sample", "TEST", 190, 205]]], ["Serum levels for cardiac troponin I, CK-MB, and N-terminal pro-brain natriuretic peptide were all in normal range.", [["Serum", "ANATOMY", 0, 5], ["cardiac", "ANATOMY", 17, 24], ["N", "CHEMICAL", 48, 49], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["cardiac troponin I", "GENE_OR_GENE_PRODUCT", 17, 35], ["CK-MB", "GENE_OR_GENE_PRODUCT", 37, 42], ["N-terminal pro-brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 48, 88], ["cardiac troponin I", "PROTEIN", 17, 35], ["CK", "PROTEIN", 37, 39], ["Serum levels", "TEST", 0, 12], ["cardiac troponin I", "TEST", 17, 35], ["CK", "TEST", 37, 39], ["MB", "TEST", 40, 42], ["N-terminal pro-brain natriuretic peptide", "TEST", 48, 88], ["normal range", "OBSERVATION", 101, 113]]], ["Transthoracic echocardiogram findings were unremarkable.", [["Transthoracic echocardiogram", "TEST", 0, 28], ["unremarkable", "OBSERVATION", 43, 55]]], ["Serum isoenzyme electrophoresis revealed 100% of CK-MM, while CK-MB and CK-BB both constituted 0%.CASE REPORTThe patient received empirical antibiotics of intravenous cefotaxime and clarithromycin, with daily supplements of fresh frozen plasma and cryoprecipitates.", [["Serum", "ANATOMY", 0, 5], ["CK-MM", "ANATOMY", 49, 54], ["intravenous", "ANATOMY", 155, 166], ["plasma", "ANATOMY", 237, 243], ["cefotaxime", "CHEMICAL", 167, 177], ["clarithromycin", "CHEMICAL", 182, 196], ["cefotaxime", "CHEMICAL", 167, 177], ["clarithromycin", "CHEMICAL", 182, 196], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["CK-MM", "GENE_OR_GENE_PRODUCT", 49, 54], ["CK-MB", "GENE_OR_GENE_PRODUCT", 62, 67], ["CK-BB", "GENE_OR_GENE_PRODUCT", 72, 77], ["patient", "ORGANISM", 113, 120], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 155, 166], ["cefotaxime", "SIMPLE_CHEMICAL", 167, 177], ["clarithromycin", "SIMPLE_CHEMICAL", 182, 196], ["plasma", "ORGANISM_SUBSTANCE", 237, 243], ["CK", "PROTEIN", 49, 51], ["CK", "PROTEIN", 62, 64], ["CK", "PROTEIN", 72, 74], ["patient", "SPECIES", 113, 120], ["Serum isoenzyme electrophoresis", "TEST", 0, 31], ["CK", "TEST", 49, 51], ["MM", "TEST", 52, 54], ["CK", "TEST", 62, 64], ["MB", "TEST", 65, 67], ["CK", "TEST", 72, 74], ["BB", "TEST", 75, 77], ["empirical antibiotics", "TREATMENT", 130, 151], ["intravenous cefotaxime", "TREATMENT", 155, 177], ["clarithromycin", "TREATMENT", 182, 196], ["fresh frozen plasma", "TREATMENT", 224, 243], ["cryoprecipitates", "TREATMENT", 248, 264]]], ["Fever and abdominal pain subsided on the third hospital day and laboratory exams showed gradual improvement.", [["abdominal", "ANATOMY", 10, 19], ["Fever", "DISEASE", 0, 5], ["abdominal pain", "DISEASE", 10, 24], ["abdominal", "ORGANISM_SUBDIVISION", 10, 19], ["Fever", "PROBLEM", 0, 5], ["abdominal pain", "PROBLEM", 10, 24], ["laboratory exams", "TEST", 64, 80], ["abdominal", "ANATOMY", 10, 19], ["pain", "OBSERVATION", 20, 24], ["gradual", "OBSERVATION_MODIFIER", 88, 95], ["improvement", "OBSERVATION_MODIFIER", 96, 107]]], ["Although tachycardia was observed during the events of fever, blood pressure was continuously within normal range, and no oliguria was observed.", [["blood", "ANATOMY", 62, 67], ["tachycardia", "DISEASE", 9, 20], ["fever", "DISEASE", 55, 60], ["oliguria", "DISEASE", 122, 130], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["tachycardia", "PROBLEM", 9, 20], ["fever", "PROBLEM", 55, 60], ["blood pressure", "TEST", 62, 76], ["oliguria", "PROBLEM", 122, 130], ["tachycardia", "OBSERVATION", 9, 20], ["normal range", "OBSERVATION", 101, 113], ["no", "UNCERTAINTY", 119, 121], ["oliguria", "OBSERVATION", 122, 130]]], ["Laboratory exams performed on the seventh hospital day revealed a hemoglobin of 11.8 g/dL, hematocrit 34.7%, WBC count of 7,710/mm3 with 27% neutrophils, 49% lymphocytes, 15% monocytes, and platelet count of 278,000/mm3.", [["WBC", "ANATOMY", 109, 112], ["neutrophils", "ANATOMY", 141, 152], ["lymphocytes", "ANATOMY", 158, 169], ["monocytes", "ANATOMY", 175, 184], ["platelet", "ANATOMY", 190, 198], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 66, 76], ["neutrophils", "CELL", 141, 152], ["lymphocytes", "CELL", 158, 169], ["monocytes", "CELL", 175, 184], ["platelet", "CELL", 190, 198], ["hemoglobin", "PROTEIN", 66, 76], ["neutrophils", "CELL_TYPE", 141, 152], ["lymphocytes", "CELL_TYPE", 158, 169], ["monocytes", "CELL_TYPE", 175, 184], ["Laboratory exams", "TEST", 0, 16], ["a hemoglobin", "TEST", 64, 76], ["dL", "TEST", 87, 89], ["hematocrit", "TEST", 91, 101], ["WBC count", "TEST", 109, 118], ["neutrophils", "TEST", 141, 152], ["lymphocytes", "TEST", 158, 169], ["monocytes", "TEST", 175, 184], ["platelet count", "TEST", 190, 204], ["platelet count", "OBSERVATION_MODIFIER", 190, 204]]], ["Chemistry exams revealed a CRP level of 0.32 mg/dL (normal range, 0-0.3 mg/dL), AST of 203 IU/L (normal range, 0-40 IU/L), ALT of 281 IU/L (normal range, 0-40 IU/L), total serum bilirubin of 0.7 mg/dL (normal range, 0-1.5 mg/dL), direct serum bilirubin of 0.3 mg/dL (normal range, 0-0.5 mg/dL), total serum protein of 6.5 g/dL (normal range, 6.0-8.2 g/dL), serum albumin of 3.8 g/dL (normal range, 3.5-5.2 g/dL), CK of 457 IU/dL (normal range, 24-204 IU/dL), and LD of 3,919 IU/L (normal range, 240-480 IU/L).", [["serum", "ANATOMY", 172, 177], ["serum", "ANATOMY", 237, 242], ["serum", "ANATOMY", 301, 306], ["serum", "ANATOMY", 357, 362], ["bilirubin", "CHEMICAL", 178, 187], ["bilirubin", "CHEMICAL", 243, 252], ["bilirubin", "CHEMICAL", 178, 187], ["bilirubin", "CHEMICAL", 243, 252], ["CRP", "GENE_OR_GENE_PRODUCT", 27, 30], ["AST", "SIMPLE_CHEMICAL", 80, 83], ["ALT", "SIMPLE_CHEMICAL", 123, 126], ["serum", "ORGANISM_SUBSTANCE", 172, 177], ["bilirubin", "SIMPLE_CHEMICAL", 178, 187], ["serum", "ORGANISM_SUBSTANCE", 237, 242], ["bilirubin", "SIMPLE_CHEMICAL", 243, 252], ["serum", "ORGANISM_SUBSTANCE", 301, 306], ["serum", "ORGANISM_SUBSTANCE", 357, 362], ["albumin", "GENE_OR_GENE_PRODUCT", 363, 370], ["CK", "GENE_OR_GENE_PRODUCT", 413, 415], ["CRP", "PROTEIN", 27, 30], ["serum protein", "PROTEIN", 301, 314], ["Chemistry exams", "TEST", 0, 15], ["a CRP level", "TEST", 25, 36], ["AST", "TEST", 80, 83], ["ALT", "TEST", 123, 126], ["IU", "TEST", 134, 136], ["total serum bilirubin", "TEST", 166, 187], ["direct serum bilirubin", "TEST", 230, 252], ["total serum protein", "TEST", 295, 314], ["serum albumin", "TEST", 357, 370], ["CK", "TEST", 413, 415], ["dL", "TEST", 426, 428], ["LD", "TEST", 463, 465]]], ["Coagulation studies revealed a PT of 13.0 seconds (normal range, 12.6-14.9 seconds), and 1.04 INR (normal range, 0.90-1.10 INR), aPTT of 31.1 seconds (normal range, 29.1-41.9 seconds), fibrinogen of 93 mg/dL (normal range, 182-380 mg/dL).", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 185, 195], ["fibrinogen", "PROTEIN", 185, 195], ["Coagulation studies", "TEST", 0, 19], ["PT", "TEST", 31, 33], ["INR", "TEST", 94, 97], ["INR", "TEST", 123, 126], ["aPTT", "TEST", 129, 133], ["fibrinogen", "TEST", 185, 195]]], ["The patient was discharged on the eighth hospital day without any complaints nor any remaining signs and symptoms.CASE REPORTThe patient was followed at the outpatient clinic two weeks after discharge.", [["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 129, 136], ["any complaints", "PROBLEM", 62, 76], ["any remaining signs and symptoms", "PROBLEM", 81, 113]]], ["Laboratory exams showed normalization of levels that were above normal range prior to discharge, revealing a CRP of 0.03 mg/dL, AST of 33 IU/L, ALT of 24 IU/L, CK of 87 IU/L, LD of 412 IU/L. Serum antibodies to M. pneumoniae detected by ELISA were 79.6 AU/mL for IgG, and 2.6 index value for IgM, confirming the diagnosis of M. pneumoniae infection.DISCUSSIONM. pneumoniae are primarily mucosal pathogens, which attach and enter the ciliated cells of the respiratory tract to produce proinflammatory cytokines causing acute cellular inflammatory reaction and resultant airway damage [4].", [["Serum", "ANATOMY", 191, 196], ["mucosal", "ANATOMY", 387, 394], ["ciliated cells", "ANATOMY", 433, 447], ["respiratory tract", "ANATOMY", 455, 472], ["cellular", "ANATOMY", 524, 532], ["airway", "ANATOMY", 569, 575], ["M. pneumoniae infection", "DISEASE", 325, 348], ["airway damage", "DISEASE", 569, 582], ["CRP", "GENE_OR_GENE_PRODUCT", 109, 112], ["AST", "SIMPLE_CHEMICAL", 128, 131], ["CK", "GENE_OR_GENE_PRODUCT", 160, 162], ["Serum", "ORGANISM_SUBSTANCE", 191, 196], ["M. pneumoniae", "ORGANISM", 211, 224], ["IgG", "GENE_OR_GENE_PRODUCT", 263, 266], ["IgM", "GENE_OR_GENE_PRODUCT", 292, 295], ["M. pneumoniae", "ORGANISM", 325, 338], ["pneumoniae", "ORGANISM", 362, 372], ["ciliated cells", "CELL", 433, 447], ["respiratory tract", "ORGANISM_SUBDIVISION", 455, 472], ["cellular", "CELL", 524, 532], ["airway", "MULTI-TISSUE_STRUCTURE", 569, 575], ["CRP", "PROTEIN", 109, 112], ["AST", "PROTEIN", 128, 131], ["Serum antibodies", "PROTEIN", 191, 207], ["IgG", "PROTEIN", 263, 266], ["IgM", "PROTEIN", 292, 295], ["ciliated cells", "CELL_TYPE", 433, 447], ["proinflammatory cytokines", "PROTEIN", 484, 509], ["M. pneumoniae", "SPECIES", 211, 224], ["M. pneumoniae", "SPECIES", 325, 338], ["pneumoniae", "SPECIES", 362, 372], ["M. pneumoniae", "SPECIES", 211, 224], ["M. pneumoniae", "SPECIES", 325, 338], ["pneumoniae", "SPECIES", 362, 372], ["Laboratory exams", "TEST", 0, 16], ["normalization of levels", "PROBLEM", 24, 47], ["a CRP", "TEST", 107, 112], ["AST", "TEST", 128, 131], ["ALT", "TEST", 144, 147], ["CK", "TEST", 160, 162], ["LD", "TEST", 175, 177], ["Serum antibodies", "TEST", 191, 207], ["M. pneumoniae", "TEST", 211, 224], ["ELISA", "TEST", 237, 242], ["IgG", "TEST", 263, 266], ["IgM", "TEST", 292, 295], ["M. pneumoniae infection", "PROBLEM", 325, 348], ["pneumoniae", "PROBLEM", 362, 372], ["mucosal pathogens", "PROBLEM", 387, 404], ["the respiratory tract", "PROBLEM", 451, 472], ["proinflammatory cytokines", "PROBLEM", 484, 509], ["acute cellular inflammatory reaction", "PROBLEM", 518, 554], ["resultant airway damage", "PROBLEM", 559, 582], ["pneumoniae", "OBSERVATION_MODIFIER", 328, 338], ["infection", "OBSERVATION", 339, 348], ["mucosal pathogens", "OBSERVATION", 387, 404], ["ciliated cells", "OBSERVATION", 433, 447], ["respiratory tract", "ANATOMY", 455, 472], ["proinflammatory", "OBSERVATION_MODIFIER", 484, 499], ["acute", "OBSERVATION_MODIFIER", 518, 523], ["cellular", "OBSERVATION_MODIFIER", 524, 532], ["inflammatory", "OBSERVATION_MODIFIER", 533, 545], ["resultant", "OBSERVATION_MODIFIER", 559, 568], ["airway damage", "OBSERVATION", 569, 582]]], ["Hence, the consequence of M. pneumoniae infection is mainly pneumonia, known to account for up to 40% of cases of community-acquired pneumonia in children [4].", [["M. pneumoniae infection", "DISEASE", 26, 49], ["pneumonia", "DISEASE", 60, 69], ["pneumonia", "DISEASE", 133, 142], ["M. pneumoniae", "ORGANISM", 26, 39], ["children", "ORGANISM", 146, 154], ["M. pneumoniae", "SPECIES", 26, 39], ["children", "SPECIES", 146, 154], ["M. pneumoniae", "SPECIES", 26, 39], ["M. pneumoniae infection", "PROBLEM", 26, 49], ["pneumonia", "PROBLEM", 60, 69], ["community-acquired pneumonia", "PROBLEM", 114, 142], ["pneumoniae", "OBSERVATION_MODIFIER", 29, 39], ["infection", "OBSERVATION", 40, 49], ["pneumonia", "OBSERVATION", 60, 69], ["pneumonia", "OBSERVATION", 133, 142]]], ["Although pneumonia is well known as the hallmark of M. pneumoniae infection, cases of extrapulmonary manifestations presenting in the absence of pneumonia have been rarely reported in both children and adults [23567].", [["extrapulmonary", "ANATOMY", 86, 100], ["pneumonia", "DISEASE", 9, 18], ["M. pneumoniae infection", "DISEASE", 52, 75], ["extrapulmonary manifestations", "DISEASE", 86, 115], ["pneumonia", "DISEASE", 145, 154], ["M. pneumoniae", "ORGANISM", 52, 65], ["children", "ORGANISM", 189, 197], ["M. pneumoniae", "SPECIES", 52, 65], ["children", "SPECIES", 189, 197], ["M. pneumoniae", "SPECIES", 52, 65], ["pneumonia", "PROBLEM", 9, 18], ["M. pneumoniae infection", "PROBLEM", 52, 75], ["extrapulmonary manifestations", "PROBLEM", 86, 115], ["pneumonia", "PROBLEM", 145, 154], ["pneumonia", "OBSERVATION", 9, 18], ["M.", "OBSERVATION_MODIFIER", 52, 54], ["pneumoniae", "OBSERVATION_MODIFIER", 55, 65], ["infection", "OBSERVATION", 66, 75], ["extrapulmonary", "ANATOMY", 86, 100], ["manifestations", "OBSERVATION", 101, 115], ["pneumonia", "OBSERVATION", 145, 154]]], ["The pathomechanism of how extrapulmonary manifestations are capable of occurring in the absence of pneumonia remains unknown.", [["extrapulmonary", "ANATOMY", 26, 40], ["pneumonia", "DISEASE", 99, 108], ["how extrapulmonary manifestations", "PROBLEM", 22, 55], ["pneumonia", "PROBLEM", 99, 108], ["extrapulmonary", "ANATOMY", 26, 40], ["manifestations", "OBSERVATION", 41, 55], ["pneumonia", "OBSERVATION", 99, 108]]], ["However it seems that extrapulmonary manifestations due to M. pneumoniae infection occur according to one of the following mechanisms; 1) a direct type in which local inflammatory cytokines plays an important role induced by M. pneumoniae at the site of inflammation, 2) an indirect type in which autoimmunity or the formation of immune complexes plays an important role in the absence of M. pneumoniae at the site of inflammation, and 3) a vascular occlusion type in which obstruction of blood flow plays an important role, induced either directly or indirectly by M. pneumoniae infection [78].DISCUSSIONElevated liver enzymes are frequently observed during M. pneumoniae infection in children.", [["extrapulmonary", "ANATOMY", 22, 36], ["vascular", "ANATOMY", 441, 449], ["blood", "ANATOMY", 489, 494], ["liver", "ANATOMY", 614, 619], ["M. pneumoniae infection", "DISEASE", 59, 82], ["inflammation", "DISEASE", 254, 266], ["autoimmunity", "DISEASE", 297, 309], ["inflammation", "DISEASE", 418, 430], ["vascular occlusion", "DISEASE", 441, 459], ["M. pneumoniae infection", "DISEASE", 566, 589], ["M. pneumoniae infection", "DISEASE", 659, 682], ["M. pneumoniae", "ORGANISM", 59, 72], ["M. pneumoniae", "ORGANISM", 225, 238], ["M. pneumoniae", "ORGANISM", 389, 402], ["vascular", "MULTI-TISSUE_STRUCTURE", 441, 449], ["blood", "ORGANISM_SUBSTANCE", 489, 494], ["M. pneumoniae", "ORGANISM", 566, 579], ["liver", "ORGAN", 614, 619], ["M. pneumoniae", "ORGANISM", 659, 672], ["children", "ORGANISM", 686, 694], ["inflammatory cytokines", "PROTEIN", 167, 189], ["immune complexes", "PROTEIN", 330, 346], ["liver enzymes", "PROTEIN", 614, 627], ["M. pneumoniae", "SPECIES", 59, 72], ["M. pneumoniae", "SPECIES", 225, 238], ["M. pneumoniae", "SPECIES", 389, 402], ["M. pneumoniae", "SPECIES", 566, 579], ["M. pneumoniae", "SPECIES", 659, 672], ["children", "SPECIES", 686, 694], ["M. pneumoniae", "SPECIES", 59, 72], ["M. pneumoniae", "SPECIES", 225, 238], ["M. pneumoniae", "SPECIES", 389, 402], ["M. pneumoniae", "SPECIES", 566, 579], ["M. pneumoniae", "SPECIES", 659, 672], ["extrapulmonary manifestations", "PROBLEM", 22, 51], ["M. pneumoniae infection", "PROBLEM", 59, 82], ["a direct type in which local inflammatory cytokines", "PROBLEM", 138, 189], ["M. pneumoniae", "PROBLEM", 225, 238], ["inflammation", "PROBLEM", 254, 266], ["an indirect type in which autoimmunity", "PROBLEM", 271, 309], ["immune complexes", "PROBLEM", 330, 346], ["M. pneumoniae", "PROBLEM", 389, 402], ["inflammation", "PROBLEM", 418, 430], ["a vascular occlusion type", "PROBLEM", 439, 464], ["obstruction of blood flow", "PROBLEM", 474, 499], ["M. pneumoniae infection", "PROBLEM", 566, 589], ["liver enzymes", "TEST", 614, 627], ["M. pneumoniae infection", "PROBLEM", 659, 682], ["extrapulmonary", "ANATOMY", 22, 36], ["pneumoniae", "OBSERVATION", 62, 72], ["inflammatory", "OBSERVATION_MODIFIER", 167, 179], ["pneumoniae", "OBSERVATION", 228, 238], ["inflammation", "OBSERVATION", 254, 266], ["immune complexes", "OBSERVATION", 330, 346], ["pneumoniae", "OBSERVATION", 392, 402], ["inflammation", "OBSERVATION", 418, 430], ["vascular", "ANATOMY", 441, 449], ["occlusion", "OBSERVATION", 450, 459], ["obstruction", "OBSERVATION", 474, 485], ["blood flow", "OBSERVATION", 489, 499], ["pneumoniae", "OBSERVATION", 569, 579], ["liver", "ANATOMY", 614, 619], ["pneumoniae", "OBSERVATION_MODIFIER", 662, 672], ["infection", "OBSERVATION", 673, 682]]], ["According to previous studies, 8-30% of children presenting with serologically confirmed M. pneumoniae infection had an evidence of liver involvement [910].", [["liver", "ANATOMY", 132, 137], ["M. pneumoniae infection", "DISEASE", 89, 112], ["children", "ORGANISM", 40, 48], ["M. pneumoniae", "ORGANISM", 89, 102], ["liver", "ORGAN", 132, 137], ["children", "SPECIES", 40, 48], ["M. pneumoniae", "SPECIES", 89, 102], ["M. pneumoniae", "SPECIES", 89, 102], ["previous studies", "TEST", 13, 29], ["M. pneumoniae infection", "PROBLEM", 89, 112], ["liver involvement", "PROBLEM", 132, 149], ["pneumoniae", "OBSERVATION", 92, 102], ["liver", "ANATOMY", 132, 137]]], ["Based on the duration from the onset of fever and liver enzyme elevation, it seems that hepatic involvement of M. pneumoniae is bimodal [7].", [["liver", "ANATOMY", 50, 55], ["hepatic", "ANATOMY", 88, 95], ["fever", "DISEASE", 40, 45], ["liver", "ORGAN", 50, 55], ["hepatic", "ORGAN", 88, 95], ["M. pneumoniae", "ORGANISM", 111, 124], ["M. pneumoniae", "SPECIES", 111, 124], ["M. pneumoniae", "SPECIES", 111, 124], ["fever", "PROBLEM", 40, 45], ["liver enzyme elevation", "PROBLEM", 50, 72], ["M. pneumoniae", "PROBLEM", 111, 124], ["fever", "OBSERVATION", 40, 45], ["liver", "ANATOMY", 50, 55], ["elevation", "OBSERVATION", 63, 72], ["hepatic", "ANATOMY", 88, 95], ["M. pneumoniae", "OBSERVATION", 111, 124]]], ["While liver dysfunction is observed at the first hospital visit in early-onset hepatitis, it becomes evident later in the course, usually 7-10 days after the onset of fever, in late-onset hepatitis [7].", [["liver", "ANATOMY", 6, 11], ["liver dysfunction", "DISEASE", 6, 23], ["hepatitis", "DISEASE", 79, 88], ["fever", "DISEASE", 167, 172], ["hepatitis", "DISEASE", 188, 197], ["liver", "ORGAN", 6, 11], ["liver dysfunction", "PROBLEM", 6, 23], ["early-onset hepatitis", "PROBLEM", 67, 88], ["fever", "PROBLEM", 167, 172], ["late-onset hepatitis", "PROBLEM", 177, 197], ["liver", "ANATOMY", 6, 11], ["dysfunction", "OBSERVATION", 12, 23], ["hepatitis", "OBSERVATION", 79, 88], ["fever", "OBSERVATION", 167, 172], ["hepatitis", "OBSERVATION", 188, 197]]], ["Narita et al. [3] reported that bacteremia with M. pneumoniae might be required for early-onset hepatitis, implying that early-onset hepatitis, which sometimes develops in the absence of pneumonia, may be related with a direct-type extrapulmonary manifestation [3567].", [["extrapulmonary", "ANATOMY", 232, 246], ["bacteremia", "DISEASE", 32, 42], ["M. pneumoniae", "DISEASE", 48, 61], ["hepatitis", "DISEASE", 96, 105], ["hepatitis", "DISEASE", 133, 142], ["pneumonia", "DISEASE", 187, 196], ["M. pneumoniae", "ORGANISM", 48, 61], ["M. pneumoniae", "SPECIES", 48, 61], ["M. pneumoniae", "SPECIES", 48, 61], ["bacteremia", "PROBLEM", 32, 42], ["M. pneumoniae", "PROBLEM", 48, 61], ["early-onset hepatitis", "PROBLEM", 84, 105], ["early-onset hepatitis", "PROBLEM", 121, 142], ["pneumonia", "PROBLEM", 187, 196], ["a direct-type extrapulmonary manifestation", "PROBLEM", 218, 260], ["bacteremia", "OBSERVATION", 32, 42], ["pneumoniae", "OBSERVATION", 51, 61], ["hepatitis", "OBSERVATION", 96, 105], ["early", "OBSERVATION_MODIFIER", 121, 126], ["-onset", "OBSERVATION_MODIFIER", 126, 132], ["hepatitis", "OBSERVATION", 133, 142], ["pneumonia", "OBSERVATION", 187, 196]]], ["Meanwhile, late-onset hepatitis may be related with an indirect-type mechanism, in which cross-reactive antibodies induced by M. pneumoniae interact with sialo-oligosaccharides on hepatic cells [811].DISCUSSIONIn our case, body temperature elevation up to 37.6\u2103 and mild cough had been documented 10 days before admission, although fever over 38\u2103 developed just 4 days before admission.", [["hepatic cells", "ANATOMY", 180, 193], ["body", "ANATOMY", 223, 227], ["hepatitis", "DISEASE", 22, 31], ["sialo-oligosaccharides", "CHEMICAL", 154, 176], ["cough", "DISEASE", 271, 276], ["fever", "DISEASE", 332, 337], ["M. pneumoniae", "ORGANISM", 126, 139], ["sialo-oligosaccharides", "SIMPLE_CHEMICAL", 154, 176], ["hepatic cells", "CELL", 180, 193], ["body", "ORGANISM_SUBDIVISION", 223, 227], ["cross-reactive antibodies", "PROTEIN", 89, 114], ["hepatic cells", "CELL_TYPE", 180, 193], ["M. pneumoniae", "SPECIES", 126, 139], ["M. pneumoniae", "SPECIES", 126, 139], ["late-onset hepatitis", "PROBLEM", 11, 31], ["an indirect-type mechanism", "PROBLEM", 52, 78], ["cross-reactive antibodies", "PROBLEM", 89, 114], ["M. pneumoniae", "PROBLEM", 126, 139], ["body temperature elevation", "TEST", 223, 249], ["mild cough", "PROBLEM", 266, 276], ["fever", "PROBLEM", 332, 337], ["late", "OBSERVATION_MODIFIER", 11, 15], ["-onset", "OBSERVATION_MODIFIER", 15, 21], ["hepatitis", "OBSERVATION", 22, 31], ["may be related with", "UNCERTAINTY", 32, 51], ["hepatic", "ANATOMY", 180, 187], ["mild", "OBSERVATION_MODIFIER", 266, 270], ["cough", "OBSERVATION", 271, 276]]], ["Thus, there is a possibility that primary infection with M. pneumonia may have started 10 days prior to admission.", [["primary infection", "DISEASE", 34, 51], ["pneumonia", "DISEASE", 60, 69], ["primary infection", "PROBLEM", 34, 51], ["M. pneumonia", "PROBLEM", 57, 69], ["primary", "OBSERVATION_MODIFIER", 34, 41], ["infection", "OBSERVATION", 42, 51], ["pneumonia", "OBSERVATION", 60, 69]]], ["The self-limiting course of mild cough and body temperature elevation within a 2 days period may explain the mild course of pulmonary involvement and the absence of pneumonia in our case.", [["body", "ANATOMY", 43, 47], ["pulmonary", "ANATOMY", 124, 133], ["cough", "DISEASE", 33, 38], ["pneumonia", "DISEASE", 165, 174], ["body", "ORGANISM_SUBDIVISION", 43, 47], ["pulmonary", "ORGAN", 124, 133], ["mild cough", "PROBLEM", 28, 38], ["body temperature elevation", "PROBLEM", 43, 69], ["pulmonary involvement", "PROBLEM", 124, 145], ["pneumonia", "PROBLEM", 165, 174], ["mild", "OBSERVATION_MODIFIER", 28, 32], ["cough", "OBSERVATION", 33, 38], ["mild", "OBSERVATION_MODIFIER", 109, 113], ["course", "OBSERVATION_MODIFIER", 114, 120], ["pulmonary", "ANATOMY", 124, 133], ["involvement", "OBSERVATION", 134, 145], ["pneumonia", "OBSERVATION", 165, 174]]], ["Meanwhile, fever over 38\u2103 developed concurrently with abdominal pain in the right upper quadrant, 4 days after the resolution of the initial body temperature elevation.", [["abdominal", "ANATOMY", 54, 63], ["right upper quadrant", "ANATOMY", 76, 96], ["body", "ANATOMY", 141, 145], ["fever", "DISEASE", 11, 16], ["abdominal pain", "DISEASE", 54, 68], ["abdominal", "ORGANISM_SUBDIVISION", 54, 63], ["upper quadrant", "ORGANISM_SUBDIVISION", 82, 96], ["body", "ORGANISM_SUBDIVISION", 141, 145], ["fever", "PROBLEM", 11, 16], ["abdominal pain in the right upper quadrant", "PROBLEM", 54, 96], ["the initial body temperature elevation", "PROBLEM", 129, 167], ["abdominal", "ANATOMY", 54, 63], ["pain", "OBSERVATION", 64, 68], ["right", "ANATOMY_MODIFIER", 76, 81], ["upper", "ANATOMY_MODIFIER", 82, 87], ["quadrant", "ANATOMY", 88, 96], ["elevation", "OBSERVATION", 158, 167]]], ["This clinical course of a 4 day symptom-free window period implies that the acute cholestatic hepatitis in our case may have been related with an indirect-type mechanism rather than a direct type mechanism.DISCUSSIONThe concurrent symptoms and signs of other extrapulmonary manifestations, such as erythematous maculopapular skin rash, rhabdomyolysis, and initial laboratory exams favoring disseminated intravascular coagulopathy (DIC) in our case further support the assumption that our case may have been related with an indirect-type mechanism rather than a direct type mechanism.", [["extrapulmonary", "ANATOMY", 259, 273], ["skin", "ANATOMY", 325, 329], ["intravascular", "ANATOMY", 403, 416], ["cholestatic hepatitis", "DISEASE", 82, 103], ["skin rash", "DISEASE", 325, 334], ["rhabdomyolysis", "DISEASE", 336, 350], ["intravascular coagulopathy", "DISEASE", 403, 429], ["DIC", "DISEASE", 431, 434], ["skin", "ORGAN", 325, 329], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 403, 416], ["a 4 day symptom", "PROBLEM", 24, 39], ["the acute cholestatic hepatitis", "PROBLEM", 72, 103], ["an indirect-type mechanism", "PROBLEM", 143, 169], ["concurrent symptoms", "PROBLEM", 220, 239], ["other extrapulmonary manifestations", "PROBLEM", 253, 288], ["erythematous maculopapular skin rash", "PROBLEM", 298, 334], ["rhabdomyolysis", "PROBLEM", 336, 350], ["initial laboratory exams", "TEST", 356, 380], ["disseminated intravascular coagulopathy", "PROBLEM", 390, 429], ["an indirect-type mechanism", "PROBLEM", 520, 546], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["cholestatic", "OBSERVATION_MODIFIER", 82, 93], ["hepatitis", "OBSERVATION", 94, 103], ["extrapulmonary", "ANATOMY", 259, 273], ["manifestations", "OBSERVATION", 274, 288], ["erythematous", "OBSERVATION_MODIFIER", 298, 310], ["maculopapular", "OBSERVATION_MODIFIER", 311, 324], ["skin", "ANATOMY", 325, 329], ["rash", "OBSERVATION", 330, 334], ["rhabdomyolysis", "OBSERVATION", 336, 350], ["disseminated", "OBSERVATION_MODIFIER", 390, 402], ["intravascular coagulopathy", "OBSERVATION", 403, 429]]], ["Association between M. pneumonia infection and dermatologic manifestations such as erythematous maculopapular eruptions and erythema multiforme are well known [12], and the molecular mimicry between Mycoplasma P1-adhesin molecule and keratinocyte antigen leading to the generation of cross-reacting antibodies, immune-complex formation, and complement activation have been reported to attribute to the development of Mycoplasma induced rash and mucositis (MIRM) [13].", [["maculopapular", "ANATOMY", 96, 109], ["erythema multiforme", "ANATOMY", 124, 143], ["keratinocyte", "ANATOMY", 234, 246], ["M. pneumonia infection", "DISEASE", 20, 42], ["maculopapular eruptions", "DISEASE", 96, 119], ["erythema multiforme", "DISEASE", 124, 143], ["Mycoplasma induced rash", "DISEASE", 417, 440], ["mucositis", "DISEASE", 445, 454], ["MIRM", "DISEASE", 456, 460], ["M. pneumonia", "ORGANISM", 20, 32], ["Mycoplasma P1-adhesin molecule", "GENE_OR_GENE_PRODUCT", 199, 229], ["keratinocyte antigen", "GENE_OR_GENE_PRODUCT", 234, 254], ["Mycoplasma P1-adhesin molecule", "PROTEIN", 199, 229], ["keratinocyte antigen", "PROTEIN", 234, 254], ["cross-reacting antibodies", "PROTEIN", 284, 309], ["M. pneumonia", "SPECIES", 20, 32], ["M. pneumonia", "SPECIES", 20, 32], ["M. pneumonia infection", "PROBLEM", 20, 42], ["dermatologic manifestations", "PROBLEM", 47, 74], ["erythematous maculopapular eruptions", "PROBLEM", 83, 119], ["erythema multiforme", "PROBLEM", 124, 143], ["Mycoplasma P1-adhesin molecule", "PROBLEM", 199, 229], ["keratinocyte antigen", "PROBLEM", 234, 254], ["cross-reacting antibodies", "PROBLEM", 284, 309], ["immune-complex formation", "PROBLEM", 311, 335], ["Mycoplasma induced rash", "PROBLEM", 417, 440], ["mucositis (MIRM)", "PROBLEM", 445, 461], ["pneumonia", "OBSERVATION_MODIFIER", 23, 32], ["infection", "OBSERVATION", 33, 42], ["erythematous", "OBSERVATION_MODIFIER", 83, 95], ["maculopapular", "OBSERVATION_MODIFIER", 96, 109], ["eruptions", "OBSERVATION", 110, 119], ["erythema", "OBSERVATION", 124, 132], ["Mycoplasma P1", "ANATOMY", 199, 212], ["Mycoplasma", "OBSERVATION", 417, 427]]], ["Rhabdomyolysis is often accompanied by multiple extrapulmonary manifestations in M. pneumoniae infection as in our case [714], although the exact underlying pathomechanism has not been revealed.", [["Rhabdomyolysis", "DISEASE", 0, 14], ["M. pneumoniae infection", "DISEASE", 81, 104], ["M. pneumoniae", "ORGANISM", 81, 94], ["M. pneumoniae", "SPECIES", 81, 94], ["M. pneumoniae", "SPECIES", 81, 94], ["Rhabdomyolysis", "PROBLEM", 0, 14], ["multiple extrapulmonary manifestations", "PROBLEM", 39, 77], ["M. pneumoniae infection", "PROBLEM", 81, 104], ["multiple", "OBSERVATION_MODIFIER", 39, 47], ["extrapulmonary", "ANATOMY", 48, 62], ["pneumoniae", "OBSERVATION_MODIFIER", 84, 94], ["infection", "OBSERVATION", 95, 104]]], ["Recently, it has been suggested that tumor necrosis factor-alpha may play a role in the pathogenesis of rhabdomyolysis associated with M. pneumoniae infection [15].", [["tumor", "DISEASE", 37, 42], ["necrosis", "DISEASE", 43, 51], ["rhabdomyolysis", "DISEASE", 104, 118], ["M. pneumoniae infection", "DISEASE", 135, 158], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 37, 64], ["M. pneumoniae", "ORGANISM", 135, 148], ["tumor necrosis factor-alpha", "PROTEIN", 37, 64], ["M. pneumoniae", "SPECIES", 135, 148], ["M. pneumoniae", "SPECIES", 135, 148], ["tumor necrosis factor", "PROBLEM", 37, 58], ["rhabdomyolysis", "PROBLEM", 104, 118], ["M. pneumoniae infection", "PROBLEM", 135, 158], ["tumor", "OBSERVATION_MODIFIER", 37, 42], ["necrosis", "OBSERVATION", 43, 51], ["rhabdomyolysis", "OBSERVATION", 104, 118], ["pneumoniae", "OBSERVATION", 138, 148]]], ["The development of DIC in M. pneumoniae infection is related with the vascular occlusion type mechanism in the presence of a systemic hypercoagulable state [7].", [["vascular", "ANATOMY", 70, 78], ["DIC", "DISEASE", 19, 22], ["M. pneumoniae infection", "DISEASE", 26, 49], ["M. pneumoniae", "ORGANISM", 26, 39], ["vascular", "MULTI-TISSUE_STRUCTURE", 70, 78], ["M. pneumoniae", "SPECIES", 26, 39], ["M. pneumoniae", "SPECIES", 26, 39], ["DIC in M. pneumoniae infection", "PROBLEM", 19, 49], ["the vascular occlusion type mechanism", "PROBLEM", 66, 103], ["a systemic hypercoagulable state", "PROBLEM", 123, 155], ["DIC", "OBSERVATION_MODIFIER", 19, 22], ["pneumoniae", "OBSERVATION_MODIFIER", 29, 39], ["infection", "OBSERVATION", 40, 49], ["vascular", "ANATOMY", 70, 78], ["occlusion", "OBSERVATION", 79, 88], ["systemic", "OBSERVATION_MODIFIER", 125, 133], ["hypercoagulable", "OBSERVATION", 134, 149]]], ["Abnormal immune regulation in M. pneumoniae infection has been suggested to activate complements or induce procoagulant mediators attributing to the development of DIC [161718].", [["M. pneumoniae infection", "DISEASE", 30, 53], ["DIC", "DISEASE", 164, 167], ["M. pneumoniae", "ORGANISM", 30, 43], ["procoagulant mediators", "PROTEIN", 107, 129], ["M. pneumoniae", "SPECIES", 30, 43], ["M. pneumoniae", "SPECIES", 30, 43], ["Abnormal immune regulation", "PROBLEM", 0, 26], ["M. pneumoniae infection", "PROBLEM", 30, 53], ["procoagulant mediators", "PROBLEM", 107, 129], ["DIC", "PROBLEM", 164, 167], ["pneumoniae", "OBSERVATION", 33, 43]]], ["Therefore, our case may have been related with an indirect-type plus a vascular occlusion type mechanism.DISCUSSIONThe main basis of treatment in cases of extrapulmonary manifestations associated with M. pneumoniae infection is antibiotics effective against the organism.", [["vascular", "ANATOMY", 71, 79], ["extrapulmonary", "ANATOMY", 155, 169], ["M. pneumoniae infection", "DISEASE", 201, 224], ["vascular", "MULTI-TISSUE_STRUCTURE", 71, 79], ["M. pneumoniae", "ORGANISM", 201, 214], ["M. pneumoniae", "SPECIES", 201, 214], ["M. pneumoniae", "SPECIES", 201, 214], ["a vascular occlusion type mechanism", "PROBLEM", 69, 104], ["treatment", "TREATMENT", 133, 142], ["extrapulmonary manifestations", "PROBLEM", 155, 184], ["M. pneumoniae infection", "PROBLEM", 201, 224], ["antibiotics", "TREATMENT", 228, 239], ["the organism", "PROBLEM", 258, 270], ["vascular", "ANATOMY", 71, 79], ["occlusion", "OBSERVATION", 80, 89], ["main", "OBSERVATION_MODIFIER", 119, 123], ["treatment", "OBSERVATION", 133, 142], ["extrapulmonary", "ANATOMY", 155, 169], ["pneumoniae", "OBSERVATION_MODIFIER", 204, 214], ["infection", "OBSERVATION", 215, 224]]], ["Antibiotics such as macrolides should be administered to reduce the amount of M. pneumoniae infected cells in the respiratory tract, which leads to the reduction of excessive antigenic stimuli [8].", [["cells", "ANATOMY", 101, 106], ["respiratory tract", "ANATOMY", 114, 131], ["macrolides", "CHEMICAL", 20, 30], ["macrolides", "CHEMICAL", 20, 30], ["macrolides", "SIMPLE_CHEMICAL", 20, 30], ["M. pneumoniae", "ORGANISM", 78, 91], ["cells", "CELL", 101, 106], ["respiratory tract", "ORGANISM_SUBDIVISION", 114, 131], ["M. pneumoniae", "SPECIES", 78, 91], ["M. pneumoniae", "SPECIES", 78, 91], ["Antibiotics", "TREATMENT", 0, 11], ["macrolides", "TREATMENT", 20, 30], ["M. pneumoniae infected cells in the respiratory tract", "PROBLEM", 78, 131], ["excessive antigenic stimuli", "PROBLEM", 165, 192], ["pneumoniae", "OBSERVATION_MODIFIER", 81, 91], ["infected cells", "OBSERVATION", 92, 106], ["respiratory tract", "ANATOMY", 114, 131], ["excessive", "OBSERVATION_MODIFIER", 165, 174], ["antigenic stimuli", "OBSERVATION", 175, 192]]], ["The emergence and increasing incidence of macrolide resistant M. pneumoniae strains, especially in East Asian countries, has aroused attention in the treatment of M. pneumoniae infection [1920].", [["macrolide", "CHEMICAL", 42, 51], ["M. pneumoniae infection", "DISEASE", 163, 186], ["macrolide", "CHEMICAL", 42, 51], ["M. pneumoniae", "ORGANISM", 62, 75], ["M. pneumoniae", "ORGANISM", 163, 176], ["M. pneumoniae", "SPECIES", 62, 75], ["M. pneumoniae", "SPECIES", 163, 176], ["M. pneumoniae", "SPECIES", 62, 75], ["M. pneumoniae", "SPECIES", 163, 176], ["macrolide resistant M. pneumoniae strains", "PROBLEM", 42, 83], ["M. pneumoniae infection", "PROBLEM", 163, 186], ["increasing", "OBSERVATION_MODIFIER", 18, 28], ["macrolide resistant", "OBSERVATION_MODIFIER", 42, 61], ["pneumoniae strains", "OBSERVATION", 65, 83], ["pneumoniae", "OBSERVATION", 166, 176]]], ["A recent review suggested the introduction of other potentially effective antibiotics in cases of clinical deterioration of symptoms or signs despite treatment with first line macrolides, in which the choice of the replaced antibiotic should be decided according to their in vitro activity and potential adverse events [20].", [["macrolides", "CHEMICAL", 176, 186], ["macrolides", "CHEMICAL", 176, 186], ["effective antibiotics", "TREATMENT", 64, 85], ["clinical deterioration of symptoms", "PROBLEM", 98, 132], ["signs", "PROBLEM", 136, 141], ["treatment", "TREATMENT", 150, 159], ["first line macrolides", "TREATMENT", 165, 186], ["the replaced antibiotic", "TREATMENT", 211, 234], ["potential adverse events", "PROBLEM", 294, 318]]], ["Corticosteroids or immunoglobulins are suggested to be beneficial in severe cases, and anticoagulation therapy is considered highly promising for cases of vascular occlusion type manifestations [8].", [["vascular", "ANATOMY", 155, 163], ["vascular occlusion", "DISEASE", 155, 173], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 19, 34], ["vascular", "MULTI-TISSUE_STRUCTURE", 155, 163], ["Corticosteroids", "TREATMENT", 0, 15], ["immunoglobulins", "TREATMENT", 19, 34], ["anticoagulation therapy", "TREATMENT", 87, 110], ["vascular occlusion type manifestations", "PROBLEM", 155, 193], ["vascular", "ANATOMY", 155, 163], ["occlusion", "OBSERVATION", 164, 173]]], ["In our case, early suspicion of M. pneumoniae infection based on the patient's history of mild cough, and the administration of clarithromycin could have played a crucial role in the early improvement of the disease course, despite the fact that respiratory involvement M. pneumoniae seemed to be mild in our case.DISCUSSIONIn conclusion, we report the first pediatric case in Korea of M. pneumoniae infection in a child presenting with acute cholestatic hepatitis in the absence of pneumonia.", [["respiratory", "ANATOMY", 246, 257], ["M. pneumoniae infection", "DISEASE", 32, 55], ["cough", "DISEASE", 95, 100], ["clarithromycin", "CHEMICAL", 128, 142], ["M. pneumoniae", "DISEASE", 270, 283], ["M. pneumoniae infection", "DISEASE", 386, 409], ["acute cholestatic hepatitis", "DISEASE", 437, 464], ["pneumonia", "DISEASE", 483, 492], ["clarithromycin", "CHEMICAL", 128, 142], ["M. pneumoniae", "ORGANISM", 32, 45], ["patient", "ORGANISM", 69, 76], ["clarithromycin", "SIMPLE_CHEMICAL", 128, 142], ["M. pneumoniae", "ORGANISM", 270, 283], ["M. pneumoniae", "ORGANISM", 386, 399], ["M. pneumoniae", "SPECIES", 32, 45], ["patient", "SPECIES", 69, 76], ["M. pneumoniae", "SPECIES", 270, 283], ["M. pneumoniae", "SPECIES", 386, 399], ["child", "SPECIES", 415, 420], ["M. pneumoniae", "SPECIES", 32, 45], ["M. pneumoniae", "SPECIES", 270, 283], ["M. pneumoniae", "SPECIES", 386, 399], ["M. pneumoniae infection", "PROBLEM", 32, 55], ["mild cough", "PROBLEM", 90, 100], ["clarithromycin", "TREATMENT", 128, 142], ["the disease course", "PROBLEM", 204, 222], ["respiratory involvement M. pneumoniae", "PROBLEM", 246, 283], ["M. pneumoniae infection", "PROBLEM", 386, 409], ["acute cholestatic hepatitis", "PROBLEM", 437, 464], ["pneumonia", "PROBLEM", 483, 492], ["pneumoniae", "OBSERVATION_MODIFIER", 35, 45], ["infection", "OBSERVATION", 46, 55], ["mild", "OBSERVATION_MODIFIER", 90, 94], ["cough", "OBSERVATION", 95, 100], ["early", "OBSERVATION_MODIFIER", 183, 188], ["improvement", "OBSERVATION_MODIFIER", 189, 200], ["disease", "OBSERVATION", 208, 215], ["pneumoniae", "OBSERVATION", 273, 283], ["mild", "OBSERVATION_MODIFIER", 297, 301], ["pneumoniae", "OBSERVATION_MODIFIER", 389, 399], ["infection", "OBSERVATION", 400, 409], ["acute", "OBSERVATION_MODIFIER", 437, 442], ["cholestatic", "OBSERVATION_MODIFIER", 443, 454], ["hepatitis", "OBSERVATION", 455, 464], ["pneumonia", "OBSERVATION", 483, 492]]], ["The clinical course and concurrent multiple extrapulmonary manifestations indicate that an indirect-type plus a vascular occlusion type mechanism may have played a role in the pathomechanism of extrapulmonary manifestations in our case.", [["vascular", "ANATOMY", 112, 120], ["extrapulmonary", "ANATOMY", 194, 208], ["vascular", "MULTI-TISSUE_STRUCTURE", 112, 120], ["concurrent multiple extrapulmonary manifestations", "PROBLEM", 24, 73], ["an indirect-type plus a vascular occlusion type mechanism", "PROBLEM", 88, 145], ["extrapulmonary manifestations", "PROBLEM", 194, 223], ["multiple", "OBSERVATION_MODIFIER", 35, 43], ["extrapulmonary", "ANATOMY", 44, 58], ["vascular", "ANATOMY", 112, 120], ["occlusion", "OBSERVATION", 121, 130], ["extrapulmonary", "ANATOMY", 194, 208]]], ["This case also emphasizes that M. pneumoniae infection should be considered as a possible cause of acute cholestatic hepatitis despite the absence of pneumonia, and that early treatment with proper antibiotics should be initiated from suspicion.", [["M. pneumoniae infection", "DISEASE", 31, 54], ["cholestatic hepatitis", "DISEASE", 105, 126], ["pneumonia", "DISEASE", 150, 159], ["M. pneumoniae", "ORGANISM", 31, 44], ["M. pneumoniae", "SPECIES", 31, 44], ["M. pneumoniae", "SPECIES", 31, 44], ["M. pneumoniae infection", "PROBLEM", 31, 54], ["acute cholestatic hepatitis", "PROBLEM", 99, 126], ["pneumonia", "PROBLEM", 150, 159], ["proper antibiotics", "TREATMENT", 191, 209], ["pneumoniae", "OBSERVATION", 34, 44], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["cholestatic", "OBSERVATION_MODIFIER", 105, 116], ["hepatitis", "OBSERVATION", 117, 126], ["pneumonia", "OBSERVATION", 150, 159]]]], "PMC4050516": [["IntroductionConsiderable attention has been devoted to the possibility that climate change will exacerbate the burden of mosquito-borne diseases such as malaria and dengue, with important impacts on public health (Githeko et al. 2000).", [["mosquito-borne diseases", "DISEASE", 121, 144], ["malaria", "DISEASE", 153, 160], ["dengue", "DISEASE", 165, 171], ["dengue", "SPECIES", 165, 171], ["mosquito-borne diseases", "PROBLEM", 121, 144], ["malaria", "PROBLEM", 153, 160], ["dengue", "PROBLEM", 165, 171], ["malaria", "OBSERVATION", 153, 160]]], ["Early assessments of the effects of climate change on malaria and dengue used simplistic models to assess possible effects of climate change on their basic reproductive numbers (R0, the universally recognized metric of the capacity of a parasite or pathogen to reproduce given particular environmental conditions) (Martens et al. 1995; Patz et al. 1998).", [["malaria", "DISEASE", 54, 61], ["dengue", "DISEASE", 66, 72], ["dengue", "SPECIES", 66, 72], ["Early assessments", "TEST", 0, 17], ["climate change", "PROBLEM", 36, 50], ["malaria", "PROBLEM", 54, 61], ["dengue", "PROBLEM", 66, 72], ["simplistic models", "TEST", 78, 95], ["climate change", "PROBLEM", 126, 140], ["a parasite", "PROBLEM", 235, 245], ["pathogen", "PROBLEM", 249, 257], ["malaria", "OBSERVATION", 54, 61]]], ["However, these assessments were criticized for giving weight to future increases in R0 whether or not such increases resulted in R0 rising above the critical threshold of > 1 for disease persistence (Rogers and Randolph 2000) and for being oversimplistic by only accounting for climate effects rather than the full range of nonclimatic factors that impact the occurrence of these diseases (Reiter 2001; Rogers and Randolph 2000).", [["nonclimatic factors", "PROTEIN", 324, 343], ["these assessments", "TEST", 9, 26], ["R0", "PROBLEM", 129, 131], ["disease persistence", "PROBLEM", 179, 198], ["nonclimatic factors", "PROBLEM", 324, 343], ["these diseases", "PROBLEM", 374, 388]]], ["Any impact of climate on R0 of malaria and dengue is limited by the effects of variations in human host density, mosquito control, infection prevention and treatment in humans, and human management of the environment (e.g., agriculture, forest management, logging) that affect the ecology and epidemiology of the vectors, pathogens, and diseases (Githeko et al. 2012).", [["malaria", "DISEASE", 31, 38], ["dengue", "DISEASE", 43, 49], ["infection", "DISEASE", 131, 140], ["human", "ORGANISM", 93, 98], ["humans", "ORGANISM", 169, 175], ["human", "ORGANISM", 181, 186], ["human", "SPECIES", 93, 98], ["humans", "SPECIES", 169, 175], ["human", "SPECIES", 181, 186], ["dengue", "SPECIES", 43, 49], ["human", "SPECIES", 93, 98], ["humans", "SPECIES", 169, 175], ["human", "SPECIES", 181, 186], ["malaria", "PROBLEM", 31, 38], ["dengue", "PROBLEM", 43, 49], ["variations in human host density", "PROBLEM", 79, 111], ["mosquito control", "TREATMENT", 113, 129], ["infection prevention", "TREATMENT", 131, 151], ["treatment", "TREATMENT", 156, 165], ["forest management", "TREATMENT", 237, 254], ["pathogens", "PROBLEM", 322, 331], ["diseases", "PROBLEM", 337, 345], ["climate", "OBSERVATION_MODIFIER", 14, 21], ["malaria", "OBSERVATION", 31, 38], ["human host density", "OBSERVATION_MODIFIER", 93, 111], ["infection", "OBSERVATION", 131, 140], ["vectors", "ANATOMY", 313, 320]]], ["Consequently, the strength of evidence for recent climate warming effects on malaria risk has been questioned and much debated (Reiter et al. 2004; Tanser et al. 2003).IntroductionMany vector-borne diseases of public health significance (e.g., Lyme disease, West Nile virus) are, however, maintained in transmission cycles that involve wild animal hosts.", [["malaria", "DISEASE", 77, 84], ["Lyme disease", "DISEASE", 244, 256], ["West Nile virus", "DISEASE", 258, 273], ["West Nile virus", "ORGANISM", 258, 273], ["West Nile virus", "SPECIES", 258, 273], ["West Nile virus", "SPECIES", 258, 273], ["recent climate warming effects", "PROBLEM", 43, 73], ["malaria risk", "PROBLEM", 77, 89], ["Lyme disease", "PROBLEM", 244, 256]]], ["These cycles are independent of human cases, and the spatio-temporal risk of human disease is less dependent on the direct effects of human activities than is the risk from malaria and dengue.", [["malaria", "DISEASE", 173, 180], ["dengue", "DISEASE", 185, 191], ["human", "ORGANISM", 32, 37], ["human", "ORGANISM", 77, 82], ["human", "ORGANISM", 134, 139], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 134, 139], ["dengue", "SPECIES", 185, 191], ["human disease", "PROBLEM", 77, 90], ["malaria", "PROBLEM", 173, 180], ["dengue", "PROBLEM", 185, 191], ["human disease", "OBSERVATION", 77, 90], ["less dependent", "OBSERVATION_MODIFIER", 94, 108], ["malaria", "OBSERVATION", 173, 180]]], ["Nevertheless, despite some assessments (Gubler et al. 2001), the effects of climate change on vector-borne zoonoses have also been downplayed mostly on the basis of limited evidence for recent effects of climate change (Kilpatrick and Randolph 2012).", [["zoonoses", "DISEASE", 107, 115], ["some assessments", "TEST", 22, 38], ["climate change on vector-borne zoonoses", "PROBLEM", 76, 115]]], ["Lyme disease emerged (or likely reemerged) in the northeastern United States in the late 1970s due to the expansion of tick populations, which was generally thought to have been associated with changes in land use over some decades that resulted in reforestation and expansion of the population of the deer that are key hosts for the ticks (Wood and Lafferty 2013).", [["Lyme disease", "DISEASE", 0, 12], ["deer", "ORGANISM", 302, 306], ["deer", "SPECIES", 302, 306], ["deer", "SPECIES", 302, 306], ["Lyme disease", "PROBLEM", 0, 12], ["tick populations", "PROBLEM", 119, 135], ["expansion", "OBSERVATION_MODIFIER", 267, 276]]], ["Lyme disease is now emerging in Canada and some northern U.S. states due to the northward expansion of the geographic range of the tick vector Ixodes scapularis (I. scapularis) (Hamer et al. 2010; Ogden et al. 2009), which is dispersed from source populations by migratory birds and terrestrial hosts (Leighton et al. 2012).IntroductionA mechanistic simulation model of the I. scapularis life cycle has identified temperature effects on I. scapularis population survival in order to assist in assessment of current and future on-the-ground Lyme disease risk in Canada (Ogden et al. 2005, 2006b).", [["Lyme disease", "DISEASE", 0, 12], ["Lyme disease", "DISEASE", 540, 552], ["Ixodes scapularis", "ORGANISM", 143, 160], ["I. scapularis", "ORGANISM", 162, 175], ["I. scapularis", "ORGANISM", 374, 387], ["I. scapularis", "ORGANISM", 437, 450], ["Ixodes scapularis", "SPECIES", 143, 160], ["I. scapularis", "SPECIES", 162, 175], ["I. scapularis", "SPECIES", 374, 387], ["I. scapularis", "SPECIES", 437, 450], ["Ixodes scapularis", "SPECIES", 143, 160], ["I. scapularis", "SPECIES", 162, 175], ["I. scapularis", "SPECIES", 374, 387], ["I. scapularis", "SPECIES", 437, 450], ["Lyme disease", "PROBLEM", 0, 12], ["the northward expansion", "PROBLEM", 76, 99], ["IntroductionA mechanistic simulation model", "TREATMENT", 324, 366], ["temperature effects", "PROBLEM", 414, 433], ["assessment", "TEST", 493, 503], ["northward", "OBSERVATION_MODIFIER", 80, 89], ["expansion", "OBSERVATION", 90, 99], ["scapularis", "ANATOMY", 150, 160], ["scapularis", "ANATOMY", 165, 175]]], ["Prospective field studies and retrospective analyses of surveillance data on tick and pathogen emergence in southeastern Canada validated the model findings and identified temperature as a statistically significant determinant and possible driver of emergence of the tick in Canada (Bouchard et al. 2013a, 2013b; Leighton et al. 2012; Ogden et al. 2008, 2010).", [["Prospective field studies", "TEST", 0, 25], ["retrospective analyses", "TEST", 30, 52], ["surveillance data", "TEST", 56, 73]]], ["The I. scapularis model was modified to permit the direct calculation of R0 for I. scapularis via the next generation operator approach (Wu et al. 2013), which, given the universal use of R0 and its estimation for a wide range of parasites and pathogens under many different conditions, allowed comparison of R0 variations in the present study with observed variations for other parasites and pathogens.IntroductionHere, we have estimated projected effects of climate change on R0 of an arthropod vector using a model that has been extensively ground-truthed, and we have assessed the ecological and epidemiological significance of the projected changes in R0 by comparing them with ranges of R0 values observed for other parasites and pathogens.MethodsWe estimated R0 under current and future projected climatic conditions at 30 sites in Canada that formed two roughly south\u2013north transects in Ontario and Quebec, two Canadian provinces where I. scapularis ticks are becoming established.", [["I. scapularis", "ORGANISM", 4, 17], ["I. scapularis", "ORGANISM", 80, 93], ["I. scapularis ticks", "ORGANISM", 944, 963], ["I. scapularis", "SPECIES", 4, 17], ["I. scapularis", "SPECIES", 80, 93], ["I. scapularis", "SPECIES", 944, 957], ["I. scapularis", "SPECIES", 4, 17], ["I. scapularis", "SPECIES", 80, 93], ["I. scapularis", "SPECIES", 944, 957], ["R0", "TREATMENT", 188, 190], ["its estimation", "TEST", 195, 209], ["parasites", "PROBLEM", 230, 239], ["pathogens", "PROBLEM", 244, 253], ["the present study", "TEST", 326, 343], ["other parasites", "PROBLEM", 373, 388], ["pathogens", "PROBLEM", 393, 402], ["an arthropod vector", "TREATMENT", 484, 503], ["R0 values", "TEST", 693, 702], ["other parasites", "PROBLEM", 716, 731], ["pathogens", "PROBLEM", 736, 745], ["MethodsWe", "TREATMENT", 746, 755], ["scapularis", "ANATOMY", 7, 17], ["scapularis", "ANATOMY", 83, 93], ["scapularis", "ANATOMY", 947, 957]]], ["These transects were chosen to capture the climate variability that exists in the region.", [["climate variability", "OBSERVATION", 43, 62], ["region", "ANATOMY_MODIFIER", 82, 88]]], ["For simplicity in data presentation, the sites were grouped into clusters [Southern Ontario, Huron Ontario, Upper Southern Ontario, South-Western Quebec, and the Boreal region (see Supplemental Material, Table S1 and Figure S1)] according to geographic proximity and similarity in temperature conditions (see Supplemental Material, \u201cVariation in temperature and R0 amongst sites,\u201d pp. 2\u20136, Figures S2\u2013S4), and mean values for clusters are presented.", [["the Boreal region", "PROBLEM", 158, 175], ["Supplemental Material", "TREATMENT", 181, 202], ["Table S1 and Figure S1)", "TREATMENT", 204, 227], ["mean values", "TEST", 410, 421], ["Upper", "ANATOMY_MODIFIER", 108, 113], ["Boreal", "ANATOMY", 162, 168]]], ["We also estimated R0 for two sites in the United States where Lyme disease is endemic in the Northeast and upper Midwest, respectively: Old Lyme (Connecticut), where the human Lyme disease cases were first recognized (Wood and Lafferty 2013), and Fort McCoy (Wisconsin) (Anderson et al. 1987).MethodsModeling R0.", [["Lyme disease", "DISEASE", 62, 74], ["Lyme", "DISEASE", 140, 144], ["Lyme disease", "DISEASE", 176, 188], ["human", "ORGANISM", 170, 175], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["Lyme disease", "PROBLEM", 62, 74], ["the human Lyme disease cases", "PROBLEM", 166, 194], ["Lyme disease", "OBSERVATION", 62, 74], ["endemic", "OBSERVATION_MODIFIER", 78, 85], ["upper", "ANATOMY_MODIFIER", 107, 112], ["Lyme", "OBSERVATION", 140, 144], ["Lyme disease", "OBSERVATION", 176, 188]]], ["The I. scapularis model is a deterministic model consisting of 12 ordinary differential equations as described by Wu et al. (2013), based on the mechanistic simulation model described by Ogden et al. (2005).", [["I. scapularis", "ORGANISM", 4, 17], ["I. scapularis", "SPECIES", 4, 17], ["scapularis", "ANATOMY", 7, 17]]], ["This model captures the effects of temperature on host-seeking activity and the rates of development from one life stage to the next (effects common to, but variable among, all arthropod vectors), parameterized from field and laboratory studies on I. scapularis.", [["I. scapularis", "ORGANISM", 248, 261], ["I. scapularis", "SPECIES", 248, 261], ["I. scapularis", "SPECIES", 248, 261], ["laboratory studies", "TEST", 226, 244], ["scapularis", "ANATOMY", 251, 261]]], ["Mortality rates of nonfeeding I. scapularis in Canada and the northeastern United States are similar in summer and winter, presumably due to the insulating effects of the litter layer in woodland habitats (Brunner et al. 2012; Lindsay et al. 1995).", [["I. scapularis", "ORGANISM", 30, 43], ["I. scapularis", "SPECIES", 30, 43], ["I. scapularis", "SPECIES", 30, 43], ["scapularis", "ANATOMY", 33, 43]]], ["Our analyses operated on the hypothesis that the effects of ambient temperature on I. scapularis population survival are indirect via effects on temperature-dependent rates of development of ticks from one life stage to the next.", [["I. scapularis", "ORGANISM", 83, 96], ["I. scapularis", "SPECIES", 83, 96], ["I. scapularis", "SPECIES", 83, 96], ["Our analyses", "TEST", 0, 12], ["ambient temperature", "PROBLEM", 60, 79], ["I. scapularis population survival", "TREATMENT", 83, 116], ["ticks", "PROBLEM", 191, 196]]], ["The lower the temperature, the longer is the tick life cycle and, due to constant daily per capita mortality, the fewer larval ticks survive to become mated adult female ticks.", [["The lower the temperature", "PROBLEM", 0, 25], ["lower", "OBSERVATION_MODIFIER", 4, 9]]], ["At a threshold temperature, mortality outstrips reproduction and the tick populations die out (or fail to become established)\u2014that is, at this temperature, threshold R0 falls below unity (Ogden et al. 2005).", [["a threshold temperature", "PROBLEM", 3, 26]]], ["At the latitudes under study here, effects of climate change on I. scapularis are expected to be the effect of climate warming on shortening the life cycle, resulting in increasing R0 (Ogden et al. 2006b).", [["I. scapularis", "ORGANISM", 64, 77], ["I. scapularis", "SPECIES", 64, 77], ["I. scapularis", "SPECIES", 64, 77], ["the latitudes under study", "TEST", 3, 28], ["climate change on I. scapularis", "PROBLEM", 46, 77], ["climate warming", "TREATMENT", 111, 126], ["shortening the life cycle", "TREATMENT", 130, 155], ["scapularis", "ANATOMY", 67, 77], ["increasing", "OBSERVATION_MODIFIER", 170, 180], ["R0", "OBSERVATION_MODIFIER", 181, 183]]], ["Quadratic effects of temperature on arthropod vector life history traits are common (Mordecai et al. 2013), and quadratic effects of temperature on tick activity are included in the model.", [["tick activity", "TREATMENT", 148, 161]]], ["High temperatures may impact tick survival, causing a northward contraction of the southern range of I. scapularis, resulting in a northward shift, rather than overall expansion, of the geographic range of climatic suitability for I. scapularis (Brownstein et al. 2005).", [["I. scapularis", "ORGANISM", 101, 114], ["I. scapularis", "ORGANISM", 231, 244], ["I. scapularis", "SPECIES", 101, 114], ["I. scapularis", "SPECIES", 231, 244], ["I. scapularis", "SPECIES", 101, 114], ["I. scapularis", "SPECIES", 231, 244], ["High temperatures", "PROBLEM", 0, 17], ["tick survival", "TREATMENT", 29, 42], ["a northward contraction", "PROBLEM", 52, 75], ["a northward shift", "PROBLEM", 129, 146], ["tick survival", "OBSERVATION", 29, 42], ["northward contraction", "OBSERVATION", 54, 75], ["scapularis", "ANATOMY", 104, 114], ["northward shift", "OBSERVATION", 131, 146], ["expansion", "OBSERVATION_MODIFIER", 168, 177], ["scapularis", "ANATOMY", 234, 244]]], ["Here we confined our study to Canada and the main regions of Lyme disease risk in the United States north of 40\u00b0N (Diuk-Wasser et al. 2012).", [["Lyme disease", "DISEASE", 61, 73], ["our study", "TEST", 17, 26], ["Lyme disease risk", "PROBLEM", 61, 78], ["main", "OBSERVATION_MODIFIER", 45, 49], ["Lyme disease", "OBSERVATION", 61, 73]]], ["Impacts of rainfall on off-host tick survival and on host-seeking activity are considered accounted for in the model in assuming a) tick populations only become established in woodlands where the microclimate is suitable for tick survival, and b) most temperate woodlands types occur where rainfall is sufficient for I. scapularis survival, which is supported by studies in Canada (Lindsay et al. 1995).", [["I. scapularis", "ORGANISM", 317, 330], ["I. scapularis", "SPECIES", 317, 330], ["I. scapularis", "SPECIES", 317, 330], ["tick survival", "TREATMENT", 225, 238], ["rainfall", "OBSERVATION_MODIFIER", 11, 19]]], ["Future projections for increased precipitation across much of Canada with climate warming are already being seen to occur (Environment Canada 2013), so rainfall changes are not expected to limit the northward spread of I. scapularis.", [["I. scapularis", "ORGANISM", 219, 232], ["I. scapularis", "SPECIES", 219, 232], ["I. scapularis", "SPECIES", 219, 232], ["increased precipitation", "PROBLEM", 23, 46], ["climate warming", "TREATMENT", 74, 89], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["precipitation", "OBSERVATION", 33, 46], ["scapularis", "ANATOMY", 222, 232]]], ["For the present study, we modified the simulation model of Ogden et al. (2005) in order to calculate R0 by the next generation operator as described by Wu et al. (2013).", [["the present study", "TEST", 4, 21]]], ["Apart from the temperature values used to calculate tick development and host-finding rates, the values for host numbers (20 deer and 200 rodents) and all other parameter values were those used as starting values by Wu et al. (2013).", [["the temperature values", "TEST", 11, 33], ["host numbers", "TEST", 108, 120]]], ["R0 was estimated using mean monthly temperature data for each year and location as described in the following sections.", [["sections", "ANATOMY", 110, 118], ["mean monthly temperature data", "TEST", 23, 52]]], ["Variations in host abundance affect the final size of the tick population but not the temperature threshold (Ogden et al. 2005).", [["host", "OBSERVATION_MODIFIER", 14, 18], ["abundance", "OBSERVATION_MODIFIER", 19, 28], ["size", "OBSERVATION_MODIFIER", 46, 50]]], ["The temperature threshold would be affected by variations in the mortality rates of ticks in the environment, and slight variations in this have been observed in the field (Ogden et al. 2006a).", [["The temperature threshold", "TEST", 0, 25], ["slight", "OBSERVATION_MODIFIER", 114, 120], ["variations", "OBSERVATION_MODIFIER", 121, 131]]], ["For the sensitivity analysis of R0 to variations in model parameter values, see Supplemental Material, \u201cModel sensitivity analysis,\u201d pp. 7\u201311, Table S2 and Figures S5 and S6.MethodsModeling R0 under current climate.", [["S6", "PROTEIN", 171, 173], ["the sensitivity analysis", "TEST", 4, 28], ["model parameter values", "TEST", 52, 74], ["S2", "ANATOMY", 149, 151], ["S5", "ANATOMY_MODIFIER", 164, 166], ["S6", "ANATOMY", 171, 173]]], ["For observed temperatures, we used Australian National University Splines (ANUSPLIN) (Hutchinson et al. 2009) of 10-km gridded daily time-series data, which were obtained by thin-plate smoothing spline interpolation of daily climate station observations while accounting for latitude, longitude, and elevation.", [["Australian National University Splines", "TREATMENT", 35, 73], ["thin-plate smoothing spline interpolation", "TREATMENT", 174, 215], ["latitude, longitude, and elevation", "PROBLEM", 275, 309], ["elevation", "OBSERVATION", 300, 309]]], ["ANUSPLIN data cover the 40 years (1971\u20132010) that encompass the period of Lyme disease emergence in North America, have coverage across northern North America, and account for missing data by temporal and spatial interpolation.", [["Lyme disease", "DISEASE", 74, 86], ["Lyme disease", "PROBLEM", 74, 86], ["missing data", "PROBLEM", 176, 188], ["Lyme disease", "OBSERVATION", 74, 86]]], ["A mean daily near-surface temperature was assigned to the 32 study sites, which were weather stations located over a wide range of the orographic and forest ecosystems of Ontario and Quebec or interpolations of ANUSPLIN data for locations in the United States.", [["surface", "ANATOMY", 18, 25], ["surface temperature", "TEST", 18, 37], ["ANUSPLIN data", "TEST", 211, 224]]], ["Monthly mean near-surface air temperatures were used to parameterize the I. scapularis population model for estimating annual values of R0 for each site, for each year from 1971 to 2010 (see Supplemental Material, \u201cVariation in temperature and R0 amongst sites,\u201d pp. 2\u20136).", [["I. scapularis", "SPECIES", 73, 86], ["surface air temperatures", "PROBLEM", 18, 42], ["scapularis", "ANATOMY", 76, 86]]], ["Values for annual cumulative degree days > 0\u00b0C (DD > 0\u00b0C), contemporaneous for each estimated R0 value, were computed as the accumulation of daily temperature > 0\u00b0C for each year for each site.", [["Values", "TEST", 0, 6], ["annual cumulative degree days", "TEST", 11, 40], ["DD", "TEST", 48, 50], ["each estimated R0 value", "TEST", 79, 102], ["daily temperature", "TEST", 141, 158]]], ["The tick model calculated R0 for each year using temperature data for that year, but in reality R0 will depend on the temperature conditions over the 2- to 3-year life cycle of the tick.", [["temperature data", "TEST", 49, 65], ["the temperature conditions", "PROBLEM", 114, 140]]], ["An ensemble of modeled temperature data available from three regional climate model (RCM) and two global climate model (GCM) runs were used to estimate future changes in R0 (see Supplemental Material, \u201cValidation of climate model output,\u201d pp. 11\u201314; Table S3).", [["modeled temperature data", "TEST", 15, 39], ["climate model output", "TEST", 216, 236]]], ["We extracted time series of daily temperature for the 30 Canadian sites from each model.", [["daily temperature", "TREATMENT", 28, 45]]], ["Simulated temperature at a given site was defined as the mean of the closest grid values to that site, increasing confidence in the physical representativeness (Gachon and Dibike 2007).MethodsWe chose bias-corrected output from Canadian RCM CRCM4.2.3, version 4 (Laprise et al. 1997; Music and Caya 2007) to provide temperature data for the I. scapularis model because it relatively accurately and conservatively hindcasted observed ANUSPLIN data in comparison with other climate models and because it provided projected temperatures at a local scale.", [["I. scapularis", "ORGANISM", 341, 354], ["I. scapularis", "SPECIES", 341, 354], ["Simulated temperature", "PROBLEM", 0, 21], ["temperature data", "TEST", 316, 332], ["the I. scapularis model", "PROBLEM", 337, 360], ["ANUSPLIN data", "TEST", 433, 446], ["a local scale", "TREATMENT", 537, 550], ["increasing", "OBSERVATION_MODIFIER", 103, 113]]], ["For full details justifying the climate model selection, see Supplemental Material, \u201cValidation of climate model output,\u201dpp. 11\u201314, Figures S7 and S8.", [["climate model output", "TEST", 99, 119], ["output", "OBSERVATION_MODIFIER", 113, 119]]], ["Like other RCMs, CRCM4.2.3 dynamically downscales output from a coarser resolution GCM and produces data at a horizontal resolution of approximately 50 km.", [["RCMs", "GENE_OR_GENE_PRODUCT", 11, 15], ["CRCM4", "GENE_OR_GENE_PRODUCT", 17, 22], ["RCMs", "PROTEIN", 11, 15], ["CRCM4", "PROTEIN", 17, 22], ["dynamically downscales output", "PROBLEM", 27, 56], ["a coarser resolution GCM", "PROBLEM", 62, 86], ["dynamically", "OBSERVATION_MODIFIER", 27, 38], ["downscales", "OBSERVATION_MODIFIER", 39, 49], ["output", "OBSERVATION_MODIFIER", 50, 56], ["coarser resolution", "OBSERVATION_MODIFIER", 64, 82]]], ["CRCM4.2.3 is driven by initial and boundary conditions of the Canadian GCM CGCM3.1 T47 (McFarlane et al. 2005; Scinocca et al. 2008).", [["CRCM4", "GENE_OR_GENE_PRODUCT", 0, 5], ["CRCM4.2.3", "DNA", 0, 9], ["CRCM4", "TEST", 0, 5], ["the Canadian GCM", "TEST", 58, 74]]], ["Hindcasting up to 2000 used greenhouse gas emissions for CGCM3.1 T47 as in the Coupled Model Intercomparison Project (CMIP) 20th century experiment (Meehl et al. 2000).", [["greenhouse gas emissions", "TEST", 28, 52]]], ["For future projections starting in 2001, we chose the A2 scenario (mid-high Green-House-Gas emission scenario) of the Intergovernmental Panel on Climate Change Special Report on Emission Scenarios (Nakicenovic and Swart 2000) because of the availability of regional climate model output using this scenario and because current actual trajectory of emissions corresponded best to this emissions scenario.MethodsMapping R0 under current and future climate.", [["this scenario", "TREATMENT", 293, 306], ["MethodsMapping R0", "TREATMENT", 403, 420]]], ["We mapped 30-year mean values of R0 for I. scapularis using observed and projected values.", [["I. scapularis", "ORGANISM", 40, 53], ["I. scapularis", "SPECIES", 40, 53], ["I. scapularis", "SPECIES", 40, 53], ["I. scapularis", "PROBLEM", 40, 53], ["scapularis", "ANATOMY", 43, 53]]], ["Maps of DD > 0\u00b0C for North America north of 40\u00b0N and east of the Rocky Mountains were generated using observed data for 1971\u20132000, and using DD > 0\u00b0C projected by bias-corrected CRCM4.2.3 output for the period 2001\u20132070.", [["C", "GENE_OR_GENE_PRODUCT", 148, 149], ["CRCM4", "DNA", 178, 183], ["Maps", "TEST", 0, 4], ["DD", "TEST", 8, 10], ["output", "OBSERVATION_MODIFIER", 188, 194]]], ["We then computed R0 for each year from the gridded DD > 0\u00b0C data using the formula R0 = 1.072 \u00d7 10\u20136 DD > 0\u00b0C\u20134.658 \u00d7 10\u20133 DD > 0\u00b0C2 + 5.556, obtained using observed temperature data as described in Supplemental Material, \u201cMapping R0,\u201dpp. 15\u201316, Figure S9 (the threshold for R0 \u2265 1 was DD > 0\u00b0C \u2265 2859.6\u00b0C).", [["the gridded DD", "TEST", 39, 53], ["C data", "TEST", 58, 64], ["the formula R0", "TEST", 71, 85], ["DD", "TEST", 101, 103], ["\u00b0C", "TEST", 107, 109], ["DD", "TEST", 123, 125], ["temperature data", "TEST", 166, 182], ["Figure S9", "TEST", 246, 255], ["R0", "TEST", 275, 277], ["DD", "TEST", 286, 288], ["\u00b0C", "TEST", 303, 305]]], ["Regions west of the Rocky Mountains were masked because it was assumed that I. scapularis will not cross the Rocky Mountains, west of which Lyme disease risk will continue to depend on transmission of Borrelia burgdorferi by the tick I. pacificus (Ogden et al. 2009).MethodsLiterature search on R0 ranges for parasite and pathogen systems.", [["Lyme disease", "DISEASE", 140, 152], ["Borrelia burgdorferi", "DISEASE", 201, 221], ["I. scapularis", "ORGANISM", 76, 89], ["Borrelia burgdorferi", "ORGANISM", 201, 221], ["I. pacificus", "ORGANISM", 234, 246], ["I. scapularis", "SPECIES", 76, 89], ["Borrelia burgdorferi", "SPECIES", 201, 221], ["I. pacificus", "SPECIES", 234, 246], ["I. scapularis", "SPECIES", 76, 89], ["Borrelia burgdorferi", "SPECIES", 201, 221], ["I. pacificus", "SPECIES", 234, 246], ["I. scapularis", "PROBLEM", 76, 89], ["Lyme disease risk", "PROBLEM", 140, 157], ["Borrelia burgdorferi", "PROBLEM", 201, 221], ["parasite and pathogen systems", "PROBLEM", 309, 338], ["Rocky Mountains", "OBSERVATION", 20, 35], ["scapularis", "ANATOMY", 79, 89]]], ["However, to better comprehend the ecological or epidemiological importance of projected changes of R0 of I. scapularis, we performed a literature review to obtain published estimates of how R0 for parasites and pathogens varies due to changes in factors already recognized as having ecological or epidemiological importance.", [["I. scapularis", "ORGANISM", 105, 118], ["I. scapularis", "SPECIES", 105, 118], ["I. scapularis", "SPECIES", 105, 118], ["parasites", "PROBLEM", 197, 206], ["pathogens", "PROBLEM", 211, 220], ["changes in factors", "PROBLEM", 235, 253], ["scapularis", "ANATOMY", 108, 118]]], ["These include variations in geographic location, host density, strain or genotype, disease control effort, and variations among different epidemics.", [["host density", "PROBLEM", 49, 61], ["strain", "PROBLEM", 63, 69], ["genotype, disease control effort", "PROBLEM", 73, 105], ["variations", "OBSERVATION_MODIFIER", 14, 24], ["geographic", "OBSERVATION_MODIFIER", 28, 38], ["host density", "OBSERVATION", 49, 61]]], ["Articles were searched in the National Centre for Biotechnology Information PubMed search site (http://www.ncbi.nlm.nih.gov/pubmed/) using search terms a) \u201cbasic reproduction number,\u201d without specifying pathogens or parasites, and then b) \u201cbasic reproductive number,\u201d repeated with one of the following terms: tick, mosquito, chagas, malaria, dengue, nematode, \u201cseasonal influenza,\u201d \u201cpandemic influenza\u201d, pH1N1, \u201cavian influenza,\u201d measles, HIV (human immunodeficiency virus), and fluke.", [["fluke", "ANATOMY", 480, 485], ["malaria", "DISEASE", 334, 341], ["dengue", "DISEASE", 343, 349], ["influenza", "DISEASE", 371, 380], ["influenza\u201d", "DISEASE", 393, 403], ["H1N1", "DISEASE", 406, 410], ["avian influenza", "DISEASE", 413, 428], ["measles", "DISEASE", 431, 438], ["HIV (human immunodeficiency virus), and fluke", "DISEASE", 440, 485], ["HIV", "ORGANISM", 440, 443], ["human immunodeficiency virus", "ORGANISM", 445, 473], ["fluke", "ORGAN", 480, 485], ["avian influenza", "SPECIES", 413, 428], ["HIV", "SPECIES", 440, 443], ["human", "SPECIES", 445, 450], ["immunodeficiency virus", "SPECIES", 451, 473], ["HIV", "SPECIES", 440, 443], ["human immunodeficiency virus", "SPECIES", 445, 473], ["parasites", "PROBLEM", 216, 225], ["tick", "PROBLEM", 310, 314], ["malaria", "PROBLEM", 334, 341], ["dengue", "PROBLEM", 343, 349], ["seasonal influenza", "PROBLEM", 362, 380], ["pandemic influenza\u201d", "PROBLEM", 384, 403], ["H1N1", "PROBLEM", 406, 410], ["influenza", "PROBLEM", 419, 428], ["measles", "PROBLEM", 431, 438], ["HIV (human immunodeficiency virus)", "PROBLEM", 440, 474], ["fluke", "PROBLEM", 480, 485], ["fluke", "ANATOMY", 480, 485]]], ["Relevant articles were those in which R0 for parasites and pathogens was calculated to explicitly estimate its value under field, rather than theoretical, conditions.", [["parasites", "PROBLEM", 45, 54], ["pathogens", "PROBLEM", 59, 68]]], ["This meant articles that employed simulation models using field data, fitting of epidemiological data (e.g., age\u2013seroprevalence or age\u2013infection prevalence), or other methods such as estimates from phylogenetic analysis.", [["field data", "TEST", 58, 68], ["epidemiological data", "TEST", 81, 101], ["phylogenetic analysis", "TEST", 198, 219]]], ["We did not review and use R0 ranges obtained in model-based sensitivity analyses, variations in R0 associated with seasonal variations in mosquito abundance in one location (which may vary from zero to very high values), estimates where control methods effectively eradicated disease resulting in almost infinite values for changes in R0, or model-predicted variations across whole potential geographic ranges that range from a theoretical high to zero values (e.g., Estrada-Pe\u00f1a et al. 2013).", [["R0 ranges", "TEST", 26, 35], ["variations in R0", "PROBLEM", 82, 98], ["seasonal variations in mosquito abundance", "PROBLEM", 115, 156], ["eradicated disease", "PROBLEM", 265, 283], ["changes in R0", "PROBLEM", 324, 337]]], ["We also did not use some very high modeled ranges of R0 for malaria [e.g., 1\u201311,000 (Smith et al. 2007)] when the modeling of empirical age\u2013infection prevalence data produced strongly contrasting single-digit estimates of R0 (Hagmann et al. 2003; Hay et al. 2005).", [["malaria", "DISEASE", 60, 67], ["malaria", "PROBLEM", 60, 67]]], ["The goal of the literature search was to provide an illustration of how important projected changes in R0 of I. scapularis could be, compared with R0 of other parasites and pathogens; it was not intended to be an exhaustive cataloging of all literature in this field.", [["I. scapularis", "ORGANISM", 109, 122], ["I. scapularis", "SPECIES", 109, 122], ["I. scapularis", "SPECIES", 109, 122], ["other parasites", "PROBLEM", 153, 168], ["pathogens", "PROBLEM", 173, 182], ["scapularis", "ANATOMY", 112, 122], ["parasites", "OBSERVATION", 159, 168]]], ["Further, we recognized that R0 estimates are not precise and vary according to the estimation method used (Heffernan et al. 2005; Li et al. 2011).ResultsUsing observed (ANUSPLIN) temperature data, R0 for I. scapularis in the late 1970s\u2014when Lyme disease emerged in the northeastern United States (Wood and Lafferty 2013)\u2014was estimated at approximately 3 and 1.9 in Old Lyme and Fort McCoy, respectively; at between 2 and 3 in Southern Ontario; approximately 1.5 in Huron Ontario and South-Western Quebec, but mostly < 1 in Upper Southern Ontario and the Boreal region (Figure 1).", [["Lyme disease", "DISEASE", 241, 253], ["Lyme", "DISEASE", 369, 373], ["I. scapularis", "ORGANISM", 204, 217], ["I. scapularis", "SPECIES", 204, 217], ["I. scapularis", "SPECIES", 204, 217], ["temperature data", "TEST", 179, 195], ["Lyme disease", "PROBLEM", 241, 253], ["scapularis", "ANATOMY", 207, 217], ["Upper", "ANATOMY_MODIFIER", 523, 528], ["Boreal", "ANATOMY_MODIFIER", 554, 560]]], ["In Old Lyme, R0 increased almost linearly to approximately 3.5 by 1999 during the first period of expansion of I. scapularis in the northeastern United States.", [["Lyme", "DISEASE", 7, 11], ["I. scapularis", "ORGANISM", 111, 124], ["I. scapularis", "SPECIES", 111, 124], ["I. scapularis", "SPECIES", 111, 124], ["Old Lyme", "PROBLEM", 3, 11], ["Old", "OBSERVATION_MODIFIER", 3, 6], ["Lyme", "OBSERVATION", 7, 11], ["R0", "OBSERVATION_MODIFIER", 13, 15], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["almost", "OBSERVATION_MODIFIER", 26, 32], ["linearly", "OBSERVATION_MODIFIER", 33, 41], ["expansion", "OBSERVATION_MODIFIER", 98, 107], ["scapularis", "ANATOMY", 114, 124]]], ["In Fort McCoy, R0 increased slightly, but this increase was small compared with interannual variations.", [["R0", "OBSERVATION_MODIFIER", 15, 17], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["slightly", "OBSERVATION_MODIFIER", 28, 36], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["small", "OBSERVATION_MODIFIER", 60, 65]]], ["In Southern Ontario, R0 increased to 4 by the early 2000s; during which time I. scapularis populations emerged at a number of locations in this region (Point Pelee National Park, Turkey Point, Rondeau Provincial Park; Figure 1A).", [["I. scapularis", "ORGANISM", 77, 90], ["I. scapularis", "SPECIES", 77, 90], ["I. scapularis", "SPECIES", 77, 90], ["Southern", "OBSERVATION_MODIFIER", 3, 11], ["Ontario", "OBSERVATION_MODIFIER", 12, 19], ["scapularis", "ANATOMY", 80, 90]]], ["In Huron Ontario and South-Western Quebec, R0 increased from 1.5 to 2.5 by the early 2000s; and subsequent to this (mostly from 2000 onward), I. scapularis populations began to emerge in South-Western Quebec (Figure 1D).", [["I. scapularis", "ORGANISM", 142, 155], ["I. scapularis", "SPECIES", 142, 155], ["I. scapularis", "SPECIES", 142, 155], ["scapularis", "ANATOMY", 145, 155]]], ["In Upper Southern Ontario, R0 increased to > 1 in the late 1990s, but in the Boreal region R0 remained below unity for the whole 1971\u20132010 period (Figure 1).ResultsR0 values for I. scapularis obtained in model simulations using projected climate data were similar for an ensemble of climate models, and we used bias-corrected output from the regional climate model CRCM4.2.3 as a representative of the ensemble because of its spatial resolution and predictive accuracy.", [["I. scapularis", "ORGANISM", 178, 191], ["ResultsR0", "PROTEIN", 157, 166], ["I. scapularis", "SPECIES", 178, 191], ["I. scapularis", "SPECIES", 178, 191], ["ResultsR0 values", "TEST", 157, 173], ["I. scapularis", "PROBLEM", 178, 191], ["projected climate data", "TEST", 228, 250], ["bias", "TEST", 311, 315], ["predictive accuracy", "TEST", 449, 468], ["Upper", "ANATOMY_MODIFIER", 3, 8], ["R0", "OBSERVATION_MODIFIER", 27, 29], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["Boreal", "ANATOMY_MODIFIER", 77, 83], ["scapularis", "ANATOMY", 181, 191]]], ["R0 for I. scapularis in Canada was projected to increase 1.5 to 2.3 times from the period 1971\u20132000 to 2001\u20132050, and 2.2 to 4.6 times from the period 1971\u20132000 to 2051\u20132069 depending on location (Figure 1, Table 1); and in the United States, R0 was predicted to approximately double to 7.1 and 5.2 in Old Lyme (Figure 1) and Fort McCoy, respectively, by 2051\u20132069 (Table 1).", [["Lyme", "DISEASE", 306, 310], ["I. scapularis", "ORGANISM", 7, 20], ["I. scapularis", "SPECIES", 7, 20], ["I. scapularis", "SPECIES", 7, 20], ["scapularis", "ANATOMY", 10, 20]]], ["Increases in R0 to values > 1 predicted in regions where R0 was < 1 during the period 1970\u20132000 would be expected to facilitate range expansion of I. scapularis northward and possibly westward (Figure 2).ResultsThe projected increases in R0 are equivalent, for the most part, to ranges of values of R0 estimated for other globally important parasites and pathogens associated with variations in major determinants of their ecology and epidemiology such as geographic location, pathogen genotype, different epidemics, reservoir host or vector density, and control efforts (Table 1).DiscussionThese findings suggest that increasing temperatures in northern North America that support an R0 for I. scapularis of > 1.5 have been coincident with, or in advance of, but not subsequent to, expanding numbers of locations where I. scapularis populations have become established.", [["I. scapularis", "ORGANISM", 147, 160], ["I. scapularis", "ORGANISM", 692, 705], ["I. scapularis", "ORGANISM", 820, 833], ["I. scapularis", "SPECIES", 147, 160], ["I. scapularis", "SPECIES", 692, 705], ["I. scapularis", "SPECIES", 820, 833], ["I. scapularis", "SPECIES", 147, 160], ["I. scapularis", "SPECIES", 692, 705], ["I. scapularis", "SPECIES", 820, 833], ["pathogens", "PROBLEM", 355, 364], ["pathogen genotype", "PROBLEM", 477, 494], ["reservoir host", "TREATMENT", 517, 531], ["increasing temperatures", "PROBLEM", 619, 642], ["scapularis", "ANATOMY", 150, 160], ["projected", "OBSERVATION_MODIFIER", 215, 224], ["increases", "OBSERVATION_MODIFIER", 225, 234], ["equivalent", "OBSERVATION_MODIFIER", 245, 255], ["parasites", "OBSERVATION", 341, 350], ["increasing", "OBSERVATION_MODIFIER", 619, 629], ["temperatures", "OBSERVATION_MODIFIER", 630, 642], ["scapularis", "ANATOMY", 823, 833]]], ["In Canada, where we have tracked the spread of I. scapularis, temperature has remained a statistically significant determinant of I. scapularis occurrence in field studies and analyses of surveillance data that accounted for alternative environmental determinants (e.g., host abundance, altitude, rainfall, habitat types, tick immigration rates) (Bouchard et al. 2013a, 2013b; Leighton et al. 2012; Ogden et al. 2008; 2010).", [["I. scapularis", "ORGANISM", 47, 60], ["I. scapularis", "ORGANISM", 130, 143], ["I. scapularis", "SPECIES", 47, 60], ["I. scapularis", "SPECIES", 130, 143], ["I. scapularis", "SPECIES", 47, 60], ["I. scapularis", "SPECIES", 130, 143], ["field studies", "TEST", 158, 171], ["surveillance data", "TEST", 188, 205], ["spread", "OBSERVATION_MODIFIER", 37, 43], ["scapularis", "ANATOMY", 50, 60]]], ["These observations supported a key role for temperature in I. scapularis populations becoming established at the northern edge of the tick\u2019s range.", [["I. scapularis", "ORGANISM", 59, 72], ["I. scapularis", "SPECIES", 59, 72], ["I. scapularis", "SPECIES", 59, 72], ["temperature in I. scapularis populations", "PROBLEM", 44, 84], ["scapularis", "ANATOMY", 62, 72]]], ["Also, I. scapularis population expansion in Canada is occurring despite an overall deforestation (Natural Resources Canada 2013) rather than the reforestation thought to have driven the initial reemergence of Lyme disease in the United States (Barbour and Fish 1993).", [["Lyme disease", "DISEASE", 209, 221], ["I. scapularis", "ORGANISM", 6, 19], ["I. scapularis", "SPECIES", 6, 19], ["I. scapularis", "SPECIES", 6, 19], ["I. scapularis population expansion", "PROBLEM", 6, 40], ["Lyme disease", "PROBLEM", 209, 221], ["scapularis", "ANATOMY", 9, 19], ["population", "OBSERVATION_MODIFIER", 20, 30], ["expansion", "OBSERVATION_MODIFIER", 31, 40], ["overall", "OBSERVATION_MODIFIER", 75, 82], ["deforestation", "OBSERVATION", 83, 96], ["Lyme disease", "OBSERVATION", 209, 221]]], ["Forest fragmentation may enhance Lyme disease risk for a variety of reasons; however, I. scapularis ticks are invading Canada where forest fragmentation occurred over time scales long predating current I. scapularis invasion (Elliott 1998).", [["Lyme disease", "DISEASE", 33, 45], ["I. scapularis ticks", "ORGANISM", 86, 105], ["I. scapularis", "ORGANISM", 202, 215], ["I. scapularis", "SPECIES", 86, 99], ["I. scapularis", "SPECIES", 202, 215], ["I. scapularis", "SPECIES", 86, 99], ["I. scapularis", "SPECIES", 202, 215], ["Forest fragmentation", "PROBLEM", 0, 20], ["Lyme disease risk", "PROBLEM", 33, 50], ["I. scapularis ticks", "PROBLEM", 86, 105], ["forest fragmentation", "PROBLEM", 132, 152], ["Lyme", "OBSERVATION_MODIFIER", 33, 37], ["scapularis", "ANATOMY", 89, 99], ["forest fragmentation", "OBSERVATION", 132, 152], ["scapularis", "ANATOMY", 205, 215], ["invasion", "OBSERVATION", 216, 224]]], ["Together, these findings suggest that even if recent warming in the region (5\u201310% increases in DD > 0\u00b0C; Figure 1) was not associated with global warming, a future warming climate will increase R0 of I. scapularis in northern North America.", [["I. scapularis", "ORGANISM", 200, 213], ["I. scapularis", "SPECIES", 200, 213], ["I. scapularis", "SPECIES", 200, 213], ["recent warming in the region", "PROBLEM", 46, 74], ["DD", "TEST", 95, 97], ["global warming", "TREATMENT", 139, 153], ["a future warming climate", "TREATMENT", 155, 179], ["scapularis", "ANATOMY", 203, 213]]], ["Increases in R0 may drive increased Lyme disease risk where it is already endemic (within limits determined by density-dependent regulation of the tick) and drive range expansion into more northern regions where it is currently absent.", [["Lyme disease", "DISEASE", 36, 48], ["Increases in R0", "PROBLEM", 0, 15], ["increased Lyme disease risk", "PROBLEM", 26, 53], ["Lyme disease", "OBSERVATION", 36, 48], ["absent", "OBSERVATION", 228, 234]]], ["Furthermore, they support the hypothesis that climate warming in northeastern North America may have co-driven the emergence of Lyme disease risk, alongside other hypothesized factors such as reforestation and burgeoning deer populations (Wood and Lafferty 2013), by facilitating the spread of I. scapularis from refuges.", [["Lyme disease", "DISEASE", 128, 140], ["I. scapularis", "ORGANISM", 294, 307], ["I. scapularis", "SPECIES", 294, 307], ["I. scapularis", "SPECIES", 294, 307], ["Lyme disease risk", "PROBLEM", 128, 145], ["scapularis", "ANATOMY", 297, 307]]], ["Expansion of I. scapularis in the northern United States has then provided the source of ticks to fuel its northward expansion into Canada.DiscussionThe immediate importance of future increased R0 of I. scapularis in the northeast and upper Midwest of North America is that a) regions currently climatically unsuitable become suitable for I. scapularis establishment (i.e., R0 changes from < 1 to > 1; Figure 2); b) in regions currently suitable for I. scapularis (where R0 > 1), tick invasion speed will accelerate as the likelihood of stochastic tick population fade-out reduces (May et al. 2001), and tick-borne pathogen invasion speed increases due to increasing tick abundance (Ogden et al. 2007); and c) risk from I. scapularis\u2013transmitted pathogens may increase where the tick and pathogen are already established due to increased tick abundance up to a point at which this is limited by density-dependent regulation (Ogden et al. 2007).", [["I. scapularis", "ORGANISM", 13, 26], ["I. scapularis", "ORGANISM", 200, 213], ["I. scapularis", "ORGANISM", 339, 352], ["I. scapularis", "ORGANISM", 450, 463], ["I. scapularis", "SPECIES", 13, 26], ["I. scapularis", "SPECIES", 200, 213], ["I. scapularis", "SPECIES", 339, 352], ["I. scapularis", "SPECIES", 450, 463], ["I. scapularis", "SPECIES", 13, 26], ["I. scapularis", "SPECIES", 200, 213], ["I. scapularis", "SPECIES", 339, 352], ["I. scapularis", "SPECIES", 450, 463], ["I. scapularis establishment", "PROBLEM", 339, 366], ["I. scapularis", "PROBLEM", 450, 463], ["tick invasion speed", "PROBLEM", 480, 499], ["stochastic tick population", "PROBLEM", 537, 563], ["tick-borne pathogen invasion speed", "PROBLEM", 604, 638], ["increasing tick abundance", "PROBLEM", 656, 681], ["I. scapularis\u2013transmitted pathogens", "PROBLEM", 720, 755], ["pathogen", "PROBLEM", 788, 796], ["increased tick abundance", "PROBLEM", 828, 852], ["I.", "OBSERVATION_MODIFIER", 13, 15], ["scapularis", "ANATOMY", 16, 26], ["scapularis", "ANATOMY", 203, 213], ["upper", "ANATOMY_MODIFIER", 235, 240], ["scapularis", "ANATOMY", 453, 463], ["density", "OBSERVATION", 895, 902]]], ["To date, I. scapularis invasion in the northern United States and Canada has been followed by invasion of the agent of Lyme disease, B. burgdorferi sensu stricto (Hamer et al. 2010; Ogden et al. 2013), hence we assume northward I. scapularis range expansion is synonymous with expansion in Lyme disease risk.DiscussionThe magnitude of projected increases in R0 of I. scapularis in the present study is of importance for the ecology and epidemiology of vector-borne diseases in general.", [["Lyme disease", "DISEASE", 119, 131], ["B. burgdorferi sensu stricto", "DISEASE", 133, 161], ["Lyme disease", "DISEASE", 290, 302], ["vector-borne diseases", "DISEASE", 452, 473], ["I. scapularis", "ORGANISM", 9, 22], ["B. burgdorferi sensu stricto", "ORGANISM", 133, 161], ["I. scapularis", "ORGANISM", 228, 241], ["I. scapularis", "ORGANISM", 364, 377], ["I. scapularis", "SPECIES", 9, 22], ["B. burgdorferi", "SPECIES", 133, 147], ["I. scapularis", "SPECIES", 228, 241], ["I. scapularis", "SPECIES", 364, 377], ["I. scapularis", "SPECIES", 9, 22], ["B. burgdorferi", "SPECIES", 133, 147], ["I. scapularis", "SPECIES", 228, 241], ["I. scapularis", "SPECIES", 364, 377], ["Lyme disease", "PROBLEM", 119, 131], ["Lyme disease risk", "PROBLEM", 290, 307], ["borne diseases", "PROBLEM", 459, 473], ["scapularis", "ANATOMY", 12, 22], ["invasion", "OBSERVATION", 23, 31], ["Lyme disease", "OBSERVATION", 119, 131], ["scapularis", "ANATOMY", 231, 241], ["expansion", "OBSERVATION_MODIFIER", 277, 286], ["Lyme disease", "OBSERVATION", 290, 302], ["scapularis", "ANATOMY", 367, 377]]], ["This was illustrated by R0 ranges estimated for other globally important parasites and pathogens associated with variations in known key determinants of their ecology and epidemiology (Table 1).", [["pathogens", "PROBLEM", 87, 96], ["parasites", "OBSERVATION", 73, 82]]], ["These ranges were of a similar magnitude to projected increases in R0 of I. scapularis with climate change.", [["I. scapularis", "ORGANISM", 73, 86], ["I. scapularis", "SPECIES", 73, 86], ["I. scapularis", "SPECIES", 73, 86], ["increases", "OBSERVATION_MODIFIER", 54, 63], ["scapularis", "ANATOMY", 76, 86], ["climate change", "OBSERVATION", 92, 106]]], ["Tick species are likely to respond to the central tendency of increasing temperatures due to a) the long periods of inter-stadial development that take place in the surface layers of the soil where fluctuating air temperature are buffered, b) latency in responses of development rates to temperature changes minimizing effects of very short-term temperature fluctuations (Ogden et al. 2004), c) their ability to return to soil-level refugia during extremes of heat, cold, drought, or rainfall while host seeking, d) their associations with woodland habitats within which a microclimate is buffered from extremes of temperature occurring in treeless areas (Lindsay et al. 1999b; Morecroft et al. 1998), and e) ticks have no nonparasitic immature feeding stages whose survival is susceptible to short-term changes in weather as do dipteran vectors such as mosquitoes.", [["surface layers", "ANATOMY", 165, 179], ["Tick species", "PROBLEM", 0, 12], ["increasing temperatures", "PROBLEM", 62, 85], ["inter-stadial development", "PROBLEM", 116, 141], ["fluctuating air temperature", "PROBLEM", 198, 225], ["temperature changes", "PROBLEM", 288, 307], ["very short-term temperature fluctuations", "PROBLEM", 330, 370], ["cold", "PROBLEM", 466, 470], ["nonparasitic immature feeding stages", "PROBLEM", 723, 759], ["short-term changes", "PROBLEM", 793, 811], ["no", "UNCERTAINTY", 720, 722], ["nonparasitic", "OBSERVATION_MODIFIER", 723, 735]]], ["Therefore, the increases in R0 projected here represent a possible magnitude of increase in mean R0 values arthropod vectors may experience with climate change.", [["the increases in R0", "PROBLEM", 11, 30], ["increase in mean R0 values arthropod vectors", "PROBLEM", 80, 124], ["increases", "OBSERVATION_MODIFIER", 15, 24], ["possible", "UNCERTAINTY", 58, 66], ["magnitude", "OBSERVATION_MODIFIER", 67, 76], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["mean R0", "OBSERVATION", 92, 99]]], ["Around this mean, dipteran population R0 may fluctuate seasonally and annually over a much wider range due to the rapid effects of rainfall and temperature on reproduction and mortality rates.", [["dipteran population R0", "TREATMENT", 18, 40], ["mortality rates", "TEST", 176, 191]]], ["Abundance and geographic distributions of many mosquito-borne diseases are currently driven primarily by control efforts that superimpose on any climate effects.", [["mosquito-borne diseases", "DISEASE", 47, 70], ["many mosquito-borne diseases", "PROBLEM", 42, 70], ["geographic", "OBSERVATION_MODIFIER", 14, 24], ["distributions", "OBSERVATION_MODIFIER", 25, 38], ["many", "OBSERVATION_MODIFIER", 42, 46], ["mosquito", "OBSERVATION_MODIFIER", 47, 55], ["borne diseases", "OBSERVATION", 56, 70]]], ["Large increases in vector R0 may, however, render current vector and vector-borne disease control methods ineffective as vector multiplication outstrips control efforts (Massad, 2008; Reithinger et al. 2003; Smith et al. 2007).DiscussionR0 increases associated with climate change may be limited in some circumstances.", [["Large increases in vector R0", "PROBLEM", 0, 28], ["vector-borne disease control methods", "TREATMENT", 69, 105], ["vector multiplication", "TREATMENT", 121, 142], ["increases", "OBSERVATION_MODIFIER", 6, 15], ["vector R0", "OBSERVATION", 19, 28]]], ["Host population densities and habitat do not seem to be currently limiting on I. scapularis range expansion, but they may be in the future.", [["I. scapularis", "ORGANISM", 78, 91], ["I. scapularis", "SPECIES", 78, 91], ["I. scapularis", "SPECIES", 78, 91], ["Host population densities", "PROBLEM", 0, 25], ["population", "OBSERVATION_MODIFIER", 5, 15], ["densities", "OBSERVATION", 16, 25]]], ["I. scapularis are dispersed over long distances by migratory birds, but ticks that are not carried by migratory animals would be expected to have less capacity to invade climatically suitable environments.", [["I. scapularis", "ORGANISM", 0, 13], ["I. scapularis", "SPECIES", 0, 13], ["I. scapularis", "SPECIES", 0, 13], ["scapularis", "ANATOMY", 3, 13], ["dispersed", "OBSERVATION_MODIFIER", 18, 27]]], ["Ticks of public health importance such as I. ricinus and I. scapularis are mostly host and woodland habitat generalists, which facilitates range changes, whereas the more highly specialized the niche of a species, the less likely it will be to be dispersed and/or capable of becoming established in new locations (Morin and Chuine 2006).ConclusionsWe estimated the degree to which projected climate change may impact the ecology of arthropod vectors and, by inference, vector-borne diseases.", [["I. ricinus", "ORGANISM", 42, 52], ["I. scapularis", "ORGANISM", 57, 70], ["I. ricinus", "SPECIES", 42, 52], ["I. scapularis", "SPECIES", 57, 70], ["I. ricinus", "SPECIES", 42, 52], ["I. scapularis", "SPECIES", 57, 70], ["arthropod vectors", "TREATMENT", 432, 449], ["vector-borne diseases", "PROBLEM", 469, 490], ["scapularis", "ANATOMY", 60, 70], ["arthropod vectors", "OBSERVATION", 432, 449]]], ["The emergence of Lyme disease in North America may itself have been partly driven by recent climate change.", [["Lyme disease", "DISEASE", 17, 29], ["Lyme disease", "PROBLEM", 17, 29], ["Lyme disease", "OBSERVATION", 17, 29]]], ["Confidence in our projections is increased by observed changes in temperature and estimated R0 for the vector associated with the actual emergence of the vector and the vector-borne diseases it transmits.", [["increased", "OBSERVATION_MODIFIER", 33, 42]]], ["Our findings suggest that effort should be refocused on assessing the health risks due to vector-borne disease, particularly vector-borne zoonoses, associated with our changing climate.", [["vector-borne disease", "DISEASE", 90, 110], ["vector-borne zoonoses", "DISEASE", 125, 146], ["vector-borne disease", "PROBLEM", 90, 110]]]], "bcc8d89091ba062c1ce590dbbab60a8ab0b5a1b3": [["\u25a0 INTRODUCTIONEnterovirus 71 (EV71) is a major pathogen that causes hand, foot, and mouth disease (HFMD).", [["hand", "ANATOMY", 68, 72], ["foot", "ANATOMY", 74, 78], ["mouth", "ANATOMY", 84, 89], ["hand, foot, and mouth disease", "DISEASE", 68, 97], ["HFMD", "DISEASE", 99, 103], ["INTRODUCTIONEnterovirus 71", "ORGANISM", 2, 28], ["EV71", "ORGANISM", 30, 34], ["hand", "ORGANISM_SUBDIVISION", 68, 72], ["foot", "ORGANISM_SUBDIVISION", 74, 78], ["mouth", "ORGANISM_SUBDIVISION", 84, 89], ["EV71", "SPECIES", 30, 34], ["INTRODUCTIONEnterovirus", "TREATMENT", 2, 25], ["hand, foot", "PROBLEM", 68, 78], ["mouth disease", "PROBLEM", 84, 97], ["hand", "ANATOMY", 68, 72], ["foot", "ANATOMY", 74, 78], ["mouth", "ANATOMY", 84, 89]]], ["HFMD has been breaking out widely in recent years in the Asia Pacific region.", [["HFMD", "DISEASE", 0, 4], ["HFMD", "PROBLEM", 0, 4], ["widely", "OBSERVATION_MODIFIER", 27, 33]]], ["1 It is a common communicable disease that usually affects children under 5 years old.", [["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67], ["a common communicable disease", "PROBLEM", 8, 37]]], ["Children suffering from this disease manifest fever or herpes.", [["fever", "DISEASE", 46, 51], ["herpes", "DISEASE", 55, 61], ["Children", "ORGANISM", 0, 8], ["herpes", "ORGANISM", 55, 61], ["Children", "SPECIES", 0, 8], ["this disease", "PROBLEM", 24, 36], ["fever", "PROBLEM", 46, 51], ["herpes", "PROBLEM", 55, 61]]], ["It is self-limited in general, but a minority of children infected by EV71 develop severe complications in the nervous system due to its neurotropism, such as aseptic meningitis, brain stem encephalitis, and neurogenic pulmonary edema, leading to fatal cases.", [["nervous system", "ANATOMY", 111, 125], ["brain stem", "ANATOMY", 179, 189], ["neurogenic pulmonary edema", "ANATOMY", 208, 234], ["EV71", "DISEASE", 70, 74], ["complications in the nervous system", "DISEASE", 90, 125], ["neurotropism", "DISEASE", 137, 149], ["meningitis", "DISEASE", 167, 177], ["brain stem encephalitis", "DISEASE", 179, 202], ["neurogenic pulmonary edema", "DISEASE", 208, 234], ["children", "ORGANISM", 49, 57], ["EV71", "ORGANISM", 70, 74], ["nervous system", "ANATOMICAL_SYSTEM", 111, 125], ["pulmonary", "ORGAN", 219, 228], ["edema", "PATHOLOGICAL_FORMATION", 229, 234], ["children", "SPECIES", 49, 57], ["EV71", "SPECIES", 70, 74], ["severe complications in the nervous system", "PROBLEM", 83, 125], ["its neurotropism", "PROBLEM", 133, 149], ["aseptic meningitis", "PROBLEM", 159, 177], ["brain stem encephalitis", "PROBLEM", 179, 202], ["neurogenic pulmonary edema", "PROBLEM", 208, 234], ["fatal cases", "PROBLEM", 247, 258], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["complications", "OBSERVATION", 90, 103], ["nervous", "ANATOMY", 111, 118], ["neurotropism", "OBSERVATION", 137, 149], ["aseptic", "OBSERVATION_MODIFIER", 159, 166], ["meningitis", "OBSERVATION", 167, 177], ["brain stem", "ANATOMY", 179, 189], ["encephalitis", "OBSERVATION", 190, 202], ["neurogenic", "OBSERVATION_MODIFIER", 208, 218], ["pulmonary", "ANATOMY", 219, 228], ["edema", "OBSERVATION", 229, 234]]], ["2\u22124 EV71 belongs to the genus Enterovirus within the family Picornaviridae.", [["Enterovirus", "DISEASE", 30, 41], ["2\u22124 EV71", "ORGANISM", 0, 8], ["Enterovirus", "ORGANISM", 30, 41], ["EV71", "PROBLEM", 4, 8], ["the genus Enterovirus", "PROBLEM", 20, 41], ["Picornaviridae", "TREATMENT", 60, 74], ["genus Enterovirus", "OBSERVATION", 24, 41]]], ["It is a singlestranded positive-sense RNA virus, encoding VP1, VP2, VP3, and VP4 four structural proteins and seven nonstructural proteins.", [["VP1", "GENE_OR_GENE_PRODUCT", 58, 61], ["VP2", "GENE_OR_GENE_PRODUCT", 63, 66], ["VP3", "GENE_OR_GENE_PRODUCT", 68, 71], ["VP4", "GENE_OR_GENE_PRODUCT", 77, 80], ["VP1", "PROTEIN", 58, 61], ["VP2", "PROTEIN", 63, 66], ["VP3", "PROTEIN", 68, 71], ["VP4", "PROTEIN", 77, 80], ["structural proteins", "PROTEIN", 86, 105], ["nonstructural proteins", "PROTEIN", 116, 138], ["a singlestranded positive-sense RNA virus", "PROBLEM", 6, 47], ["VP1", "TEST", 58, 61], ["VP2", "TEST", 63, 66], ["VP3", "TEST", 68, 71], ["sense RNA virus", "OBSERVATION", 32, 47], ["nonstructural proteins", "OBSERVATION", 116, 138]]], ["VP1 is the most important one since neutralizing epitopes of EV71 chiefly lie on the protein.", [["VP1", "GENE_OR_GENE_PRODUCT", 0, 3], ["EV71", "ORGANISM", 61, 65], ["VP1", "PROTEIN", 0, 3], ["neutralizing epitopes", "PROTEIN", 36, 57], ["VP1", "TREATMENT", 0, 3], ["neutralizing epitopes of EV71", "PROBLEM", 36, 65], ["most important", "OBSERVATION_MODIFIER", 11, 25]]], ["5,6 VP1 is verified to be related to virus titer and the emergence of severe clinical cases during EV71 infection.", [["EV71 infection", "DISEASE", 99, 113], ["VP1", "GENE_OR_GENE_PRODUCT", 4, 7], ["EV71", "ORGANISM", 99, 103], ["EV71", "SPECIES", 99, 103], ["VP1", "PROBLEM", 4, 7], ["virus titer", "PROBLEM", 37, 48], ["severe clinical cases", "PROBLEM", 70, 91], ["EV71 infection", "PROBLEM", 99, 113], ["verified to be related to", "UNCERTAINTY", 11, 36], ["virus", "OBSERVATION", 37, 42], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["infection", "OBSERVATION", 104, 113]]], ["Currently, there is no effective medicine for HFMD.", [["HFMD", "DISEASE", 46, 50], ["effective medicine", "TREATMENT", 23, 41], ["HFMD", "PROBLEM", 46, 50], ["no", "UNCERTAINTY", 20, 22], ["effective", "OBSERVATION_MODIFIER", 23, 32]]], ["The three vaccines against EV71 launched so far are univalent and have deficiencies, for instance, a short duration of immunological effects, no immune body production, adverse immune reaction, and high cost.", [["immune body", "ANATOMY", 145, 156], ["EV71", "DISEASE", 27, 31], ["adverse immune reaction", "DISEASE", 169, 192], ["EV71", "ORGANISM", 27, 31], ["EV71", "SPECIES", 27, 31], ["The three vaccines", "TREATMENT", 0, 18], ["EV71", "PROBLEM", 27, 31], ["immunological effects", "PROBLEM", 119, 140], ["immune body production", "PROBLEM", 145, 167], ["adverse immune reaction", "PROBLEM", 169, 192], ["high cost", "PROBLEM", 198, 207], ["no", "UNCERTAINTY", 142, 144], ["high cost", "OBSERVATION", 198, 207]]], ["7 Hence, it is significant for new drug research against EV71.", [["EV71", "DISEASE", 57, 61], ["EV71", "ORGANISM", 57, 61], ["EV71", "SPECIES", 57, 61], ["EV71", "PROBLEM", 57, 61]]], ["EV71 infection can induce apoptosis in host cells.", [["cells", "ANATOMY", 44, 49], ["EV71 infection", "DISEASE", 0, 14], ["EV71", "ORGANISM", 0, 4], ["host cells", "CELL", 39, 49], ["host cells", "CELL_TYPE", 39, 49], ["EV71", "SPECIES", 0, 4], ["EV71 infection", "PROBLEM", 0, 14], ["apoptosis in host cells", "PROBLEM", 26, 49], ["infection", "OBSERVATION", 5, 14], ["host cells", "OBSERVATION", 39, 49]]], ["Bax is a key protein in the Bcl-2 family, which induces apoptosis.", [["Bax", "GENE_OR_GENE_PRODUCT", 0, 3], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 28, 33], ["Bax", "PROTEIN", 0, 3], ["Bcl-2 family", "PROTEIN", 28, 40], ["apoptosis", "PROBLEM", 56, 65], ["apoptosis", "OBSERVATION", 56, 65]]], ["To explore the relationship between EV71 infection and Bax protein in nerve cells is important to clarify the pathogenic mechanism of severe cases with EV71 infection.\u25a0 INTRODUCTIONRNA interference (RNAi) is a post-transcriptional gene silencing process mediated by double-stranded RNA with gene sequence specificity.", [["nerve cells", "ANATOMY", 70, 81], ["EV71 infection", "DISEASE", 36, 50], ["EV71 infection", "DISEASE", 152, 166], ["EV71", "ORGANISM", 36, 40], ["Bax", "GENE_OR_GENE_PRODUCT", 55, 58], ["nerve cells", "CELL", 70, 81], ["EV71", "ORGANISM", 152, 156], ["Bax protein", "PROTEIN", 55, 66], ["nerve cells", "CELL_TYPE", 70, 81], ["double-stranded RNA", "RNA", 266, 285], ["EV71", "SPECIES", 36, 40], ["EV71", "SPECIES", 152, 156], ["EV71 infection", "PROBLEM", 36, 50], ["Bax protein in nerve cells", "PROBLEM", 55, 81], ["severe cases", "PROBLEM", 134, 146], ["EV71 infection", "PROBLEM", 152, 166], ["a post-transcriptional gene silencing process", "PROBLEM", 208, 253], ["gene sequence specificity", "TEST", 291, 316], ["infection", "OBSERVATION", 41, 50], ["nerve", "ANATOMY", 70, 75], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["infection", "OBSERVATION", 157, 166]]], ["It ubiquitously exists in eukaryotes for resisting virus invasion, inhibiting activity of transposons, and regulating gene expression.", [["transposons", "DNA", 90, 101], ["resisting virus invasion", "PROBLEM", 41, 65], ["virus invasion", "OBSERVATION", 51, 65]]], ["Since small interfering RNA (siRNA) induces RNAi in mammals, it has been used widely in biomedicine research and drug development.", [["small interfering RNA", "GENE_OR_GENE_PRODUCT", 6, 27], ["small interfering RNA", "RNA", 6, 27], ["small interfering RNA (siRNA)", "PROBLEM", 6, 35], ["small", "OBSERVATION_MODIFIER", 6, 11], ["interfering RNA", "OBSERVATION", 12, 27]]], ["In virus research, siRNA is designed to target genes of virus or vital virus receptors in cells to interfere with viral replication and suppress infection, such as EV71 virus, human immunodeficiency virus, hepatitis virus, influenza virus, respiratory syncytial virus, dengue virus, and so on.", [["cells", "ANATOMY", 90, 95], ["infection", "DISEASE", 145, 154], ["human immunodeficiency virus, hepatitis virus", "DISEASE", 176, 221], ["influenza virus", "DISEASE", 223, 238], ["respiratory syncytial virus", "DISEASE", 240, 267], ["dengue", "DISEASE", 269, 275], ["cells", "CELL", 90, 95], ["EV71 virus", "ORGANISM", 164, 174], ["human immunodeficiency virus", "ORGANISM", 176, 204], ["hepatitis virus", "ORGANISM", 206, 221], ["influenza virus", "ORGANISM", 223, 238], ["respiratory syncytial virus", "ORGANISM", 240, 267], ["EV71 virus", "SPECIES", 164, 174], ["human immunodeficiency virus", "SPECIES", 176, 204], ["hepatitis virus, influenza virus", "SPECIES", 206, 238], ["respiratory syncytial virus", "SPECIES", 240, 267], ["dengue virus", "SPECIES", 269, 281], ["EV71 virus", "SPECIES", 164, 174], ["human immunodeficiency virus", "SPECIES", 176, 204], ["hepatitis virus", "SPECIES", 206, 221], ["respiratory syncytial virus", "SPECIES", 240, 267], ["dengue virus", "SPECIES", 269, 281], ["siRNA", "PROBLEM", 19, 24], ["virus", "PROBLEM", 56, 61], ["vital virus receptors in cells", "PROBLEM", 65, 95], ["viral replication", "PROBLEM", 114, 131], ["suppress infection", "PROBLEM", 136, 154], ["EV71 virus", "PROBLEM", 164, 174], ["human immunodeficiency virus", "PROBLEM", 176, 204], ["hepatitis virus", "PROBLEM", 206, 221], ["influenza virus", "PROBLEM", 223, 238], ["respiratory syncytial virus", "PROBLEM", 240, 267], ["dengue virus", "PROBLEM", 269, 281], ["virus", "OBSERVATION", 3, 8], ["syncytial virus", "OBSERVATION", 252, 267]]], ["8, 9 It has been reported that siRNA targeted 3'UTR, 2C, 3C, 3D, 2A, and 5'UTR genes of EV71 blocked the viral replication.", [["EV71", "DISEASE", 88, 92], ["3C", "GENE_OR_GENE_PRODUCT", 57, 59], ["3D", "GENE_OR_GENE_PRODUCT", 61, 63], ["2A", "GENE_OR_GENE_PRODUCT", 65, 67], ["EV71", "ORGANISM", 88, 92], ["3'UTR, 2C, 3C, 3D, 2A, and 5'UTR genes", "DNA", 46, 84], ["5'UTR genes", "TREATMENT", 73, 84], ["EV71", "PROBLEM", 88, 92], ["the viral replication", "TREATMENT", 101, 122], ["viral replication", "OBSERVATION", 105, 122]]], ["10, 11 Nevertheless, the application of siRNA is still facing challenges since siRNA is easy to degrade in a physiological environment and is difficult to pass through the cell membrane or release to the cytoplasm.", [["cell membrane", "ANATOMY", 172, 185], ["cytoplasm", "ANATOMY", 204, 213], ["cell membrane", "CELLULAR_COMPONENT", 172, 185], ["cytoplasm", "ORGANISM_SUBSTANCE", 204, 213], ["siRNA", "TREATMENT", 40, 45], ["siRNA", "PROBLEM", 79, 84], ["the cell membrane", "TREATMENT", 168, 185], ["siRNA", "OBSERVATION", 40, 45]]], ["As a cationic polymer, polyethyleneimine (PEI) can compress the negative nucleic acids and help them pass through the cell membrane, reaching a high transfection efficiency.", [["cell membrane", "ANATOMY", 118, 131], ["polyethyleneimine", "CHEMICAL", 23, 40], ["PEI", "CHEMICAL", 42, 45], ["nucleic acids", "CHEMICAL", 73, 86], ["polyethyleneimine", "CHEMICAL", 23, 40], ["PEI", "CHEMICAL", 42, 45], ["polyethyleneimine", "SIMPLE_CHEMICAL", 23, 40], ["PEI", "SIMPLE_CHEMICAL", 42, 45], ["cell membrane", "CELLULAR_COMPONENT", 118, 131], ["a cationic polymer, polyethyleneimine (PEI)", "TREATMENT", 3, 46], ["the negative nucleic acids", "PROBLEM", 60, 86], ["the cell membrane", "TREATMENT", 114, 131], ["a high transfection efficiency", "PROBLEM", 142, 172], ["nucleic acids", "OBSERVATION", 73, 86], ["cell membrane", "OBSERVATION", 118, 131], ["high transfection efficiency", "OBSERVATION", 144, 172]]], ["However, toxicity of PEI is still a major limiting factor for application.", [["toxicity", "DISEASE", 9, 17], ["PEI", "CHEMICAL", 21, 24], ["PEI", "CHEMICAL", 21, 24], ["PEI", "SIMPLE_CHEMICAL", 21, 24], ["toxicity of PEI", "PROBLEM", 9, 24]]], ["Therefore, it is important to find out promising vectors for siRNA delivery.\u25a0 INTRODUCTIONWith the rapid development of nanotechnology, functionalized nanomaterials with unique chemical and physical properties have emerged as promising alternatives for treatment of disease.", [["siRNA delivery", "TREATMENT", 61, 75], ["disease", "PROBLEM", 266, 273]]], ["12 Nanoparticles are good drug delivery vectors due to their small particle size leading to stable structures and are easier to enter cells.", [["cells", "ANATOMY", 134, 139], ["cells", "CELL", 134, 139], ["12 Nanoparticles", "TREATMENT", 0, 16], ["good drug delivery vectors", "TREATMENT", 21, 47], ["their small particle size", "PROBLEM", 55, 80], ["small", "OBSERVATION_MODIFIER", 61, 66], ["particle size", "OBSERVATION_MODIFIER", 67, 80], ["stable", "OBSERVATION_MODIFIER", 92, 98]]], ["13 Inorganic nanoparticles, including silver, gold, iron, silica, titanium dioxide, and selenium nanoparticles, have been used as drug or siRNA delivery vectors in biomedical research.", [["silver", "CHEMICAL", 38, 44], ["iron", "CHEMICAL", 52, 56], ["silica", "CHEMICAL", 58, 64], ["titanium dioxide", "CHEMICAL", 66, 82], ["selenium", "CHEMICAL", 88, 96], ["silver", "CHEMICAL", 38, 44], ["iron", "CHEMICAL", 52, 56], ["silica", "CHEMICAL", 58, 64], ["titanium dioxide", "CHEMICAL", 66, 82], ["selenium", "CHEMICAL", 88, 96], ["Inorganic nanoparticles", "SIMPLE_CHEMICAL", 3, 26], ["silver", "SIMPLE_CHEMICAL", 38, 44], ["gold", "SIMPLE_CHEMICAL", 46, 50], ["iron", "SIMPLE_CHEMICAL", 52, 56], ["silica", "SIMPLE_CHEMICAL", 58, 64], ["titanium dioxide", "SIMPLE_CHEMICAL", 66, 82], ["selenium nanoparticles", "SIMPLE_CHEMICAL", 88, 110], ["Inorganic nanoparticles", "TREATMENT", 3, 26], ["silver, gold, iron, silica, titanium dioxide", "TREATMENT", 38, 82], ["selenium nanoparticles", "TREATMENT", 88, 110], ["siRNA delivery vectors", "TREATMENT", 138, 160]]], ["14,15 Among them, selenium nanoparticles modified with PEI and loaded with siRNA have been verified to downregulate the gene level effectively.", [["selenium", "CHEMICAL", 18, 26], ["PEI", "CHEMICAL", 55, 58], ["selenium", "CHEMICAL", 18, 26], ["PEI", "CHEMICAL", 55, 58], ["selenium nanoparticles", "SIMPLE_CHEMICAL", 18, 40], ["PEI", "SIMPLE_CHEMICAL", 55, 58], ["selenium nanoparticles", "TREATMENT", 18, 40], ["PEI", "TREATMENT", 55, 58], ["siRNA", "TREATMENT", 75, 80]]], ["16 In addition, antiviral drugs loaded with selenium nanoparticles present a stronger ability in inhibiting H1N1 influenza virus infection.", [["selenium", "CHEMICAL", 44, 52], ["influenza virus infection", "DISEASE", 113, 138], ["selenium", "CHEMICAL", 44, 52], ["selenium nanoparticles", "SIMPLE_CHEMICAL", 44, 66], ["H1N1 influenza virus", "ORGANISM", 108, 128], ["H1N1 influenza virus", "SPECIES", 108, 128], ["H1N1 influenza virus", "SPECIES", 108, 128], ["antiviral drugs", "TREATMENT", 16, 31], ["selenium nanoparticles", "TREATMENT", 44, 66], ["H1N1 influenza virus infection", "PROBLEM", 108, 138]]], ["17, 18 Inhibition of enteroviurs A71 by selenium nanoparticles, which interferes with the JNK signaling pathway, was reported by Li et al. 19 In this study, siRNA targeted VP1 gene of EV71 was synthesized.", [["selenium", "CHEMICAL", 40, 48], ["selenium", "CHEMICAL", 40, 48], ["enteroviurs A71", "SIMPLE_CHEMICAL", 21, 36], ["selenium nanoparticles", "SIMPLE_CHEMICAL", 40, 62], ["JNK", "GENE_OR_GENE_PRODUCT", 90, 93], ["VP1", "ORGANISM", 172, 175], ["EV71", "ORGANISM", 184, 188], ["JNK", "PROTEIN", 90, 93], ["VP1 gene", "DNA", 172, 180], ["EV71", "SPECIES", 184, 188], ["enteroviurs", "TREATMENT", 21, 32], ["selenium nanoparticles", "TREATMENT", 40, 62], ["this study", "TEST", 145, 155], ["siRNA", "TREATMENT", 157, 162], ["EV71", "PROBLEM", 184, 188]]], ["Cells were transfected with the siRNA carried by selenium nanoparticles modified with PEI before EV71 infection.", [["Cells", "ANATOMY", 0, 5], ["selenium", "CHEMICAL", 49, 57], ["PEI", "CHEMICAL", 86, 89], ["EV71 infection", "DISEASE", 97, 111], ["selenium", "CHEMICAL", 49, 57], ["PEI", "CHEMICAL", 86, 89], ["Cells", "CELL", 0, 5], ["selenium nanoparticles", "SIMPLE_CHEMICAL", 49, 71], ["PEI", "SIMPLE_CHEMICAL", 86, 89], ["EV71", "ORGANISM", 97, 101], ["EV71", "SPECIES", 97, 101], ["the siRNA", "TREATMENT", 28, 37], ["selenium nanoparticles", "TREATMENT", 49, 71], ["PEI", "TREATMENT", 86, 89], ["EV71 infection", "PROBLEM", 97, 111], ["infection", "OBSERVATION", 102, 111]]], ["Subsequently, cell viability and virus titer were detected after transfection efficiency was checked.", [["cell", "ANATOMY", 14, 18], ["cell", "CELL", 14, 18], ["cell viability", "TEST", 14, 28], ["virus titer", "TEST", 33, 44], ["transfection efficiency", "TEST", 65, 88], ["cell viability", "OBSERVATION", 14, 28]]], ["The relationship between the siRNA-loading selenium nanosystem and apoptosis induced by EV71 infection was further explored.\u25a0 RESULTS AND DISCUSSIONPreparation and Characterization of Se@PEI.", [["selenium", "CHEMICAL", 43, 51], ["EV71 infection", "DISEASE", 88, 102], ["Se@PEI", "CHEMICAL", 184, 190], ["selenium", "CHEMICAL", 43, 51], ["selenium", "SIMPLE_CHEMICAL", 43, 51], ["EV71", "ORGANISM", 88, 92], ["EV71", "SPECIES", 88, 92], ["the siRNA-loading selenium nanosystem", "TREATMENT", 25, 62], ["apoptosis", "PROBLEM", 67, 76], ["EV71 infection", "PROBLEM", 88, 102], ["Se@PEI", "TEST", 184, 190], ["siRNA", "ANATOMY", 29, 34], ["EV71", "OBSERVATION_MODIFIER", 88, 92], ["infection", "OBSERVATION", 93, 102]]], ["The TEM observation in Figure 1A showed that SeNPs, Se@ PEI, and Se@PEI presented spherical structures.", [["Se@ PEI", "CHEMICAL", 52, 59], ["Se@PEI", "CHEMICAL", 65, 71], ["SeNPs", "CHEMICAL", 45, 50], ["PEI", "CHEMICAL", 56, 59], ["Se@PEI", "CHEMICAL", 65, 71], ["SeNPs", "SIMPLE_CHEMICAL", 45, 50], ["Se@ PEI", "SIMPLE_CHEMICAL", 52, 59], ["Se@PEI", "SIMPLE_CHEMICAL", 65, 71], ["The TEM observation", "TEST", 0, 19], ["SeNPs", "TEST", 45, 50], ["Se@ PEI", "TREATMENT", 52, 59], ["spherical structures", "OBSERVATION", 82, 102]]], ["Figure 1B shows the image of the Tyndall effect of Se@ PEI@siRNA solution, inferring that Se@PEI was synthesized as nanoparticles.", [["Se@ PEI@siRNA", "CHEMICAL", 51, 64], ["Se@PEI", "CHEMICAL", 90, 96], ["Se@ PEI@siRNA", "CHEMICAL", 51, 64], ["Se@PEI", "CHEMICAL", 90, 96], ["Se@", "SIMPLE_CHEMICAL", 51, 54], ["PEI@siRNA", "SIMPLE_CHEMICAL", 55, 64], ["Se@PEI", "SIMPLE_CHEMICAL", 90, 96], ["Se@ PEI@siRNA solution", "TREATMENT", 51, 73]]], ["SeNPs without modification agglomerated together.", [["SeNPs", "CHEMICAL", 0, 5], ["SeNPs", "SIMPLE_CHEMICAL", 0, 5], ["SeNPs", "TREATMENT", 0, 5], ["modification agglomerated", "TREATMENT", 14, 39], ["without", "UNCERTAINTY", 6, 13], ["modification", "OBSERVATION_MODIFIER", 14, 26], ["agglomerated", "OBSERVATION", 27, 39]]], ["It became monodisperse and diminished when modified with PEI.", [["PEI", "CHEMICAL", 57, 60], ["PEI", "CHEMICAL", 57, 60], ["PEI", "SIMPLE_CHEMICAL", 57, 60], ["PEI", "TREATMENT", 57, 60], ["monodisperse", "OBSERVATION_MODIFIER", 10, 22], ["diminished", "OBSERVATION_MODIFIER", 27, 37]]], ["Moreover, size distribution in Figure 1C further verified that diameters of SeNPs and Se@ PEI were approximately 200 and 100 nm, respectively, while Se@PEI was about 80 nm.", [["PEI", "CHEMICAL", 90, 93], ["Se@PEI", "CHEMICAL", 149, 155], ["SeNPs", "CHEMICAL", 76, 81], ["PEI", "CHEMICAL", 90, 93], ["Se@PEI", "CHEMICAL", 149, 155], ["SeNPs", "SIMPLE_CHEMICAL", 76, 81], ["Se@ PEI", "SIMPLE_CHEMICAL", 86, 93], ["Se@PEI", "SIMPLE_CHEMICAL", 149, 155], ["Se@PEI", "PROTEIN", 149, 155], ["SeNPs", "TEST", 76, 81], ["Se@ PEI", "TEST", 86, 93], ["Se@PEI", "TEST", 149, 155], ["size", "OBSERVATION_MODIFIER", 10, 14], ["distribution", "OBSERVATION_MODIFIER", 15, 27], ["diameters", "OBSERVATION_MODIFIER", 63, 72], ["SeNPs", "OBSERVATION_MODIFIER", 76, 81]]], ["The small size of Se@ PEI@siRNA contributed to its stable nanostructure, which made it easy to pass through the cell membrane.", [["cell membrane", "ANATOMY", 112, 125], ["Se@ PEI@siRNA", "CHEMICAL", 18, 31], ["Se@ PEI@siRNA", "CHEMICAL", 18, 31], ["Se@ PEI@siRNA", "SIMPLE_CHEMICAL", 18, 31], ["cell membrane", "CELLULAR_COMPONENT", 112, 125], ["Se@ PEI@siRNA", "PROTEIN", 18, 31], ["The small size of Se@ PEI@siRNA", "PROBLEM", 0, 31], ["small", "OBSERVATION_MODIFIER", 4, 9], ["size", "OBSERVATION_MODIFIER", 10, 14], ["stable", "OBSERVATION_MODIFIER", 51, 57], ["nanostructure", "OBSERVATION", 58, 71], ["cell membrane", "OBSERVATION", 112, 125]]], ["20 As shown in Figure 1D , the zeta potential of SeNPs alone was \u221225 mV, and it increased to 6 mV after modification with PEI and reached 12 mV when loading siRNA, explaining the higher stability of Se@PEI.\u25a0 RESULTS AND DISCUSSIONInterference Efficiency and Cell Viability.", [["Cell", "ANATOMY", 258, 262], ["SeNPs", "CHEMICAL", 49, 54], ["PEI", "CHEMICAL", 122, 125], ["Se@PEI", "CHEMICAL", 199, 205], ["PEI", "CHEMICAL", 122, 125], ["Se@PEI", "CHEMICAL", 199, 205], ["SeNPs", "SIMPLE_CHEMICAL", 49, 54], ["PEI", "SIMPLE_CHEMICAL", 122, 125], ["Se@PEI", "SIMPLE_CHEMICAL", 199, 205], ["Cell", "CELL", 258, 262], ["Se@PEI", "PROTEIN", 199, 205], ["SeNPs alone", "TREATMENT", 49, 60], ["PEI", "TREATMENT", 122, 125], ["loading siRNA", "TREATMENT", 149, 162], ["Cell Viability", "OBSERVATION", 258, 272]]], ["SK-N-SH cells were transfected with SeNPs, Se@PEI, and Se@PEI@ siRNA for 12 h before EV71 infection.", [["SK-N-SH cells", "ANATOMY", 0, 13], ["Se@PEI", "CHEMICAL", 43, 49], ["EV71 infection", "DISEASE", 85, 99], ["SeNPs", "CHEMICAL", 36, 41], ["Se@PEI", "CHEMICAL", 43, 49], ["SK-N-SH cells", "CELL", 0, 13], ["SeNPs", "SIMPLE_CHEMICAL", 36, 41], ["Se@PEI", "SIMPLE_CHEMICAL", 43, 49], ["EV71", "ORGANISM", 85, 89], ["SK-N-SH cells", "CELL_LINE", 0, 13], ["EV71", "SPECIES", 85, 89], ["SK", "TEST", 0, 2], ["SH cells", "PROBLEM", 5, 13], ["SeNPs", "TREATMENT", 36, 41], ["Se@PEI", "TREATMENT", 43, 49], ["Se@PEI@ siRNA", "TREATMENT", 55, 68], ["EV71 infection", "PROBLEM", 85, 99], ["infection", "OBSERVATION", 90, 99]]], ["In Figure 2A , the nucleic acid level of EV71 VP1 gene fell to 27% in cells treated with Se@PEI before infection compared to cells without any treatment.", [["cells", "ANATOMY", 70, 75], ["cells", "ANATOMY", 125, 130], ["nucleic acid", "CHEMICAL", 19, 31], ["Se@PEI", "CHEMICAL", 89, 95], ["infection", "DISEASE", 103, 112], ["Se@PEI", "CHEMICAL", 89, 95], ["EV71", "ORGANISM", 41, 45], ["VP1", "GENE_OR_GENE_PRODUCT", 46, 49], ["cells", "CELL", 70, 75], ["Se@PEI", "SIMPLE_CHEMICAL", 89, 95], ["cells", "CELL", 125, 130], ["EV71 VP1 gene", "DNA", 41, 54], ["EV71", "SPECIES", 41, 45], ["the nucleic acid level", "TEST", 15, 37], ["EV71 VP1 gene", "TEST", 41, 54], ["Se@PEI", "TREATMENT", 89, 95], ["infection", "PROBLEM", 103, 112], ["any treatment", "TREATMENT", 139, 152], ["infection", "OBSERVATION", 103, 112]]], ["Moreover, the expression amount of VP1 protein depressed in that group either.", [["depressed", "DISEASE", 47, 56], ["VP1", "GENE_OR_GENE_PRODUCT", 35, 38], ["VP1 protein", "PROTEIN", 35, 46], ["VP1 protein depressed", "PROBLEM", 35, 56], ["amount", "OBSERVATION_MODIFIER", 25, 31], ["VP1 protein", "OBSERVATION", 35, 46], ["depressed", "OBSERVATION_MODIFIER", 47, 56]]], ["These results suggested that proliferation of EV71 was inhibited by Se@ PEI@siRNA, and siRNA targeting EV71 VP1 got a good interference efficiency when loaded with selenium nanoparticles.", [["EV71", "DISEASE", 46, 50], ["Se@ PEI@siRNA", "CHEMICAL", 68, 81], ["selenium", "CHEMICAL", 164, 172], ["selenium", "CHEMICAL", 164, 172], ["EV71", "ORGANISM", 46, 50], ["Se@ PEI@siRNA", "SIMPLE_CHEMICAL", 68, 81], ["EV71", "ORGANISM", 103, 107], ["VP1", "ORGANISM", 108, 111], ["selenium nanoparticles", "SIMPLE_CHEMICAL", 164, 186], ["EV71 VP1", "PROTEIN", 103, 111], ["EV71", "SPECIES", 46, 50], ["EV71", "SPECIES", 103, 107], ["proliferation of EV71", "PROBLEM", 29, 50], ["siRNA targeting EV71 VP1", "PROBLEM", 87, 111], ["selenium nanoparticles", "TREATMENT", 164, 186]]], ["The cytotoxic effect of SK-N-SH cells was detected by the MTT assay.", [["SK-N-SH cells", "ANATOMY", 24, 37], ["MTT", "CHEMICAL", 58, 61], ["SK-N-SH cells", "CELL", 24, 37], ["SK-N-SH cells", "CELL_LINE", 24, 37], ["SK", "TEST", 24, 26], ["SH cells", "PROBLEM", 29, 37], ["the MTT assay", "TEST", 54, 67], ["cytotoxic", "OBSERVATION_MODIFIER", 4, 13], ["effect", "OBSERVATION_MODIFIER", 14, 20]]], ["As Figure 2B indicates, cell viability without any treatment before infection was 39%, while cells treated with SeNPs and Se@PEI were 42 and 36%, respectively.", [["cell", "ANATOMY", 24, 28], ["cells", "ANATOMY", 93, 98], ["infection", "DISEASE", 68, 77], ["SeNPs", "CHEMICAL", 112, 117], ["Se@PEI", "CHEMICAL", 122, 128], ["SeNPs", "CHEMICAL", 112, 117], ["Se@PEI", "CHEMICAL", 122, 128], ["cell", "CELL", 24, 28], ["cells", "CELL", 93, 98], ["SeNPs", "SIMPLE_CHEMICAL", 112, 117], ["Se@PEI", "SIMPLE_CHEMICAL", 122, 128], ["cell viability", "PROBLEM", 24, 38], ["infection", "PROBLEM", 68, 77], ["SeNPs", "TREATMENT", 112, 117], ["Se@PEI", "TEST", 122, 128], ["cell viability", "OBSERVATION", 24, 38]]], ["In addition, cells transfected with Se@PEI reached 68% significantly.", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["Se@PEI", "SIMPLE_CHEMICAL", 36, 42], ["Se@PEI", "TEST", 36, 42]]], ["This assay presented that Se@PEI effectively resisted the EV71 proliferation.\u25a0 RESULTS AND DISCUSSIONSuppression of Apoptosis by Se@PEI.", [["Se@PEI", "CHEMICAL", 26, 32], ["Se@PEI", "CHEMICAL", 26, 32], ["Se@PEI", "SIMPLE_CHEMICAL", 26, 32], ["EV71", "ORGANISM", 58, 62], ["EV71", "SPECIES", 58, 62], ["This assay", "TEST", 0, 10], ["the EV71 proliferation", "PROBLEM", 54, 76], ["Apoptosis", "PROBLEM", 116, 125], ["EV71 proliferation", "OBSERVATION", 58, 76], ["Apoptosis", "OBSERVATION", 116, 125]]], ["Flow cytometric analysis was performed to evaluate the antiviral mechanisms of Se@PEI.", [["Se@PEI", "CHEMICAL", 79, 85], ["Se@PEI", "CHEMICAL", 79, 85], ["Se@PEI", "SIMPLE_CHEMICAL", 79, 85], ["Flow cytometric analysis", "TEST", 0, 24]]], ["In Figure 3 , cells in sub-G1 rose to 24.6% proportion when SK-N-SH cells were infected with EV71 without treatment.", [["cells", "ANATOMY", 14, 19], ["SK-N-SH cells", "ANATOMY", 60, 73], ["EV71", "DISEASE", 93, 97], ["cells", "CELL", 14, 19], ["SK-N-SH cells", "CELL", 60, 73], ["EV71", "ORGANISM", 93, 97], ["SK-N-SH cells", "CELL_LINE", 60, 73], ["EV71", "SPECIES", 93, 97], ["cells", "TEST", 14, 19], ["SK", "TEST", 60, 62], ["SH cells", "PROBLEM", 65, 73], ["EV71", "PROBLEM", 93, 97], ["treatment", "TREATMENT", 106, 115]]], ["However, cells treated with Se@ PEI@siRNA before infection reduced the sub-G1 proportion to 10.0%.", [["cells", "ANATOMY", 9, 14], ["Se@ PEI@siRNA", "CHEMICAL", 28, 41], ["infection", "DISEASE", 49, 58], ["cells", "CELL", 9, 14], ["Se@ PEI@siRNA", "SIMPLE_CHEMICAL", 28, 41], ["cells", "PROBLEM", 9, 14], ["Se@ PEI@siRNA", "TREATMENT", 28, 41], ["infection", "PROBLEM", 49, 58], ["infection", "OBSERVATION", 49, 58]]], ["These data indicated that SK-N-SH cells were protected by Se@PEI from EV71-virus-induced apoptosis.", [["SK-N-SH cells", "ANATOMY", 26, 39], ["Se@PEI", "CHEMICAL", 58, 64], ["Se@PEI", "CHEMICAL", 58, 64], ["SK-N-SH cells", "CELL", 26, 39], ["Se@PEI", "SIMPLE_CHEMICAL", 58, 64], ["EV71-virus", "ORGANISM", 70, 80], ["SK-N-SH cells", "CELL_LINE", 26, 39], ["EV71-virus", "SPECIES", 70, 80], ["These data", "TEST", 0, 10], ["SK", "TEST", 26, 28], ["SH cells", "PROBLEM", 31, 39], ["Se@PEI", "TEST", 58, 64], ["EV71", "TEST", 70, 74], ["apoptosis", "PROBLEM", 89, 98]]], ["SK-N-SH cells were transfected with Se@PEI and then infected with EV71.", [["SK-N-SH cells", "ANATOMY", 0, 13], ["Se@PEI", "CHEMICAL", 36, 42], ["EV71", "DISEASE", 66, 70], ["Se@PEI", "CHEMICAL", 36, 42], ["SK-N-SH cells", "CELL", 0, 13], ["Se@PEI", "SIMPLE_CHEMICAL", 36, 42], ["EV71", "ORGANISM", 66, 70], ["SK-N-SH cells", "CELL_LINE", 0, 13], ["EV71", "SPECIES", 66, 70], ["SK", "TEST", 0, 2], ["SH cells", "PROBLEM", 5, 13], ["Se@PEI", "TREATMENT", 36, 42], ["EV71", "PROBLEM", 66, 70]]], ["Proteins related to apoptosis were detected by Western blot.", [["Proteins", "PROBLEM", 0, 8], ["apoptosis", "PROBLEM", 20, 29], ["apoptosis", "OBSERVATION", 20, 29]]], ["The Bax protein was known to induce apoptosis increased when infected with EV71.", [["EV71", "DISEASE", 75, 79], ["Bax", "GENE_OR_GENE_PRODUCT", 4, 7], ["EV71", "ORGANISM", 75, 79], ["Bax protein", "PROTEIN", 4, 15], ["EV71", "SPECIES", 75, 79], ["The Bax protein", "TREATMENT", 0, 15], ["apoptosis", "PROBLEM", 36, 45], ["EV71", "PROBLEM", 75, 79], ["apoptosis", "OBSERVATION_MODIFIER", 36, 45], ["increased", "OBSERVATION_MODIFIER", 46, 55]]], ["22 Meanwhile, as seen in Figure 4 , the expression reduced when cells were treated with Se@PEI before infection.", [["cells", "ANATOMY", 64, 69], ["Se@PEI", "CHEMICAL", 88, 94], ["infection", "DISEASE", 102, 111], ["Se@PEI", "CHEMICAL", 88, 94], ["cells", "CELL", 64, 69], ["Se@PEI", "SIMPLE_CHEMICAL", 88, 94], ["Se@PEI", "TREATMENT", 88, 94], ["infection", "PROBLEM", 102, 111], ["infection", "OBSERVATION", 102, 111]]], ["Bax is an important apoptosis-promoting protein in the Bcl-2 family.", [["Bax", "GENE_OR_GENE_PRODUCT", 0, 3], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 55, 60], ["Bax", "PROTEIN", 0, 3], ["apoptosis-promoting protein", "PROTEIN", 20, 47], ["Bcl-2 family", "PROTEIN", 55, 67], ["Bax", "TREATMENT", 0, 3], ["important", "OBSERVATION_MODIFIER", 10, 19], ["apoptosis", "OBSERVATION", 20, 29], ["promoting protein", "OBSERVATION_MODIFIER", 30, 47]]], ["This result illustrated that Se@PEI resists EV71 infection by inhibiting the Bax signaling pathway.\u25a0 CONCLUSIONSIn conclusion, the nanocompound (Se@PEI) comprising selenium nanoparticles and the siRNA targeting EV71 VP1 gene was synthesized.", [["Se@PEI", "CHEMICAL", 29, 35], ["infection", "DISEASE", 49, 58], ["nanocompound", "CHEMICAL", 131, 143], ["Se@PEI", "CHEMICAL", 145, 151], ["selenium", "CHEMICAL", 164, 172], ["Se@PEI", "CHEMICAL", 29, 35], ["nanocompound", "CHEMICAL", 131, 143], ["Se@PEI", "CHEMICAL", 145, 151], ["selenium", "CHEMICAL", 164, 172], ["Se@PEI", "SIMPLE_CHEMICAL", 29, 35], ["EV71", "ORGANISM", 44, 48], ["Bax", "GENE_OR_GENE_PRODUCT", 77, 80], ["nanocompound", "SIMPLE_CHEMICAL", 131, 143], ["Se@PEI", "SIMPLE_CHEMICAL", 145, 151], ["selenium nanoparticles", "SIMPLE_CHEMICAL", 164, 186], ["EV71", "ORGANISM", 211, 215], ["VP1", "ORGANISM", 216, 219], ["Bax", "PROTEIN", 77, 80], ["EV71 VP1 gene", "DNA", 211, 224], ["EV71", "SPECIES", 44, 48], ["EV71", "SPECIES", 211, 215], ["EV71 infection", "PROBLEM", 44, 58], ["the nanocompound (Se@PEI)", "TREATMENT", 127, 152], ["selenium nanoparticles", "TREATMENT", 164, 186], ["the siRNA", "TREATMENT", 191, 200]]], ["The siRNA showed a higher interference efficiency, which was more than 70% against the EV71 VP1 gene in the nerve cell line SK-N-SH when loaded with Se@PEI.", [["nerve cell line SK-N-SH", "ANATOMY", 108, 131], ["SK-N-SH", "CHEMICAL", 124, 131], ["Se@PEI", "CHEMICAL", 149, 155], ["Se@PEI", "CHEMICAL", 149, 155], ["EV71", "ORGANISM", 87, 91], ["VP1", "GENE_OR_GENE_PRODUCT", 92, 95], ["nerve cell line SK-N-SH", "CELL", 108, 131], ["Se@PEI", "SIMPLE_CHEMICAL", 149, 155], ["EV71 VP1 gene", "DNA", 87, 100], ["nerve cell line SK-N-SH", "CELL_LINE", 108, 131], ["EV71", "SPECIES", 87, 91], ["The siRNA", "TEST", 0, 9], ["a higher interference efficiency", "PROBLEM", 17, 49], ["the EV71 VP1 gene", "TEST", 83, 100], ["SK", "TEST", 124, 126], ["Se@PEI", "TREATMENT", 149, 155], ["siRNA", "ANATOMY", 4, 9], ["higher", "OBSERVATION_MODIFIER", 19, 25], ["interference efficiency", "OBSERVATION", 26, 49], ["nerve", "ANATOMY", 108, 113], ["cell line", "OBSERVATION", 114, 123]]], ["Se@PEI increased the cell viability to prevent EV71 virus infection.", [["cell", "ANATOMY", 21, 25], ["Se@PEI", "CHEMICAL", 0, 6], ["EV71 virus infection", "DISEASE", 47, 67], ["Se@PEI", "CHEMICAL", 0, 6], ["Se@PEI", "SIMPLE_CHEMICAL", 0, 6], ["cell", "CELL", 21, 25], ["EV71 virus", "ORGANISM", 47, 57], ["EV71 virus", "SPECIES", 47, 57], ["Se@PEI", "TREATMENT", 0, 6], ["the cell viability", "PROBLEM", 17, 35], ["EV71 virus infection", "PROBLEM", 47, 67], ["cell viability", "OBSERVATION", 21, 35], ["prevent", "UNCERTAINTY", 39, 46], ["EV71 virus infection", "OBSERVATION", 47, 67]]], ["This may be associated with the decrease of cells in the sub-G1 phase due to treatment with Se@PEI.", [["cells", "ANATOMY", 44, 49], ["Se@PEI", "CHEMICAL", 92, 98], ["Se@PEI", "CHEMICAL", 92, 98], ["cells", "CELL", 44, 49], ["Se@PEI", "SIMPLE_CHEMICAL", 92, 98], ["the decrease of cells", "PROBLEM", 28, 49], ["Se@PEI", "TREATMENT", 92, 98], ["may be associated with", "UNCERTAINTY", 5, 27], ["decrease", "OBSERVATION_MODIFIER", 32, 40], ["sub-G1 phase", "OBSERVATION_MODIFIER", 57, 69]]], ["EV71 infection can induce apoptosis in host cells.", [["cells", "ANATOMY", 44, 49], ["EV71 infection", "DISEASE", 0, 14], ["EV71", "ORGANISM", 0, 4], ["host cells", "CELL", 39, 49], ["host cells", "CELL_TYPE", 39, 49], ["EV71", "SPECIES", 0, 4], ["EV71 infection", "PROBLEM", 0, 14], ["apoptosis in host cells", "PROBLEM", 26, 49], ["infection", "OBSERVATION", 5, 14], ["host cells", "OBSERVATION", 39, 49]]], ["Bax is a key protein in the Bcl-2 family that induces apoptosis.", [["Bax", "GENE_OR_GENE_PRODUCT", 0, 3], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 28, 33], ["Bax", "PROTEIN", 0, 3], ["Bcl-2 family", "PROTEIN", 28, 40], ["apoptosis", "PROBLEM", 54, 63], ["apoptosis", "OBSERVATION", 54, 63]]], ["The apoptosis signaling induced by Bax was restrained.", [["Bax", "GENE_OR_GENE_PRODUCT", 35, 38], ["Bax", "PROTEIN", 35, 38], ["The apoptosis signaling", "PROBLEM", 0, 23]]], ["Altogether, this study illustrates that Se@PEI@ siRNA can effectively prevent the nerve cell line SK-N-SH cells from apoptosis induced by EV71 virus infection through the Bax protein signaling pathway.", [["nerve cell line SK-N-SH cells", "ANATOMY", 82, 111], ["Se@PEI@", "CHEMICAL", 40, 47], ["EV71 virus infection", "DISEASE", 138, 158], ["Se@PEI@", "SIMPLE_CHEMICAL", 40, 47], ["nerve cell line SK-N-SH cells", "CELL", 82, 111], ["EV71 virus", "ORGANISM", 138, 148], ["Bax", "GENE_OR_GENE_PRODUCT", 171, 174], ["nerve cell line", "CELL_LINE", 82, 97], ["SK-N-SH cells", "CELL_LINE", 98, 111], ["Bax protein", "PROTEIN", 171, 182], ["EV71 virus", "SPECIES", 138, 148], ["this study", "TEST", 12, 22], ["Se@PEI@ siRNA", "TREATMENT", 40, 53], ["the nerve cell line SK", "TEST", 78, 100], ["SH cells", "PROBLEM", 103, 111], ["apoptosis", "PROBLEM", 117, 126], ["EV71 virus infection", "PROBLEM", 138, 158], ["the Bax protein signaling pathway", "TREATMENT", 167, 200], ["nerve", "ANATOMY", 82, 87], ["cell line", "OBSERVATION", 88, 97], ["EV71 virus", "OBSERVATION", 138, 148]]], ["Na 2 SeO 3 and ascorbic acid (VC) from Sigma were used in the study.", [["Na 2 SeO 3 and", "CHEMICAL", 0, 14], ["ascorbic acid", "CHEMICAL", 15, 28], ["Na 2 SeO 3", "CHEMICAL", 0, 10], ["ascorbic acid", "CHEMICAL", 15, 28], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 0, 10], ["ascorbic acid", "SIMPLE_CHEMICAL", 15, 28], ["VC", "SIMPLE_CHEMICAL", 30, 32], ["Na", "TEST", 0, 2], ["ascorbic acid", "TEST", 15, 28], ["the study", "TEST", 58, 67]]], ["The one-step qPCR kit was acquired from Takara.", [["The one-step qPCR kit", "TEST", 0, 21]]], ["SiRNAs and primers were designed and synthesized by Sangon Biotech, China.", [["SiRNAs", "GENE_OR_GENE_PRODUCT", 0, 6], ["SiRNAs", "PROTEIN", 0, 6], ["SiRNAs and primers", "TREATMENT", 0, 18]]], ["The VP1 monoclonal antibody was bought from Abnova.", [["VP1", "ORGANISM", 4, 7], ["VP1 monoclonal antibody", "PROTEIN", 4, 27], ["The VP1 monoclonal antibody", "TEST", 0, 27], ["Abnova", "PROBLEM", 44, 50], ["VP1", "ANATOMY", 4, 7], ["monoclonal antibody", "OBSERVATION", 8, 27]]], ["Bax and \u03b2-actin monoclonal antibodies were supplied by Cell Signaling Technology.\u25a0 CONCLUSIONSSynthesis of Se@PEI.", [["Cell", "ANATOMY", 55, 59], ["Se@PEI", "CHEMICAL", 107, 113], ["Bax", "GENE_OR_GENE_PRODUCT", 0, 3], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 8, 15], ["Cell", "CELL", 55, 59], ["Se@PEI", "SIMPLE_CHEMICAL", 107, 113], ["Bax", "PROTEIN", 0, 3], ["\u03b2-actin monoclonal antibodies", "PROTEIN", 8, 37], ["Se@PEI", "PROTEIN", 107, 113], ["Bax", "TREATMENT", 0, 3], ["\u03b2-actin monoclonal antibodies", "TREATMENT", 8, 37]]], ["0.1 M Na 2 SeO 3 solution, 0.05 M VC solution, and ultrapure water were mixed at a volume ratio of 1:8:91 followed by 60 min of stirring and overnight dialysis in ultrapure water.", [["Na", "CHEMICAL", 6, 8], ["Na 2 SeO 3", "CHEMICAL", 6, 16], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 6, 16], ["0.05 M VC solution", "TREATMENT", 27, 45], ["ultrapure water", "TREATMENT", 51, 66], ["overnight dialysis in ultrapure water", "TREATMENT", 141, 178]]], ["23 Then 1.2 nmol of siRNA and 37.92 mg of PEI were added into 20 mL of solution prepared above.", [["PEI", "CHEMICAL", 42, 45], ["PEI", "CHEMICAL", 42, 45], ["PEI", "SIMPLE_CHEMICAL", 42, 45], ["siRNA", "TREATMENT", 20, 25], ["PEI", "TREATMENT", 42, 45]]], ["24 The Se@PEI compoud was purified through centrifugation at 8000 rpm for 20 min.", [["Se@PEI compoud", "CANCER", 7, 21], ["Se@PEI compoud", "DNA", 7, 21]]], ["The sequence of VP1 siRNA is as follows: sense 5\u2032 CACAUUCGGAGAA-CACAAATT 3\u2032 and anti-sense 5\u2032 UUUGUGUUCUCC-GAAUGUGTT 3\u2032.", [["VP1", "GENE_OR_GENE_PRODUCT", 16, 19], ["VP1 siRNA", "RNA", 16, 25], ["The sequence of VP1 siRNA", "TEST", 0, 25], ["CACAUUCGGAGAA", "TEST", 50, 63], ["VP1 siRNA", "OBSERVATION", 16, 25]]], ["The sequence of negative control is as follows: sense 5\u2032 UUCUCCGAACGUGUCACGUTT 3\u2032 and anti-sense 5\u2032 ACGUGACACGUUCGGAGAATT 3\u2032.\u25a0 CONCLUSIONSCharacterization of Se@PEI.", [["Se@PEI", "CHEMICAL", 158, 164], ["Se@PEI", "CHEMICAL", 158, 164], ["Se@PEI", "SIMPLE_CHEMICAL", 158, 164], ["Se@PEI", "PROTEIN", 158, 164], ["UUCUCCGAACGUGUCACGUTT", "TEST", 57, 78], ["Se@PEI", "TEST", 158, 164]]], ["Morphology of Se@PEI was observed by transmission electron microscopy (TEM).", [["Se@PEI", "CHEMICAL", 14, 20], ["Se@PEI", "SIMPLE_CHEMICAL", 14, 20], ["transmission electron microscopy", "TEST", 37, 69]]], ["The Tyndall effect was studied in a dark room with a laser pointer.", [["a laser pointer", "TREATMENT", 51, 66]]], ["Size distributions and zeta potentials of SeNPs, Se@PEI, and Se@PEI were determined by a Zetasizer analyzer.", [["Se@PEI", "CHEMICAL", 49, 55], ["Se@PEI", "CHEMICAL", 61, 67], ["SeNPs", "CHEMICAL", 42, 47], ["Se@PEI", "CHEMICAL", 49, 55], ["Se@PEI", "CHEMICAL", 61, 67], ["SeNPs", "SIMPLE_CHEMICAL", 42, 47], ["Se@PEI", "SIMPLE_CHEMICAL", 49, 55], ["Se@PEI", "SIMPLE_CHEMICAL", 61, 67], ["SeNPs", "TREATMENT", 42, 47], ["Se@PEI", "TREATMENT", 49, 55], ["Se@PEI", "TREATMENT", 61, 67], ["zeta", "OBSERVATION_MODIFIER", 23, 27], ["potentials", "OBSERVATION_MODIFIER", 28, 38], ["SeNPs", "OBSERVATION_MODIFIER", 42, 47]]], ["25 Cells and Infection.", [["Cells", "ANATOMY", 3, 8], ["Cells", "CELL", 3, 8], ["Infection", "PROBLEM", 13, 22], ["Infection", "OBSERVATION", 13, 22]]], ["SK-N-SH cells were cultured in DMEM with 10% FBS.", [["SK-N-SH cells", "ANATOMY", 0, 13], ["FBS", "ANATOMY", 45, 48], ["SK-N-SH cells", "CELL", 0, 13], ["FBS", "ORGANISM_SUBSTANCE", 45, 48], ["SK-N-SH cells", "CELL_LINE", 0, 13], ["SK", "TEST", 0, 2], ["SH cells", "PROBLEM", 5, 13]]], ["Cells were plated for 24 h and then adsorbed by EV71 for 1 h.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["EV71", "ORGANISM", 48, 52], ["EV71", "SPECIES", 48, 52], ["Cells", "TEST", 0, 5]]], ["The supernatant was removed, and DMEM with 2% FBS was added.", [["supernatant", "ANATOMY", 4, 15], ["FBS", "ANATOMY", 46, 49], ["FBS", "ORGANISM_SUBSTANCE", 46, 49], ["The supernatant", "TREATMENT", 0, 15], ["DMEM", "TREATMENT", 33, 37], ["2% FBS", "TREATMENT", 43, 49]]], ["The 50% tissue culture infective dose (TCID50) was calculated using the Reed\u2212 Muench method.", [["tissue", "ANATOMY", 8, 14], ["tissue", "TISSUE", 8, 14], ["The 50% tissue culture infective dose", "TREATMENT", 0, 37], ["the Reed\u2212 Muench method", "TREATMENT", 68, 91]]], ["EV71 used was at a titer of 100 TCID50/ mL.", [["EV71", "DISEASE", 0, 4], ["EV71", "ORGANISM", 0, 4], ["EV71", "SPECIES", 0, 4], ["EV71", "PROBLEM", 0, 4]]], ["26 SK-N-SH cells were transfected with Se@PEI for 12 h followed by EV71 infection.\u25a0 CONCLUSIONSTransfection with Se@PEI.", [["SK-N-SH cells", "ANATOMY", 3, 16], ["Se@PEI", "CHEMICAL", 39, 45], ["EV71 infection", "DISEASE", 67, 81], ["Se@PEI", "CHEMICAL", 113, 119], ["Se@PEI", "CHEMICAL", 113, 119], ["SK-N-SH cells", "CELL", 3, 16], ["Se@PEI", "SIMPLE_CHEMICAL", 39, 45], ["EV71", "ORGANISM", 67, 71], ["Se@PEI", "SIMPLE_CHEMICAL", 113, 119], ["SK-N-SH cells", "CELL_LINE", 3, 16], ["EV71", "SPECIES", 67, 71], ["SK", "TEST", 3, 5], ["Se@PEI", "TREATMENT", 39, 45], ["EV71 infection", "PROBLEM", 67, 81], ["infection", "OBSERVATION", 72, 81]]], ["SK-N-SH cells were seeded in 6-well plates for 5 \u00d7 10 5 cells per well.", [["SK-N-SH cells", "ANATOMY", 0, 13], ["cells", "ANATOMY", 56, 61], ["SK-N-SH cells", "CELL", 0, 13], ["cells", "CELL", 56, 61], ["SK-N-SH cells", "CELL_LINE", 0, 13], ["SK", "TEST", 0, 2], ["SH cells", "TREATMENT", 5, 13]]], ["24 h later, cells were treated with Se@PEI.", [["cells", "ANATOMY", 12, 17], ["Se@PEI", "CHEMICAL", 36, 42], ["Se@PEI", "CHEMICAL", 36, 42], ["cells", "CELL", 12, 17], ["Se@PEI", "SIMPLE_CHEMICAL", 36, 42], ["Se@PEI", "TREATMENT", 36, 42]]], ["12 h later, the cells were infected with EV71.", [["cells", "ANATOMY", 16, 21], ["EV71", "DISEASE", 41, 45], ["cells", "CELL", 16, 21], ["EV71", "ORGANISM", 41, 45], ["EV71", "SPECIES", 41, 45], ["the cells", "PROBLEM", 12, 21], ["EV71", "PROBLEM", 41, 45]]], ["After 48 h, the transfection efficiency was detected by qPCR and Western blot.\u25a0 CONCLUSIONSMTT Assay.", [["the transfection efficiency", "PROBLEM", 12, 39], ["CONCLUSIONSMTT Assay", "TEST", 80, 100]]], ["Cell viability was determined by the MTT assay.", [["Cell", "ANATOMY", 0, 4], ["MTT", "CHEMICAL", 37, 40], ["Cell", "CELL", 0, 4], ["Cell viability", "TEST", 0, 14], ["the MTT assay", "TEST", 33, 46]]], ["Briefly, 7 \u00d7 10 3 cells were incubated in a well of 96-well cell culture plate for 24 h.", [["cells", "ANATOMY", 18, 23], ["cell", "ANATOMY", 60, 64], ["cells", "CELL", 18, 23], ["cell", "CELL", 60, 64]]], ["After siRNA transfection and virus infection, 5 mg/mL MTT solution was added and incubated for 4 h before 150 \u03bcL of dimethyl sulfoxide was added.", [["infection", "DISEASE", 35, 44], ["dimethyl sulfoxide", "CHEMICAL", 116, 134], ["MTT", "CHEMICAL", 54, 57], ["dimethyl sulfoxide", "CHEMICAL", 116, 134], ["MTT", "SIMPLE_CHEMICAL", 54, 57], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 116, 134], ["siRNA transfection", "TREATMENT", 6, 24], ["virus infection", "PROBLEM", 29, 44], ["dimethyl sulfoxide", "TREATMENT", 116, 134], ["siRNA transfection", "OBSERVATION", 6, 24]]], ["The OD value was measured at 570 nm.", [["The OD value", "TEST", 0, 12]]], ["27 Polymerase Chain Reaction.", [["Chain Reaction", "OBSERVATION", 14, 28]]], ["The mRNA level of EV71 was tested by qPCR.", [["EV71", "ORGANISM", 18, 22], ["EV71", "SPECIES", 18, 22], ["The mRNA level of EV71", "TEST", 0, 22]]], ["SK-N-SH cells were transfected with Se@ PEI@siRNA and infected with EV71. qPCR was performed with a one-step kit according to the instrument.", [["SK-N-SH cells", "ANATOMY", 0, 13], ["EV71", "DISEASE", 68, 72], ["SK-N-SH cells", "CELL", 0, 13], ["Se@ PEI@siRNA", "SIMPLE_CHEMICAL", 36, 49], ["EV71", "ORGANISM", 68, 72], ["SK-N-SH cells", "CELL_LINE", 0, 13], ["EV71", "SPECIES", 68, 72], ["N-SH cells", "PROBLEM", 3, 13], ["EV71", "PROBLEM", 68, 72], ["qPCR", "TEST", 74, 78], ["a one-step kit", "TREATMENT", 98, 112], ["infected", "OBSERVATION_MODIFIER", 54, 62]]], ["Primers are as follows: EV71 VP1 gene forward primer 5\u2032 GGAGA-TAGGGTGGCAGATGTAATTGAAAGC 3\u2032 and reverse primer 5\u2032 AAGAGTGGTGATCGCTGTGCG 3\u2032.", [["EV71", "ORGANISM", 24, 28], ["GGAGA-TAGGGTGGCAGATGTAATTGAAAGC 3", "GENE_OR_GENE_PRODUCT", 56, 89], ["EV71 VP1 gene forward primer 5", "DNA", 24, 54], ["GGAGA-TAGGGTGGCAGATGTAATTGAAAGC 3\u2032 and reverse primer 5", "DNA", 56, 111], ["GGAGA", "TEST", 56, 61]]], ["GAPDH forward primer 5\u2032 GAAGGTGAAGGTCGGAGTC 3\u2032 and reverse primer 5\u2032 GAAGATGGTGATGGGATTTC 3\u2032.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAPDH forward primer 5", "DNA", 0, 22], ["GAAGGTGAAGGTCGGAGTC 3\u2032 and reverse primer 5", "DNA", 24, 67]]], ["28, 29 Cell Cycle Assay.", [["Cell", "ANATOMY", 7, 11], ["Cell", "CELL", 7, 11], ["Cell Cycle Assay", "TEST", 7, 23]]], ["The cell cycle assay was performed as described previously.", [["cell", "ANATOMY", 4, 8], ["cell", "CELL", 4, 8], ["The cell cycle assay", "TEST", 0, 20]]], ["After treatment with Se@PEI for 12 h, SK-N-SH cells were infected with EV71.", [["SK-N-SH cells", "ANATOMY", 38, 51], ["Se@PEI", "CHEMICAL", 21, 27], ["EV71", "DISEASE", 71, 75], ["Se@PEI", "CHEMICAL", 21, 27], ["Se@PEI", "SIMPLE_CHEMICAL", 21, 27], ["SK-N-SH cells", "CELL", 38, 51], ["EV71", "ORGANISM", 71, 75], ["SK-N-SH cells", "CELL_LINE", 38, 51], ["EV71", "SPECIES", 71, 75], ["treatment", "TREATMENT", 6, 15], ["Se@PEI", "TREATMENT", 21, 27], ["SK", "TEST", 38, 40], ["SH cells", "PROBLEM", 43, 51], ["EV71", "PROBLEM", 71, 75]]], ["After 48 h, cells were harvested and resuspended in ice cold 70% ethanol for fixation.", [["cells", "ANATOMY", 12, 17], ["ethanol", "CHEMICAL", 65, 72], ["ethanol", "CHEMICAL", 65, 72], ["cells", "CELL", 12, 17], ["ethanol", "SIMPLE_CHEMICAL", 65, 72], ["fixation", "TREATMENT", 77, 85]]], ["After incubation with propidium iodide for 30 min, cells were measured by flow cytometry.", [["cells", "ANATOMY", 51, 56], ["propidium iodide", "CHEMICAL", 22, 38], ["propidium iodide", "CHEMICAL", 22, 38], ["propidium iodide", "SIMPLE_CHEMICAL", 22, 38], ["cells", "CELL", 51, 56], ["propidium iodide", "TREATMENT", 22, 38], ["flow cytometry", "TEST", 74, 88]]], ["30 Cell cycle phase quantification was analyzed using ModFit LT 3.1 software.\u25a0 CONCLUSIONSWestern Blot.", [["Cell", "ANATOMY", 3, 7], ["Cell", "CELL", 3, 7], ["Cell cycle phase quantification", "TEST", 3, 34]]], ["SK-N-SH cells transfected with Se@PEI@ siRNA were infected with EV71 for 48 h.", [["SK-N-SH cells", "ANATOMY", 0, 13], ["EV71", "DISEASE", 64, 68], ["SK-N-SH cells", "CELL", 0, 13], ["EV71", "ORGANISM", 64, 68], ["SK-N-SH cells", "CELL_LINE", 0, 13], ["EV71", "SPECIES", 64, 68], ["N-SH cells", "PROBLEM", 3, 13], ["Se@PEI@ siRNA", "TREATMENT", 31, 44], ["EV71", "TREATMENT", 64, 68]]], ["EV71 VP1, Bax, and \u03b2-actin monoclonal antibodies were used for incubation.", [["EV71", "ORGANISM", 0, 4], ["VP1", "GENE_OR_GENE_PRODUCT", 5, 8], ["Bax", "GENE_OR_GENE_PRODUCT", 10, 13], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 19, 26], ["EV71 VP1", "PROTEIN", 0, 8], ["Bax", "PROTEIN", 10, 13], ["\u03b2-actin monoclonal antibodies", "PROTEIN", 19, 48], ["EV71", "SPECIES", 0, 4], ["EV71 VP1", "TEST", 0, 8], ["Bax", "TEST", 10, 13], ["\u03b2-actin monoclonal antibodies", "TREATMENT", 19, 48]]], ["31, 32 Statistical Analysis.", [["Statistical Analysis", "TEST", 7, 27]]], ["GraphPad Prism 7.0 software was used for data analysis.", [["data analysis", "TEST", 41, 54]]], ["Student's t test and one-way analysis of variance were used to evaluate the significance of the data.", [["Student's t test", "TEST", 0, 16]]], ["33 Author Contributions \u2021 Z.L. and Y.L. contributed equally to the work.Author ContributionsY.L. and Z.L. designed the study.", [["the study", "TEST", 115, 124]]]], "513bafef235c8b1a15690cbd81f6b7f5ca60f250": [["IntroductionDuring a pandemic or disaster critical care clinicians may be unprepared to provide appropriate crisis standards of care unless they have received rigorous training or have experience in military or disaster medicine.", [["pandemic", "DISEASE", 21, 29], ["rigorous training", "TREATMENT", 159, 176]]], ["In the event of resource scarcities and excess demands, access to care will be restricted, and the level of care will be altered (see \"Surge Capacity Principles\" article by Hick et al 1 in this consensus statement ).", [["resource scarcities", "PROBLEM", 16, 35], ["excess demands", "PROBLEM", 40, 54], ["excess demands", "OBSERVATION", 40, 54]]], ["Overall, this involves a shift from individual patient-based medicine to population-based medicine.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54]]], ["Th e requirement to restrict and alter standards of medical care inherent in the shift to population-based medicine is perhaps one of the most challenging transitions for clinicians to make in delivering critical care to an overwhelming number of patients.", [["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["medical care", "TREATMENT", 52, 64]]], ["Addressing these issues during the planning and training process is essential to ensuring appropriate use and stewardship of resources during a disaster.IntroductionVery little information exists on the best method to proactively engage clinicians so that they are prepared to eff ectively implement and coordinate the care of critically ill or injured patients during a pandemic or disaster.", [["critically ill", "DISEASE", 327, 341], ["patients", "ORGANISM", 353, 361], ["patients", "SPECIES", 353, 361], ["training process", "TREATMENT", 48, 64]]], ["Furthermore, strategies to incorporate the viewpoints and preferences of the public in all aspects of disaster and pandemic planning are essential to maintain trust, transparency, and community support for crisis standards of care plans.", [["pandemic planning", "TREATMENT", 115, 132]]], ["Although individual hospital plans are important, these regional relationships can contribute to a more robust community response and resilience in any disaster.IntroductionTh e American College of Chest Physicians (CHEST) Mass Critical Care Task Force believes that clinician engagement and education is an important aspect of pandemic and disaster preparedness and is a major gap in our preparedness eff orts.", [["pandemic", "PROBLEM", 328, 336], ["a major gap", "PROBLEM", 370, 381], ["Chest", "ANATOMY", 198, 203], ["CHEST", "ANATOMY", 216, 221]]], ["ICU care involves a multidisciplinary approach typically led by critical care physicians; however, disaster training oft en has focused on hospital-based administration and some ancillary staff .", [["ICU care", "TREATMENT", 0, 8]]], ["Although it is important for all providers to be familiar with all aspects of the critical care response to a pandemic or disaster, Table 1 provides an overview of the suggestions of most interest to each group.Materials and MethodsFollowing the CHEST Guidelines Oversight Committee's methodology, the Engagement and Education topic panels separately developed key questions and conducted systematic literature searches to identify evidence on which to develop recommendations.", [["CHEST", "ANATOMY", 246, 251]]], ["Th erefore, the panel developed expert opinion-based suggestions using a modifi ed Delphi process.", [["the panel", "TEST", 12, 21], ["a modifi ed Delphi process", "TREATMENT", 71, 97]]], ["Th e results from the two groups were combined and summarized in this article.We suggest integrated communication systems and a robust infrastructure of the electronic health record system to facilitate tracking the number of people aff ected by a mass event, including the types and severity of injuries and detection of secondary illnesses.In the absence of accurate and meaningful communication during a disaster, clinicians may become frustrated, fragmented, and disheartened, especially if resources become scarce .", [["injuries", "DISEASE", 296, 304], ["people", "ORGANISM", 226, 232], ["people", "SPECIES", 226, 232], ["a mass event", "PROBLEM", 246, 258], ["injuries", "PROBLEM", 296, 304], ["secondary illnesses", "PROBLEM", 322, 341], ["frustrated", "PROBLEM", 439, 449], ["mass", "OBSERVATION", 248, 252], ["injuries", "OBSERVATION", 296, 304], ["secondary", "OBSERVATION_MODIFIER", 322, 331], ["illnesses", "OBSERVATION", 332, 341]]], ["5 During a pandemic or disaster, the collection of real-time information regarding the total scope of the event (eg, the number of patients aff ected, the types of injuries and illnesses sustained, the severity of injuries and illnesses) as well as a clearly defi ned source of updated clinical guidance for the event is vital for all hospitals involved in caring for the aff ected patients.", [["injuries", "DISEASE", 164, 172], ["injuries", "DISEASE", 214, 222], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 382, 390], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 382, 390], ["injuries", "PROBLEM", 164, 172], ["illnesses", "PROBLEM", 177, 186], ["injuries", "PROBLEM", 214, 222], ["illnesses", "PROBLEM", 227, 236]]], ["Th is requires rapid activation of vertical communication networks within hospitals as well as a horizontal flow of information among hospitals; nongovernmental organizations; and local, regional, and national public health jurisdictions to adequately respond to the event.", [["rapid", "OBSERVATION_MODIFIER", 15, 20]]], ["Although many systems allow collection of regional information (eg, bed availability), facilitate resource management, or permit information sharing through electronic health records, few systems focus on ICU clinician engagement with subject matter experts and incident command leaders in pre-event planning and disaster response.", [["resource management", "TREATMENT", 98, 117]]], ["Although this can be facilitated quickly on a regional level, defi ning participants, platforms, and goals ahead of time should substantially improve clinician acceptance, eff ectiveness, and engagement.We suggest integrated communication systems and a robust infrastructure of the electronic health record system to facilitate tracking the number of people aff ected by a mass event, including the types and severity of injuries and detection of secondary illnesses.In some countries with national health-care systems, electronic health records may already be in place.", [["injuries", "DISEASE", 421, 429], ["people", "ORGANISM", 351, 357], ["participants", "SPECIES", 72, 84], ["people", "SPECIES", 351, 357], ["a mass event", "PROBLEM", 371, 383], ["injuries", "PROBLEM", 421, 429], ["secondary illnesses", "PROBLEM", 447, 466], ["mass", "OBSERVATION", 373, 377], ["injuries", "OBSERVATION", 421, 429], ["secondary", "OBSERVATION_MODIFIER", 447, 456], ["illnesses", "OBSERVATION", 457, 466]]], ["Current opportunities to partner with public health offi cials to discuss the meaningful use of data programs should be leveraged to develop the ability to share such information.", [["data programs", "TREATMENT", 96, 109]]], ["Th e ability to track aff ected people also relies on standardization of registry processes and shared information that are currently not in place in most areas of the United States and other countries.2.We suggest, when power is intact, virtual ICUs, point-of-care testing, portable monitoring systems with Global Positioning System, and telemedicine facilitate transfer and sharing of clinical information.", [["people", "SPECIES", 32, 38], ["care testing", "TEST", 261, 273], ["portable monitoring systems", "TEST", 275, 302]]], ["Such technologies need to be established and used prior to mass critical care delivery in order to provide familiarity to the users.2.Th ese technologies may help overcome some barriers that may occur due to limitations of personnel and resources during a mass casualty event.2.3.", [["mass critical care delivery", "TREATMENT", 59, 86], ["a mass casualty event", "PROBLEM", 254, 275]]], ["We suggest aggregated essential clinical information be included with other key ICU logistical communication so that bidirectional transfer of information permits a consistent delivery of health care across the spectrum.2.Hospitals should share updated daily patient information without personal identifi ers ( Table 2 ) .", [["patient", "ORGANISM", 259, 266], ["patient", "SPECIES", 259, 266], ["a consistent delivery of health care", "TREATMENT", 163, 199]]], ["Clinical data variables for reporting during mass casualty events should be established and standardized in advance in collaboration with key medical and public health partners.", [["Clinical data variables", "TEST", 0, 23], ["mass casualty events", "PROBLEM", 45, 65]]], ["8 -16 A mechanism for clinical discussions across regional systems (see \"System-Level Planning, Coordination, and Communication\" article by Dichter et al 17 in this consensus statement) during and aft er events will greatly facilitate dialogue among critical care physicians about treatments, clinical trends, and outcomes, thereby enhancing engagement and participation.4.We suggest public health/government offi cials at centralized or regional emergency management coordinating centers use expert medical guidance, such as burn, neuro, or trauma critical care, specifi c to the nature of the incident to inform decision-making for mass critical care delivery.4.Th e emergency management coordinating center should ask professional medical societies or governmental organizations with expertise specifi c to the type of disaster event to collaborate, develop, and keep updated evidence-based or best-practice clinical guidelines.", [["burn", "DISEASE", 526, 530], ["trauma", "DISEASE", 542, 548], ["regional emergency management", "TREATMENT", 438, 467], ["mass critical care delivery", "TREATMENT", 634, 661], ["Th e emergency management", "TREATMENT", 664, 689]]], ["18 -22 Critical care physicians should be engaged to provide expertise with prioritizing transfers, allocating resources, developing treatment protocols, supporting providers through telemedicine or other means of consultation, and contributing to policy development for facility and regional response.", [["treatment protocols", "TREATMENT", 133, 152]]], ["8We suggest every ICU clinician participate in disaster response training and education.Successful hospital engagement in the United States has resulted from preparedness funds from the Department of Health and Human Services, Offi ce of the Assistant Secretary for Preparedness and Response, Hospital Preparedness Program grants and from expansion of Th e Joint Commission preparedness requirements.", [["Human", "ORGANISM", 211, 216], ["Human", "SPECIES", 211, 216], ["Joint", "ANATOMY", 357, 362]]], ["31 , 32 Although Th e Joint Commission standards for emergency preparedness are implemented in most US hospitals (and government standards exist in other nations), in practice, these standards revolve around incident management and primarily aff ect the ED and administrative levels of the organization.", [["incident management", "TREATMENT", 208, 227], ["Joint", "ANATOMY", 22, 27]]], ["We suggest expectations regarding clinician response to pandemics or disasters be delineated in contractual agreements, medical staff bylaws, or other formal documents that govern the array of responsibilities to the health-care system.", [["pandemics", "DISEASE", 56, 65], ["pandemics", "PROBLEM", 56, 65]]], ["Unless contractually delineated, eff orts toward personal and professional preparedness will be voluntary and ad hoc and may be especially complicated when a physician has responsibilities at multiple facilities, unless expectations are defi ned in advance.ICU clinician leadersTh e Task Force panelists had mixed views and concerns regarding mandates for preparedness and legal ramifi cations of various labor contracts.", [["legal ramifi cations", "TREATMENT", 373, 393]]], ["Contractual mandates in uncertain hazardous situations, scope of practice, and enforcement of these agreements raise logistical issues outside of the task force's expertise.", [["logistical issues", "PROBLEM", 117, 134]]], ["However, the task force believed that hospital systems should have a reciprocal obligation to clinicians to provide them with adequate planning, education, and infrastructure to meet patient care needs during a disaster to support engagement.", [["patient", "ORGANISM", 183, 190], ["patient", "SPECIES", 183, 190]]], ["Hospitals also should be required to include ICU medical directors in system and regional planning for pandemics or disasters (currently, many do not).", [["pandemics", "DISEASE", 103, 112], ["pandemics", "PROBLEM", 103, 112]]], ["Without this expertise and leadership, even response systems optimally resourced to provide critical care will fail.9.We suggest critical care leaders be invited to participate in health-care coalitions so they can facilitate sharing expertise, resources, and knowledge between ICUs in the event of a regional disaster.9.Successful disaster response relies on collaboration and communication within the hospital system and in the region.", [["region", "ANATOMY_MODIFIER", 430, 436]]], ["However, critical care physicians have generally not been invited to participate in regional systems and oft en are learning about emergency management in the midst of providing critical care during a pandemic or disaster.", [["emergency management", "TREATMENT", 131, 151]]], ["We suggest incorporation of disaster medicine into critical care training curricula will facilitate future ICU clinician training and engagement in disaster preparedness and response activities.9.ICU clinicians will need to interact with persons and organizations from across the spectrum of emergency preparedness and response.", [["persons", "SPECIES", 238, 245], ["disaster medicine", "TREATMENT", 28, 45], ["critical care training curricula", "TREATMENT", 51, 83], ["future ICU clinician training", "TREATMENT", 100, 129]]], ["Emergency management skills are not commonly taught in medical professional education or training, 54 nor are the abilities to triage patients or provide MCC.", [["patients", "ORGANISM", 134, 142], ["MCC", "CANCER", 154, 157], ["patients", "SPECIES", 134, 142]]], ["As disaster medicine principles and practices become incorporated into medical education, physicians will have access to uniform information to enhance preparedness, communication, and response at every medical facility.", [["disaster medicine", "TREATMENT", 3, 20]]], ["42 , 55 -57 Core competencies in MCC, including development and deployment of an educational program, implementation with regulatory oversight (where applicable) of the competencies, and ongoing reevaluation of competency needs and eff ectiveness, are necessary.", [["MCC", "CANCER", 33, 36], ["eff ectiveness", "TREATMENT", 232, 246]]], ["60 -64 To address this need, international guidelines and standards of education in the multidisciplinary fi eld of disaster health have been developed for medical professional education.", [["medical professional education", "TREATMENT", 156, 186]]], ["66 , 67 Opportunities for intensive education in disaster preparedness and opportunities to reinforce MCC principles should be sought in various contexts outside medical school curricula ( Table 4 ).11.", [["intensive education", "TREATMENT", 26, 45], ["MCC principles", "TREATMENT", 102, 116]]], ["We suggest expert opinions be considered in mass critical care education curricula.11MCC education poses challenges to health-care systems and communities because advanced training, highly technical equipment, and critical resources (eg, oxygen, pharmaceuticals) are necessary.", [["11MCC", "CHEMICAL", 83, 88], ["oxygen", "CHEMICAL", 238, 244], ["oxygen", "CHEMICAL", 238, 244], ["oxygen", "SIMPLE_CHEMICAL", 238, 244], ["advanced training", "TREATMENT", 163, 180], ["oxygen, pharmaceuticals", "TREATMENT", 238, 261]]], ["In addition, the development of an educational framework and approach that can increase the pool of trained individuals is hampered due to costs, logistics, and capacity.", [["approach", "TREATMENT", 61, 69]]], ["68 To date, no educational methods have been rigorously tested in an MCC setting; thus, training approaches are unvalidated and must rely on expert opinion.", [["MCC", "CANCER", 69, 72]]], ["However, the education methods used should conform to usual adult learning and curricula development principles.", [["the education methods", "TREATMENT", 9, 30]]], ["A similar, specialty-specifi c eff ort for critical care disaster education would be of immense value to the specialty and should help to defi ne the basis for the core materials and competencies for critical care clinicians to respond to pandemics or disasters.1113.", [["critical care disaster education", "TREATMENT", 43, 75]]], ["We suggest translating competencies into multidisciplinary learning modules become a core focus of academic, professional organizations, governmental, and nongovernmental organizations whose students and responsible agencies may be called upon to provide mass critical care.11Th ere are limited data on MCC education theory and practice.", [["mass critical care", "TREATMENT", 255, 273]]], ["However, critical care environments are stressful, and a catastrophic event with at least twice the normal capacity of critically ill patients likely will stress the cadre of workers routinely available to care for the anticipated surge.", [["critically ill", "DISEASE", 119, 133], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["a catastrophic event", "PROBLEM", 55, 75]]], ["What is unknown is the minimum amount of training or expertise needed by noncritical care clinicians to appropriately care for critically ill or injured patients in a pandemic or disaster.", [["critically ill", "DISEASE", 127, 141], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161]]], ["Another challenge is determining the timing and delivery of this education.", [["this education", "TREATMENT", 60, 74]]], ["A starting point in this process is to identify areas in which nonspecialists may contribute (as Project Xtreme's approach to mechanical ventilation 71 ) and determine the education they would need, including just-in-time education, to support the extension of critical care under a critical care physician's supervision.", [["mechanical ventilation", "TREATMENT", 126, 148]]], ["ICU order and standard work templates may contribute greatly to safely engaging noncritical care physicians in these activities.We suggest standing committees in education, or a reasonable equivalent in relevant stakeholder groups, review and endorse the curriculum and competencies.By developing and promoting MCC educational standards, the overall preparedness of hospitals and health-care systems may improve, 68 yet, little has been done to assemble relevant critical care stakeholders and determine the standards and competencies for a disaster or pandemic response.", [["MCC", "CANCER", 311, 314], ["standard work templates", "TREATMENT", 14, 37]]], ["Finally, the emerging role of telemedicine in health care off ers another viable mechanism for supporting inexperienced health-care teams in MCC.We suggest educational activities draw on all modern modalities of education (including access via web-based learning, simulation, or other modalities for remote learners) and include incremental (individual, organizational, community), realistic, and challenging training opportunities.Beyond health professional schools, innovative methods of disaster education need to occur.", [["MCC", "CANCER", 141, 144], ["disaster education", "TREATMENT", 490, 508]]], ["A specifi c disaster This is not designed to be a comprehensive list but, rather, to stimulate ideas on opportunities for short, targeted, and specifi c disaster educational materials to be integrated into existing curricula.We suggest educational activities draw on all modern modalities of education (including access via web-based learning, simulation, or other modalities for remote learners) and include incremental (individual, organizational, community), realistic, and challenging training opportunities.medicine program has enhanced pediatric residents' knowledge, 76 and adding tabletop exercises to standard lectures may increase knowledge and comfort with disaster preparedness.", [["disaster educational materials", "TREATMENT", 153, 183], ["tabletop exercises", "TREATMENT", 588, 606]]], ["77 Virtual interactive exercises can also be useful.", [["Virtual interactive exercises", "TREATMENT", 3, 32]]], ["78 Indeed, students have mastered basic disaster management content and understood their role on an interdisciplinary team using a virtual teaching program comprising interactive videos, board games, and high-fi delity disaster simulation.", [["a virtual teaching program", "TREATMENT", 129, 155]]], ["We suggest stakeholder organizations determine the thresholds and milestones for trainer education and certifi cation.We suggest educational activities draw on all modern modalities of education (including access via web-based learning, simulation, or other modalities for remote learners) and include incremental (individual, organizational, community), realistic, and challenging training opportunities.Published data on MCC education are limited.", [["MCC", "CANCER", 423, 426], ["stakeholder organizations", "TREATMENT", 11, 36], ["trainer education", "TREATMENT", 81, 98], ["certifi cation", "TREATMENT", 103, 117], ["MCC education", "TREATMENT", 423, 436]]], ["72 In addition, the core concepts needed for other related areas, such as pharmacy, respiratory care, and other technologies, are not known.", [["respiratory care", "TREATMENT", 84, 100]]], ["Th e impact on an individual hospital may depend on its organizational structure, community affi liations, and partnerships in the region.", [["region", "ANATOMY_MODIFIER", 131, 137]]], ["Once the curriculum is developed and endorsed, then the larger issue is how the curriculum will be disseminated and evaluated in health-care settings.", [["larger", "OBSERVATION_MODIFIER", 56, 62]]], ["Th e thresholds for disaster preparedness are fairly low for the predominant hospital accrediting agency in the United States, Th e Joint Commission, so many hospitals may not implement such highly specialized training.", [["disaster preparedness", "TREATMENT", 20, 41], ["Joint", "ANATOMY", 132, 137]]], ["Another barrier is identifying the appropriate authority to certify that individuals are qualifi ed to perform MCC techniques.", [["MCC techniques", "TREATMENT", 111, 125]]], ["Research will be needed in this area, but a larger problem will likely be implementation.We suggest individuals with board certifi cation in critical care medicine be tested on the core competencies (when developed) by their certifi cation process.18.", [["a larger problem", "PROBLEM", 42, 58], ["board certifi cation", "TREATMENT", 117, 137]]], ["We suggest those involved with critical care disaster education develop ongoing, internal process improvement methodologies and metrics to ensure their programs remain current, responsive, and relevant.We suggest individuals with board certifi cation in critical care medicine be tested on the core competencies (when developed) by their certifi cation process.Educational processes need to be formalized to address knowledge gaps in pandemic and disaster response.", [["board certifi cation", "TREATMENT", 230, 250]]], ["Th ese actions should not only focus on content teaching but also include evaluation of education, pandemic, and disaster interventions as well as meaningful disaster and pandemic research.", [["content teaching", "TREATMENT", 40, 56], ["evaluation", "TEST", 74, 84], ["disaster interventions", "TREATMENT", 113, 135]]], ["We suggest accreditation bodies that ensure safe and eff ective critical care delivery processes for hospitals consult with professional societies to develop metrics and tools of assessment to ensure ICUs can continue to provide quality care during a pandemic or disaster.We suggest individuals with board certifi cation in critical care medicine be tested on the core competencies (when developed) by their certifi cation process.Content and virtual drills alone do not suffi ce.", [["accreditation bodies", "TREATMENT", 11, 31], ["assessment", "TEST", 179, 189], ["board certifi cation", "TREATMENT", 300, 320], ["virtual drills alone", "TREATMENT", 443, 463]]], ["Exercises must include assessment with feedback to improve preparedness capabilities.", [["assessment", "TEST", 23, 33]]], ["68 , 80 Translating these activities into standard operating procedures may prove useful as a checklist and as refresher tools for ICU providers faced with a disaster.", [["standard operating procedures", "TREATMENT", 42, 71]]], ["82 Another important component of educational settings is the nature and timing of the pandemic or disaster.", [["educational settings", "TREATMENT", 34, 54]]], ["83 However, most education and training regarding MCC delivery is achieved at the time of a pandemic or disaster, and adult learners have diffi culty fi nding relevance of education and training when a crisis is not imminent.", [["MCC", "CANCER", 50, 53], ["MCC delivery", "TREATMENT", 50, 62], ["a crisis", "PROBLEM", 200, 208]]], ["Additionally, it is important to identify that many of the skills required for eff ective pandemic and disaster response (leadership, communication, teamwork, planning) are transferable to day-to-day practice as well.We suggest individuals with board certifi cation in critical care medicine be tested on the core competencies (when developed) by their certifi cation process.Considering all hazards, the timing of education for a particular crisis depends on the nature of the hazard:We suggest individuals with board certifi cation in critical care medicine be tested on the core competencies (when developed) by their certifi cation process.\u2022 Adult learner principles should be used in developing MCC educational approaches. \u2022 Disaster educators should develop competencies and lessons that account for the time needed to respond to a crisis. \u2022 Disaster planners should determine the core competencies for each relevant job description in the Hospital Incident Command System approach appropriate to care for critically ill or injured patients during a pandemic or disaster.Community EngagementBurkle 84 and Hanfl ing 2 discussed the importance of connecting providers directly with the community when allocating scarce resources during a disaster or administering crisis care.", [["critically ill", "DISEASE", 1012, 1026], ["MCC", "CANCER", 700, 703], ["patients", "ORGANISM", 1038, 1046], ["patients", "SPECIES", 1038, 1046], ["board certifi cation", "TREATMENT", 245, 265], ["a particular crisis", "PROBLEM", 429, 448], ["board certifi cation", "TREATMENT", 513, 533], ["a crisis", "PROBLEM", 836, 844], ["critically ill", "PROBLEM", 1012, 1026], ["Community EngagementBurkle", "TREATMENT", 1077, 1103], ["crisis care", "TREATMENT", 1268, 1279]]], ["85 -94 Figure 2 illustrates an approach that was used successfully in Harris County, Texas.", [["an approach", "TREATMENT", 28, 39]]], ["94 Community engagement sessions in the United States on the topic of mass critical care and the allocation of scarce resources reveal that the American public has a great deal of confi dence in medical providers to make sound clinical decisions during a crisis; however, the public believes that end-of-life care decisions should be made by the patient's family.", [["patient", "ORGANISM", 346, 353], ["patient", "SPECIES", 346, 353], ["mass critical care", "TREATMENT", 70, 88]]], ["We suggest engagement of critical care clinicians in disaster preparedness eff orts occur in advance of and in preparation for pandemics and disasters in order to enhance mass critical care delivery and coordination.Community EngagementReviews by the Agency for Healthcare Research and Quality and the Institute of Medicine emphasized the engagement of the lay public and clinicians in pandemic and disaster preparedness eff orts in advance of and during large-scale emergencies to enhance MCC delivery and coordination.", [["MCC", "CANCER", 490, 493], ["pandemics", "TREATMENT", 127, 136], ["disasters", "TREATMENT", 141, 150], ["mass critical care delivery", "TREATMENT", 171, 198], ["disaster preparedness eff orts", "TREATMENT", 399, 429], ["large-scale emergencies", "TREATMENT", 455, 478], ["MCC delivery", "TREATMENT", 490, 502], ["mass", "OBSERVATION", 171, 175]]], ["85 , 88 , 91 , 92 , 95 Th e types of strategies used for the public oft en will be markedly diff erent from those used to engage ICU clinicians.We suggest ICU clinicians and disaster planners incorporate community values into critical care decision-making through pre-event inclusion of clinicians and community perspectives.Experience from Harris County, Texas; Seattle & King County, Washington; and Michigan has shown that the public can comprehend diffi cult clinical scenarios and contribute to forming community values toward crisis standards of care.", [["strategies", "TREATMENT", 37, 47], ["markedly diff erent", "PROBLEM", 83, 102]]], ["We suggest hospitals provide education, training, and community conversation opportunities for their ICU clinicians on the topic of mass critical care delivery.We suggest ICU clinicians and disaster planners incorporate community values into critical care decision-making through pre-event inclusion of clinicians and community perspectives.Helping ICU clinicians understand community-based value decisions, train in implementation of resource allocation decisions, and incorporate community values into the process of delivering MCC are crucial components to eff ective provider engagement.", [["MCC", "CANCER", 530, 533], ["mass critical care delivery", "TREATMENT", 132, 159]]], ["88 , 91 Having physicians complete a brief tabletop exercise on ventilator triage to illustrate some of the issues before introducing the key concepts of crisis care may be benefi cial.", [["ventilator triage", "TREATMENT", 64, 81], ["crisis care", "TREATMENT", 154, 165]]], ["Th is has been a successful strategy used in metropolitan Minnesota (J. L. Hick, MD, personal communication, September 2013). and (e) family engagement and community guidance during resource allocation.We suggest ICU clinicians and disaster planners incorporate community values into critical care decision-making through pre-event inclusion of clinicians and community perspectives.Eff ective public engagement will require active and ongoing planning in concert with critical care providers to engender trust in MCC decisions.", [["MCC", "CANCER", 514, 517]]], ["Once these partnerships are established, it is important to share best practices and models that communities have undertaken to address MCC.", [["MCC", "DISEASE", 136, 139], ["MCC", "CANCER", 136, 139]]], ["99 , 100 Although the task force suggests that critical care providers need to be actively involved in community engagement initiatives, no clear mechanism to ensure these opportunities exists.Areas for ResearchResearch initiatives are limited by the lack of seed funding to stimulate collaboration and explore issues.", [["ResearchResearch initiatives", "TREATMENT", 203, 231]]], ["57 , 101, 102 As reforms in health care, notably in the United States with the Aff ordable Care Act, begin to change the dynamics of provider employment, public and private institutions will increasingly bear the responsibility to ensure that all members are trained, prepared, and supported during a pandemic or disaster.Areas for ResearchTh ere are several key questions for which further research is needed.", [["ResearchTh ere", "TREATMENT", 332, 346]]], ["Whether the degree to which individuals engage in public education activities determines how prepared they are for mass critical disasters is unknown and should be explored.", [["mass critical disasters", "PROBLEM", 115, 138]]], ["Do cultural diff erences indicate a need for diff erent methods of disaster education for the public?", [["cultural diff erences", "PROBLEM", 3, 24], ["disaster education", "TREATMENT", 67, 85]]], ["Failure to address these issues poses a risk for preventable morbidity and mortality and is just as important as the \"space, staff , and stuff \" that are the logistical portion of usual pandemic and disaster preparedness activities.", [["Failure", "PROBLEM", 0, 7], ["these issues", "PROBLEM", 19, 31], ["preventable morbidity", "PROBLEM", 49, 70]]], ["We also need to improve our understanding of engagement gaps and commit to addressing these for future pandemic and disaster preparedness in health-care systems.Areas for ResearchFinancial/nonfi nancial disclosures: Th e authors have reported to CHEST the following confl icts of interest: Dr Hanfl ing is an anthrax consultant to GlaxoSmithKline plc.", [["pandemic", "DISEASE", 103, 111], ["anthrax", "DISEASE", 309, 316], ["CHEST", "ANATOMY", 246, 251]]]], "247afa6d0f742905cce4a8e8e4681c00086bd37d": [["IntroductionThe World Health Organization (WHO) declared the novel coronavirus disease 2019 outbreak, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), to be a public health emergency of international concern on 30 January 2020 (World Health Organization 2020).", [["coronavirus disease", "DISEASE", 67, 86], ["acute respiratory syndrome coronavirus", "DISEASE", 119, 157], ["coronavirus", "ORGANISM", 67, 78], ["SARS-CoV-2", "ORGANISM", 161, 171], ["severe acute respiratory syndrome coronavirus", "SPECIES", 112, 157], ["SARS-CoV-2", "SPECIES", 161, 171], ["the novel coronavirus disease", "PROBLEM", 57, 86], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 112, 157], ["coronavirus disease", "OBSERVATION", 67, 86], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["respiratory syndrome coronavirus", "OBSERVATION", 125, 157]]], ["The number of infections has risen quickly, as has the number of deaths attributed to the virus.IntroductionFollowing the first diagnosed case in late 2019, there have been more than 13 million confirmed cases of COVID-19 and half a million deaths worldwide.", [["infections", "DISEASE", 14, 24], ["deaths", "DISEASE", 65, 71], ["COVID", "DISEASE", 213, 218], ["deaths", "DISEASE", 241, 247], ["infections", "PROBLEM", 14, 24], ["the virus", "PROBLEM", 86, 95], ["COVID", "TEST", 213, 218], ["number", "OBSERVATION_MODIFIER", 4, 10], ["infections", "OBSERVATION", 14, 24], ["risen", "OBSERVATION_MODIFIER", 29, 34], ["quickly", "OBSERVATION_MODIFIER", 35, 42], ["virus", "OBSERVATION", 90, 95]]], ["The early experience of China, followed by countries such as Italy, Iran, and more recently the UK and USA, where health systems have quickly become overwhelmed and struggled to cope with the demand from large numbers of infected patients, has motivated countries to take drastic action and implement a wide range of proactive and reactive measures to limit the spread of Collectively referred to as \"containment measures,\" these strategies are designed to limit community transmission between individuals.", [["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 230, 238], ["drastic action", "TREATMENT", 272, 286], ["proactive and reactive measures", "TREATMENT", 317, 348], ["early", "OBSERVATION_MODIFIER", 4, 9], ["infected", "OBSERVATION", 221, 229]]], ["There is, unsurprisingly, a great deal of variation in the ways in which different countries have approached the pandemic, and the types of containment measures they have employed.", [["containment measures", "TREATMENT", 140, 160], ["great", "OBSERVATION_MODIFIER", 28, 33], ["variation", "OBSERVATION_MODIFIER", 42, 51]]], ["Despite these differences, each jurisdiction's response has involved some combination of travel restrictions and border controls, quarantine requirements, social isolation and distancing requirements, and the large-scale closure of various services, business, and educational facilities.", [["travel restrictions", "TREATMENT", 89, 108], ["border controls", "TREATMENT", 113, 128], ["quarantine requirements", "TREATMENT", 130, 153], ["social isolation", "TREATMENT", 155, 171], ["distancing requirements", "TREATMENT", 176, 199], ["the large-scale closure", "TREATMENT", 205, 228]]], ["While the primary concern of government has been to minimize the health impacts of COVID-19, attention has also turned to the other effects of the pandemic.", [["COVID-19", "CHEMICAL", 83, 91], ["COVID-19", "CHEMICAL", 83, 91], ["COVID", "TREATMENT", 83, 88], ["the pandemic", "PROBLEM", 143, 155]]], ["Significant societal and economic impacts have raised questions about potential increases in organized crime (Global Initiative Against Transnational Organized Crime 2020), cybercrime (Europol 2020) , and violent crime , particularly domestic violence (Fitz-Gibbon and Meyer 2020; van Gelder et al. 2020) .", [["violent crime", "DISEASE", 205, 218], ["domestic violence", "DISEASE", 234, 251]]], ["Conversely, reductions in opportunistic, property crimes have been anticipated (Farrell and Tilley 2020) .", [["reductions", "OBSERVATION_MODIFIER", 12, 22]]], ["The impact of COVID-19 on law enforcement (Lum et al. 2020) , courts (Rossner and Tait 2020) , and correctional systems (Kinner et al. 2020) have also been the subject of speculation and analysis.", [["COVID", "TREATMENT", 14, 19]]], ["Here, the focus has been primarily on the emerging health risks and the impact of containment measures on how these agencies and systems operate.", [["containment measures", "TREATMENT", 82, 102]]], ["Particular attention has focused on the need for empirical research into the impact of COVID-19 and associated containment measures on violent crime Peterman et al. 2020) .", [["empirical research", "TREATMENT", 49, 67], ["COVID", "TEST", 87, 92]]], ["Changes in the routine activities of individuals, limited social interaction, the potential strain on relationships, fear and anxiety resulting from isolation, and the financial stress of job losses and reduced incomes each have the potential to influence violent crime in different ways.", [["anxiety", "DISEASE", 126, 133], ["anxiety", "PROBLEM", 126, 133]]], ["Understanding these impacts is important to inform how to respond, particularly as the pandemic and containment measures are likely to persist for some time yet.IntroductionIn this study, we use officially recorded police data from Queensland, Australia, to look for early signs that violent crime has changed in the context of the COVID-19 pandemic.", [["violent crime", "DISEASE", 284, 297], ["containment measures", "TREATMENT", 100, 120], ["this study", "TEST", 176, 186], ["early signs that violent crime", "PROBLEM", 267, 297], ["the COVID", "TEST", 328, 337], ["pandemic", "PROBLEM", 341, 349]]], ["In an international context, Australia is a unique site of analysis because the rapid introduction of strong social distancing regulations has coincided with the transition to winter-a time when seasonal crime rates are expected to fall.", [["seasonal crime rates", "PROBLEM", 195, 215]]], ["Without accounting for these seasonal effects, there is a risk that any observed short-term decline in crime may be overstated or incorrectly attributed as a consequence of .", [["any observed short-term decline", "PROBLEM", 68, 99]]], ["In this study, we examine officially recorded violent crime rates for the month of March and April 2020.", [["this study", "TEST", 3, 13]]], ["We conduct this analysis in Queensland because it was the first state or territory in Australia to declare a public health emergency on January 29, 2020.", [["this analysis", "TEST", 11, 24]]], ["It is also the first jurisdiction to provide open access to up-to-date data.What restrictions have been introduced in Australia?Compared with other countries, the infection rate in Australia has remained relatively low.", [["infection", "DISEASE", 163, 172], ["the infection rate", "TEST", 159, 177], ["infection", "OBSERVATION", 163, 172], ["relatively", "OBSERVATION_MODIFIER", 204, 214], ["low", "OBSERVATION_MODIFIER", 215, 218]]], ["The first Australian case was recorded in January; however, the number of new cases increased rapidly during March ( Fig. 1 ).", [["new", "OBSERVATION_MODIFIER", 74, 77], ["increased", "OBSERVATION_MODIFIER", 84, 93]]], ["There have been more than 7700 confirmed cases recorded in Australia (June 30) and more than 100 people have died as a result of the disease (Australian Government Department of Health 2020).", [["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103]]], ["Most confirmed cases acquired their infection during overseas travel, or via contact with someone who had travelled overseas, and onboard cruise ships (Australian Government Department of Health 2020).What restrictions have been introduced in Australia?Importantly, as a federated nation, responsibility for implementing containment measures is shared between the federal and state and territory governments, while states and territories are able to choose how to enforce them.", [["infection", "DISEASE", 36, 45], ["their infection", "PROBLEM", 30, 45], ["implementing containment measures", "TREATMENT", 308, 341], ["infection", "OBSERVATION", 36, 45]]], ["Although there has been a strong emphasis on a consistent national approach, there has also been variation in some of the measures employed in each jurisdiction.", [["strong", "OBSERVATION_MODIFIER", 26, 32], ["variation", "OBSERVATION_MODIFIER", 97, 106]]], ["This has included strategies such as border controls and school closures.What restrictions have been introduced in Australia?Containment measures have been introduced incrementally (see Ting and Palmer 2020 for a detailed timeline).", [["strategies", "TREATMENT", 18, 28], ["school closures", "TREATMENT", 57, 72], ["Containment measures", "TREATMENT", 125, 145]]], ["This was followed by self-isolation requirements on all travelers arriving in Australia introduced on March 16.", [["self-isolation requirements", "TREATMENT", 21, 48]]], ["Large, non-essential, and organized public gatherings of more than 500 people were also restricted from this date, as were indoor gatherings of more than 100 people.", [["people", "ORGANISM", 71, 77], ["people", "ORGANISM", 158, 164], ["people", "SPECIES", 71, 77], ["people", "SPECIES", 158, 164], ["non-essential", "OBSERVATION_MODIFIER", 7, 20]]], ["The Biosecurity (Human Biosecurity Emergency) (Human Coronavirus with Pandemic Potential) Declaration 2020 was announced on March 18, followed by a further announcement that Australian borders were closed to all non-Australian citizens and non-residents effective March 20.", [["Human", "ORGANISM", 17, 22], ["Human", "ORGANISM", 47, 52], ["Human", "SPECIES", 17, 22], ["Human", "SPECIES", 47, 52]]], ["The following day, the requirement that there be 4 m 2 per person in any enclosed space was introduced.", [["person", "SPECIES", 59, 65], ["any enclosed space", "TREATMENT", 69, 87]]], ["On the 22nd of March, the Prime Minister announced large-scale closures of take-away liquor outlets, licensed premises, restaurants and cafes (except for takeaway food), entertainment venues, and places of worship, which took effect the following day.", [["large", "OBSERVATION_MODIFIER", 51, 56]]], ["Further restrictions were imposed on a range of other venues, including indoor and outdoor markets, on March 26, while limits were placed on the number of people who are allowed to attend weddings and funerals.", [["people", "ORGANISM", 155, 161], ["people", "SPECIES", 155, 161]]], ["Public gatherings were limited to two people (non-family members) from March 30, and Australians were advised that they were only allowed to leave home for essential shopping, medical needs, exercise, or for work or education.What restrictions have been introduced in Australia?Queensland became the first Australian state or territory to declare a public health emergency under the Public Health Act 2005 on January 29, 2020, providing the Chief Health Officer with broad powers to make directions regarding the types of restrictions that may be imposed to limit the transmission of COVID-19.", [["COVID-19", "CHEMICAL", 584, 592], ["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44], ["COVID", "TEST", 584, 589]]], ["Since the non-essential business, activity, and undertaking closure direction was first released on March 23, a series of revisions have been made in line with national requirements, imposing further limits on which venues and businesses may continue to operate.", [["undertaking closure direction", "TREATMENT", 48, 77], ["a series of revisions", "TREATMENT", 110, 131], ["non-essential", "OBSERVATION_MODIFIER", 10, 23], ["business", "OBSERVATION", 24, 32]]], ["School closures came into effect on March 30, remaining open to the children of essential service workers.", [["children", "ORGANISM", 68, 76], ["children", "SPECIES", 68, 76], ["School closures", "TREATMENT", 0, 15]]], ["Queensland borders were closed effective March 26, with entry limited to Queensland residents, residents of border communities undertaking essential activities, and other exempt persons.", [["persons", "ORGANISM", 178, 185], ["persons", "SPECIES", 178, 185]]], ["These restrictions are enforceable by law.What restrictions have been introduced in Australia?Why is violent crime likely to be impacted by COVID-19?What restrictions have been introduced in Australia?Broadly speaking, there are several mechanisms through which the COVID-19 containment measures are likely to influence violence.", [["COVID-19", "CHEMICAL", 140, 148], ["COVID", "TEST", 140, 145], ["the COVID-19 containment measures", "TREATMENT", 262, 295]]], ["We limit our discussion here to the most likely short-term situational effects that are best explained by routine activities theory (Cohen and Felson 1979) and the short-to-longer-term financial and emotional pressure (General Strain Theory, Agnew 1992) that might spur a range of negative emotions which, in turn, manifest as violence as the pandemic progresses.Routine activitiesThe first, and most obvious of these mechanisms, is the impact on the routine activities of individuals.", [["violence", "DISEASE", 327, 335]]], ["Crime is more common in places where these three things converge on a regular basis.", [["more common", "OBSERVATION_MODIFIER", 9, 20]]], ["Obviously, major disruptions of these routine activities may have a significant impact on when, and where, we might expect crime to occur.", [["significant", "OBSERVATION_MODIFIER", 68, 79]]], ["Containment measures are likely to mean that much less time is spent interacting with other people in public settings and much more time spent at home.Routine activitiesWhen asked, adult Australians have reported a high degree of compliance with recommended social distancing practices, including keeping distance between people, avoiding public spaces, and avoiding large gatherings (Australian Bureau of Statistics 2020c).", [["people", "ORGANISM", 92, 98], ["Australians", "ORGANISM", 187, 198], ["people", "SPECIES", 92, 98], ["people", "SPECIES", 322, 328], ["Containment measures", "TREATMENT", 0, 20]]], ["Google's (Google 2020) mobility data highlights how much peoples' movement and time spent in public and private spaces has changed as a result of the containment measures.", [["mobility data", "TEST", 23, 36], ["the containment measures", "TREATMENT", 146, 170]]], ["Location data reported by Google on community mobility has tracked how often and for how long people travel to different location types, compared with a baseline value (the median value for the same day of the week in January and early February).", [["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100]]], ["Figure 2 shows these changes over time and demonstrates that there have been significant reductions in visits to public spaces, including parks (down 43% as of April 30), retail and recreation premises (down 39%), workplaces (down 34%), and transit stations (down 60%).", [["transit stations", "TEST", 241, 257], ["significant", "OBSERVATION_MODIFIER", 77, 88], ["reductions", "OBSERVATION_MODIFIER", 89, 99]]], ["Not surprisingly, the time spent in residential locations has increased by 18%, which may help to increase the opportunity for interpersonal violence.", [["interpersonal violence", "DISEASE", 127, 149], ["increased", "OBSERVATION_MODIFIER", 62, 71]]], ["Nevertheless, similar trends in mobility were observed in Queensland in the second half of March, and these changes were sustained until the end of April.", [["mobility", "OBSERVATION_MODIFIER", 32, 40]]], ["That significant changes in mobility were observed in March, seemingly in advance of the introduction of major restrictions, indicating that people changed their behavior in response to the perceived threat from the pandemic before measures were formally implemented.", [["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["significant changes in mobility", "PROBLEM", 5, 36], ["significant", "OBSERVATION_MODIFIER", 5, 16], ["mobility", "OBSERVATION_MODIFIER", 28, 36]]], ["In large part, this was also due to many business implementing work-from-home policies and only limiting on-premise work to essential employees.Routine activitiesLimiting the amount of time that people are permitted to spend outside of the home, and the number of people outside the home with whom people may have contact, reduces opportunities for interactions between potential victims and offenders.", [["people", "ORGANISM", 195, 201], ["people", "ORGANISM", 264, 270], ["people", "ORGANISM", 298, 304], ["people", "SPECIES", 195, 201], ["people", "SPECIES", 264, 270], ["people", "SPECIES", 298, 304], ["large", "OBSERVATION_MODIFIER", 3, 8]]], ["Spending significantly less time socializing in recreational areas, such as in entertainment precincts, may lead to less public forms of violence.", [["violence", "DISEASE", 137, 145]]], ["A sizeable proportion of assaultsbetween 37 and 70%, depending on which state or territory-occur in public locations (Australian Bureau of Statistics 2019).", [["sizeable", "OBSERVATION_MODIFIER", 2, 10], ["proportion", "OBSERVATION_MODIFIER", 11, 21]]], ["We know, for example, that a significant proportion of violent crime in Australia is attributable to the night time economy and peaks on weekends during periods of high alcohol consumption, particularly in major urban centers (Miller et al. 2016) .", [["violent crime", "DISEASE", 55, 68], ["alcohol", "CHEMICAL", 169, 176], ["alcohol", "CHEMICAL", 169, 176], ["alcohol", "SIMPLE_CHEMICAL", 169, 176], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["violent", "OBSERVATION_MODIFIER", 55, 62], ["crime", "OBSERVATION", 63, 68]]], ["Excessive consumption of alcohol, common in these settings, is directly related to physical aggression and is a contributing factor in physical and sexual violence (Graham et al. 1998 ).", [["alcohol", "CHEMICAL", 25, 32], ["aggression", "DISEASE", 92, 102], ["physical and sexual violence", "DISEASE", 135, 163], ["alcohol", "CHEMICAL", 25, 32], ["alcohol", "SIMPLE_CHEMICAL", 25, 32]]], ["Rates of self-reported involvement in physical aggression in and around licensed premises in the previous 3 months among thousands of patrons surveyed in nine different cities ranged from 7 to 17% (Miller et al. 2016) .Routine activitiesEntertainment precincts are also a known hotspot for sexual violence.", [["physical aggression", "DISEASE", 38, 57], ["sexual violence", "DISEASE", 290, 305]]], ["Conversely, the increase in time spent at home increases the risk of violence in residential locations.", [["violence", "DISEASE", 69, 77], ["increase", "OBSERVATION_MODIFIER", 16, 24]]], ["According to the latest ABS ( 2019) data, between 30 and 63% of assaults and between 40 and 73% of sexual assaults normally occur in residential settings (with most jurisdictions closer to the upper end of that range).", [["the latest ABS", "TEST", 13, 27]]], ["This might be expected to increase during COVID-19.", [["COVID-19", "CHEMICAL", 42, 50], ["COVID", "TEST", 42, 47], ["increase", "OBSERVATION_MODIFIER", 26, 34]]], ["There is particular concern about the increased risk of family and domestic violence, which is already a significant problem in Australia (Fitz-Gibbon and Meyer 2020; Usher et al. 2020) .", [["family and domestic violence", "DISEASE", 56, 84], ["significant", "OBSERVATION_MODIFIER", 105, 116], ["problem", "OBSERVATION", 117, 124]]], ["The most obvious risk is from intimate partner violence, which accounts for more than half of all family violence-related assaults (Australian Bureau of Statistics 2019).", [["intimate partner violence", "DISEASE", 30, 55], ["violence", "DISEASE", 105, 113], ["most obvious", "OBSERVATION_MODIFIER", 4, 16]]], ["Former partners may pose less of a threat (at least in terms of physical violence) in periods of social isolation; however, around four in five assaults by an intimate partner are committed by the victim's current partner (Australian Bureau of Statistics 2019).", [["social isolation", "OBSERVATION", 97, 113]]], ["Adolescent family violence is also an area of concern and, with the closure of schools and many recreational facilities, may increase due to increased contact between young people who use violence and their parents.", [["family violence", "DISEASE", 11, 26], ["violence", "DISEASE", 188, 196], ["people", "ORGANISM", 173, 179], ["people", "SPECIES", 173, 179]]], ["As well as being at a greater risk of violence in the home due to increased contact with their abuser, victims of family and domestic violence face increasing social isolation, have limited opportunities to seek help from family and friends, may be unable or fearful of seeking help due to surveillance by their partner, or face challenges with seeking assistance from formal support services due to social distancing measures preventing face to face contact ; van Gelder et al. 2020; Usher et al. 2020 ).", [["violence", "DISEASE", 38, 46], ["domestic violence", "DISEASE", 125, 142], ["formal support services", "TREATMENT", 369, 392], ["social distancing measures", "TREATMENT", 400, 426]]], ["This raises the potential risk of repeat violence.Routine activitiesOf course, not everyone will comply with social distancing measures.", [["social distancing measures", "TREATMENT", 109, 135]]], ["Unsurprisingly, there is some overlap between the profile of those people who are less likely to comply and those people who are more likely to be involved in crime.", [["people", "ORGANISM", 67, 73], ["people", "ORGANISM", 114, 120], ["people", "SPECIES", 67, 73], ["people", "SPECIES", 114, 120], ["some", "OBSERVATION_MODIFIER", 25, 29], ["overlap", "OBSERVATION", 30, 37]]], ["Specifically, Nivette et al. (2020) found that non-compliance was associated with antisocial potential, including delinquent behavior.", [["delinquent behavior", "DISEASE", 114, 133]]], ["It is plausible that these non-compliant individuals will be more likely to offend, reducing any effect from the changes to routine activities of compliant individuals.General strainThe other potential consequence of the Queensland lockdowns is an increase in criminal-especially violent-behavior-that might occur as a result of the emotional and financial pressure of the pandemic.", [["General strain", "PROBLEM", 168, 182], ["the Queensland lockdowns", "PROBLEM", 217, 241], ["the pandemic", "PROBLEM", 369, 381], ["strain", "OBSERVATION", 176, 182], ["increase", "OBSERVATION_MODIFIER", 248, 256]]], ["Levels of anxiety are also much higher than usually observed (Australian Bureau of Statistics 2020b).", [["anxiety", "DISEASE", 10, 17], ["anxiety", "PROBLEM", 10, 17], ["anxiety", "OBSERVATION", 10, 17]]], ["The Australian Bureau of Statistics (2020a) reported that 72% of businesses have experienced a reduced cash flow that is expected to harm business activity and employment over the coming months.", [["a reduced cash flow", "PROBLEM", 93, 112], ["reduced", "OBSERVATION_MODIFIER", 95, 102], ["cash flow", "OBSERVATION", 103, 112]]], ["In fact, throughout March, these challenging economic circumstances have resulted in a 7.5% decrease in employee jobs and an 8.2% reduction in wages paid to employees (Australian Bureau of Statistics 2020c).", [["a 7.5% decrease in employee jobs", "PROBLEM", 85, 117], ["an 8.2% reduction", "TREATMENT", 122, 139]]], ["The implication of this financial stress is not insubstantial; violence, including domestic violence, is concentrated in areas with higher socio-economic disadvantage (Hulme et al. 2019) , while financial stress has been identified as a risk factor for repeat offending (Dowling and Morgan 2016) .General strainThe restrictions on movement are likely to be compounded by the negative psychological impacts of quarantine measures.", [["violence", "DISEASE", 63, 71], ["domestic violence", "DISEASE", 83, 100], ["General strain", "PROBLEM", 297, 311], ["quarantine measures", "TREATMENT", 409, 428], ["concentrated", "OBSERVATION_MODIFIER", 105, 117], ["strain", "OBSERVATION", 305, 311]]], ["A recent rapid review by Brooks et al. (2020) concluded that there are likely to be wide ranging and long-lasting psychological impacts, including a high prevalence of stress disorders, irritability, emotional disturbance, anger, and depression, among other symptoms.", [["stress disorders", "DISEASE", 168, 184], ["irritability", "DISEASE", 186, 198], ["emotional disturbance", "DISEASE", 200, 221], ["depression", "DISEASE", 234, 244], ["stress disorders", "PROBLEM", 168, 184], ["irritability", "PROBLEM", 186, 198], ["emotional disturbance", "PROBLEM", 200, 221], ["depression", "PROBLEM", 234, 244], ["among other symptoms", "PROBLEM", 246, 266], ["likely to be", "UNCERTAINTY", 71, 83], ["wide", "OBSERVATION_MODIFIER", 84, 88]]], ["Recent findings from a cohort study showed increased levels of perceived stress and anger among young people during the pandemic .", [["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108], ["a cohort study", "TEST", 21, 35], ["perceived stress", "PROBLEM", 63, 79], ["increased", "OBSERVATION_MODIFIER", 43, 52]]], ["Data from call centers in the USA, for example, reveals substantial increases in calls to mental health and suicide prevention hotlines (Goodman 2020; Jackson 2020) .", [["substantial", "OBSERVATION_MODIFIER", 56, 67], ["increases", "OBSERVATION_MODIFIER", 68, 77]]], ["Although this may not, in and of itself, lead to increased violence, people who experience these symptoms may be more likely to engage in substance misuse (Clay and Parker 2020) which, together with poor mental health, is associated with an increased risk of violence (Elbogen and Johnson 2009) .", [["violence", "DISEASE", 59, 67], ["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["these symptoms", "PROBLEM", 91, 105]]], ["Also, there is evidence of increased alcohol consumption in the home due to onpremise restrictions and increased home delivery (Foundation for Alcohol Research {and} Education, 2020).", [["alcohol", "CHEMICAL", 37, 44], ["alcohol", "CHEMICAL", 37, 44], ["alcohol", "SIMPLE_CHEMICAL", 37, 44], ["increased home delivery", "TREATMENT", 103, 126], ["evidence of", "UNCERTAINTY", 15, 26], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["alcohol consumption", "OBSERVATION", 37, 56]]], ["While debate persists regarding the causal role of substance use and domestic violence (Graham et al. 2011) , these are situational stressors that can further exacerbate the risk of family and domestic violence.General strainOne criminological theory that is apt to help explain a potential increase in violence, in particular violence in the home, is Agnew's (1992) general strain theory.", [["domestic violence", "DISEASE", 69, 86], ["domestic violence", "DISEASE", 193, 210], ["violence", "DISEASE", 303, 311]]], ["Specifically, Agnew posited the existence of three broad categories of strain: (1) failure to achieve positive goals, (2) presentation of noxious stimuli, and (3) removal of positive stimuli.", [["failure", "PROBLEM", 83, 90], ["noxious stimuli", "TEST", 138, 153], ["removal", "TREATMENT", 163, 170], ["positive stimuli", "TEST", 174, 190], ["positive stimuli", "OBSERVATION", 174, 190]]], ["Within the context of COVID-19, it is relatively easy to identify examples of each of these types of strain.", [["COVID-19", "DNA", 22, 30], ["COVID", "TEST", 22, 27], ["strain", "PROBLEM", 101, 107], ["strain", "OBSERVATION", 101, 107]]], ["For example, being furloughed from work is a good example of the first type of strain as people may not be able to pay their rent or mortgage.", [["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95]]], ["An example of the second type of strain is the built-up tension that may exist because individuals find themselves in cramped quarters with little room for escape.", [["strain", "PROBLEM", 33, 39]]], ["And finally, with respect to the removal of positive stimuli, lockdowns prevent individuals from visiting restaurants, bars, shopping centers, and gyms-all of which are activities people may enjoy and for which may also offer stress relief.General strainFor Agnew, however, there is more to understanding criminal behavior than just the presence of these types of strain.", [["people", "ORGANISM", 180, 186], ["people", "SPECIES", 180, 186], ["the removal of positive stimuli", "TREATMENT", 29, 60], ["stress relief", "TREATMENT", 226, 239], ["General strain", "PROBLEM", 240, 254], ["strain", "PROBLEM", 364, 370], ["positive stimuli", "OBSERVATION", 44, 60], ["strain", "OBSERVATION", 248, 254]]], ["Most importantly, he contends that these types of strains produce a wide range of negative behaviors within persons including anger, rage, fear, depression, anxiety, and so forth.", [["depression", "DISEASE", 145, 155], ["anxiety", "DISEASE", 157, 164], ["persons", "ORGANISM", 108, 115], ["persons", "SPECIES", 108, 115], ["strains", "PROBLEM", 50, 57], ["depression", "PROBLEM", 145, 155], ["anxiety", "PROBLEM", 157, 164]]], ["It is the experience of these negative emotions that, left unchecked by coping mechanisms, are expected to lead to a higher likelihood of criminal behavior-but especially violence.General strainDuring the period of enforced social distancing associated with COVID-19, it is easy to envision that Agnew would predict an increase in interpersonal, domestic partneroriented violence because of the anger and rage that may occur because people do not have much physical separation and because the victim may not be able to reach out for help because their aggressor lives with them.", [["violence", "DISEASE", 171, 179], ["people", "ORGANISM", 433, 439], ["people", "SPECIES", 433, 439], ["criminal behavior", "PROBLEM", 138, 155], ["increase", "OBSERVATION_MODIFIER", 319, 327]]], ["With respect to child abuse, there may be reasons to think there would be both an increase and a decrease in real and reported rates of abuse.", [["increase", "OBSERVATION_MODIFIER", 82, 90]]], ["A reduction in reported child abuse could be anticipated during school closures given teachers are the ones who are most often able to \"see\" the after-effects of physical child abuse.", [["A reduction", "TREATMENT", 0, 11], ["reduction", "OBSERVATION_MODIFIER", 2, 11]]], ["At the same time, there is limited evidence of an increase in physical injuries associated with child abuse being reported in some US hospitals due to increased presentations associated with COVID-19 (Santhanam 2020) .", [["injuries", "DISEASE", 71, 79], ["an increase in physical injuries", "PROBLEM", 47, 79], ["increased presentations", "PROBLEM", 151, 174], ["COVID", "TEST", 191, 196], ["limited evidence of", "UNCERTAINTY", 27, 46], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["injuries", "OBSERVATION", 71, 79]]], ["And with respect to property crime, it is expected, within the theory, that many forms of burglaries and thefts would drop because people are home and not out and about, but cybercrime and other fishing-related scams could increase as people use the internet more often.General strainWhat trends have been observed around the world?General strainScholars have been quick to examine the impact of COVID-19 on violent crime, particularly in large US cities with open source crime data.", [["burglaries", "DISEASE", 90, 100], ["violent crime", "DISEASE", 408, 421], ["people", "ORGANISM", 131, 137], ["people", "ORGANISM", 235, 241], ["people", "SPECIES", 131, 137], ["people", "SPECIES", 235, 241], ["burglaries", "PROBLEM", 90, 100], ["COVID", "TEST", 396, 401]]], ["They observed no change in assault/battery calls for service in either city; however, there was a significant increase in domestic violence calls for service of between 13.6 and 15.2 events per day.", [["no", "UNCERTAINTY", 14, 16], ["change", "OBSERVATION_MODIFIER", 17, 23], ["significant", "OBSERVATION_MODIFIER", 98, 109], ["increase", "OBSERVATION_MODIFIER", 110, 118]]], ["Domestic violence assaults could not be distinguished from other assaults in recorded crime data.", [["Domestic violence assaults", "DISEASE", 0, 26]]], ["Mohler et al. (2020) also observed significant declines in burglary and robbery calls for service in Los Angeles and a small increase in vehicle theft, but no change in Indianapolis.", [["a small increase in vehicle theft", "PROBLEM", 117, 150], ["change in Indianapolis", "PROBLEM", 159, 181], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["declines", "OBSERVATION_MODIFIER", 47, 55], ["small", "OBSERVATION_MODIFIER", 119, 124], ["increase", "OBSERVATION_MODIFIER", 125, 133], ["no", "UNCERTAINTY", 156, 158], ["change", "OBSERVATION_MODIFIER", 159, 165]]], ["In terms of recorded crime, only robbery in Los Angeles was significantly reduced.", [["reduced", "OBSERVATION_MODIFIER", 74, 81]]], ["Yet, their results are limited because of the short-term analysis and inability to disentangle seasonal trends and more longer-term(yearly) crime patterns.", [["the short-term analysis", "PROBLEM", 42, 65]]], ["Campedelli et al. (2020) analyzed daily recorded crime counts over a 3-year period in Los Angeles using Bayesian structural time-series models, incorporating controls for weather (seasonality) and holiday periods.", [["crime counts", "TEST", 49, 61]]], ["This approach allowed them to produce a synthetic counterfactual-what would have occurred had there been no containment measures-which they compared with observed crime counts during a period of increasingly stringent social distancing measures in March.", [["crime counts", "TEST", 163, 175], ["no", "UNCERTAINTY", 105, 107], ["containment", "OBSERVATION_MODIFIER", 108, 119]]], ["They found no impact on homicide, assault with deadly weapons, and intimate partner assault, but observed a decrease in robberies and battery (simple assault)-the latter only during the period with more stringent social distancing measures.", [["homicide", "DISEASE", 24, 32], ["a decrease in robberies", "PROBLEM", 106, 129], ["no", "UNCERTAINTY", 11, 13], ["impact", "OBSERVATION_MODIFIER", 14, 20], ["decrease", "OBSERVATION_MODIFIER", 108, 116]]], ["Property crimes, including shoplifting and thefts, decreased, as did crime overall.General strainMost recently, Ashby (2020) analyzed data for 16 large US cities.", [["General strain", "PROBLEM", 83, 97], ["decreased", "OBSERVATION_MODIFIER", 51, 60]]], ["Similar to Campedelli et al. (2020) , Ashby forecasted the expected frequency of crime during the pandemic based on data from 2016 to early 2020, but used seasonal autoregressive integrated moving average models to produce the synthetic counterfactual for the period after January 21 (the first confirmed case of COVID-19 in the USA).", [["COVID", "TEST", 313, 318]]], ["There was no change in crime levels between the observed and predicted values before early March, when social distancing measures (like closing schools and then stay-at-home orders) were introduced.", [["change in crime levels", "PROBLEM", 13, 35], ["no", "UNCERTAINTY", 10, 12], ["change", "OBSERVATION_MODIFIER", 13, 19]]], ["In terms of violent crime, there was no impact in any of the cities on serious assaults in public places or in residences.", [["violent crime", "DISEASE", 12, 25]]], ["The latter was used as a proxy for domestic violence.", [["domestic violence", "DISEASE", 35, 52]]], ["There was some evidence of an impact on property crime, including burglary and theft from vehicles; however, Ashby observed significant variation between the cities, with no two cities exhibiting the same trends in crime.General strainFinally, Piquero et al. (2020) used data from the Dallas, Texas, Police Department in order to examine the extent to which domestic violence incidents increased as a result of the city's stay-at-home orders.", [["domestic violence", "DISEASE", 358, 375], ["some evidence of", "UNCERTAINTY", 10, 26], ["impact", "OBSERVATION", 30, 36], ["significant", "OBSERVATION_MODIFIER", 124, 135], ["variation", "OBSERVATION", 136, 145]]], ["Their analysis showed that there was an immediate spike in the first 2 weeks after the stay-at-home order went into effect followed by a decrease in the 2 weeks that followed.", [["Their analysis", "TEST", 0, 14], ["an immediate spike", "PROBLEM", 37, 55], ["immediate", "OBSERVATION_MODIFIER", 40, 49], ["spike", "OBSERVATION_MODIFIER", 50, 55]]], ["At the same time, their analysis also suggested that domestic violence incidents were trending higher just before the stay-at-home orders were implemented, which likely reflects the fact that many people were starting to stay at home before the formal orders were enacted.General strainIn Sweden, where containment measures have been less stringent than elsewhere, Gerell et al. (2020) compared the weekly crime numbers in 2020 with the median from three previous years.", [["domestic violence", "DISEASE", 53, 70], ["people", "ORGANISM", 197, 203], ["people", "SPECIES", 197, 203], ["their analysis", "TEST", 18, 32]]], ["There were differences between the observed and expected values for indoor and outdoor assault; however, these differences were relatively small and, in the case of outdoor assault, not consistent for all of the weeks examined.", [["relatively", "OBSERVATION_MODIFIER", 128, 138], ["small", "OBSERVATION_MODIFIER", 139, 144]]], ["Gerell et al. (2020) also observed declines in residential burglary, commercial burglary, and pickpocketing.General strainOverall, there is mixed support for the suggestion that COVID-19 and associated containment measures has had an impact violent crime, and in the more robust studies using longer-term time series analysis, there was no evidence of an impact on domestic violence (Ashby 2020; Campedelli et al. 2020 ; though see Piquero et al. 2020) .", [["COVID", "TEST", 178, 183], ["series analysis", "TEST", 310, 325], ["containment", "OBSERVATION_MODIFIER", 202, 213], ["no evidence of", "UNCERTAINTY", 337, 351]]], ["Importantly, each of these studies has focused on the initial weeks following the introduction of containment measures, meaning that it might still be too early to have detected any meaningful impact on crime.", [["these studies", "TEST", 21, 34], ["containment measures", "TREATMENT", 98, 118]]], ["The impact on simple assault in Los Angeles only emerged in the most recent iteration of the analysis (Campedelli et al. 2020) , when social distancing measures had become more stringent.", [["the analysis", "TEST", 89, 101], ["simple", "OBSERVATION_MODIFIER", 14, 20], ["assault", "OBSERVATION", 21, 28]]], ["The limitations of using police recorded crime data to measure certain crime types when reporting rates might also be affected, particularly for domestic violence, were also acknowledged.How has COVID-19 impacted crime in Australia?Most of the evidence around the impact of crime impacts of COVID-19 in Australia is based on media reports, which draw on information supplied by police agencies.", [["domestic violence", "DISEASE", 145, 162], ["COVID-19", "CHEMICAL", 291, 299], ["crime data", "TEST", 41, 51], ["COVID", "TEST", 195, 200], ["COVID", "TREATMENT", 291, 296]]], ["Limited detailed analyses have been conducted, although as the pandemic continues, it is likely that more data will become available and studies will be published.", [["Limited detailed analyses", "TEST", 0, 25], ["studies", "TEST", 137, 144]]], ["Further, it is recognized that many law enforcement agencies and other data custodians will be conducting their own in-house analyses of crime to help inform their respective government's response.How has COVID-19 impacted crime in Australia?There is emerging evidence of the impact of restrictions on family violence and, to date, that evidence has produced something of a mixed picture.", [["COVID", "TEST", 205, 210], ["a mixed picture", "PROBLEM", 372, 387]]], ["Some police jurisdictions have seen an increase in family violence incidents, others have not.", [["increase", "OBSERVATION_MODIFIER", 39, 47]]], ["But there has been no increase in recorded assaults.", [["no", "UNCERTAINTY", 19, 21], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["assaults", "OBSERVATION", 43, 51]]], ["Most recently, and in the only published analyses that we are aware of, the New South Wales (NSW) Bureau of Crime Statistics and Research concluded there had been no increase in recorded domestic violence (Freeman 2020 ).", [["no", "UNCERTAINTY", 163, 165], ["increase", "OBSERVATION_MODIFIER", 166, 174]]], ["Freeman (2020) acknowledges that social isolation may have impacted the willingness or ability of victims to report to police; however, trends in serious forms of violence, less susceptible to changes in reporting rates, were also stable.", [["violence", "DISEASE", 163, 171], ["stable", "OBSERVATION_MODIFIER", 231, 237]]], ["Still, the study did not involve any time series analysis; rather, the frequency of recorded offenses in March 2020 was compared with March 2019.How has COVID-19 impacted crime in Australia?Data from other sources has provided a slightly different picture.", [["the study", "TEST", 7, 16], ["any time series analysis", "TEST", 33, 57], ["COVID", "TEST", 153, 158], ["a slightly different picture", "PROBLEM", 227, 255]]], ["Fifty percent of domestic violence service providers in NSW reported an increase in demand following the onset of the pandemic in February (Women's Safety NSW 2020).", [["Women", "SPECIES", 140, 145], ["increase", "OBSERVATION_MODIFIER", 72, 80]]], ["But elsewhere, demand has not increased.", [["not", "UNCERTAINTY", 26, 29], ["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["Similarly, there have been reports of a decrease in calls to domestic violence helplines-by as much as 30% to 1800 RESPECT have been reported (Talwar 2020)-but these numbers are climbing again (Pearson 2020) .", [["decrease", "OBSERVATION_MODIFIER", 40, 48]]], ["Conversely, there has been an increase in calls to men's helplines from perpetrators reaching out for help to stop them from being violent (Tuohy 2020) .", [["men", "ORGANISM", 51, 54], ["men", "SPECIES", 51, 54], ["increase", "OBSERVATION_MODIFIER", 30, 38]]], ["Finally, trauma surgeons in the Northern Territory have reported a 15% increase in surgeries related to domestic violence (Davey 2020) .", [["trauma", "DISEASE", 9, 15], ["domestic violence", "DISEASE", 104, 121], ["surgeries", "TREATMENT", 83, 92]]], ["However, none of these data sources have been subjected to rigorous analysis.Current studyThe problem with some of the published studies conducted to date-Australian and overseas-is that they have tended to rely on short time series.", [["rigorous analysis", "TEST", 59, 76], ["Current study", "TEST", 77, 90], ["the published studies", "TEST", 115, 136]]], ["The benefit of shorter-term studies is that they have used daily offense counts and because of this they are able to detect immediate, short-term changes in crime.", [["shorter-term studies", "TEST", 15, 35], ["short-term changes in crime", "PROBLEM", 135, 162]]], ["However, analyzing short time periods does not account for longer term trends and seasonal variation that might occur, leading to masked or exaggerated effects.", [["analyzing short time periods", "PROBLEM", 9, 37], ["longer term trends", "PROBLEM", 59, 77], ["seasonal variation", "PROBLEM", 82, 100], ["exaggerated effects", "PROBLEM", 140, 159]]], ["Our study overcomes these limitations by using officially recorded violent crime rates to model the series trend over 6 years between February 2014 and 2020.", [["Our study", "TEST", 0, 9]]], ["We then compute 6-month ahead forecasts for the various crime types and compare these with the observed rates for March and April 2020, when COVID-19 social distancing regulations were in place.DataThese data are drawn from the Queensland Government's Open Data Portal (Queensland Government 2020).", [["COVID", "TREATMENT", 141, 146], ["DataThese data", "TEST", 194, 208], ["Portal", "ANATOMY", 262, 268]]], ["For this study, we use the offense rates for four types of violent crime-common assault, serious assault, sexual offenses, and breaches of domestic violence orders.Analytical approachFor each of the four violent offense categories, we operationalize an Auto Regressive Integrated Moving Average (ARIMA) model on the monthly offense rate between February 2014 and February 2020.1 ARIMA models are a specific type of time series forecasting technique which capitalize on several key time-seriesparameters-the series trend and seasonality, its lagged auto-correlations and its lagged partial autocorrelations (correlations between residual errors).", [["sexual offenses", "DISEASE", 106, 121], ["this study", "TEST", 4, 14]]], ["Like all models, the relative accuracy of any forecast depends on the strength of the relationship between past and future values.Analytical approachIn each series, we exclude from the analysis the observed value for March 2020 onwards since this is the month when social distancing restrictions were first introduced in Queensland.", [["the analysis", "TEST", 181, 193]]], ["1 Each series also requires a unique ARIMA specification, depending on the presence (or absence) of seasonality and the unique nature of the series trend, autocorrelation and partial auto-correlation.Analytical approachProcedurally, we begin each model with a statistical assessment of the presence of a unit-root (non-stationarity).", [["root", "ANATOMY", 309, 313], ["a statistical assessment", "TEST", 258, 282]]], ["A unit-root is a stochastic trend which represents a systematic pattern that is unpredictable.", [["root", "ANATOMY", 7, 11], ["A unit-root", "TREATMENT", 0, 11], ["root", "OBSERVATION_MODIFIER", 7, 11], ["unpredictable", "OBSERVATION_MODIFIER", 80, 93]]], ["Any time-series which evidence a unit-root must be first de-seasonalized or first-differenced before ARIMA modeling can be performed.", [["root", "ANATOMY", 38, 42], ["ARIMA modeling", "TEST", 101, 115]]], ["The null hypothesis of the ADF test is that raw series is non-stationary (i.e., includes a unit-root).", [["root", "ANATOMY", 96, 100], ["ADF", "PROTEIN", 27, 30], ["the ADF test", "TEST", 23, 35], ["null", "OBSERVATION", 4, 8]]], ["Failure to reject the null-hypothesis at p < 0.05 indicates the presence of a unit-root and necessitates its removal.Analytical approachWhere there is some evidence of non-stationarity, the unit root is removed by seasonal and trend differencing.", [["root", "ANATOMY", 83, 87], ["root", "ANATOMY", 195, 199], ["root", "ORGAN", 195, 199], ["Failure to reject the null", "PROBLEM", 0, 26], ["a unit-root", "TREATMENT", 76, 87], ["its removal", "TREATMENT", 105, 116], ["non-stationarity", "PROBLEM", 168, 184], ["root", "ANATOMY", 83, 87], ["some evidence of", "UNCERTAINTY", 151, 167], ["non-stationarity", "OBSERVATION", 168, 184]]], ["The raw series is used for subsequent ARIMA modeling if the ADF test indicates stationarity.", [["ADF", "PROTEIN", 60, 63], ["the ADF test", "TEST", 56, 68]]], ["The base seasonality adjustment is SARIMA (0,1,0,12) , where the purpose of seasonality differencing is to parameterize the additive seasonal patterns in the raw data.", [["base", "ANATOMY_MODIFIER", 4, 8], ["seasonality", "OBSERVATION_MODIFIER", 9, 20]]], ["The base adjustment for non-stationarity in the trend is ARIMA(0,1,0).", [["The base adjustment", "TREATMENT", 0, 19], ["non-stationarity", "PROBLEM", 24, 40], ["base", "ANATOMY_MODIFIER", 4, 8]]], ["Therefore, a series that requires both trend and seasonality differencing is known as ARIMA(0,1,0) SARIMA(0,1,0,12).Analytical approachSubsequent to any adjustments, each offense series is then explored using autocorrelation(AC) and partial auto-correlation(PAC) plots.", [["autocorrelation(AC)", "TREATMENT", 209, 228]]], ["These plots help to determine the most likely specification of the seasonal and trend-level moving average (MA) and auto-regressive(AR) parameters.", [["auto-regressive(AR) parameters", "PROBLEM", 116, 146]]], ["From here, the modeling is iterative and each specification seeks to identify the unique AR and MA specifications which best fit the observed data.", [["AR", "GENE_OR_GENE_PRODUCT", 89, 91], ["AR", "PROTEIN", 89, 91]]], ["As with all modeling, there is a trade-off between parsimony and best fit, so we use the Akaike information criteria (AIC) and the Bayesian information criteria (BIC) to guide final model selection.Analytical approachAt the conclusion of the modeling procedure for each violent offense, we use the final ARIMA specification to forecast both point estimates and their mean square errors (MSE).", [["the modeling procedure", "TREATMENT", 238, 260]]], ["We also consider its position within the confidence interval of the forecast and we only conclude that the offense rate has changed under COVID-19 conditions if the observed value (for March and April 2020) falls outside the upper or lower bounds of the 95% confidence interval.", [["the offense rate", "TEST", 103, 119], ["upper", "ANATOMY_MODIFIER", 225, 230]]], ["2Common assaultBetween February 2014 and February 2020, the rate of common assault in Queensland has fluctuated between 9.0 and 15.5 recorded offenses per 100,000 of the population.", [["assault", "OBSERVATION", 8, 15], ["common", "OBSERVATION_MODIFIER", 68, 74], ["assault", "OBSERVATION", 75, 82]]], ["2 A 95% confidence interval in this case suggests the range in which 95% of plausible values will fall given the statistical relationships in the historical data.", [["plausible values", "PROBLEM", 76, 92]]], ["However, since Queensland relaxed social distancing regulations in May 2020, and since these data are only produced by Queensland police as monthly crime rates, we have only the month of April to explore the 100% dosage effect of social distancing across Queensland.Common assaultThe observed rate in March 2020 was 14.6 per 100,000, up from the previous month (13.5 per 100,000) and slightly lower than the same time in the previous year (15.1 per 100,000).", [["Common assault", "PROBLEM", 266, 280], ["assault", "OBSERVATION", 273, 280], ["slightly", "OBSERVATION_MODIFIER", 384, 392], ["lower", "OBSERVATION_MODIFIER", 393, 398]]], ["Comparative tests (Table 1 ) confirm the need for both seasonality adjustment and trend-level first-differencing and inspection of the AC and PAC plots indicate significant auto-correlations at lags 1 and 12.Common assaultThe specification that best fit these data was ARIMA(0,1,1 12) SARIMA(0,1,0,12) (AIC = 209.97).", [["Comparative tests", "TEST", 0, 17], ["both seasonality adjustment", "TREATMENT", 50, 77], ["inspection", "TEST", 117, 127], ["the AC and PAC plots", "TEST", 131, 151], ["Common assault", "PROBLEM", 208, 222], ["ARIMA", "TEST", 269, 274], ["SARIMA", "TEST", 285, 291], ["AIC", "TEST", 303, 306], ["significant", "OBSERVATION_MODIFIER", 161, 172], ["auto", "OBSERVATION", 173, 177], ["assault", "OBSERVATION", 215, 222]]], ["We note that the observed rate (14.6 per 100,000) of common assault for Marchthe month when social distancing regulations first came into effect-was almost equal to the forecasted rate (14.7 per 100,000) for that month.", [["the observed rate", "TEST", 13, 30]]], ["In April, the common assault rate fell further to 10.9 offenses per 100,000, which was below the forecast (12.1 per 100,000) but still within the 95% confidence interval of the prediction for that month.", [["the common assault rate", "TEST", 10, 33]]], ["Source: Queensland Offence rates, Open Data Portal that common assault rates have been negatively impacted during the first 2 months of COVID-19.", [["COVID", "TEST", 136, 141], ["Portal", "ANATOMY", 44, 50]]], ["Source: Queensland Offence rates, Open Data Portal evidence suggests that this could have occurred irrespective of COVID-19.", [["COVID", "TEST", 115, 120], ["Portal", "ANATOMY", 44, 50]]], ["Importantly, this result exemplifies the challenge and uniqueness of conducting this analysis in the southern hemisphere where the crimes rates are expected to fall naturally during the colder months.Serious assaultSince February 2014, the rate of serious assault in Queensland has fluctuated between 12.2 and 21.3 offenses per 100,000 of the population.", [["this analysis", "TEST", 80, 93], ["Serious assault", "PROBLEM", 200, 215], ["assault", "OBSERVATION", 208, 215], ["serious", "OBSERVATION_MODIFIER", 248, 255], ["assault", "OBSERVATION", 256, 263]]], ["In March 2020, the observed rate was 18.9 per 100,000.", [["the observed rate", "TEST", 15, 32]]], ["This was lower than the previous month (19.5 per 100,000) and lower than at the same time in the previous year (19.4 per 100,000).", [["lower", "OBSERVATION_MODIFIER", 9, 14]]], ["Comparative model tests (Table 3) indicate the need for both trend and seasonality differencing, which AC and PAC plots indicate the need for seasonal AR and trend-level MA parameters.", [["Comparative model tests", "TEST", 0, 23], ["PAC plots", "TEST", 110, 119], ["seasonal AR", "TEST", 142, 153]]], ["The best fitting model was specified as ARIMA(1,1,0) SARIMA(0,1,1,12) (AIC = 209.51) and the final modelled parameters are provided in Table 4 .", [["ARIMA", "TEST", 40, 45], ["SARIMA", "TEST", 53, 59], ["AIC", "TEST", 71, 74]]], ["Overall, the model captures both the series trend and its seasonal peaks and troughs; however, there is still some period-specific variability that was not easily predicted.", [["specific variability", "OBSERVATION", 122, 142]]], ["Overall, the observed rate of serious assault in March 2020 (18.9 per 100,000) was lower than forecast from the historical series (20.2 per 100,000), but not beyond the range of statistically plausible values for that month (18.3-22.1 per 100,000) (Fig. 5) .", [["serious", "OBSERVATION_MODIFIER", 30, 37], ["assault", "OBSERVATION", 38, 45]]], ["In fact, not since July 2015 has the serious assault rate been as low as it was in April 2020 and the statistical evidence suggests that this decline would not have occurred in the absence of some significant exogenous changes.Sexual offendingSince February 2014, sexual offense rates in Queensland have ranged between 8.3 and 15.4 per 100,000 of the population.", [["some significant exogenous changes", "PROBLEM", 192, 226], ["sexual offense rates", "TEST", 264, 284], ["significant", "OBSERVATION_MODIFIER", 197, 208], ["exogenous", "OBSERVATION", 209, 218]]], ["This was lower than in the previous month (11.3 per 100,000) and lower than the same time in the previous year (14.5 per 100,000).", [["lower", "OBSERVATION_MODIFIER", 9, 14]]], ["The ADF test confirmed that the series is stationary and comparative model tests (Table 5 ) confirm that neither trend nor seasonality differencing was required.", [["ADF", "PROTEIN", 4, 7], ["The ADF test", "TEST", 0, 12], ["comparative model tests", "TEST", 57, 80]]], ["Inspection of the AC and PAC plots indicate significant auto-correlation at lags 1 and 2 and so several specifications of the AR and MA parameters were compared.", [["AR", "GENE_OR_GENE_PRODUCT", 126, 128], ["AR", "PROTEIN", 126, 128], ["the AC and PAC plots", "TEST", 14, 34], ["significant auto-correlation at lags", "PROBLEM", 44, 80], ["MA parameters", "TEST", 133, 146], ["significant", "OBSERVATION_MODIFIER", 44, 55]]], ["It was apparent from the fitted data that the model performs relatively poorly and does In other words, there is significant fluctuation in the series which has no discernible or reliably predictable pattern.", [["significant fluctuation in the series", "PROBLEM", 113, 150], ["significant", "OBSERVATION_MODIFIER", 113, 124], ["fluctuation", "OBSERVATION", 125, 136], ["no discernible", "UNCERTAINTY", 161, 175], ["predictable", "OBSERVATION_MODIFIER", 188, 199]]], ["As for the observed rate of sexual offending in March 2020, the rate (9.2 per 100,000) was considerably lower than forecast by the model (11.1 per 100,000) ( Fig. 6 ) but within the boundary of plausible outcomes (8.3 to 13.9 per 100,000) given the history of the series.", [["the rate", "TEST", 60, 68]]], ["In April, the sexual assault rate fell again to 8.3 per 100,000 and this observed rate fell beyond the lower limit of the confidence interval for that month.", [["the sexual assault rate", "TEST", 10, 33], ["lower limit", "OBSERVATION_MODIFIER", 103, 114]]], ["It is notable that the rate of sexual offending in April 2020 was the lowest recorded in the 6year series.Breaches of domestic violence ordersThe rate at which domestic violence orders are breached in Queensland has increased steadily between 2014 and 2020.", [["The rate", "TEST", 142, 150], ["increased", "OBSERVATION_MODIFIER", 216, 225]]], ["In early 2014, the breach rate averaged at 26 per 100,000 of the population.", [["the breach rate", "TEST", 15, 30]]], ["The observed DVO breach rate in March 2020 was 57.5 per 100,000 which was higher than in the previous month (55.2 per 100,000) and higher than it was in March of the previous year (52.0 per 100,000).", [["higher", "OBSERVATION_MODIFIER", 74, 80]]], ["In the present data, the longer-term upward trend, including in the past 12 months, is likely a strong reflection of the increased number of orders being made by the courts and not necessarily any trend in the relative rate of breach events when calculated as function of the number of active orders.", [["breach events", "PROBLEM", 227, 240], ["strong", "OBSERVATION_MODIFIER", 96, 102], ["increased", "OBSERVATION_MODIFIER", 121, 130]]], ["Nevertheless, the ADF statistic confirmed that without adjustment the DVO breach series is non-stationary (ADF = \u2212 1.628, p = 0.47).", [["ADF", "PROTEIN", 18, 21], ["the ADF statistic", "TEST", 14, 31], ["ADF", "TEST", 107, 110], ["p", "TEST", 122, 123]]], ["Comparative model analysis (Table 7) indicated the need for both seasonal and trend differencing.", [["Comparative model analysis", "TEST", 0, 26]]], ["AC and PAC plots suggested significant auto-correlations and partial auto-correlations at lag 1.", [["AC and PAC plots", "TEST", 0, 16], ["significant auto-correlations", "PROBLEM", 27, 56]]], ["The best fitting model-ARIMA(1,1,0) SARIMA(0,1,1,12)-required an AR parameter at lag 1 for the trend and an MA parameter at lag 1 in the seasonal pattern (AIC = 337.75).", [["AR", "PROTEIN", 65, 67], ["SARIMA", "TEST", 36, 42], ["an AR parameter", "TEST", 62, 77], ["an MA parameter", "TEST", 105, 120], ["AIC", "TEST", 155, 158]]], ["As for the observed breach rate of domestic violence orders in March 2020, the rate (57.5 per 100,000) was lower than forecast by the model (59.2 per 100,000) ( Fig. 7) but well within the range (54.9 to 63.4 per 100,000) of plausible values given the history of the series.", [["the rate", "TEST", 75, 83]]], ["In April, the DVO breach rate declined slightly, although not as much as was forecast and remained within the confidence interval.", [["the DVO breach rate", "TEST", 10, 29]]], ["We conclude that there is insufficient evidence to suggest that breaches of domestic violence orders increased or decreased in the context of COVID-19.DiscussionThe COVID-19 pandemic has had deleterious consequences on the health and wellbeing of individuals worldwide.", [["individuals", "ORGANISM", 247, 258], ["COVID", "TEST", 142, 147], ["decreased", "OBSERVATION_MODIFIER", 114, 123]]], ["One outcome of this easily contagious and deadly disease was the response that governments had with respect to travel restrictions, social distancing recommendations, and lockdown orders.", [["deadly disease", "PROBLEM", 42, 56]]], ["Accordingly, this study offers one of the first Australian-based analyses of the extent to which crime has changed during the COVID-19 pandemic.", [["this study", "TEST", 13, 23], ["the COVID", "TEST", 122, 131], ["pandemic", "PROBLEM", 135, 143]]], ["Specifically, we used an iterative univariate ARIMA framework to model the 6-year trend in the state-wide rates of four violent crime types (common assault, serious assault, sexual offenses, and breaches of domestic violence orders) in Queensland, Australia.", [["sexual offenses", "DISEASE", 174, 189]]], ["This delayed effect is likely a consequence of the incremental measures that were introduced and the timing of these measures.", [["the incremental measures", "TREATMENT", 47, 71], ["these measures", "TREATMENT", 111, 125]]], ["March 2020 was the month in which the most significant social distancing rules were first introduced in Queensland.", [["significant", "OBSERVATION_MODIFIER", 43, 54], ["social", "OBSERVATION_MODIFIER", 55, 61], ["distancing", "OBSERVATION", 62, 72]]], ["However, their introduction occurred in the second half of the month and Google's mobility trend data showed there was a large but gradual decrease in the use of public spaces and an increase in time spent at home, towards the end of March.", [["Google's mobility trend data", "TEST", 73, 101], ["public spaces", "TREATMENT", 162, 175], ["large", "OBSERVATION_MODIFIER", 121, 126], ["gradual", "OBSERVATION_MODIFIER", 131, 138], ["decrease", "OBSERVATION_MODIFIER", 139, 147], ["increase", "OBSERVATION_MODIFIER", 183, 191]]], ["The impact of these containment measures, particularly in terms of influencing routine activities, was therefore not observed until April.", [["these containment measures", "TREATMENT", 14, 40], ["containment", "OBSERVATION_MODIFIER", 20, 31]]], ["This was consistent with the findings of Campedelli et al.'s (2020) study of assaults in Los Angeles, where a reduction was not observed until the more stringent stay-at-home measures were introduced.", [["a reduction", "TREATMENT", 108, 119], ["consistent with", "UNCERTAINTY", 9, 24]]], ["Importantly, the effect of major job losses and associated financial stress may not become evident until future months.", [["major job losses", "PROBLEM", 27, 43], ["financial stress", "PROBLEM", 59, 75], ["major", "OBSERVATION_MODIFIER", 27, 32], ["job losses", "OBSERVATION", 33, 43]]], ["The dynamic forecasts presented in this study, and their confidence intervals, will be a useful tool in making an assessment as to whether the strain caused by COVID-19 impacts violent crime in the longer term.DiscussionIn the absence of more detailed data, it is difficult to offer definitive explanations for the different trends observed for the four crime categories reported here.", [["COVID-19", "CHEMICAL", 160, 168], ["violent crime", "DISEASE", 177, 190], ["this study", "TEST", 35, 45], ["an assessment", "TEST", 111, 124], ["the strain", "PROBLEM", 139, 149], ["COVID", "TEST", 160, 165]]], ["It is possible that the decline in serious assault and sexual offenses is largely a function of the impact of containment measures on the night time economy, which have seen these major weekend attractions all but shutdown.", [["the decline", "PROBLEM", 20, 31], ["containment measures", "TREATMENT", 110, 130], ["decline", "OBSERVATION_MODIFIER", 24, 31], ["serious", "OBSERVATION_MODIFIER", 35, 42], ["assault", "OBSERVATION", 43, 50]]], ["It is well-known that alcohol intoxication is associated with more serious forms of violence and is a contributing factor in a large number of sexual assaults.", [["alcohol", "CHEMICAL", 22, 29], ["violence", "DISEASE", 84, 92], ["alcohol", "CHEMICAL", 22, 29], ["alcohol", "SIMPLE_CHEMICAL", 22, 29], ["alcohol intoxication", "PROBLEM", 22, 42], ["large", "OBSERVATION_MODIFIER", 127, 132]]], ["It seems unlikely that crimes associated with the night time economy-particularly less serious common assaults-have not been affected to a larger degree by the closures.", [["seems unlikely", "UNCERTAINTY", 3, 17], ["serious", "OBSERVATION_MODIFIER", 87, 94], ["larger degree", "OBSERVATION_MODIFIER", 139, 152], ["closures", "OBSERVATION", 160, 168]]], ["Violence in the night time economy accounts for a significant proportion of violence overall (Miller et al. 2016) .", [["Violence", "DISEASE", 0, 8]]], ["It is plausible that the lack of an observable effect in common assault is a function of competing trends between violence occurring in different contexts.", [["violence", "DISEASE", 114, 122]]], ["The decrease in violence associated with the night time economy may be offset by increases in assaults in residential settings, especially domestic violence.", [["domestic violence", "DISEASE", 139, 156], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["increases", "OBSERVATION_MODIFIER", 81, 90]]], ["This can only be determined through a more detailed analysis of data on offense location, relationship between offender and victim, alcohol and drug involvement, and so on.DiscussionYet, there are also limitations associated with relying on recorded crime data to measure changes in violence, particularly violence in the home.", [["alcohol", "CHEMICAL", 132, 139], ["violence", "DISEASE", 306, 314], ["alcohol", "CHEMICAL", 132, 139]]], ["While there is widespread concern about the impact of containment measures on domestic violence, this does not necessarily mean this would translate to an increase in recorded assault.", [["widespread", "OBSERVATION_MODIFIER", 15, 25], ["containment", "OBSERVATION", 54, 65], ["increase", "OBSERVATION_MODIFIER", 155, 163], ["assault", "OBSERVATION", 176, 183]]], ["This is particularly important in the context of domestic violence, which often goes unreported to police (Voce and Boxall 2018) and for sexual assault that is perpetrated by family members.", [["domestic violence", "DISEASE", 49, 66], ["sexual assault", "DISEASE", 137, 151]]], ["We have attempted to provide some insight into this by examining the domestic violence order breach rates, but again, we are hesitant about interpreting these data as a true measure of the extent of domestic violence.", [["domestic violence", "DISEASE", 199, 216]]], ["Although these data themselves suffer a number of limitations, they would provide some signal of a shift from community to home-based violence.DiscussionWe believe that our effort offers an important first step in trying to understand the crime implications of the COVID-19 pandemic and associated containment measures in the Australian context.", [["violence", "DISEASE", 134, 142]]], ["Our univariate ARIMA models provide an important opportunity for a rapid and robust assessment.", [["a rapid and robust assessment", "TEST", 65, 94]]], ["Ideally, these Queensland data will soon be complemented by equivalent analyses conducted with data from other Australian jurisdictions, once they are publicly available and offer a nice counterpoint to the research in the USA and elsewhere in order to provide a more complete picture of the government's policy responses to COVID-19.", [["COVID", "TEST", 325, 330]]], ["Only through continued data collection and analyses will this portrait begin to be filled out.", [["continued data collection", "TEST", 13, 38]]], ["Only through the combination of quantitative and qualitative data will social scientists have a complete understanding of COVID-19.", [["COVID-19", "DNA", 122, 130], ["COVID", "TEST", 122, 127]]]]}